

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>6</sup> :</b> <b>C12N 15/00, 9/00, A01N 63/00</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 98/06835</b> <b>(43) International Publication Date:</b> 19 February 1998 (19.02.98)
<b>(21) International Application Number:</b> PCT/US97/14428 <b>(22) International Filing Date:</b> 15 August 1997 (15.08.97) <b>(30) Priority Data:</b> 60/024,078 16 August 1996 (16.08.96) US <b>(60) Parent Application or Grant</b> (63) Related by Continuation US 60/024,078 (CIP) Filed on 16 August 1996 (16.08.96) <b>(71) Applicant (for all designated States except US):</b> THE TEXAS A & M UNIVERSITY SYSTEM [US/US]; 310 Wisenbaker, College Station, TX 77843-3369 (US). <b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> JARVIS, Donald, L. [US/US]; 4028 Viceroy Drive, Bryan, TX 77802 (US). <b>(74) Agent:</b> HIBLER, David, W.; Arnold, White & Durkee, P.O. Box 4433, Houston, TX 77210 (US).		<b>(81) Designated States:</b> AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> MODIFYING INSECT CELL GLYCOSYLATION PATHWAYS WITH BACULOVIRUS EXPRESSION VECTORS		
<b>(57) Abstract</b>  Disclosed are a variety of recombinant baculovirus vectors, and host insect cells, which comprise at least one oligosaccharide processing enzyme gene. The vectors and cells may optionally comprise other heterologous structural genes, including further protein processing enzymes. Methods of making and using the recombinant baculoviruses and vectors are provided, including their uses in recombinant protein production and as insecticides.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon		Republic of Korea	PT	Portugal		
CN	China	KR	Republic of Korea	RO	Romania		
CU	Cuba	KZ	Kazakhstan	RU	Russian Federation		
CZ	Czech Republic	LC	Saint Lucia	SD	Sudan		
DE	Germany	LI	Liechtenstein	SE	Sweden		
DK	Denmark	LK	Sri Lanka	SG	Singapore		
EE	Estonia	LR	Liberia				

- 1 -

**DESCRIPTION****MODIFYING INSECT CELL GLYCOSYLATION PATHWAYS  
WITH BACULOVIRUS EXPRESSION VECTORS**

5

**BACKGROUND OF THE INVENTION**

The government owns rights in the present invention pursuant to grant number GM49734 from the National Institutes of Health.

10

**1. Field of the Invention**

The present invention relates generally to the field of recombinant DNA vectors, and particularly concerns vectors useful for producing a desired protein of interest in an insect cell that has modifications similar to the same protein produced in mammalian cells. More particularly, it concerns recombinant baculovirus vectors that are used to infect or stably transform insect cells, directing the production of oligosaccharide processing enzymes, other protein modification enzymes and proteins which aid in proper protein folding, thereby obtaining the desired protein. The invention also concerns insect cells with stably integrated protein modification enzymes, and methods utilizing the vectors, viruses and cells disclosed herein.

20

**2. Description of Related Art**

One of the major benefits provided by recombinant DNA technology is the ability to express cloned genes in a heterologous host, which facilitates the isolation of large amounts of foreign gene products for further study or direct practical applications. Bacterial systems typically provide high expression levels, but lack eucaryotic protein processing capabilities. Many biomedically important proteins are processed, and the lack of processing can alter their folding, transport, stability and/or function (Welpy, 1991). Also, the foreign gene product is often deposited as an insoluble inclusion body. Mammalian systems can provide protein processing, but expression levels are much lower and mammalian cells are much more expensive to cultivate. An ideal system would

25

30

- 2 -

combine high expression levels, proper protein processing, and still be relatively inexpensive.

Baculoviruses are DNA-containing viruses that infect insects or other invertebrates (Adams and McClintock 1991). Baculovirus vectors usually provide high levels of foreign gene expression, and the insect cell hosts have some eucaryotic protein processing capabilities. Also, while insect cells remain more expensive to cultivate than bacteria, recent developments have significantly reduced the cost of producing foreign gene products in this system. Based on these properties, the baculovirus-insect cell system is a widely used tool for the production of foreign gene products, particularly eucaryotic proteins that must be co- and post-translationally processed (Summers and Smith, 1987, Luckow and Summers, 1988; Miller, 1988; O'Reilly *et al.*, 1992).

However, a major limitation of using the baculovirus-insect cell system for recombinant glycoprotein production is that the N-glycosylation pathway in insect cells differs from the pathway found in higher eukaryotes (Jarvis and Summers, 1992; Kornfeld and Kornfeld, 1985). This is a significant drawback as there is increasing evidence that proper glycosylation imparts important functions to many eukaryotic proteins (Welply, 1991).

Most of the information on the N-glycosylation pathway in insect cells has come from structural studies on foreign glycoproteins expressed in baculovirus-infected cell lines or in larvae (reviewed by Jarvis and Summers, 1992; O'Reilly *et al.*, 1992; Jarvis, 1993a). These studies have demonstrated that insect cells have processing glucosidases and mannosidases which convert high mannose oligosaccharides to trimmed structures with as few as three mannose residues. Several lines of evidence indicate that these cells also have a fucosyltransferase that can add fucose to the core Asn-linked GlcNAc residue (Staudacher *et al.*, 1992).

However, mammalian cells extend such trimmed oligosaccharide structures by adding N-acetylglucosamine, galactose, fucose, and sialic acid residues to produce a complex biantennary structure containing penultimate galactose and terminal sialic acid residues (Kornfeld and Kornfeld, 1985; Paulson and Colley, 1989; Moremen *et al.*, 1994). Insect cells generally do not produce these extended complex structures, indicating that the requisite processing activities are either absent or too low to be generally effective in these



- 3 -

cells. This limits the current usefulness of insect cells. Although some recent studies indicate that insect cell lines can produce glycoproteins with certain terminal glycosylation patterns more similar to those found in higher eukaryotes (Kubelka *et al.*, 1994; Ackermann *et al.*, 1995, Ogonah *et al.*, 1996, Davidson *et al.*, 1990; Davidson and  
5 Castellino, 1991a), the vast majority of recombinant proteins produced in insect cells lack these structures.

### **SUMMARY OF THE INVENTION**

The present invention overcomes the drawbacks in the prior art by providing new  
10 and improved baculoviral expression vectors, insect cell lines, compositions and various methods of use. The invention first provides a baculovirus expression vector characterized as either: (a) comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned  
15 under the control of and in frame with a promoter; or (b) comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

Recombinant vectors form important aspects of the present invention. The term  
20 "expression vector or construct" means any type of genetic construct containing a nucleic acid coding for a gene product in which part or all of the nucleic acid encoding sequence is capable of being transcribed. The transcript may be translated into a protein, but it need not be. Thus, in certain embodiments, expression includes both transcription of a gene and translation of a RNA into a gene product. In other embodiments, expression only includes  
25 transcription of the nucleic acid, for example, to generate antisense or ribozyme constructs. It will naturally be understood that the transcriptional units each comprise the appropriate transcription and translation initiation and termination signals, such as ATG start signals, and are positioned in the proper orientation to allow transcription of the gene.

Where the present invention comprises the vector of part (a) above, it will be  
30 understood that the vector may advantageously further include a third, fourth, fifth, sixth, seventh, eighth and/or a ninth glycosylation enzyme transcriptional unit, the third, fourth,

fifth, sixth, seventh, eighth and/or a ninth transcriptional unit comprising a structural gene for a third, fourth, fifth, sixth, seventh, eighth and/or a ninth oligosaccharide processing enzyme, operatively positioned under the control of a promoter.

5 Equally, where the present invention comprises the vector of part (b) above, the vector may also further include a second, third, fourth, fifth, sixth, seventh, eighth and/or a ninth glycosylation enzyme transcriptional unit, the second, third, fourth, fifth, sixth, seventh, eighth and/or a ninth transcriptional unit comprising a structural gene for a second, third, fourth, fifth, sixth, seventh, eighth and/or a ninth oligosaccharide processing enzyme, operatively positioned under the control of a promoter.

10 Exemplary oligosaccharide processing enzymes for use in the invention include, but are not limited to  $\alpha$ -glucosidases, including  $\alpha$ -glucosidase I and  $\alpha$ -glucosidase II,  $\alpha$ -mannosidases, such as  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II, N-acetylglucosaminyltransferases, including, but not limited to N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II,  
15 fucosyltransferases, galactosyltransferases and sialyltransferases. The oligosaccharide processing enzymes contemplated for use in the present invention include, but are not limited to, the extensive list provided herein below in Table 1.

The oligosaccharide processing enzymes may be used individually, or in any combination. In certain preferred embodiments, the oligosaccharide processing enzyme  
20 will be a galactosyltransferase. In other preferred embodiments, a galactosyltransferase will be used in combination with a sialyltransferase. In further preferred embodiments, a galactosyltransferase will and a sialyltransferase will be used in conjunction with N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II.

Particularly useful vectors are contemplated to be those vectors in which the  
25 coding portion of a DNA segment, whether encoding a full length protein or smaller peptide, is positioned under the transcriptional control of a promoter. A "promoter" refers to a DNA sequence recognized by the synthetic machinery of the cell, or introduced synthetic machinery, required to initiate the specific transcription of a gene. The phrases "operatively positioned", "under control" or "under transcriptional control" means that the  
30 promoter is in the correct location and orientation in relation to the nucleic acid to control RNA polymerase initiation and expression of the gene. Promoters for use in the present

- 5 -

invention include insect cell promoters, viral promoters, and preferably baculovirus promoters, such as IE1, IEN (IE2), IE0, 39K, gp64, DA26, ETL, 35K, capsid (p39) p10 and the polyhedrin promoter.

5 The viral promoters for use in the present invention may be obtained from the viral DNA of *Autographa californica* NPV, *Trichoplusia ni* NPV, *Rachipulsia ou* NPV, *Orgyia pseudosugata* NPV, *Bombyx mori* NPV, *Heliothis zea* NPV, *Spodoptera exigua* NPV or *Galleria mellonella* NPV.

10 Additionally, the current invention provides for the use of enhancer elements operatively positioned to enhance expression of the transcriptional units. All eukaryotic enhancers are contemplated for use in the present invention, with preferred enhancers being the baculovirus enhancers hr1, hr2, hr3, hr4 and/or hr5, with the viral DNA of *Autographa californica* NPV, *Trichoplusia ni* NPV, *Rachipulsia ou* NPV, *Orgyia pseudosugata* NPV, *Bombyx mori* NPV, *Heliothis zea* NPV, *Spodoptera exigua* NPV or *Galleria mellonella* NPV being the preferred sources for the baculoviral enhancer  
15 elements.

Additional proteins that modify or stabilize proteins are contemplated for use in the present invention, either alone, or in conjunction with the oligosaccharide processing enzymes. Certain embodiments of the present invention provide a structural gene encoding a modification protein, including, but not limited to, a protein kinase, a protein  
20 methylase, and proteins involved in acylation, acetylation and/or amidation of proteins, operatively positioned under the control of a promoter. Other embodiments of the present invention provide a structural gene encoding a protein involved in the stabilization or proper folding of proteins, including, but not limited to, protein disulphide isomerase, peptidyl prolyl *cis-trans* isomerase and/or a chaperone protein, operatively positioned  
25 under the control of a promoter. Preferred from this class of proteins is a structural gene for BiP/GRP78, and particularly preferred is BiP/GRP78 from an insect cell.

Further embodiments of the present invention include a structural gene encoding a screenable or selectable marker protein, operatively positioned under the control of a promoter. Exemplary of these screenable marker proteins are  $\beta$ -galactosidase,  
30 chloramphenicol acetyltransferase,  $\beta$ -glucuronidase, luciferase and green fluorescent protein. Preferred for use in the present invention are selectable marker proteins,

- 6 -

including, but not limited to, antibiotic or toxin resistance genes such as neomycin resistance, hygromycin resistance and dihydrofolate reductase, which confers resistance to methotrexate.

In particular aspects of the present invention, the vectors further comprise a baculovirus structural gene, with gp64, p10 and/or polyhedrin being preferred examples. Further embodiments of the present invention include a cloning restriction site, optionally, and preferably, for insertion of one or more heterologous coding regions or genes that encode one or more proteins or polypeptides to be expressed. In particularly preferred embodiments, the cloning restriction site comprises a DNA insert including a multiple cloning cassette.

Certain embodiments of the present invention include at least one heterologous structural gene encoding a selected protein, the gene operatively positioned under the control of and in frame with a promoter. Preferred are baculoviral promoters, more preferred are very late baculoviral promoters, and particularly preferred are the polyhedrin and/or p10 promoter. Alternatively, the promoter is a promoter naturally associated with the heterologous structural gene.

In additional embodiments of the present invention, the vectors comprise a structural gene encoding an insecticidal protein. Insecticidal proteins preferred for use include, but are not limited to, *Bacillus thuringiensis* crystal toxins, protease inhibitors, lectins, chitinases, proteases, insect-specific neurotoxins and trypsin inhibitors. Particularly preferred are juvenile hormone esterase and the insect-specific toxins *Androctonus australis* toxin (AaIT) and *Leiurus quinquestriatus hebraeus* toxin (LqhIT2).

The present invention additionally provides a 5' end flanking baculovirus viral DNA and a 3' end flanking baculovirus viral DNA, allowing recombination of the transcriptional units into the baculovirus genome, thereby replacing a portion of the baculovirus genome. Preferred portions of the baculovirus genome for replacement are the gp64, p10 and/or polyhedrin loci.

In certain preferred embodiments of the present invention, the first oligosaccharide processing enzyme structural gene encodes a galactosyltransferase and the second oligosaccharide processing enzyme structural gene encodes a sialyltransferase. In preferred embodiments, at least one of the first or second oligosaccharide processing

- 7 -

enzyme structural genes is operatively positioned under the control of a baculovirus promoter. Preferred baculovirus promoters are baculovirus immediate early, delayed early and/or early promoters. Further preferred uses of the current invention provide the structural gene encoding N-acetylglucosaminyltransferase I and  
5 N-acetylglucosaminyltransferase II, operatively positioned under the control of the above promoters. Particularly preferred embodiments further include a baculoviral enhancer. Preferred embodiments provide these components irrespective of the particular vector construct used. In certain embodiments of the present invention, the vectors are encapsulated within a baculovirus.

10 Thus in particular aspects the present invention provides a baculovirus expression vector comprising a gene encoding an oligosaccharide processing enzyme, a chaperone protein, a protein stabilization protein and/or another type of protein modification enzyme operatively positioned under the control of a promoter, a baculoviral structural gene, a 5' end flanking baculovirus viral DNA, a 3' end flanking baculovirus viral DNA, and a  
15 structural gene encoding a chaperone protein operatively positioned under the control of a promoter.

In further embodiments, the gene encoding the oligosaccharide processing enzyme is operatively positioned under the control of a promoter and a baculoviral enhancer. Additional embodiments include a structural gene encoding a screenable or selectable  
20 marker protein operatively positioned under the control of a promoter. In preferred embodiments, the gene encoding the selectable marker protein encodes an antibiotic or toxin resistance gene. Particularly preferred embodiments include a DNA insert including a multiple cloning site. Exemplary embodiments further include a heterologous structural gene inserted into the multiple cloning site.

25 The present invention also provides a baculovirus particle comprising a baculovirus expression vector characterized as: (a) comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or (b) comprising at  
30 least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene operatively

positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

5 An embodiment of the present invention is an insecticidal composition comprising a population of baculovirus particles, the baculovirus particles comprising a baculovirus expression vector characterized as: (a) comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or (b) comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

15 An additional embodiment of the present invention is an insect cell comprising a baculovirus expression vector characterized as: (a) comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or (b) comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

20 The insect cell may have integrated into its genome one or more functional units from the baculovirus expression vector. Thus, in further embodiments of the current invention, the insect cell is a stably transformed insect cell line or clone that expresses or continually expresses at least a first glycosylation enzyme not normally expressed, or not normally expressed at sufficiently functional levels, in the natural insect cell. Preferred insect cells are Lepidopteran insect cells, and particularly preferred are *Spodoptera frugiperda*, *Bombyx mori*, *Heliothis virescens*, *Heliothis zea*, *Mamestra brassicae*, *Estigmene acrea* or *Trichoplusia ni* insect cells.

30 In certain aspects, the vectors of the present invention are contemplated for use in the preparation of a recombinant baculovirus. Thus, the present invention provides a

5 baculovirus containing any of the baculovirus expression vectors disclosed herein. The present invention also provides for the use of the vectors of the instant invention in the preparation of a recombinant baculovirus. In further aspects, the invention provides a population of baculovirus particles containing any of the instant baculovirus expression  
10 vectors. In other preferred embodiments, a baculovirus containing any of the baculovirus expression vectors disclosed herein are contemplated for use in the preparation of an insecticidal formulation. Thus, the present invention also provides for the use of a baculovirus containing any of the baculovirus expression vectors of the present invention in the preparation of an insecticidal formulation.

10 Also provided by the present invention is a method for metabolically engineering an insect cell, comprising providing to the cell at least a first baculovirus expression vector characterized as: (a) comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned  
15 under the control of a promoter operative in the insect cell; or (b) comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in the insect cell.

20 The invention further provides a method for metabolically engineering an insect cell, comprising providing to an insect any of the baculovirus expression vectors disclosed herein. Also provided are baculovirus expression vectors for use in metabolically engineering an insect cell. Thus, the present invention provides for the use of any of the disclosed baculovirus expression vectors in the metabolic engineering an insect cell.

25 In further embodiments, the insect cell line is provided with the first baculovirus expression vector by infection. Alternatively, the insect cell line is provided with the first baculovirus expression vector by transfection. In an additional method of practicing the present invention, the first baculovirus expression vector is maintained extrachromosomally in the insect cell to provide an insect cell that transiently expresses  
30 the oligosaccharide processing enzyme or enzymes. In an alternate method of the current invention, the first baculovirus expression vector stably integrates into the genome of the

insect cell line to provide a stably transformed insect cell that continuously expresses the oligosaccharide processing enzyme or enzymes.

5 The present invention thus further provides an insect cell containing any of the baculovirus expression vectors disclosed herein. In further aspects, a baculovirus containing any of the disclosed baculovirus expression vectors are provided for use in the preparation of an engineered insect cell. Thus, the present invention provides for the use of a baculovirus containing any of the disclosed baculovirus expression vectors in the preparation of an engineered insect cell. The invention also provides an engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme. A  
10 further embodiment of the instant invention is an engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme and at least a first heterologous gene that encodes a selected protein.

In a preferred method, the first baculovirus expression vector expresses a galactosyltransferase and a sialyltransferase oligosaccharide processing enzyme.  
15 Particularly preferred is where the first baculovirus expression vector further expresses N-acetylglucosaminyltransferase II and N-acetylglucosaminyltransferase II. In certain methods of the present invention, the insect cell is a Lepidopteran insect cell. In preferred methods, the insect cell is a cultured insect cell, or in the alternative is housed within a living insect.

20 In additional methods of the present invention, the insect cell is further provided with a heterologous structural gene that expresses a selected protein in the insect cell. In particular methods, the heterologous structural gene is provided to the insect cell by means of a baculovirus expression vector. In certain methods of the present invention, the heterologous structural gene is comprised within the first baculovirus expression vector.  
25 In additional methods, the heterologous structural gene is comprised within a second baculovirus expression vector that is provided to the insect cell.

The present invention provides a method for producing a selected protein in an insect cell, comprising preparing an engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme and expressing in the engineered insect  
30 cell a heterologous gene that encodes the selected protein. Additional methods comprise collecting the selected protein expressed by the cell.



The present invention also provides a method for producing a selected protein in an insect cell, comprising providing to an insect any of the baculovirus expression vectors of the instant invention and an expressible nucleic acid segment encoding said selected protein. Additionally, baculovirus expression vectors for use in producing an oligosaccharide-containing selected protein in an insect cell are provided. Thus, the present invention provides for the use of any of the disclosed baculovirus expression vectors in the production of an oligosaccharide-containing selected protein in an insect cell. In other embodiments, baculovirus expression vectors are provided for use in preparing a formulation for use in producing an oligosaccharide-containing selected protein in an insect cell. Therefore, the present invention additionally provides for the use of any of the instant baculovirus expression vectors in the preparation of a formulation for use in producing an oligosaccharide-containing selected protein in an insect cell.

The present invention also provides a method for producing a selected protein in an insect cell, comprising providing to the insect cell at least a first baculovirus expression vector that expresses at least a first oligosaccharide processing enzyme in the insect cell, and further providing to the cell a heterologous gene that expresses the selected protein in the insect cell. The method may be characterized as comprising the steps of preparing a first baculovirus expression vector in which an oligosaccharide processing enzyme gene is positioned under the control of a promoter operative in the insect cell, introducing the baculovirus expression vector into an insect cell, and maintaining the insect cell under conditions effective to allow expression of the encoded selected protein. Preferred methods of the present invention include collecting the expressed selected protein and purifying the expressed protein away from total cell components.

In additional methods, the heterologous structural gene is provided to the insect cell by means of a baculovirus expression vector. In alternate methods of the present invention, the heterologous structural gene is comprised within the first baculovirus expression vector, or within a second baculovirus expression vector that is provided to the insect cell.

In a preferred method of the present invention, the first baculovirus expression vector expresses galactosyltransferase and sialyltransferase oligosaccharide processing

- 12 -

enzymes. In additional methods, the first baculovirus expression vector further expresses N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II enzymes.

5 The present invention provides a selected recombinant protein polypeptide prepared by expressing a heterologous gene encoding the protein or polypeptide in a recombinant insect cell, as disclosed herein, and purifying the expressed protein or polypeptide away from total recombinant host cell components.

10 The present invention further provides a method for producing a selected protein in an insect cell, comprising the steps of creating an engineered insect cell by providing to an insect cell at least a first baculovirus expression vector characterized as comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned under the control of a promoter operative in the insect cell, or comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in the insect cell, and expressing in the engineered insect cell a heterologous gene that expresses the selected protein.

20 The present invention also provides a method for producing a selected protein in an insect cell, comprising preparing a stably transformed insect cell that expresses at least a first oligosaccharide processing enzyme and infecting the stably transformed cell with a baculovirus comprising an expression vector that comprises a heterologous gene that expresses the selected protein in the insect cell.

25 Additionally, the present invention provides a method for killing an insect cell, comprising contacting the insect cell with at least a first baculovirus expression vector that expresses at least a first oligosaccharide processing enzyme in the insect cell. In a preferred method, the baculovirus expression vector is encapsulated within a baculovirus. Thus in certain embodiments, the invention provides an insect containing one or more of the baculovirus expression vectors disclosed herein.

30 These methods are generally based upon the classical use of baculovirus alone to kill insects. As the virus life cycle requires the virus to infect an insect cell, to reproduce

and ultimately to kill the host insect cell and release new viruses, baculovirus alone is insecticidal. The narrow host cell specificity means that the use of baculovirus in the environment is not generally deleterious to cells, plants and animals other than insect cells.

However, the insect target cells can adapt to be less-sensitive to baculovirus infection. This process is believed to include, at least in part, recognition and activity of glycosylated proteins. Therefore, the new baculovirus expression vectors of the present invention that express at least one oligosaccharide processing enzyme, the enzyme not normally present or significantly present in insect cells, will function to change the glycosylation pattern of the proteins in the cells, which should hamper the ability of the cells to become resistant to baculovirus.

In further methods, the insect cell is housed within a living insect. That is, the methods are applicable to insect cells in culture, and to whole, live insects. In additional methods of the present invention, the baculovirus expression vector is characterized as comprising at least a first and a second glycosylation enzyme transcriptional unit, the transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned under the control of a promoter operative in the insect cell, or comprising at least a first glycosylation enzyme transcriptional unit, the transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, the gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in the insect cell.

In preferred methods of the present invention, the baculovirus expression vector further expresses an insecticidal protein in the insect cell. In particularly preferred methods, the insecticidal protein is *Bacillus thuringiensis* crystal toxin, a protease inhibitor, a protease, an insect-specific neurotoxin or other toxins, a lectin, a chitinase, juvenile hormone esterase or a trypsin inhibitor insecticidal protein. In exemplary examples of the present invention, the insecticidal proteins are lectins such as wheat germ agglutinin, rice lectin or stinging nettle lectin, *Bacillus thuringiensis* crystal toxin genes such as CryIA (b) or CryIA(c), or insect-specific toxins such as AaIT or LqhIT2.

In additional methods of the present invention, the vector expresses a glycosylatable insecticidal protein and the oligosaccharide processing enzyme functions to modify the glycosylation pattern of the insecticidal protein, wherein the vector expresses a

glycosylatable insecticidal protein that requires a defined glycosylation pattern to achieve significant insecticidal activity and wherein the co-expressed oligosaccharide processing enzyme functions to modify the glycosylation pattern of the insecticidal protein expressed in the insect cell sufficiently to increase its insecticidal activity, *i.e.*, wherein the  
5 oligosaccharide processing enzyme modifies the glycosylation pattern of the insecticidal protein by adding one or more terminal glycosyl residues that are not normally added to the protein when the protein alone is expressed in the insect cell.

In preferred methods of the present invention, the vector expresses the insecticidal protein juvenile hormone esterase, AaIT and/or LqhIT2 and the oligosaccharide processing  
10 enzyme galactosyltransferase and/or sialyltransferase. In other aspects, the vector expresses a chaperone protein, such as BiP/GRP78, in conjunction with an insecticidal protein, such as the insect-specific toxins AaIT and/or LqhIT2.

The present invention further provides DNA segments that comprise an isolated insect  $\alpha$ -mannosidase I and/or  $\alpha$ -mannosidase II gene or cDNA, as may be isolated from  
15 lepidopteran insect cells, such as Sf9, High Five or Ea cells. The  $\alpha$ -mannosidase II or  $\alpha$ -mannosidase I genes or cDNAs are DNA segments that comprise gene sequences, or coding regions, that encode  $\alpha$ -mannosidase II or  $\alpha$ -mannosidase I proteins, polypeptides or peptides.

In certain embodiments, the  $\alpha$ -mannosidase II genes and cDNAs will include a  
20 contiguous nucleic acid sequence that encodes an  $\alpha$ -mannosidase II protein, polypeptide or peptide that comprises a contiguous amino acid sequence from the amino acid sequence of SEQ ID NO:4. In further embodiments, the  $\alpha$ -mannosidase II genes and cDNAs will include a contiguous nucleic acid sequence that corresponds to a contiguous nucleic acid sequence from the nucleic acid sequence of SEQ ID NO:3, and preferably, from the open  
25 reading frame thereof. Nucleic acid sequences comprising the complement of SEQ ID NO:3 are also provided.

In certain other embodiments, the  $\alpha$ -mannosidase I genes and cDNAs will include a contiguous nucleic acid sequence that encodes an  $\alpha$ -mannosidase I protein, polypeptide or peptide that comprises a contiguous amino acid sequence from the amino acid sequence  
30 of SEQ ID NO:2. In further other embodiments, the  $\alpha$ -mannosidase I genes and cDNAs will include a contiguous nucleic acid sequence that corresponds to a contiguous nucleic

- 15 -

acid sequence from the nucleic acid sequence of SEQ ID NO:1, and preferably, from the open reading frame thereof. Nucleic acid sequences comprising the complement of SEQ ID NO:1 are also provided.

It will be understood that nucleic acid segments of from 14 to about 10,000 nucleotides in length that hybridize to the nucleic acid segment of SEQ ID NO:3 or SEQ ID NO:1, or the complement thereof, under standard or high stringency hybridization conditions are also included within the present invention. Where the insect  $\alpha$ -mannosidase II and I gene constructs encode  $\alpha$ -mannosidase II and I polypeptides or peptides, contiguous amino acid sequences of from about 15 to about 50, or from about 15 to about 30 amino acids in length are contemplated. These may be used in, *e.g.*, immunization to generate antibodies to  $\alpha$ -mannosidase II and I.

Insect  $\alpha$ -mannosidase II and I gene constructs encoding full length proteins will generally be preferred in embodiments concerning the production of active proteins. The insect  $\alpha$ -mannosidase II and I genes and cDNAs of the present invention may be positioned under the control of a promoter, preferably a promoter that directs the expression of the  $\alpha$ -mannosidase II or I proteins in an insect cell. As such, the present invention also provides recombinant vectors comprising insect  $\alpha$ -mannosidase II and I genes and/or cDNAs that express  $\alpha$ -mannosidase II and/or I proteins. The present invention also provides recombinant host cells, preferably insect cells, comprising or incorporating DNA segments that comprise isolated  $\alpha$ -mannosidase II and/or I genes or cDNAs that encode insect  $\alpha$ -mannosidase II and/or I proteins. The genes or cDNAs are preferably introduced by means of a recombinant vector and the cell preferably expresses the vector.

The invention thus further provides methods of using a DNA segment that includes an isolated insect  $\alpha$ -mannosidase II and/or I gene or cDNA that encodes an  $\alpha$ -mannosidase II and/or I protein, comprising the steps of preparing a recombinant vector in which an insect  $\alpha$ -mannosidase II and/or I -encoding DNA segment is positioned under the control of a promoter, introducing the recombinant vector into a recombinant host cell, preferably an insect cell, culturing the recombinant host cell under conditions effective to allow expression of an insect encoded  $\alpha$ -mannosidase II and/or I protein or peptide, and collecting the expressed  $\alpha$ -mannosidase II and/or I protein or peptide.

- 16 -

Recombinant insect  $\alpha$ -mannosidase II and/or I protein, polypeptide or peptide compositions prepared by expressing  $\alpha$ -mannosidase II and/or I in a recombinant host cell are also provided, with preferred compositions comprising  $\alpha$ -mannosidase II and/or I polypeptide or peptide composition purified, or substantially, purified away from total recombinant host cell components. Antibodies that specifically bind to, i.e., have immunospecificity for insect  $\alpha$ -mannosidase II and/or I proteins, polypeptides or peptides are also provided.

Methods for detecting insect  $\alpha$ -mannosidase II and/or I sequences in a sample are also provided, which comprise obtaining sample nucleic acids from a sample suspected of containing insect  $\alpha$ -mannosidase II and/or I, contacting the sample nucleic acids with a nucleic acid segment that encodes an insect  $\alpha$ -mannosidase II and/or I protein or peptide under conditions effective to allow hybridization of substantially complementary nucleic acids, and detecting the hybridized complementary nucleic acids thus formed.

*In situ* hybridization, Northern and Southern blotting are contemplated. Also, pairs of nucleic acid primers that hybridize to distant sequences from insect  $\alpha$ -mannosidase II and/or I nucleic acid sequences may be used, wherein the primers are capable of amplifying an insect  $\alpha$ -mannosidase II and/or I nucleic acid segment when used in conjunction with a polymerase chain reaction. In such a polymerase chain reaction, amplification products are created and the amplification products thus formed are then detected. Thus, nucleic acid detection kits are provided which comprise, in suitable container means, one or more isolated insect  $\alpha$ -mannosidase II and/or I nucleic acid segments and, optionally, detection reagents.

### **BRIEF DESCRIPTION OF THE DRAWINGS**

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

**FIG. 1A, FIG. 1B and FIG. 1C.** Immediate early expression plasmids. **FIG. 1A:** pIE1HR1-4. **FIG. 1B:** pAcP(-)IE1TV5 and 6. **FIG. 1C:** pAcP(+)IE1TV1-4. The key features of the immediate early expression plasmids described herein below are shown in

FIG. 1A through FIG. 1C. In each case, the thin lines indicate pUC8 sequences, the open boxes represent the hr5 enhancer, the lightly-shaded boxes represent the *ie1* promoter and downstream sequences, and the darkly shaded boxes represent *polyhedrin* coding and/or flanking sequences. The early transcription unit in each plasmid is indicated by the arrow spanning the *ie1* transcriptional initiation (CAGT) and polyadenylation sites. The very late transcription unit in the plasmids shown in FIG. 1C is indicated by the arrow spanning the *polyhedrin* initiation (ATAAG) and polyadenylation sites. All plasmids within a set (FIG. 1A, FIG. 1B, or FIG. 1C) are identical except for their mcs sequences. Multiple cloning site 1 (mcs1: GTGACTATGGATCTAGATCTGCGGCCGCAGGCCTCGCGAC TAGTTTAAACCC; SEQ ID NO:7) has *Xba*I, *Bgl*II, *Not*I, *Stu*I, *Nru*I, *Spe*I and *Pme*I sites. Multiple cloning site 2 (mcs2: GTGACTATGGATCCCCGGGTTTAACTAGTC GCGAGGCCTGCG GCCGCAGATC; SEQ ID NO:8) has *Pme*I, *Spe*I, *Nru*I, *Stu*I and *Not*I sites. Multiple cloning site 3 (mcs3: GTGACCGCGGATCTAGATCTGCGGCCGC AGGCCTCGCGACTAGTTTAAACCC; SEQ ID NO:9) has *Sac*II, *Xba*I, *Bgl*II, *Not*I, *Stu*I, *Nru*I, *Spe*I and *Pme*I sites. Multiple cloning site 4 (mcs4: GTGACCGCGGATCCCCGG GTTTAACTAGTCGCGAGGCCTGCGGCCGCAGATC; SEQ ID NO:10) has *Sac*II, *Pme*I, *Spe*I, *Nru*I, *Stu*I and *Not*I sites. Multiple cloning site 5 (mcs5: GTGACTATGGAT CCGGGTACCTTCTAGAATTCCGGAGCGGCCGCTGCAGATCTGATCC; SEQ ID NO:11) has *Bam*HI, *Sma*I, *Kpn*I, *Xba*I, *Not*I, *Bgl*II and *Pst*I sites. Multiple cloning site 6 (mcs6: GTGACCGCGGATCCCCGGGTACCTTCTAGAATTCCGGAGCGGCCGCTG CAGATCT GATCC; SEQ ID NO:12) has *Sac*II, *Bam*HI, *Sma*I, *Kpn*I, *Xba*I, *Not*I, *Bgl*II and *Pst*I sites. The number designating each individual plasmid (#1-6) specifies which mcs sequence it contains. pIE1HR1-4 (FIG. 1A) are designed for optimal *ie1*-mediated expression of fused (pIE1HR1 and 2) or nonfused (pIE1HR3 and 4) proteins in uninfected insect cells. Except for *Stu*I and *Spe*I, all of the restriction sites in the mcs are unique, but the *Xba*I site in mcs 1 and 3 has an overlapping *dam* methylation site and can be cut only if the DNA is produced in a *dam*<sup>-</sup> strain of *E. coli*. A foreign gene can be inserted at *Stu*I or *Spe*I, but the insert must have its own polyadenylation site because there are additional *Stu*I and *Spe*I sites downstream that result in deletion of a plasmid fragment including the *ie1* polyadenylation site. The mcs also includes a *Sma*I site, but it is only useful for insertions if partial digests are done because there is another *Sma*I site upstream of the hr5

enhancer element. pAcP(-)IE1TV5 and 6 (FIG. 1B) are designed for the isolation of occlusion-negative recombinant baculoviruses capable of expressing fused (pAcP-IE1TV5) or nonfused (pAcP-IE1TV6) proteins under *ie1* control. pAcP(+)IE1TV1-4 (FIG. 1C) are designed for the isolation of occlusion-positive recombinant baculoviruses capable of expressing fused (pAcP+IE1TV1 and 2) or nonfused (pAcP+IE1TV3 and 4) proteins under *ie1* control. Each of the restriction sites in the mcs's of the various pAcP-IE1TV and pAcP+IE1TV plasmids are unique and the *Xba*I site in the AcP-IE1TV plasmids is not blocked by an overlapping dam methylase site. The mcs in pAcP+IE1TV2 and 4 also include *Bam*HI sites, but these are not unique and are not useful for insertions.

**FIG. 2.** Production of  $\beta$ -gal activity by immediate early and conventional baculovirus vectors. This log-scale plot shows the relative levels of  $\beta$ -gal activity in cytoplasmic extracts from Sf9 cells infected for various times with AcP(-)IE1 $\beta$ gal (open bars), AcP(+)IE1 $\beta$ gal (stippled bars), 941 $\beta$ gal (cross-hatched bars), or wild-type AcMNPV (closed bars).  $\beta$ -gal activity is expressed as nmol of o-nitrophenol produced per minute per million infected cells.

**FIG. 3.** Production of *E. coli* CAT activity by immediate early and conventional baculovirus vectors. This log scale plot shows the relative levels of CAT activity in cytoplasmic extracts from Sf9 cells infected for various times with AcP(-)IE1CAT (open bars), AcP(+)IE1CAT (light stippled bars), or Ac360CAT (dark stippled bars). CAT activity is expressed as pmol of acetylated chloramphenicol produced per 30 min per million infected cells.

**FIG. 4.** Production of  $\alpha$ -mannosidase II activity by immediate early and conventional baculovirus vectors. This plot shows the relative levels of  $\alpha$ -mannosidase II activity in total extracts of Sf9 cells infected for various times with wild-type AcMNPV (closed bars), AcSfManII (open bars), or AcP(+)SfManII (cross-hatched bars). Activity is expressed as nmol of p-nitrophenol produced per min per ml of cell extract.

**FIG. 5A and FIG. 5B.** Isolation of the Sf9  $\alpha$ -mannosidase II cDNA. **FIG. 5A:** A diagram of the partial Sf9  $\alpha$ -mannosidase II cDNA clone is shown (top) and a diagram showing the ligation-anchored PCR™ strategy used to isolate the 5' end of the cDNA (bottom). **FIG. 5B:** Assembly of the full-length Sf9  $\alpha$ -mannosidase II cDNA.



**FIG. 6.** A dendrogram of the  $\alpha$ -mannosidase polypeptide sequences generated with the Pileup subroutine as described in Example 6. The numbers in parentheses represent the percent identity of the indicated sequence to the Sf9  $\alpha$ -mannosidase II polypeptide.

**FIG. 7A and FIG. 7B.** Enzymatic activity of the Sf9  $\alpha$ -mannosidase II protein in baculovirus-infected Sf9 cells. **FIG. 7A:**  $\alpha$ -Mannosidase II activity assays were performed on cell extracts with the p-nitrophenyl  $\alpha$ -mannoside substrate (open bars, wild type; cross-hatched bars, recombinant). **FIG. 7B:** Activity assays also were performed in the presence of various concentrations of swainsonine (dotted lines, wild-type; solid lines, recombinant; open squares, 24 h postinfection; crosses, 36 h postinfection; closed circles, 48 h postinfection).

**FIG. 8A and FIG. 8B.** Genetic structures of the plasmids used to produce immediate early recombinant baculoviruses. **FIG. 8A** is the genetic structure of pAcP(-)IE1GalT. **FIG. 8B** is the genetic structure of pAcP(+)IE1GalT. The key genetic features of both plasmids are shown in the context of the linear AcMNPV map, in which the *polyhedrin* open reading frame extends from left to right (Summers and Smith, 1987; O'Reilly *et al.*, 1992). The viral DNA sequences upstream and downstream of the *polyhedrin* open reading frame are labeled polh-up and polh-dn, respectively. The hr5 enhancer is labeled hr5, the *ie1* promoter is labeled IE1, and the *polyhedrin* promoter is labeled PH. The *polyhedrin* and  $\beta$ 1,4-galactosyltransferase open reading frames are labeled Polh and Gal-T, respectively.

**FIG. 9.** Expression of  $\beta$ 1,4-galactosyltransferase activity by immediate early recombinant baculoviruses. Sf9 cells were mock-infected (open circles) or infected with wild type AcMNPV (closed circles), AcP(-)IE1GalT (open squares), or AcP(+)IE1GalT (closed squares), and cell extracts were prepared at various times after infection. Triplicate samples of each extract were assayed for  $\beta$ 1,4-galactosyltransferase activity as described in Example 2. The results were plotted as average  $^3\text{H}$ -galactose counts per minute (cpm) incorporated versus time of infection with standard errors indicated by the bars. The absence of error bars for some time points indicates that the margin of error is too small to be indicated on the present scale.

**FIG. 10A and FIG. 10B.** Modification of the insect cell N-glycosylation pathway by an immediate early recombinant baculovirus. **FIG. 10A:** Progeny budded virions were

- 20 -

partially purified from Sf9 cells infected with wild type AcMNPV and gp64 was extracted and immunoprecipitated as described in Example 3. **FIG. 10B:** Progeny budded virions were partially purified from Sf9 cells infected with AcP(+)IE1GalT and gp64 was extracted and immunoprecipitated as described in Example 3. The disrupted immunoprecipitates were resolved by SDS-PAGE, transferred to Immobilon, and the blots were cut into strips and probed with various lectins or rabbit anti-gp64 (Ab), as described in Example 3. The lectins were concanavalin A (Con A; binds  $\alpha$ -linked mannose or glucose), *Aleuria aurantia* agglutinin (AAA; binds  $\alpha$ -linked fucose), *Datura stramonium* agglutinin (DSA; binds terminal O-linked N-acetylglucosamine or Gal- $\beta$ 1,4-GalNAc), RCA (binds  $\beta$ -linked Gal), or *Sambucus nigra* agglutinin (SNA; binds terminal  $\alpha$ -2-6-linked sialic acid). Lectins were preincubated in buffer alone (-) or buffer containing excess competing sugar (+) prior to being used to probe the filters as described previously (Jarvis and Finn, 1995). For the DSA lanes marked (+), excess N-acetylglucosamine was used for reaction on the left and excess galactose for the reaction on the right. Lectin or antibody binding was detected with alkaline phosphatase-conjugated secondary antibodies and a standard color reaction, as described in Example 3. The arrows on the right mark the positions of gp64 and the IgG heavy chain, which served as an internal standard for the lectin blots.

**FIG. 11.** Linkage of galactose-containing oligosaccharides on gp64 from recombinant virions. gp64 was isolated from either wild type AcMNPV (WT) or AcP(+)IE1GalT (GT) virions and treated with buffer (Control) or peptide:N-glycosidase F (PNGase) as described in Example 3. The reaction products were resolved by SDS-PAGE and analyzed by either immunoblotting with rabbit anti-gp64 (Ab) or RCA lectin blotting (RCA) in the absence (-) or presence (+) of competing galactose as described in the description of FIG. 10A and FIG. 10B. The arrows on the right indicate the positions of glycosylated gp64 (gp64), deglycosylated gp64 (p64), and IgG heavy chain (IgG).

**FIG. 12.** Influence of galactosylation on glycoprotein function. One-step growth curves were done by infecting triplicate Sf9 cell cultures with wild-type AcMNPV (circles), AcP(+)IE1GalT (squares), or AcP(+)IE1 $\beta$ gal (triangles) at a multiplicity of infection of 5 plaque-forming units per cell. After a 1 hr adsorption period, the inocula were removed and the cells were washed and fed with fresh growth medium. At various

times postinfection, the media from triplicate cultures were harvested, pooled, and clarified by low speed centrifugation. The supernatants were titered by TCID<sub>50</sub> assays on Sf9 cells and the data were converted to average plaque forming units (pfu) per ml and plotted against time of infection, as described in Example 4.

5           **FIG. 13.** N-linked oligosaccharide processing. The oligosaccharide processing steps in insect cells (left branch) or higher eukaryotes (right branch) is shown. N-acetylglucosamine residues are depicted as open squares, mannose residues are depicted as open circles, glucose residues are depicted as stippled triangles, fucose residues are depicted as open triangles, galactose residues are depicted as stippled circles and sialic acid residues are depicted as stippled diamonds. The enzymes catalyzing each step are listed.

10           **FIG. 14.** Modified 5'-RACE procedure used to screen the Sf9 cDNA library for a full-length  $\alpha$ 1,2-mannosidase clone. T7-adapter primer (SEQ ID NO:23) is complementary to the T7 promoter sequence in the  $\lambda$ -ZAP II vector and also includes a 17-base adapter sequence at its 5' end. Sf9 ManI primer (SEQ ID NO:30) is complementary to an internal sequence near the 5' end of the partial Sf9  $\alpha$ 1,2-mannosidase cDNA clone. Adapter primer (SEQ ID NO:24) consists of just the adapter sequence at the 5' end of the T7-adapter primer. In the first step, the T7-adapter primer anneals to the T7 promoter in the  $\lambda$ -ZAP II vector portion of every cDNA clone and is extended by Taq DNA polymerase. Next, the Sf9 ManI primer anneals only to those single-stranded DNAs derived from cDNA clones containing Sf9  $\alpha$ 1,2-mannosidase sequences and is extended in the antisense direction. This generates a product that can be amplified with the adapter primer and Sf9 ManI primer, as shown in the last step. The size of the amplification product is determined by how far the cDNA sequence extends upstream of the position of the Sf9 Man I primer in the clone being amplified.

25           **FIG. 15A and FIG. 15B.** Enzymatic activity of the protein encoded by the Sf9  $\alpha$ 1,2-mannosidase cDNA. Sf9 cells were infected with wild-type baculovirus (WT) or a recombinant (Rec) encoding the Sf9  $\alpha$ 1,2-mannosidase cDNA under the control of the polyhedrin promoter. Lysates were prepared at the indicated times postinfection and used for  $\alpha$ -mannosidase activity assays, as described in Example 19. A portion of the lysates from cells infected with the recombinant virus was boiled and used as a negative control.

- 22 -

$\alpha$ -mannosidase activity was measured in counts per minute (cpm) of [ $^3$ H]mannose released from [ $^3$ H]Man<sub>5</sub>GlcNAc, as described in Example 19. FIG. 15A shows the activity levels in cell lysates at various times postinfection. These reaction mixtures included 10 mM CaCl<sub>2</sub>, and 5 mM MgCl<sub>2</sub>. FIG. 15B shows assays done under various conditions with cell lysates at 48 hours postinfection. As indicated on the abscissa, the various reaction mixtures included 500  $\mu$ M dMNJ, 10 mM EDTA, 10 mM CaCl<sub>2</sub>, and/or 10 mM MgCl<sub>2</sub>. The arrow (->) indicates cell lysates that were treated with EDTA, then supplemented with CaCl<sub>2</sub> and/or MgCl<sub>2</sub>.

**FIG. 16A and FIG. 16B.** Extended N-glycosylation pathway of SfGalT cells.

Progeny budded virions were partially purified from Sf9 or SfGalT cells infected with wild type baculovirus (wt) or AcP(+)IE1GalT (rec) and gp64 was extracted and immunoprecipitated. The disrupted immunoprecipitates were resolved by SDS-PAGE, transferred to immobilon, and the blots were cut into strips and probed with rabbit anti-gp64 (Ab) or the lectins Con A (binds  $\alpha$ -linked mannose or glucose) or RCA (binds  $\beta$ -linked Gal). Each lectin was preincubated in buffer alone (FIG. 16A) or buffer containing excess competing sugar (FIG. 16B) prior to being used to probe the filters. Lectin or antibody binding was detected with alkaline phosphatase-conjugated secondary antibodies and a standard color reaction. The arrows on the right mark the positions of gp64 and the IgG heavy chain, which served as an internal standard for the lectin blots. The results show clearly that only the gp64 produced in SfGalT cells bound to RCA, indicating that only these cells were able to produce a galactosylated end-product.

**FIG. 17A, FIG. 17B, FIG. 17C and FIG. 17D.** Galactosylation of a human glycoprotein expressed by a recombinant baculovirus in SfGalT cells. Sf9 or SfGalT cells were mock-infected (mock), infected with wild type baculovirus (wt), or infected with Ac941t-PA (rec), which is a conventional recombinant baculovirus that encodes human tissue plasminogen activator under the transcriptional control of the polyhedrin promoter. The cells were radiolabeled from 24-48 hr postinfection and the extracellular fraction was collected and immunoprecipitated with a goat antibody against t-PA ( $\alpha$ -tPA) or normal goat serum (NGS). The disrupted immunoprecipitates were resolved by SDS-PAGE, transferred to immobilon, and the blots were probed with the lectin RCA, which is specific for  $\beta$ -linked galactose. The lectin was preincubated in buffer alone (FIG. 17A) or buffer

containing excess competing galactose (**FIG. 17B**) prior to being used to probe the filters. Lectin binding was detected with alkaline phosphatase-conjugated secondary antibodies and a standard color reaction. Autoradiographs of the lectin blot of **FIG. 17A** is shown in **FIG. 17C**, and of the lectin blot of **FIG. 17B** is shown in **FIG. 17D**. The arrows on the right mark the positions of t-PA and the IgG heavy chain, which served as an internal standard for the lectin blots. The results clearly show that t-PA was produced, secreted, and specifically immunoprecipitated from either Sf9 or SfGalT cells infected with the recombinant virus. However, only the t-PA from the recombinant virus-infected SfGalT cells bound to RCA, indicating that only these cells produced a galactosylated end-product.

**FIG. 18A and FIG. 18B.** Further extension of the N-glycosylation pathway in SfGalT cells. Progeny budded virions were partially purified from Sf9 (**FIG. 18A**) or SfGalT (**FIG. 18B**) cells infected with wild type baculovirus (E2) or AcP(+)IE1ST, which is an immediate early recombinant baculovirus that encodes rat  $\alpha$ 2,6-sialyltransferase cDNA under the transcriptional control of the IE1 promoter (ST). gp64 was extracted and immunoprecipitated and the disrupted immunoprecipitates were resolved by SDS-PAGE and transferred to immobilon. The blots were cut into strips and probed with rabbit anti-gp64 (Ab) or the lectins RCA (binds  $\beta$ -linked Gal) or SNA (binds to  $\alpha$ 2,6-linked sialic acid). Each lectin was preincubated in buffer alone (-) or buffer containing excess competing sugars (+) prior to being used to probe the filters. Lectin or antibody binding was detected with alkaline phosphatase-conjugated secondary antibodies and a standard color reaction. The arrows on the right mark the positions of gp64 and the IgG heavy chain, which served as an internal standard for the lectin blots. The results show clearly that only the gp64 produced in SfGalT cells by the ST recombinant virus bound to SNA, indicating that only this virus-cell combination was able to produce a galactosylated and sialylated end-product.

**FIG. 19.** Linkage analysis of sialylated oligosaccharides on gp64. gp64 was extracted and immunoprecipitated from the progeny virions produced by SfGalT cells infected with AcP(+)IE1ST. The immunoprecipitates were stored frozen without any treatment (Ab) or treated with buffer alone (C), peptide:N-glycosidase F (F), or neuraminidase (N). The reaction products were resolved by SDS-PAGE, transferred to

- 24 -

immobilon filters, and analyzed by either immunoblotting with rabbit anti-gp64 (Ab) or lectin blotting with RCA (to detect galactose) or SNA (to detect sialic acid). The arrows on the right indicate the positions of gp64 and IgG heavy chain. The results showed clearly that SNA binding was precluded by either neuraminidase or peptide:N-glycosidase F treatment, whereas RCA binding was precluded only by peptide:N-glycosidase F treatment. Furthermore, there was a slight increase in the relative electrophoretic mobility of gp64 after neuraminidase treatment and a major increase after peptide:N-glycosidase F treatment. These results strongly support the conclusion that at least one N-linked oligosaccharide side-chain on gp64 was galactosylated and sialylated when SfGalT cells were infected with the AcP(+)*IE1*ST recombinant baculovirus.

**FIG. 20A, FIG. 20B, FIG. 20C and FIG. 20D.** Recombinant baculoviruses and transfer plasmids. **FIG. 20A.** Recombinant baculovirus AcP(+)*DIE-GTST*. **FIG. 20B.** Transfer plasmid AcP(-)*DIE-GTST*. **FIG. 20C.** Recombinant baculovirus AcSWT-1. **FIG. 20D.** Recombinant baculovirus AcSWT-2.

**FIG. 21A, FIG. 21B, FIG. 21C and FIG. 21D.** Expression plasmids for creation of stable insect cell lines expressing glycosylation enzymes, and selected stable insect cell lines. **FIG. 21A.** Expression plasmid p*DIE-GTST*. **FIG. 21B.** Expression plasmid p*DIE-GlcNAc-TI-II*. **FIG. 21C.** Expression plasmid p*IE1GT*, used to create stable cell line SfGalT, plus recombinant baculovirus AcP(+)*IE1ST*, used to infect SfGalT to incorporate ST activity. **FIG. 21D.** Expression plasmid p*IE1GT*, used to create stable cell line SfGalT, plus recombinant baculovirus AcP(-)*IE1ST*, used to infect SfGalT to incorporate ST activity and a desired gene of interest.

### **DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS**

The baculovirus-insect cell expression system is well-suited for recombinant glycoprotein production because baculovirus vectors can provide high levels of expression and insect cells can modify newly-synthesized proteins in eucaryotic fashion. However, the N-glycosylation pathway in baculovirus-infected insect cells differs from the pathway found in higher eukaryotes, as indicated by the fact that glycoproteins produced in the baculovirus system typically lack complex biantennary N-linked oligosaccharide side chains containing penultimate galactose and terminal sialic acid residues.

Previous work has shown that the N-glycosylation capabilities of other eucaryotic expression systems can be modified by transfecting cells with genes encoding new processing enzymes and isolating stably-transformed clones that express those genes constitutively. For example, clones of stably-transformed CHO or BHK-21 cells have been isolated that express newly-introduced genes encoding  $\alpha$ -2,6-sialyltransferase (Lee *et al.*, 1989; Minch *et al.*, 1995; Grabenhorst *et al.*, 1995) or  $\alpha$ -1,3-galactosyltransferase (Smith *et al.*, 1990) and produce differentially modified glycoproteins. Similarly, it has been shown that *Aspergillus nidulans* can be transformed to express a heterologous  $\beta$ -1,2-N-acetylglucosaminyltransferase I gene (Kalsner *et al.*, 1995).

Similar efforts to modify the N-glycosylation pathway in lepidopteran insect cells have been extremely limited. The only published report known to the inventor describes elongation of N-linked oligosaccharides by the addition of an N-acetylglucosamine residue, which was absent on a fowl plague virus glycoprotein expressed in insect cells infected with a conventional baculovirus vector (Wagner *et al.*, 1996b). Addition of the extra monosaccharide was accomplished by coinfecting insect cells with two recombinant baculoviruses, one encoding the fowl plague virus glycoprotein and the other encoding the human processing enzyme,  $\beta$ -1,2-N-acetylglucosaminyltransferase I. Expression of both foreign genes was controlled by the *polyhedrin* promoter.

There are at least three limitations associated with the Wagner (1996b) approach. First, it can sometimes be difficult to obtain homogeneous populations of cells coinfecting with more than one baculovirus. Second, expression of the processing enzyme will not precede expression of the protein to be processed, so only a subpopulation of the protein of interest will be exposed to the new processing activity. Third, expression of this single enzyme would not be sufficient to convert an expressed heterologous protein to a processed state similar to a mammalian protein. It also should be noted that insect cells contain N-acetylglucosaminyltransferase I activity (Altmann *et al.*, 1993; Velardo *et al.*, 1993), so the study by Wagner *et al.* (1996b) actually does not describe the introduction of a new processing activity, merely the upregulation of a preexisting processing activity.

The present inventor realized that modification of the insect cell N-linked oligosaccharide processing pathway to the point where these cells will be able to produce glycoproteins with higher eukaryotic-type N-linked side-chains will require the addition of

- 26 -

two processing enzymes that are thought to be completely missing in these cells (a galactosyltransferase and a sialyltransferase) and possibly two more that are expressed at very low levels by these cells (N-acetylglucosaminyltransferases I and II). This complexity may explain why there have been so few attempts to modify the insect N-glycosylation pathway given that many genes would need to be introduced into an insect cell, while simultaneously preserving the ability to express a foreign protein of interest. Moreover, the inventor considered the *polyhedrin* promoter to have limitations in the context of expressing modification enzymes, but promoters capable of providing temporal expression before *polyhedrin* are not widely used and are relatively unrecognized. Similarly, the use of vectors and methods needed for insect cell transformation, available for more than five years, have generally been limited.

The inventor contemplated that a vector comprising one or more eukaryotic protein processing genes could be used to modify the insect cell N-glycosylation pathway by directing the expression of heterologous processing enzyme(s). The one or more encoded enzyme(s) will then function as part of the insect cell machinery and contribute to the processing of a protein of interest. As shown herein, this approach was demonstrated to have practical utility. The use of a novel baculovirus vector to introduce and express active bovine  $\beta$ 1,4-galactosyltransferase (Harduin-Lepers *et al.*, 1993; Russo *et al.*, 1992) in insect cells is shown herein to modify the N-linked oligosaccharide(s) on gp64, the major baculovirus virion glycoprotein (Examples 11-14).

Furthermore, another novel baculovirus vector was used to create a stably transformed insect cell subclone capable of modifying the N-linked oligosaccharides of the gp64 protein or of human tissue plasminogen activator, when genes encoding these proteins comprised within conventional baculovirus vectors were introduced into the transformed cells by infection (Example 20). Finally, these same cells produced galactosylated and sialylated N-linked oligosaccharides on the gp64 protein when infected with a novel baculovirus vector encoding a sialyltransferase and the gp64 protein (Example 21).

The current invention takes advantage of the present discovery of altered protein processing in insect cells through the introduction of heterologous processing enzymes, thus providing various novel improvements to the baculovirus expression system.



## **I. Baculovirus Expression Vehicles**

A baculovirus expression vehicle (BEV) is a recombinant baculovirus with a double-stranded circular DNA genome that has been genetically modified to include a foreign gene of interest. BEVs are viable and can infect susceptible hosts, usually cultured lepidopteran insect cells or larvae, in a helper-independent fashion. Therefore, BEVs can efficiently transfer foreign genes into these eukaryotic host cells. The foreign gene is usually a chimeric construct with the sequence encoding a protein of interest placed under the transcriptional control of a viral promoter. This arrangement enables viral functions to transcribe the gene during infection. The resulting mRNA is translated and the newly-synthesized protein modified by host-encoded biosynthetic machinery. In essence, then, BEVs and their insect cell hosts are two separate components of a binary eukaryotic expression system, which will be referred to as "the BEV system" herein below.

The BEV system is among the best tools currently available for the expression of recombinant genes in a eukaryotic host. The BEV system has contributed immensely to basic research, as it has been used to produce hundreds of different recombinant proteins for further studies. This system also holds great promise for the industrial production of proteins with direct applications as vaccines, therapeutic agents, and/or diagnostic reagents. Finally, BEVs are being developed as improved biological pest control agents.

The most significant advantage of the BEV system over other expression systems is that it can be used to produce exceptionally large amounts of functional foreign proteins. The production levels provided by the BEV system are often comparable to those provided by prokaryotic systems and, at late times after infection, the recombinant protein usually constitutes a significant proportion of the total protein in the host cell. Unlike prokaryotic expression systems, however, the BEV system has eukaryotic protein processing capabilities, which enables it to produce more authentic foreign proteins. Thus, it is the potential of this system to provide prokaryotic levels of foreign gene expression in a eukaryotic background that makes it so powerful and attractive. Finally, the actual process of isolating BEVs has become increasingly fast, simple, and efficient as more sophisticated molecular tools have been developed. Additional background information on baculoviruses and the BEV system are available (Montreuil *et al.*, 1995; Richardson,

1995; King and Possee, 1992; O'Reilly *et al.*, 1992; Adams and McClintock, 1991; Blissard and Rohrmann, 1990; Luckow and Summers, 1988; Miller, 1988; Summers and Smith, 1987).

5           **A.     Baculoviruses**

          The family Baculoviridae consists of a large group of double-stranded DNA-containing viruses that infect arthropods (Volkman *et al.*, 1995). The majority of these viruses infect insects and the type species is *Autographa californica* nuclear polyhedrosis virus (AcMNPV). There are two phenotypically distinct forms of AcMNPV, occluded  
10       virus (OV) and budded virus (BV). OV consists of rod-shaped nucleocapsids enclosed by an envelope and embedded within a polyhedral-shaped crystalline matrix, or polyhedron. The "M" in AcMNPV indicates that one enveloped OV particle can contain multiple nucleocapsids. BV also consists of rod-shaped nucleocapsids enclosed by an envelope, but BV particles contain only one nucleocapsid and are released as free, nonoccluded  
15       virions by budding from the surface of the infected cell. OV and BV have different relative infectivities for insect larvae or cultured insect cells, which reflects their distinct roles in baculovirus infections, as discussed further below.

          AcMNPV was originally isolated (Vail *et al.*, 1971) as a mixture of genotypic variants with different restriction patterns (Lee and Miller, 1978) and different variants  
20       were used by investigators who went on to study this baculovirus and develop the first BEVs. Other nucleopolyhedroviruses also have been used to develop BEVs. Among these, BEVs derived from *Bombyx mori* nuclear polyhedrosis virus (BmNPV) are notable for their frequent use for foreign gene expression in insect larvae (Maeda, 1989). The discussion in this section will focus on generic "baculoviruses" and "BEVs" except where  
25       it is important to be more specific.

          Natural baculovirus infections begin when a susceptible insect ingests OV in the form of polyhedra-contaminated food. The crystalline polyhedral matrix dissociates in the insect midgut and the liberated virus particles infect columnar epithelial and regenerative cells (Keddie *et al.*, 1989). The infected midgut cells produce BV progeny that invade the  
30       insect circulatory and respiratory systems (Engelhard *et al.*, 1994; Keddie, *et al.*, 1989), where they initiate secondary infections and produce both BV and OV. BV progeny are

produced when newly-assembled viral nucleocapsids migrate from the nucleus and bud from the infected cell surface. These virions acquire a lipid envelope and plasma membrane-bound glycoproteins during the process of budding. OV progeny are produced when nucleocapsids are enveloped within the nucleus (Stoltz *et al.*, 1973) and the resulting virions are surrounded by the polyhedral matrix.

Polyhedra remain in the nuclei of infected cells until being released when the cell dies. Baculovirus-infected insect larvae are ultimately liquefied by virus-encoded digestive enzymes (Hawtin *et al.*, 1995; Ohkawa *et al.*, 1994) and when the cuticle ruptures, BV and polyhedra are released into the environment. Occluded virions are protected by the crystalline polyhedral matrix and, as a result, are relatively resistant to inactivation by adverse environmental conditions. Moreover, this form of the virus is significantly more infectious than BV for orally-inoculated insect larvae (Volkman and Summers, 1977). Accordingly, OV is responsible for horizontal transmission of baculovirus infection in nature and is used to experimentally infect larvae *via* the oral route. Conversely, BV is significantly more infectious than OV for cultured insect cells (Volkman and Summers, 1977; Volkman *et al.*, 1976) and is used to experimentally infect these cells in the laboratory.

The complete nucleotide sequences of AcMNPV (C6 isolate; Ayres *et al.*, 1994; GenBank Accession No. L22858) and BmNPV (GenBank Accession No. L33180) have been determined. The AcMNPV genome is a double-stranded circular DNA molecule consisting of 133,894 nucleotides that probably encode about 150 proteins. Viral genes are distributed evenly throughout the genome on both strands of the DNA and are expressed in a temporally regulated fashion after infection. The immediate early genes, such as *ie1* (Guarino and Summers, 1987), are expressed immediately after infection in the absence of other viral functions. At least some of the immediate early genes encode transcription factors that function to stimulate the expression of other early genes like *39K* (Guarino and Smith, 1990). The early phase of baculovirus infection is followed by viral DNA replication and the onset of late viral gene expression. Many baculovirus late genes encode proteins needed for the assembly of progeny virions. For example, *vp39* is a late gene which encodes the major nucleocapsid structural protein (Thiem and Miller, 1989) and *p6.9* is a late gene which encodes a basic, protamine-like protein found in association

- 30 -

with viral DNA (Wilson *et al.*, 1987). Late gene expression is followed by expression of the very late genes, including *polh* (Hooft van Iddekinge *et al.*, 1983) and *p10* (Kuzio *et al.*, 1984), which are needed for the assembly and envelopment of polyhedra, respectively.

5           There have been significant advances in the understanding of baculovirus gene expression during the past decade. The immediate early genes are transcribed by host cell factors and transcription of later classes of viral genes is increasingly influenced by virus-encoded factors. In particular, studies have identified nearly twenty virus-encoded proteins that are required for late and very late gene expression (Lu and Miller, 1995; Todd  
10 *et al.*, 1995; McLachlin and Miller, 1994) and at least some of these must assemble into a virus-modified or -encoded transcriptional complex (Beniya *et al.*, 1996; Passarelli *et al.*, 1994; Fuchs *et al.*, 1983). This is an important concept because it is the nature of the transcriptional complex that is assembled during the very late phase of baculovirus infection, together with the structure of the promoters in baculovirus very late genes (Qin  
15 *et al.*, 1989; Weyer and Possee, 1989; Rankin *et al.*, 1988; Possee and Howard, 1987), that determines one of the most attractive properties of BEVs-their ability to express foreign genes at extremely high levels.

By the end of the baculovirus replication cycle, the nucleus occupies most of the volume of the infected host cell and it is literally stuffed with polyhedra. The major  
20 component of polyhedra is a protein called polyhedrin (Rohrmann, 1986), which forms the crystalline matrix. Thus, baculoviruses must be able to produce copious amounts of polyhedrin protein. In fact, polyhedrin comprises at least 25% of the total protein in baculovirus-infected insect cells during the very late phase of infection (Smith *et al.*, 1983c). The ability to produce such large amounts of polyhedrin reflects the availability  
25 of a huge pool of polyhedrin mRNA, which represents about 25% of the total polyadenylated RNA in the cell during the very late phase of infection (Adang and Miller, 1982).

The *polh* promoter contains a critical core sequence, TAAG, which also serves as the transcriptional initiation site and is conserved in baculovirus very late and late  
30 promoters (Rohrmann, 1986). However, very late promoters are transcribed later in infection and produce more mRNA than late promoters (Thiem and Miller, 1990).

Therefore, the very late promoters and/or the very late transcriptional complex must have additional features, in addition to the TAAG sequence, which account for these differences. Indeed, studies have identified a region in the *polh* promoter (Ooi *et al.*, 1989) and a virus-encoded factor (McLachlin and Miller, 1994) that specifically enhance very late transcription and transcriptional complexes have been isolated that exhibit preferential activity towards late or very late promoters *in vitro* (Xu *et al.*, 1995). Furthermore, various differences in the behavior of the *polh* and *p10* promoters have been reported (Tomita *et al.*, 1995; McLachlin and Miller, 1994; Roelvink *et al.*, 1992; Min and Bishop, 1991) indicating that even individual very late promoters are not functionally homologous.

The ability to produce large amounts of polyhedrin during infection was the fundamental property of baculoviruses that led to their development as expression vehicles. The AcMNPV *polh* gene was mapped, cloned, and sequenced (Hooft van Iddekinge, *et al.*, 1983; Adang and Miller, 1982; Vlak *et al.*, 1981) and, together with the establishment of marker rescue in the baculovirus system (Miller, 1981), these studies provided some of the molecular tools that were needed to develop BEVs. In addition, the *polh* gene was shown to be nonessential for virus replication in cultured insect cells (Smith *et al.*, 1983a). This indicated that one could create a BEV simply by replacing the *polh* open reading frame in the wild-type viral genome with a nucleotide sequence encoding a foreign protein of interest. The resulting BEV could be phenotypically distinguished from wild-type by its inability to produce polyhedra. Moreover, the BEV would be viable and could be used to infect cultured insect cells, in which the foreign coding sequences would be expressed under the transcriptional control of the *polh* promoter and large quantities of the foreign protein would be produced. The feasibility of this concept was demonstrated when it was shown that BEVs could be isolated and used to express human  $\beta$ -interferon (Smith *et al.*, 1983b) or *E. coli*  $\beta$ -galactosidase (Pennock *et al.*, 1984) in cultured insect cells.

## B. Producing BEVs

The first step in the original procedure used to produce a BEV is to clone the sequences encoding a protein of interest into a suitable "transfer plasmid". A classic

transfer plasmid contains the *polh* promoter and long upstream and downstream flanking sequences, but lacks some or all of the *polh* open reading frame, which is usually replaced by a convenient cloning site. Once the DNA sequence encoding a protein of interest has been inserted into this site, the recombinant transfer plasmid is purified, mixed with  
5 genomic DNA from wild-type baculovirus, and the mixture is cotransfected into cultured insect cells. Upon entering the cell, the viral DNA will be replicated and wild-type progeny will be produced.

In addition, homologous recombination can occur between the *polh* flanking sequences in the transfer plasmid and the same sequences in the viral DNA. This process, called "allelic replacement", produces recombinant viral DNAs in which the *polh* open  
10 reading frame in the parental virus has been replaced by sequences from the recombinant transfer plasmid encoding the protein of interest. These viral DNAs are replicated and packaged to produce recombinant viral progeny. Allelic replacement of *polh* occurs at a maximum frequency of only about 1% (Smith, *et al.*, 1983a), but this is no problem  
15 because it is relatively easy to distinguish wild-type and recombinant progeny by their plaque phenotypes. The mixture of viruses is simply harvested from the cotransfected cells and resolved in a plaque assay. The wild-type progeny, which retain the polyhedrin gene, produce polyhedron-positive plaques, whereas the recombinant progeny, which lack the polyhedrin gene, produce polyhedron-negative plaques. Once identified, recombinant  
20 viral clones can be further plaque-purified, amplified, and characterized, then large BV stocks can be produced and used to infect cultured insect cells for foreign gene expression and foreign protein production.

### 1. Transfer Plasmids

25 There are many different transfer plasmids that can be used to construct a chimeric gene and insert it into the baculovirus genome by allelic replacement. This section describes the general features of some of these plasmids. Maps and more detailed descriptions are available in several other places, including the primary literature (cited below), technical manuals (Richardson, 1995; King and Possee, 1992; O'Reilly, *et al.*,  
30 1992; Summers and Smith, 1987), and commercial literature and catalogs from various scientific supply houses, including Clontech (Palo Alto), InVitroGen (San Diego),

Novagen (Madison), Pharmingen (San Diego), and Stratagene (La Jolla). Many different transfer plasmids can be purchased from these companies.

5 The first transfer plasmids were designed to produce BEVs in which the *polh* gene had been replaced by a new, chimeric gene consisting of the very late *polh* promoter and the sequence encoding the protein of interest positioned downstream, as described above (Pennock, *et al.*, 1984; Smith, *et al.*, 1983b). These transfer plasmids were constructed before it was clearly determined precisely which sequences from the 5' untranslated region (UTR) of the *polh* gene were needed for optimal levels of *polh* promoter-mediated transcription (Rankin, *et al.*, 1988; Matsuura *et al.*, 1987; Possee and Howard, 1987).  
10 Once this information became available, it was easier to ensure that the transfer plasmid included all of the critical promoter sequences and to decide exactly where to place multiple cloning sites to facilitate subcloning of the foreign coding sequence. The *polh* promoter and multiple cloning site in the transfer plasmid must be flanked by sequences which normally flank the *polh* gene in the viral genome, as these sequences are needed for homologous recombination between the transfer plasmid and the viral DNA. This process  
15 mediates allelic replacement of the *polh* gene, as described above. Transfer plasmids containing the *polh* promoter are still the most widely used tools for the production of BEVs. However, the increased popularity of the BEV system has led to the design and construction of many variations on this basic theme.

20 For example, there are transfer plasmids that can be used to produce BEVs which will express a foreign gene under the control of the very late *p10* promoter. Some of these transfer plasmids contain both the *p10* promoter and *p10* flanking sequences and, after the sequence encoding the protein of interest has been inserted, the resulting plasmid is used to replace the nonessential baculovirus *p10* gene (Vlak *et al.*, 1990). This approach requires  
25 special screening procedures to identify recombinant viruses, as loss of the viral *p10* gene is not accompanied by an easily distinguishable change in plaque phenotype. Usually, this type of transfer plasmid includes a marker gene, such as *E. coli lacZ*, which is incorporated together with the chimeric gene of interest into the recombinant virus genome during allelic replacement.

30 Another approach is to use a hybrid transfer plasmid, in which the *p10* promoter is embedded within *polh* flanking sequences, to construct the chimeric gene and insert it into

the *polh* region of the baculovirus genome (Weyer *et al.*, 1990). This latter approach takes advantage of the simple visual screen that can be used to distinguish between parental (occlusion-positive plaques) and recombinant (occlusion-negative plaques) viruses whenever *polh* is used as the target for allelic replacement. The *p10* promoter has been  
5 used to produce BEVs for foreign protein production (Bozon *et al.*, 1995; Tomita, *et al.*, 1995; van Lier *et al.*, 1994; Roelvink, *et al.*, 1992; Vlak, *et al.*, 1990), but it provides lower levels of foreign gene expression and is used much less frequently than the *polh* promoter for this purpose. The *p10* promoter is more commonly used to construct BEVs for biopesticide applications because allelic replacement of *p10* is one way to produce  
10 recombinants that can express a foreign gene without deleting the *polh* gene (McCutchen *et al.*, 1991; Stewart *et al.*, 1991; Merryweather *et al.*, 1990). This is important because BEVs intended for use as pesticides must be able to produce polyhedra to infect insect larvae naturally in the field.

Other transfer plasmids can be used to construct BEVs that will express foreign  
15 genes under the transcriptional control of alternative promoters, including both viral and cellular promoters. These plasmids typically contain the promoter of choice embedded within *polh* flanking sequences and are used for allelic replacement of the *polh* gene as described above. Baculoviral promoters that have been used most commonly for this purpose include the late *p6.9* (Hill-Perkins and Possee, 1990) and *vp39* (Thiem and Miller,  
20 1990) promoters and the early *etl* (Morris and Miller, 1992) and *iel* (Examples 1-5 below) promoters. Cellular promoters include *Drosophila hsp70* (Vlak, *et al.*, 1990) and *B. mori actin* (Johnson *et al.*, 1992). Transfer plasmids with a hybrid *vp39-polh* promoter (Thiem and Miller, 1990) or tandem *polh-etl* promoters (Xia *et al.*, 1993) also have been described. Except for the last two, none of these promoters are as strong as the *polh*  
25 promoter (Examples 1-5 below; Morris and Miller, 1992; Thiem and Miller, 1990).

Considering that high-level expression is one of the most attractive features of the BEV system, it might seem foolish to use any promoter besides *polh* for baculovirus-mediated foreign gene expression. But, there are some good reasons to do this. BEVs cannot produce all classes of foreign proteins in equal abundance or quality under *polh*  
30 control. Generally, secretory pathway proteins are produced at much lower levels than other types of proteins and some are biologically inactive and/or insoluble when expressed



under *polh* control (Pajot-Augy *et al.*, 1995; Rankl *et al.*, 1994; Arp *et al.*, 1993; Xie *et al.*, 1992; Tsao *et al.*, 1990). This might reflect the adverse effects of baculovirus infection on host cell secretory pathway functions, which have already begun to decay by the start of the very late phase of infection (Murphy *et al.*, 1990; Jarvis and Summers, 1989).  
5 Alternatively, it might reflect saturation of the protein folding and secretory capacity of the host cell due to high-level foreign gene expression, as has been documented in a yeast system (Parekh *et al.*, 1995).

Either way, it has been shown that the *p6.9* (Chazenbalk and Rapoport, 1995; Lawrie *et al.*, 1995; Bonning *et al.*, 1994; Rankl, *et al.*, 1994; Sridhar *et al.*, 1993) and *iel*  
10 (Examples 1-5 below; Jarvis *et al.*, 1990) promoters, which are expressed earlier and produce less mRNA, and even the *p10* promoter (Bozon, *et al.*, 1995), which is expressed only slightly earlier and produces only slightly less mRNA, can sometimes be used to produce larger amounts of biologically active and/or soluble foreign protein than the *polh* promoter. The use of these alternative promoters to produce BEVs that can express  
15 foreign genes earlier in infection also represents a good approach for biopesticide applications, as the main idea is to produce a virus with a new gene that will help it to kill insects or stop their feeding more quickly (Jarvis, *et al.*, 1996; Examples 1-5 below).

Sometimes, it is important to be able to express more than one foreign protein simultaneously to study protein-protein interactions, assemble functional protein  
20 complexes, or reconstruct biochemical pathways. The BEV system is especially useful for this purpose. One approach is to use a mixture of two or more BEVs, each containing one foreign gene of interest, to coinfect host cells (St. Angelo *et al.*, 1987). Theoretically, this approach can be used to vary the ratios of the different proteins being produced. However, a problem with this approach is that it is difficult to obtain a reasonably uniform  
25 population of cells coinfecting with each virus. Another approach is to use transfer plasmids containing multiple promoters to produce a single BEV that can express multiple foreign genes. The first transfer plasmids of this type contained two copies of the *polh* promoter and were used to produce "dual" BEVs that could express two different foreign genes in a single cell (Emery and Bishop, 1987). Later, transfer plasmids were constructed  
30 that contained various combinations of different viral promoters, including the *polh*, *p10*, and *vp39* promoters, and these could be used to produce BEVs capable of expressing up to

five different foreign proteins in the same infected cell (Belyaev *et al.*, 1995; Wang *et al.*, 1991; Weyer and Possee, 1991).

One of the first specialized functions to be built into transfer plasmids was a marker gene that could be used to identify BEVs. The marker was designed to be incorporated along with the gene of interest during allelic replacement. The resulting BEV would express this marker and produce a protein that could be detected with a chromogenic substrate and identify recombinant viral plaques. This was mandatory for the identification of BEVs with allelic replacements in *p10* (Vlak, *et al.*, 1990), but it also facilitated the identification of BEVs with allelic replacements in *polh* (Vialard *et al.*, 1990), because many investigators had trouble seeing the occlusion-negative plaques produced by those recombinants. The first marker used for this purpose was *E. coli lacZ* and its expression was controlled variously by baculovirus *p10*, *iel*, *etl*, or *Drosophila hsp70* promoters. Other markers that have been used for this purpose include luciferase (Oker-Blom *et al.*, 1993) and  $\beta$ -glucuronidase (Bishop *et al.*, 1995).

The sheer diversity of transfer plasmids that have become available, with their diverse array of multiple cloning sites, has greatly simplified the process of subcloning a foreign coding sequence for insertion into the baculovirus genome. Some transfer plasmids include translational initiation signals and can be used to construct chimeric genes encoding fusion proteins. Others lack these signals and are used to construct genes encoding nonfused proteins. Still others can be used either way, depending on where the foreign coding sequence is inserted. Some transfer plasmids also have been streamlined by shortening the flanking sequences to the minimum lengths needed for efficient homologous recombination. This approach has been used to reduce the size of a transfer plasmid by nearly half, which facilitates the subcloning process by leaving more room for the insertion of larger foreign protein coding sequences (Pharmingen and InVitrogen catalogs).

Some of the newest transfer plasmids are designed for ligation-independent cloning of a foreign protein coding sequence to be incorporated into a BEV (Bishop, *et al.*, 1995, Pharmingen catalog). This approach circumvents the need to subclone the sequence of interest into the transfer plasmid and amplify it in *E. coli* prior to cotransfection with viral DNA. Transfer plasmids designed for ligation-independent cloning have long single-

stranded overhangs that can anneal to complementary single-stranded overhangs on a PCR™ amplification product encoding the foreign protein of interest. The annealed products are mixed with viral DNA and the mixture is used to cotransfect insect cells for production of BEVs by allelic replacement. This ligation-independent cloning approach is also called "direct" cloning. However, a transfer plasmid serves as an intermediate, which differentiates this approach from truly direct cloning by ligation of a DNA fragment encoding a protein of interest with restriction-digested viral DNA (Lu and Miller, 1996; Ernst *et al.*, 1994; and below).

One of the biggest challenges faced in using any expression system is purification of the overexpressed heterologous protein. This has led to the development of various generic protein purification methods (Ford *et al.*, 1991). The usual approach is to design the expression vector to include a short nucleotide sequence which encodes a short amino acid sequence that can be used as an affinity "tag" to purify any protein. The sequence encoding the protein of interest is inserted into the vector in such a way that it will be expressed as a fusion protein with the affinity tag on its N- or C-terminus. Then, the fusion protein can be solubilized and affinity-purified with a reagent that specifically recognizes and binds to the tag. A problem with this approach is that the affinity tag sometimes interferes with the biological activities of the protein of interest. Hence, some vectors also include sequences which encode a short amino acid sequence between the affinity tag and the protein of interest that can be specifically cleaved by treating the purified fusion protein with a protease.

A variety of different transfer plasmids have been constructed and used to isolate BEVs that produce affinity-tagged proteins. Many different affinity tags have been used in the BEV system. Various affinity tags can be used effectively in this system to purify recombinant proteins to varying degrees, ranging from about 80% to homogeneity. Also, antibodies against some affinity tags can be used to monitor the expression and localization of foreign proteins in BEV-infected insect cells by immunocytochemical techniques. This idea has been taken one step further with the development of transfer plasmids that can be used to produce BEVs which encode fusion proteins containing a naturally fluorescent protein, such as green fluorescent protein (Pharmingen catalog).

- 38 -

Fluorescent protein tags permit direct visualization of the fusion protein in unfixed BEV-infected cells with a fluorescence microscope.

Some transfer plasmids include sequences that encode signal peptides which can mediate secretion of a foreign protein from BEV-infected insect cells. The coding sequence of interest is inserted downstream and in-frame and the resulting construct encodes the protein of interest with a cleavable N-terminal signal peptide. The signal peptides used to direct secretion are sometimes derived from insect glycoproteins, including honeybee prepromellitin (Tessier *et al.*, 1991) and baculovirus *gp64* and *egt* (Murphy *et al.*, 1993) and it has been found that insect-derived signal peptides can increase the efficiency of secretion of some recombinant proteins from BEV-infected insect cells. However, mammalian signal peptides also can be used, sometimes with better success, to direct secretion of recombinant proteins in this system (Mroczkowski *et al.*, 1994; Jarvis *et al.*, 1993; Andersons *et al.*, 1991). Some transfer plasmids provide both an N-terminal signal peptide and a C-terminal affinity tag to facilitate purification of recombinant proteins from the growth medium (Kuhn and Zipfel, 1995).

Additionally, some transfer plasmids can be used to produce BEVs that will express a foreign protein which can be incorporated into the envelope of recombinant BV particles (Boublik *et al.*, 1995). These BEVs are eukaryotic versions of bacteriophage "display" vectors, which have been used to select rare recombinants from mixed virus populations by using ligands that bind to the protein of interest (Winter *et al.*, 1994). The transfer vectors contain the sequence encoding *gp64*, the major BV envelope glycoprotein embedded within *polh* flanking sequences. The sequence encoding the protein of interest is inserted between the sequences encoding the signal peptide and mature portions of *gp64*. The resulting plasmid is used for allelic replacement of *polh* to produce a BEV that will express the protein of interest as a fusion protein which can be incorporated into the BV envelope and "displayed" for interactions with specific ligands or antibodies.

## 2. Sequences Encoding Foreign Proteins

The promoter in the transfer plasmid is only one component of the chimeric gene that must be assembled and inserted into the baculovirus genome in order to produce a BEV by allelic replacement. Another requirement is the sequence encoding the protein of

interest, which could be either a cDNA or genomic DNA sequence. The vast majority of BEVs contain cDNA inserts, but there are a few reports of BEVs that contain and can express foreign DNA sequences containing introns (Davrinche *et al.*, 1993; Iatrou *et al.*, 1989; Jeang *et al.*, 1987) and at least one baculovirus gene has introns that are removed by splicing in infected insect cells (Kovacs *et al.*, 1991; Chisholm and Henner, 1988). However, there is evidence that RNA splicing is very inefficient at late times of baculovirus infection (Kovacs, *et al.*, 1991) and it has been reported that a human papillomavirus gene failed to be spliced when expressed in the BEV system (Park *et al.*, 1993). Thus, it is probably prudent to use cDNAs to construct BEVs.

Publication of the entire AcMNPV nucleotide sequence was accompanied by the identification of 337 open reading frames of at least 150 bp in length (Ayres, *et al.*, 1994). Among these, 154 were included in a selected set deemed most likely to be expressed during baculovirus infection. Analysis of the predicted translational initiation sites in this selected set of open reading frames revealed that 41% did not conform to Kozak's rules (1986). This might indicate that biosynthesis of some viral proteins is down-regulated by the absence of an optimal translational initiation site. Or, it might indicate that Kozak's rules do not accurately define the signals required for optimal translational initiation in baculovirus-infected insect cells. The latter interpretation is supported by experimental evidence which showed that Kozak's rules could be broken with no reduction in the levels of foreign protein produced by a BEV (Hills and Crane-Robinson, 1995).

Furthermore, three different proteins were expressed at higher levels by BEVs when fused to a bacterial leader sequence that had a pyrimidine instead of a purine at position -3 relative to the initiation codon (Peakman *et al.*, 1992a). A putative baculovirus translational initiation consensus sequence has been elucidated by computer analysis of 23 viral genes and this sequence includes a purine at position -3 (Ranjan and Hasnain, 1995). However, considering the experimental observations cited above, it is difficult to know how accurately this consensus sequence defines a translational initiation site in the BEV system. Overall, it seems that the rules governing translational initiation in this system remain unclear. Similarly, analysis of codon usage in the selected set of AcMNPV open reading frames revealed some bias, but it is not clear whether this influences the levels of foreign protein production in the BEV system (Ayres, *et al.*, 1994).

One clear finding is that AUU can sometimes serve as an inefficient translational initiation codon in baculovirus-infected insect cells (Beames *et al.*, 1991). This was discovered when a BEV was used to express hepatitis B virus core protein and about one-fifth of the end-product had a *polh* amino acid sequence fused to its N-terminus. The BEV had been produced with a transfer plasmid in which the polyhedrin ATG was changed to ATT and the sequence encoding the core protein, which had its own ATG, was inserted downstream and in-frame. It was discovered that the fusion protein was produced as a result of translational initiation at the upstream ATT (AUU in the transcript). This problem might be related to the fact that the AUU was located in precisely the same position formerly occupied by the *polh* AUG and, in any case, it can be avoided simply by cloning coding sequences out-of-frame with respect to this upstream ATT or by using a transfer plasmid that does not have the ATT in this position.

The chimeric gene in a BEV also must have appropriate signals for transcriptional termination and RNA processing. These signals might be included in the 3' untranslated region of the foreign sequence inserted into the transfer plasmid. Or, they can be provided by the transfer plasmid itself, which includes the 3' untranslated region of the *polh* gene. mRNA processing signals have not been extensively analyzed in the baculovirus system, but several baculovirus genes, including *polh*, contain the 3' motif (AAUAAA) that serves as a polyadenylation signal in higher eukaryotes (Westwood *et al.*, 1993). As in higher eukaryotes, this motif alone is insufficient for mRNA processing in baculovirus-infected insect cells. Also, heterologous mRNA processing signals from the SV40 early region or a rabbit  $\beta$ -globin gene have been included in some transfer plasmids and are functional in the BEV system (Westwood, *et al.*, 1993). These findings suggest that baculovirus-infected insect cells and higher eukaryotes have the same or similar mechanisms for transcriptional termination and mRNA processing.

### 3. Viral DNAs for Allelic Replacement

Besides the transfer plasmid, the other critical component in an allelic replacement reaction is baculoviral DNA. Baculoviral DNA is usually isolated from BV particles partially purified from the extracellular medium of wild-type baculovirus-infected insect cells, as described elsewhere (Richardson, 1995; O'Reilly, *et al.*, 1992; Summers and

- 41 -

Smith, 1987). Historically, a major problem with using wild-type viral DNA to isolate BEVs was that the frequency of allelic replacement is low and many investigators had trouble finding recombinant virus plaques among the high background of parental virus plaques. This problem was addressed by incorporating marker genes into transfer plasmids, as described above. However, this approach did not reduce parental virus background.

This problem was solved by the development of linearizable viral DNAs that could be used as the targets for allelic replacement. The first linearizable viral DNA was created by constructing an occlusion-negative recombinant virus with a unique Bsu36I site in the *polh* region (Kitts *et al.*, 1990). The circular genomic DNA from this recombinant could be linearized by digestion with Bsu36I, which significantly reduced its infectivity. Thus, when linearized viral DNA is mixed with a transfer plasmid and used to cotransfect insect cells, the recircularized recombinant viral DNAs produced by allelic replacement have a strong replicative advantage over the linear parental DNA molecules. The net result is an increase in the maximum efficiency of BEV production from about 1% to about 30%. An occlusion-positive linearizable viral DNA has been described that provides the same high efficiency of BEV production while preserving the ability to identify recombinants by using the classic visual screen (Hartig *et al.*, 1992). There also is a viral DNA that can be linearized at a unique Bsu36I site in the *p10* region and used for high efficiency production of BEVs with allelic replacements in that region (Martens *et al.*, 1995).

The development of linearizable viral DNAs was followed by the development of a viral DNA that can provide even higher efficiencies of BEV production (Kitts and Possee, 1993). This viral DNA has an *E. coli lacZ* insert in the *polh* region and Bsu36I sites in the two flanking genes on each side. Therefore, Bsu36I digestion actually deletes a fragment of the viral DNA, including part of the ORF 1629 gene located downstream of *polh*, which encodes an essential nucleocapsid-associated phosphoprotein (Vialard and Richardson, 1993). This effectively inactivates the viral DNA, but it can be rescued by homologous recombination with the transfer plasmid, which simultaneously introduces the coding sequence of interest, restores ORF 1629, and recircularizes the viral genome. The efficiency of BEV production with these Bsu36I-gapped viral DNAs is routinely over 90%.

- 42 -

Another type of baculovirus DNA that is currently being developed as a target for allelic replacement is one in which various "auxiliary" genes have been deleted (Bishop, *et al.*, 1995). These genes encode proteins that are needed for baculoviruses to infect insect larvae, but are nonessential for the replication of these viruses in cultured insect cells. The idea behind the development of these viral DNAs is that expression of the auxiliary genes might interfere with the production of a protein of interest by a BEV. For example, it would be a good idea to delete the baculoviral cathepsin-like protease gene, as this protease could degrade some BEV-expressed recombinant proteins. Similarly, deletion of the viral protein phosphatase gene (Kim and Weaver, 1993) might improve the quality of phosphoproteins produced in the BEV system.

#### 4. Producing BEVs by Allelic Replacement

After being subcloned into an appropriate transfer plasmid or annealed to a ligation-independent transfer plasmid, a sequence encoding a protein of interest is incorporated into the baculovirus genome by mixing it with viral DNA and transferring the mixture into cultured insect cells, where allelic replacement can occur by homologous recombination, as discussed above. The production of BEVs by the allelic replacement method relies upon the homology between sequences flanking the *polh* (or *p10*) genes in the viral DNA and the same sequences flanking the gene of interest in the transfer plasmid. The frequency with which BEVs are produced by this method is determined by the choice of target viral DNA, as described above, and selectable markers are not usually used. However, some selectable markers have been used to increase the frequency of BEV production, including negative selection of parental viruses containing the herpes simplex virus thymidine kinase gene (Godeau *et al.*, 1992) and positive selection of recombinant viruses containing neomycin resistance or *p35* genes (Lerch and Friesen, 1993).

#### 5. Isolating, Identifying, and Characterizing BEVs

The most common way to resolve the mixture of parental and recombinant baculovirus progeny obtained from cotransfected cells is by using a conventional viral plaque assay (Summers and Smith, 1987). However, limiting dilution (Reed and Muench, 1938) and fluorescence-activated cell sorting (Peng *et al.*, 1993) also have been used for



this purpose. The classic approach used to identify BEVs in viral plaque assays is direct visualization of occlusion-negative plaques, as described above. This screen can be used only if the parental virus had an intact *polh* gene and the transfer plasmid was designed to replace that gene. Other ways to identify BEVs in plaque assays are to do plaque-lifts with nucleic acid or antibody probes (Capone, 1989; Summers and Smith, 1987) or to rely on visualization of marker gene that was introduced during allelic replacement, as described above.

Conversely, BEVs produced using Bsu36I-gapped viral DNA can be tentatively identified by the loss of the *lacZ* marker in the parental viral DNA (Kitts and Possee, 1993). When limiting dilution is used as the isolation method, BEVs are usually identified by using nucleic acid or antibody probes in dot-blot formats (Manns and Grosse, 1991; Pen *et al.*, 1989; Summers and Smith, 1987). Finally, BEVs can be identified by direct sequencing (Slightom and Sieu, 1992; Wang and Fraser, 1991) or PCR<sup>TM</sup> analysis (Sisk *et al.*, 1992; Malitschek and Schartl, 1991; Webb *et al.*, 1991) of viral DNAs.

After a BEV has been isolated and identified by one of the above methods, it can be amplified in insect cells, titered, and used to produce the foreign protein of interest by infecting a fresh cell culture. However, it is important to carefully characterize BEVs before proceeding with foreign gene expression, as there are some traps in the isolation and screening process. The most serious trap is that recombinants are produced far more frequently by single crossovers than by allelic replacement, which requires a double crossover between the viral DNA and transfer vector (O'Reilly, *et al.*, 1992). Single-crossover recombinants contain the entire transfer plasmid at a random site in the viral genome and are genetically unstable. Depending on which screening method was used, single crossover recombinants can be mistakenly identified as BEVs in which the target gene in the parental viral DNA has been properly replaced by the gene of interest. True allelic replacement must be confirmed by verifying the location of the inserted gene in the BEV genome and/or the absence of the gene it was intended to replace. This can be done by using any of several different methods to analyze the viral DNA, including restriction mapping, Southern blotting, or PCR<sup>TM</sup>. Using linearized or gapped viral DNAs for BEV production minimizes the problem of single crossover recombination because double crossover recombination at the appropriate site is necessary to regenerate a circular viral

DNA molecule that can efficiently replicate. However, single crossover recombinants can be obtained if digestion of the viral DNA is incomplete.

Standard methods of protein analysis can be used to assess foreign protein production by BEV-infected insect cells. If expression levels are high, as expected, foreign proteins can be identified in electrophoretic profiles of total lysates prepared at late times after infection. In the best cases, this can be done simply by staining protein gels with Coomassie Brilliant Blue. More sensitive methods can be used to detect proteins produced at lower levels, including electrophoretic analysis of total protein lysates from radiolabeled cells, western blotting, radiolabeling and immunoprecipitation, or specific activity assays.

#### 6. Alternative Ways to Produce BEVs

The development of new transfer plasmids and linearizable and gappable viral DNAs for the production of BEVs by allelic replacement significantly increased the rate and efficiency and simplified the process of BEV production. Alternatives to the allelic replacement approach also have been developed to facilitate BEV production.

The first alternative method described for producing BEVs involved homologous recombination and selection of recombinant viral DNAs in yeast (Patel *et al.*, 1992). A recombinant baculovirus was constructed with a yeast autonomous replication sequence, centromere, and selectable marker in the *polh* region. This viral DNA was introduced into yeast, where it replicates as a stable, low copy number episome. A second marker, SUP4-o, which can be selected either for or against, was then added to produce the viral DNA molecule that serves as the target for homologous recombination. Recombination occurs when yeast cells containing this viral DNA are transfected with a transfer plasmid designed to replace the SUP4-o marker with a sequence encoding the foreign protein of interest. Yeast transformants are counterselected for the absence of SUP4-o and used as a source of the recombinant viral DNA, which can be isolated and transfected onto insect cells to produce BEVs.

Another alternative method that can be used to produce BEVs is enzymatic recombination with the Cre-lox system (Peakman *et al.*, 1992b). These investigators constructed a recombinant baculovirus and transfer plasmid with LoxP sites that can

mediate site-specific *in vitro* recombination by purified Cre recombinase. This method produces recombinant viral DNAs at a frequency of up to 50% and BEVs can be isolated by cotransfecting insect cells and resolving the recombinant and parental progeny by plaque assay. BEVs can be identified by the presence of a *lacZ* marker donated by the transfer plasmid. This approach provided a way to produce BEVs with high frequency before gapped viral DNAs became available. It also circumvents the single crossover problem associated with conventional allelic replacements *in vivo*.

Site-specific transposition of a foreign coding sequence into the baculovirus genome is another method that can be used for highly efficient and rapid production of BEVs (Luckow *et al.*, 1993). This approach requires the use of a "bacmid", which is a recombinant baculoviral DNA containing a mini-F replicon, selectable marker, and Tn7 transposition site. Thus, a bacmid can replicate autonomously in *E. coli* and strains harboring the bacmid and a helper plasmid that encodes the Tn7 transposase functions can be used to produce BEVs. This is done by introducing a donor plasmid containing the desired cDNA sequence and a second selectable marker positioned between the left and right arms of Tn7. The transposition functions provided by the helper plasmid will move the cDNA and selectable marker from the donor plasmid to the bacmid. This produces a recombinant bacmid that can be selected, isolated, and transfected onto cultured insect cells to produce BEVs. The bacmid system is available commercially from Life Technologies (Gaithersburg, MD). In addition, a modified bacmid system that uses an *E. coli* host strain with an occupied Tn7 attachment site and a temperature-sensitive selection step has been described (Leusch *et al.*, 1995).

Finally, baculovirus DNAs designed for the direct insertion of a foreign gene into unique cloning sites have been described (Lu and Miller, 1996; Ernst, *et al.*, 1994). Due to their large size (~130 Kb), it is difficult to construct viral DNAs with unique restriction sites and to efficiently ligate linearized viral DNA with a foreign DNA fragment *in vitro*. However, due to the replicative advantage enjoyed by the recircularized viral DNA, direct cloning can be used successfully for highly efficient production of BEVs. Direct cloning of cDNAs into baculovirus vectors containing an appropriate promoter upstream of the insertion site has been proposed as a way to produce baculovirus-based cDNA expression libraries (Lu and Miller, 1996).

## C. Using BEVs

### 1. Expression Levels

The ability to produce foreign proteins at exceptionally high levels is one of the  
5 hallmark features of the BEV system. These high production levels mainly reflect the  
ability of the transcriptional complex and *polh* promoter to produce large pools of mRNA  
during the very late phase of infection. Thus, BEVs that express a foreign coding  
sequence under the control of a different promoter will usually provide lower production  
levels. The production levels provided by *polh*-based BEVs are usually measured in the  
10 hundreds of mgs of recombinant protein per liter of infected cells (about  $1 \times 10^9$  cells).  
However, this crude generalization must be immediately qualified with a reminder that  
production levels vary widely from protein to protein. Secretory pathway proteins are  
produced at lower levels, often only 1 to 5 mg/liter of infected cells. The block to high-  
level production of secretory pathway proteins is probably post-transcriptional, as BEVs  
15 encoding these proteins can produce large amounts of the foreign mRNA (Jarvis, *et al.*,  
1993). However, the nature of this block is unknown. Possibilities include saturation of  
secretory pathway functions, misfolding of newly-synthesized proteins, and adverse  
effects of baculovirus infection (Jarvis, *et al.*, 1993; Jarvis and Summers, 1989). It is  
unlikely that high-level production of all secretory pathway proteins is blocked at one key  
20 step, however, because this system can produce some secretory pathway proteins at high  
levels. Finally, even though they produce less mRNA than the *polh* promoter, alternative  
promoters can sometimes produce larger amounts of biologically active secretory pathway  
proteins, as discussed above.

### 2. Hosts

Besides the protein to protein variation, production levels in the BEV system  
depend on the host being used (Hink *et al.*, 1991). Historically, the most widely used  
hosts were the established insect cell lines IPLB-Sf21-AE ("Sf21"), originally derived  
from *Spodoptera frugiperda* ovaries (Vaughn *et al.*, 1977), and its clonal derivative, Sf9  
30 (Summers and Smith, 1987). However, in 1992 it was reported that BTI-TN-5B1-4, an  
insect cell line derived from *Trichoplusia ni* eggs, provided higher levels of foreign protein

production (Wickham *et al.*, 1992). Subsequent studies on a larger sample of recombinant proteins generally supported this claim. As a result, BTI-TN-5B1-4 cells, more commonly known as "High Five<sup>®</sup>" cells (a tradename of InVitroGen), have become another widely-used host for BEVs. Recent data suggest that subclones of yet another established insect cell line, BTI-EaA, derived from *Estigmene acrea* (Granados and Naughton, 1975), can provide more extensive N-glycosylation of foreign glycoproteins expressed by BEVs (Ogonah *et al.*, 1996). Thus, in addition to providing different levels of foreign protein production, different cell lines also can provide different levels of processing in the BEV system.

10 Insect cells must be perfectly healthy to provide optimal levels of BEV-mediated foreign protein production. This requires high quality growth media, routine subculturing, and careful monitoring of cell doubling times and viability's. Insect cell growth media are available from several different companies and serum-free media have been developed (Maiorella *et al.*, 1988). Insect cell lines may be grown as monolayer cultures in T-flasks, 15 as suspension cultures in shake flasks or spinner flasks, or as large-scale cultures in stirred tank or airlift bioreactors (Shuler *et al.*, 1995; Weiss *et al.*, 1995a; Weiss *et al.*, 1995b). The development of scaleup methods was challenging because insect cells have an unusually high oxygen demand and large cultures must be aerated, but aeration can damage the cells because they are extremely sensitive to shear stress. This problem was 20 solved when it was found that a nonionic surfactant, Pluronic<sup>®</sup> F68, could protect insect cells from shear stress (Maiorella, *et al.*, 1988; Murhammer and Goochee, 1988). The physical and nutritive conditions needed for optimal foreign protein production by large-scale insect cell cultures have been studied extensively (Shuler *et al.*, 1995; Taticek *et al.*, 1994; Tramper *et al.*, 1993). Among many other interesting results, it has been found that 25 perfusion techniques can be used to obtain extremely high-density cultures ( $>5 \times 10^7$  cells/ml) that can produce larger amounts of recombinant protein (Deutschmann and Jager, 1994) and that oxygen demand rises even higher after baculovirus infection (Wong *et al.*, 1994).

30 Two disadvantages associated with the use of established insect cell lines as hosts for foreign protein production by BEVs are that animal cell culture media are expensive and individual insect cell lines might not have all the protein processing capabilities found

in higher eukaryotes (see below). Sometimes, these problems can be circumvented by using insect larvae as an alternative host. BmNPV has been extensively developed for this purpose and is commonly used as a BEV to express foreign proteins in silkworm larvae (Maeda, 1989; Maeda *et al.*, 1985). Methods for rearing and infecting larvae have been described (Choudary *et al.*, 1995; O'Reilly, *et al.*, 1992). However, most investigators use established cell lines this method is more familiar and it is easier to purify recombinant proteins from cultured cells than from insect larvae. Moreover, although larvae are usually cheaper to cultivate than established insect cell lines, their use does not always solve protein processing problems (Pajot-Augy, *et al.*, 1995).

### 3. Protein Processing

The other hallmark feature of the BEV system is its ability to process proteins. Biosynthesis of many eukaryotic proteins includes co- and/or post-translational processing, which can be critical for protein solubility and function, and insect cells have most of the protein processing pathways associated with higher eukaryotes. In fact, development of the BEV system has contributed immensely to the knowledge of protein processing in insect cells. Most reports of foreign protein production in the BEV system include structural analyses of the end-product and its covalent chemical modifications. These are often simple qualitative analyses designed to determine if a specific modification took place and whether there are gross differences in the structures of the recombinant and native proteins (*e.g.* differences in electrophoretic mobility). However, some studies include more detailed structural analyses, which have provided extremely valuable information on protein processing pathways in insect cells.

This information comes with a caveat, though, which is that it must be applied specifically to the protein processing pathway of a specific baculovirus-infected host. This is important because baculovirus infection probably alters cellular protein processing pathways in various ways (Velardo *et al.*, 1993; Davidson *et al.*, 1991; Murphy, *et al.*, 1990; Jarvis and Summers, 1989) and the specific protein processing capabilities of different hosts, including different insect cell lines, can be quite different (Ogonah, *et al.*, 1996; Kuroda *et al.*, 1989). The chemical modifications found on many different recombinant proteins have been catalogued elsewhere (Luckow, 1991; Luckow and

Summers, 1988). A few selected results that have provided the most definitive information are summarized below.

**a. Proteolytic Cleavages**

5 Many secretory pathway proteins have short, N-terminal signal peptides that are proteolytically cleaved during biosynthesis. Signal peptide cleavage has been carefully evaluated by directly sequencing the N-termini of many different foreign proteins produced in the BEV system. The results indicate that insect cells can accurately remove native signal peptides of plant or animal secretory pathway proteins. Insect cells also can  
10 accurately cleave heterologous signal peptides that are encoded by some transfer plasmids and used to direct secretion, as discussed above. Thus, insect cells clearly have secretory signal peptide recognition and cleavage machinery. However, the relationship between this machinery and that of other eukaryotes remains unclear because some foreign signal peptides are nonfunctional in insect cells (Pajot-Augy, *et al.*, 1995) and insect cell-derived  
15 signal peptides sometimes, but not always provide better secretion, as discussed above.

Many eukaryotic proteins also have prosequences, which are usually short amino acids sequences that need to be removed to convert a protein to its biologically active form. Prosequences may or may not be accurately and efficiently cleaved from foreign proteins produced in the BEV system. For example, the N-terminal prosequence of human  
20 tissue plasminogen activator was efficiently cleaved (Furlong *et al.*, 1988), but the N-terminal prosequences of other proteins, including a frog alpha-amidating enzyme (Suzuki *et al.*, 1990), were not. The C-terminal prosequence of the gastrin-releasing peptide precursor was cleaved at the proper site, but also at several other sites (Lebacq-Verheyden *et al.*, 1988). These problems probably reflect limiting levels of the appropriate proteases  
25 in baculovirus-infected insect cells, as well as differences in their substrate specificities.

Proteolytic cleavages at internal dibasic amino acid sites occur inefficiently in cultured insect cells. For example, influenza virus hemagglutinin (Kuroda *et al.*, 1986) and HIV gp160 (Hu *et al.*, 1987) were cleaved slowly and/or inefficiently in the BEV system. This suggests that insect cell lines have limiting amounts of the kex-2 family of  
30 processing proteases needed for these internal cleavages. This conclusion is supported by the findings that hemagglutinin was cleaved more efficiently in insect larvae (Kuroda,

*et al.*, 1989) and gp160 was cleaved more efficiently when furin is coexpressed in this system (Yamshchikov *et al.*, 1995).

### b. Glycosylation

5 Many eukaryotic proteins are modified by the covalent addition of carbohydrate side-chains. There are three well-defined protein glycosylation pathways in eukaryotic cells: N-glycosylation, O-glycosylation, and addition of O-linked N-acetylglucosamine (O-GlcNAc; Montreuil, *et al.*, 1995; Hart, 1992). Insect cells have all of these pathways, but they are not necessarily the same as those found in higher eukaryotes (Marz *et al.*,  
10 1995).

N-glycosylation begins with cotranslational addition of a preassembled oligosaccharide precursor, Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub>, to a nascent polypeptide chain (Kornfeld and Kornfeld, 1985). The glucose residues are removed by glucosidases I and II to produce a "high mannose" side chain, which can be the finished end-product. In  
15 mammalian cells, however, high mannose side chains can be converted to "complex" structures. This requires class I  $\alpha$ -mannosidases, which remove the  $\alpha$ -1,2-linked mannose residues to produce Man<sub>5</sub>GlcNAc<sub>2</sub>, GlcNAc transferase I, which adds a GlcNAc residue to produce GlcNAcMan<sub>5</sub>GlcNAc<sub>2</sub>, and  $\alpha$ -mannosidase II, which removes two mannose residues to produce GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub>. This key intermediate is then elongated by  
20 glycosyltransferases that add GlcNAc, galactose, fucose, and sialic acid residues to complete the complex side chain.

The overall conclusion from most structural data on N-linked oligosaccharides from glycoproteins produced in insect cells, together with biochemical data on the processing activities of these cells, is that the insect cell N-glycosylation pathway is a  
25 truncated version of the mammalian pathway (Jarvis and Finn, 1995; Marz, *et al.*, 1995; and references therein). Insect cells clearly can add N-linked precursors to newly-synthesized proteins and convert them to trimmed and fucosylated structures. But, these cells usually do not elongate the side-chains further to produce complex structures. Interestingly, insect cells have GlcNAc transferase I and II activities (Altmann *et al.*, 1993;  
30 Velardo, *et al.*, 1993), indicating that they should be able to add GlcNAc residues to the



trimmed structures. This idea is supported by the finding that some glycoproteins produced in insect cells have N-linked side chains consisting of GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub>.

It has been proposed that GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub> is a transient intermediate needed for fucosylation and that the terminal GlcNAc is subsequently removed to produce the fucosylated Man<sub>3</sub>GlcNAc<sub>2</sub> structure seen on many insect cell-derived glycoproteins. This possibility is supported by the discovery that some insect cells contain a membrane-bound N-acetylglucosaminidase activity (Altmann *et al.*, 1995). Alternatively, if they have the requisite glycosyltransferases, insect cells could convert GlcNAcMan<sub>3</sub>GlcNAc<sub>2</sub> to complex structures with penultimate galactose and terminal sialic acids, like those produced by mammalian cells. This possibility is supported by structural data on two foreign glycoproteins produced in BEV-infected insect cells which showed that they had N-linked side-chains with terminal galactose (Ogonah, *et al.*, 1996) or sialic acid (Davidson *et al.*, 1990).

It has been proposed that the synthesis of complex N-linked oligosaccharide side chains by insect cells requires induction of cellular processing enzymes resulting from baculovirus infection (Velardo, *et al.*, 1993; Davidson, *et al.*, 1991). However, the total glycopeptide profiles of uninfected and infected Sf9 cells are similar (Kretzschmar *et al.*, 1994) and it is generally thought that baculoviruses turn cellular gene expression off (Ooi and Miller, 1988). Another proposal is that only a select few recombinant glycoproteins can acquire complex N-linked side-chains due to special structural properties which make them excellent substrates for extremely low levels of glycosyltransferase activities or poor substrates for the processing N-acetylglucosaminidase in baculovirus-infected insect cells (Jarvis and Finn, 1995).

Although they might have different N-linked oligosaccharide side-chains, most foreign glycoproteins produced in the BEV system are biologically active and antigenically authentic (Luckow and Summers, 1988). However, it has been shown that a recombinant human glycoprotein with insect cell-derived N-linked glycans is cleared more rapidly from the mammalian circulatory system (Sareneva *et al.*, 1993). Another problem with N-glycosylation in the BEV system is that it can be inefficient, particularly at later times of infection, and the nonprocessed subpopulation of the protein of interest is often insoluble and/or inactive (Jarvis, *et al.*, 1996; Murphy, *et al.*, 1990).

- 52 -

O-glycosylation occurs in the Golgi apparatus and results in the post-translational addition of relatively small glycans O-linked through N-acetylgalactosamine (GalNAc) to serine or threonine (Montreuil, *et al.*, 1995). Structural analyses of recombinant O-glycosylated proteins produced in the BEV system reveal that the major O-linked side-chain consists of just the monosaccharide, GalNAc (Marz, *et al.*, 1995). A subpopulation of these proteins have O-linked Gal-GalNAc, but the sialylated Gal-GalNAc trisaccharides produced by mammalian cells have not been detected. Further analysis showed that various insect cell lines have comparable levels of UDP-GalNAc:polypeptide GalNAc transferase activity, but different levels of UDP-Gal:GalNAc  $\beta$ -1,3 galactosyltransferase activity (Thompson *et al.*, 1990). Sf9 cells have the lowest levels of the latter activity, which probably explains why GalNAc is the major O-linked side-chain produced by these cells. Overall, the O-glycosylation pathway in baculovirus-infected insect cells appears to be incomplete, due to the absence of sialyltransferases, and inefficient, due to limiting levels of transferase activities.

Many proteins are post-translationally glycosylated by a cytoplasmic enzyme which adds a single GlcNAc *via* O-linkage to serine or threonine residues (Hart, 1992). This process is reversible and probably regulates the functions of many nuclear and cytosolic proteins. The BEV system clearly can add O-GlcNAc to foreign proteins, as demonstrated for mammalian keratins (Ku and Omary, 1994), nucleoporins (Bailer *et al.*, 1995), and c-myc (Chou *et al.*, 1995), among others. However, the addition of O-GlcNAc to one keratin was less efficient in this system than in mammalian cells.

### c. Phosphorylation

Phosphorylation is another reversible covalent chemical modification that can regulate protein function. Phosphorylation of many different foreign proteins has been documented in the BEV system. The more detailed studies have led to the general conclusion that foreign phosphoproteins can be accurately phosphorylated in this system, but phosphorylation of specific sites is sometimes inefficient. For example, the same sites were phosphorylated on SV40 large T-antigen produced in SV40-infected monkey or BEV-infected insect cells, but certain serine residues recognized by nuclear kinases were relatively underphosphorylated in insect cells (Hoss *et al.*, 1990). Considering that T-

antigen is localized in the nucleus of BEV-infected insect cells, it appeared that the levels of these kinases might be too low to process all of the T-antigen being produced by these cells. However, another factor to consider is that baculoviruses encode a protein phosphatase and kinase (Ayres, *et al.*, 1994), which could alter the structures of recombinant phosphoproteins in unexpected ways. In fact, one recent study concluded that underphosphorylation of recombinant proteins in the BEV system may result from unusually high phosphatase activities rather than saturation of kinases with recombinant substrate (Fuchs *et al.*, 1995). Another study showed that recombinant kinases involved in cellular signaling were activated by site-specific phosphorylation in the absence of kinases which lie upstream in the signaling pathway, probably by baculovirus-encoded or -induced kinase activity (Kozma *et al.*, 1993). Finally, it is worth mentioning that various growth factor receptors expressed in the BEV system are accurately tyrosine phosphorylated, as this has led people to use this system to express multiple proteins that functionally reconstitute cellular signaling pathways (Agarwal *et al.*, 1995).

#### d. Other Covalent Chemical Modifications

**Acylation.** Many eukaryotic proteins are modified by the addition of lipid side-chains, including myristate, palmitate, isoprenoids, and glycosylphosphatidylinositols (GPIs). Studies of various foreign proteins have shown that each of these lipid modifications can occur in BEV-infected insect cells. Myristylation is dependent on protein synthesis, occurs at the expected sites, and can produce side-chains with the expected structures, as shown by site-directed mutagenesis, hydroxylamine resistance, and direct structural analyses (Risinger *et al.*, 1992; Delchambre *et al.*, 1989). Palmitylation is independent of protein synthesis and can produce structurally authentic, hydroxylamine-sensitive side-chains, but it can be quite inefficient in BEV-infected insect cells (Veit *et al.*, 1994; Page *et al.*, 1989). One study showed that palmitylation is sensitive to pharmacological regulation, suggesting that the insect and mammalian cell pathways are similar (Mouillac *et al.*, 1992). This conclusion is supported by the finding that palmitylation of some recombinant proteins produced in the BEV system is dependent upon prior isoprenylation, as in higher eukaryotes (Lowe *et al.*, 1992). Isoprenylation is inefficient in BEV-infected insect cells, but occurs at the same recognition sites and

produces the same side-chains, suggesting that prenyltransferase functions are conserved in insect cells and higher eukaryotes (Kalman *et al.*, 1995; Buss *et al.*, 1991). Finally, studies on several recombinant proteins, including human CD59 antigen (Davies and Morgan, 1993), have shown that BEV-infected insect cells can produce GPI anchors. Like many other types of protein processing provided by this system, GPI addition was inefficient, and large subpopulations of these products were unanchored and secreted into the extracellular growth medium.

**N-terminal acetylation.** N-terminal protein modifications are often a nuisance in protein sequencing projects, but N-acetylation is sometimes required for protein function. The BEV system can produce N-acetylated proteins and this system was used to show that N-acetylation is required for the function of alpha tropomyosin (Urbancikova and Hitchcock-DeGregori, 1994). Another N-terminal modification that can occur in the BEV system is removal of an N-terminal methionine, followed by acetylation of the formerly penultimate alanine (Han *et al.*, 1995) or serine (Becker *et al.*, 1994).

**C-terminal methylation.** About half of the Kirsten-ras p21 protein produced in the BEV system was modified by C-terminal methylation, as well as isoprenylation (Lowe *et al.*, 1991).

**Alpha-amidation.** Alpha-amidation is one of the few covalent chemical modifications that does not occur in BEV-infected Sf9 (Lebacq-Verheyden, *et al.*, 1988) or other insect cell lines, including High Five (Vakharia *et al.*, 1995). This covalent chemical modification results from a complex, multistep pathway which begins with proteolytic cleavage of a C-terminal prosequence, followed by the removal of additional amino acids to produce a C-terminal glycine. The glycine residue is then hydroxylated and amidated by two distinct activities. The C-terminal prosequence can be removed in BEV-infected insect cells, but alpha-amidation does not occur, suggesting that these cells lack a subsequent step(s) in this processing pathway. By contrast, alpha-amidation can occur in BEV-infected insect larvae (Hellers *et al.*, 1991).

#### e. Supramolecular Assembly

Supramolecular protein assembly is one of the best-documented capabilities of the BEV system. Individual proteins can assemble into higher order structures *via* disulfide

- 55 -

bond formation, which is virtually complete in some cases (Giese *et al.*, 1989), but not in others (Domingo and Trowbridge, 1988). This indicates that BEV-infected insect cells have protein disulfide isomerase activity, but perhaps too little to completely process highly-expressed foreign proteins. Proteins also can assemble by noncovalent interactions in BEV-infected insect cells at rates similar to (Lanford, 1988) or lower than (Kuroda *et al.*, 1991) native rates.

Hetero-oligomeric protein complexes can be assembled by infecting insect cells with multiple BEVs (St. Angelo, *et al.*, 1987) or with a single BEV encoding multiple foreign genes (Emery and Bishop, 1987). Both of these approaches have been used to produce functional IgG heterodimers with normal heavy and light chain composition in the BEV system (Hasemann and Capra, 1990). The ability of this system to produce larger, even more complex oligomeric assemblies, including virus-like particles, is well-documented. Subviral particles consisting of hepatitis B virus, bluetongue virus, or rotavirus proteins were among the first to be described (Urakawa and Roy, 1988; Estes *et al.*, 1987; Kang *et al.*, 1987). This was followed by an example of protein processing in which a BEV was used to express the poliovirus genome in insect cells and the resulting polyprotein was properly cleaved and assembled into stable, noninfectious poliovirus-like particles (Urakawa *et al.*, 1989).

These early studies led to widespread use of the BEV system to express multiple viral proteins and produce many different types of virus-like particles that hold great promise as noninfectious vaccines and diagnostic reagents (Pearson and Roy, 1993). Most recently, potential multivalent vaccines have been produced by incorporating heterologous epitopes into the virus-like particles or other supramolecular protein complexes that can be assembled in this system (Garnier *et al.*, 1995b; Belyaev and Roy, 1992). Virus-like particles containing exogenous DNA also have been produced and used to efficiently transfer DNA into eukaryotic cells, indicating that these particles could be good tools for gene therapy (Forstova *et al.*, 1995).

#### f. Protein Targeting

Protein targeting signals had not been widely investigated in insect systems when the BEV system was first developed, so it was not known whether insect cells would be

- 56 -

able to recognize protein targeting signals in foreign proteins. Today, it is known that insect cells can recognize heterologous targeting signals, which suggests that these cells have similar protein trafficking machinery. Foreign proteins destined for secretion or the cell surface can enter the insect cell secretory pathway and native or heterologous signal peptides can be cleaved accurately, as discussed above. Polarized cell-surface expression of foreign proteins can occur in midgut epithelial cells of insect larvae (Kuroda, *et al.*, 1989). Mitochondrial proteins localize to the mitochondria (Takagi *et al.*, 1992) and nuclear proteins localize to the nuclei of BEV-infected insect cells and two baculovirus-encoded nuclear proteins contain nuclear targeting signals similar to those found in higher eukaryotes (Broussard *et al.*, 1996; Jarvis *et al.*, 1991). However, lysosomal enzymes produced in the BEV system lack the lysosomal targeting signal, mannose-6-phosphate, and are secreted by default (Boose *et al.*, 1990; Martin *et al.*, 1988). Biochemical assays indicate that Sf9 cells lack the phosphotransferase activity responsible for this modification (Aeed and Elhammer, 1994). A curious feature of protein trafficking in insect cells is that they secrete the intracellular domain of rabbit prolactin receptor, which lacks a typical signal peptide (Garnier *et al.*, 1995a). Furthermore, this domain can mediate secretion and ubiquitination of heterologous proteins, which suggests that lepidopteran insect cells have an unusual secretory pathway that can respond to this novel targeting signal.

#### g. Variation and the Art of Molecular Genetics

Structural analyses of recombinant proteins and biochemical analyses of cellular protein processing activities have produced a wealth of information on protein processing pathways in the BEV system. However, it is important to recognize the limitations of these biochemical approaches. They are indirect and provide only a retrospective view of protein processing pathways, which must be inferred from the structures of the end-products or the presence or absence of processing activities. These conclusions can be confused by degradative pathways, which might alter the product of the biosynthetic pathway and lead to misinterpretations. Also, the inability to detect a processing activity clearly does not prove the absence of that activity. Conclusions drawn from structural data on any one recombinant protein need to be applied only to that protein and not to the

- 57 -

pathway in general. These conclusions also should be applied only to the specific host that was used to produce the recombinant protein under analysis. Finally, the possible effects of baculovirus infection on the host need to be considered.

5 An alternative approach which circumvents many of these problems is to use molecular genetics to isolate genes encoding insect cell processing enzymes. This makes it possible to study these genes, their expression, the conditions that influence their expression, and, ultimately, the properties of the enzymes they encode. Examples herein below detail the isolation and characterization of class I and II  $\alpha$ -mannosidase cDNAs from Sf9 cells.

10 Overall, the biochemical evidence suggests that foreign proteins can be appropriately processed in the BEV system. However, it is important to recognize that there are some exceptions and caveats to this generalization. BEV-infected cell lines clearly lack certain protein processing capabilities, like alpha-amidation and lysosomal targeting. There also are clear differences in the structures of the N-linked glycans found  
15 on most recombinant glycoproteins produced in this system. Inefficient processing of recombinant proteins is a common problem in the BEV system. Nonetheless, this problem does not preclude the use of this expression system because, if adequate yields of a perfectly processed recombinant protein can be obtained, a high background of unprocessed material can be irrelevant. The "inefficiency" of protein processing in this  
20 system might reflect adverse effects of baculovirus infection or the inability of the cellular processing machinery to cope with the high levels of foreign gene transcription provided by BEVs. There also might be subtle differences in the protein processing machinery of insect cells and higher eukaryotes, which reduce the functional efficiency of foreign protein processing in this expression system. Theoretically, any of these protein  
25 processing problems can be addressed by metabolic engineering, which could be used to improve the BEV system, as discussed further below.

#### 4. Selected Applications of BEV-Expressed Proteins

##### a. Vaccines

30 One of the best-recognized applications of the BEV system is vaccine production. There are far too many examples of this application to discuss here and a comprehensive

- 58 -

list with references is available (Luckow, 1991). However, it is appropriate to summarize some general conclusions and new discoveries that have arisen from immunological studies on recombinant proteins produced in this system. Recombinant proteins from BEV-infected insect cells are invariably recognized by antibodies produced against the corresponding native proteins, indicating that they are antigenically authentic. Moreover, recombinant proteins from the BEV system usually induce protective immunity in laboratory animals. HIV gp160 produced in this system has been used extensively for human clinical trials and the results indicate that this product is safe and immunogenic. Unfortunately, although gp160 can induce both humoral and cell-mediated immune responses, these are usually weak, transient, and non-neutralizing. On the positive side, clinical trials on BEV-expressed recombinant gp160 showed that it has a therapeutic effect in previously infected individuals and the new concept of "vaccine therapy" emerged from these results (Redfield *et al.*, 1991). It also was found that stronger humoral and cell-mediated immune responses could be obtained by using a combined vaccine regimen involving priming with a live recombinant vaccinia virus encoding gp160 and boosting with BEV-expressed recombinant gp160 (Cooney *et al.*, 1993; Graham *et al.*, 1993).

#### **b. Diagnostic Tests**

Another exciting application of recombinant proteins produced in the BEV system is diagnostic testing. Recombinant proteins produced in the BEV system have been used to develop diagnostic tests for many different infectious agents, including viruses, protozoa, rickettsia, and bacteria, as well as tests for human autoantibodies and cancer markers. Diagnostic testing with recombinant proteins from the BEV system has progressed beyond the developmental state, as these proteins have been used for several large epidemiological studies (Numata *et al.*, 1994).

#### **c. Three Dimensional Structural Analyses**

The BEV system is being used with increasing frequency to produce recombinant proteins for three dimensional structural analyses. Rat acid phosphatase was one of the first recombinant proteins to be crystallized (Vihko *et al.*, 1993) and, subsequently, many recombinant proteins have been crystallized and analyzed by x-ray diffraction. In



addition, the three-dimensional structures of many of the virus-like particles produced in this system have been examined by x-ray crystallography (Roy, 1996; Agbandje *et al.*, 1991) and electron cryomicroscopy (Prasad *et al.*, 1994).

5           **D.     Preventing Adverse Effects of Baculovirus Infection**

BEVs ultimately kill the host that is producing the foreign protein of interest. Thus, recombinant protein production with the BEV system is a "batch" process and fresh cells and virus must be used to produce each batch of recombinant protein. BEVs also have adverse effects on host protein processing pathways long before they kill the cells and encode at least one protease and phosphatase that might degrade or dephosphorylate the foreign protein being produced.

One way to address these problems is to use viral promoters to develop insect cell expression systems that avoid using a BEV altogether. This can be done by producing stably-transformed insect cells that express a foreign gene constitutively under the control of baculovirus early promoters (Jarvis, *et al.*, 1990). The production levels obtained with transformed insect cells are usually lower than those obtained by infecting insect cells with *polh*-based BEVs. However, where *polh*-based BEVs fail to produce high levels of a foreign protein, as in the case of many secretory pathway proteins, transformed insect cells can provide similar levels of recombinant product. Furthermore, stably-transformed cells can produce these proteins continuously over a long time period and process them faster and more efficiently than infected cells. Thus, stably-transformed insect cells hold promise for foreign protein production, but this approach would be significantly more attractive if it could provide higher production levels. This may be accomplished by developing gene amplification methods or using stronger promoters.

25           Another way to circumvent the adverse effects of baculovirus infection is to develop BEVs that can provide high-level foreign gene expression without the cytopathic effects. One example is a "miniviral replicon": a baculovirus-based DNA molecule encoding only the *cis*- and *trans*-acting functions needed for autonomous replication and transcription of strong viral promoters in insect cells. This replicon lacks all other viral functions. It replicates as an episome and produce a foreign protein(s) of interest at high levels, but has no adverse side-effects on the host cell and produce no progeny virus.

- 60 -

Efforts to identify the functions required for baculovirus DNA replication and late/very late transcription are proceeding at a rapid pace. Thus, these efforts may lead to the development of a miniviral replicon expression vector.

#### 5 E. Metabolic Engineering

Another reason for the relatively lower levels of secretory pathway protein production in baculovirus-infected insect cells is that host protein processing activities might be saturated. If specific cellular processing activities are limiting, it should be possible to improve the system by "metabolic engineering" to increase available levels of these activities. One approach would be to use insect cells that have been stably-  
10 transformed to overexpress processing activities as modified hosts for conventional BEVs, as proposed previously (Jarvis, *et al.*, 1990). However, this approach is complicated by the unexpected finding that baculovirus infection shuts down expression of integrated genes, even when their expression is controlled by a viral promoter that is normally active  
15 throughout infection (Jarvis, 1993). An alternative approach is to use modified BEVs that include and can overexpress genes encoding cellular protein processing enzymes.

This latter approach was used to try to improve the assembly of steroid receptors (Alnemri and Litwack, 1993) and immunoglobulins (Hsu *et al.*, 1994), both of which were inefficiently processed and formed insoluble protein aggregates when overexpressed in  
20 BEV-infected insect cells. Coexpression of the steroid receptors and hsp90 or hsp70 failed to enhance assembly and prevent aggregation. Coexpression of immunoglobulins with immunoglobulin binding protein produced higher levels of soluble intracellular immunoglobulin, but failed to increase secretion.

As provided herein by the present invention, metabolic engineering of protein  
25 glycosylation pathways is another way to improve the BEV system. Insect cell glycosylation pathways are modified by increasing the levels of existing processing activities or by adding new processing activities thought to be missing in these cells. Modified host cells or modified viruses can be used for either purpose, as described herein.

## II. Baculovirus Expression

### A. Vectors

Baculovirus expression vectors are useful tools for the production of proteins for a variety of applications (Summers and Smith, 1987; O'Reilly *et al.*, 1992; also U.S. Patent Nos., 5,077,214 (Guarino and Jarvis) and 5,162,222, (Guarino and Jarvis), each incorporated herein by reference). Baculovirus expression vectors are recombinant insect vectors in which the coding region of a particular gene of interest is placed behind a promoter in place of a nonessential baculoviral gene. The classic approach used to isolate a recombinant baculovirus expression vector is to construct a plasmid in which the foreign gene of interest is positioned downstream of the *polyhedrin* promoter. Then, *via* homologous recombination, that plasmid can be used to transfer the new gene into the viral genome in place of the wild-type *polyhedrin* gene (Summers and Smith, 1987; O'Reilly *et al.*, 1992).

The resulting recombinant virus can infect cultured lepidopteran insect cells or larvae and express the foreign gene under the control of the *polyhedrin* promoter, which is strong and provides very high levels of transcription during the very late phase of infection. The strength of the *polyhedrin* promoter is an advantage of the use of recombinant baculoviruses as expression vectors because it usually leads to the synthesis of large amounts of the foreign gene product during infection.

Ironically, while it is an advantage of conventional baculovirus expression vectors, the present inventor reasoned that the use of the *polyhedrin* promoter also presents some clear limitations. These limitations stem from the fact that this promoter requires virus-encoded factors for its transcriptional activity that only become available during the very late phase of infection (Huh and Weaver, 1990; Passarelli and Miller, 1993; McLachlin and Miller, 1994; Lu and Miller, 1995; Todd *et al.*, 1995; Xu *et al.*, 1995). Thus, while the *polyhedrin* promoter ultimately can provide high expression levels, it cannot provide any expression until the viral replication cycle is nearly complete. This is undesirable for foreign glycoprotein production as evidence suggests that cellular glycoprotein processing pathways are compromised at late times of infection (Jarvis and Summers, 1989; Jarvis *et al.*, 1990; Murphy *et al.*, 1990).

## **B. Methods**

The present invention contemplates the use of a vector comprising one or more eukaryotic oligosaccharide processing genes to modify the insect cell N-glycosylation pathway by directing the expression of heterologous processing enzyme(s). The one or more encoded enzyme(s) then function as part of the insect cell oligosaccharide processing machinery. This contributes to the production of a protein of interest that has a complex biantennary oligosaccharide structure containing penultimate galactose and terminal sialic acid residues, similar to that obtained from mammalian cell culture techniques.

The baculovirus expression vectors of the present invention also contemplate the use of additional promoter and enhancer elements, heterologous genes encoding proteins which aid in protein folding and/or other post translational modifications, and additional features which expand the breadth and utility of the current baculovirus expression vectors. Each of these features of the present invention will be discussed in greater detail below.

The present invention contemplates at least four different modes of using the novel baculovirus expression vectors. While each of the vectors will have common features, each of these modes of use requires different features to be incorporated into the vector of choice for the desired application.

### **1. Vectors for use in coinfection method**

The first method of use contemplated for the present invention would take advantage of the heterologous coding sequence of interest already being cloned into a current baculovirus expression vector, behind a promoter. The present invention provides a second baculovirus expression vector, which in a preferred embodiment supplies all of the oligosaccharide processing enzyme coding regions required to produce a protein of interest with the desired oligosaccharide structure. These two vectors are used independently to make recombinant baculoviruses, which are then used to coinfect an insect cell host.

This class of vector is the least complex, comprising only the common elements of all five classes. This class of vector comprises one or more oligosaccharide processing enzyme transcription unit(s), further comprising appropriate promoter and enhancer

- 63 -

elements to achieve optimal temporal expression (discussed in greater detail below). These vectors further comprise expression unit(s) encoding protein(s) which aid in the protein of interest folding or being otherwise modified properly in the cellular host. Additional embodiments of these vectors comprise 5' and 3' flanking DNA segments, for directing the replacement of the recombinant baculovirus expression vector into the baculovirus host. These vectors further comprise baculovirus structural genes and promoters, providing a method to identify recombinant baculoviruses, or providing essential gene function to the recombinant baculoviruses. Additional embodiments comprise selectable markers which can also be used to identify recombinant baculoviruses. These vectors are discussed in detail in Example 22 below.

## **2. Vectors for infection method**

The second method of use contemplated for the present invention comprises all of the features of the first vectors, and would further comprise a cloning site, preferably a multiple cloning site, for the insertion of the heterologous gene or cDNA encoding the protein of interest. A preferred embodiment of the second vectors would include a promoter element functionally positioned upstream of the multiple cloning site, and would further comprise an enhancer element to increase transcription of the heterologous coding region. This vector is used alone to produce recombinant baculoviruses, which are used to infect an insect cell host. These vectors are discussed in detail in Example 22 below.

## **3. Additional vectors for infection method**

The third method of use contemplated for the present invention represents an improvement over the first vectors. In addition to comprising one or more oligosaccharide processing enzyme transcription unit(s) as described for the first vectors, these vectors further comprise features that allow for the more efficient insertion of one or more genes encoding any protein of interest, under the control of a promoter. The insertion is carried out using conventional baculovirus transfer plasmids and a conventional method involving linearization of the viral DNA by digestion with Bsu36I. The resulting recombinants, which are produced at a much higher efficiency than previous methods, are used to express

the protein of interest during infection of conventional insect cell lines. These vectors are discussed in detail in Example 22 below.

#### 4. Vectors that create a stably transformed insect cell line

5 The fourth method of use contemplated for the present invention produces a stable insect cell line, which incorporates all of the desired features of the first vectors. These vectors comprise all of the features of the first vectors, wherein the selectable marker provides the insect cell host resistance to a cellular toxin. The selectable marker which provides the insect cell host resistance to a cellular toxin can be either on the same vector as the rest of the elements, in which case the single vector would be transfected into the host cell, or on a separate vector from the rest of the elements, in which case co-transfection of the two vectors would be used. A further embodiment of the present invention comprises using multiple baculovirus expression vectors with different toxin resistance markers and different regions of their genomes replaced to stepwise or in combination stably incorporate all of the desired features described above into an insect cell line. The stably transformed insect cell line is then infected with baculoviruses produced from a standard baculovirus expression vector, wherein the heterologous coding sequence of interest is cloned behind a promoter. Further, these stable cell lines can also be used for infection with one or more of the novel recombinant baculoviruses described herein.

20 The particular features of the four classes of baculovirus expression vectors will now be discussed in greater detail.

### III. Oligosaccharide Processing

#### 25 A. Oligosaccharide Processing Pathway

Insect cells and higher eukaryotes begin oligosaccharide processing along a similar pathway. Both add Glc<sub>3</sub>-Man<sub>9</sub>-GlcNAc<sub>2</sub> precursors to appropriate recognition sites in nascent polypeptides followed by the trimming of glucose residues to produce Man<sub>9</sub>-GlcNAc<sub>2</sub>. The four α-1,2-linked mannose residues are removed by "class I" α-mannosidases, producing a Man<sub>5</sub>GlcNAc<sub>2</sub> structure (Moremen *et al.*, 1994). Following the addition of a single GlcNAc residue by N-acetylglucosaminyltransferase I, two more

mannose residues are removed by  $\alpha$ -mannosidase II, a "class II" mannosidase to produce GlcNAc-Man<sub>3</sub>-GlcNAc<sub>2</sub> (Moremen *et al.*, 1994).

At this point in the pathway, insect cells and higher eukaryotes diverge. In higher eukaryotes, GlcNAc-Man<sub>3</sub>-GlcNAc<sub>2</sub> can be extended by N-acetylglucosaminyltransferase II, galactosyltransferase, and sialyltransferase to produce a complex biantennary structure containing penultimate galactose and terminal sialic acid residues (Kornfeld and Kornfeld, 1985). However, in insect cells GlcNAc-Man<sub>3</sub>-GlcNAc<sub>2</sub> appears to be converted to Man<sub>3</sub>-GlcNAc<sub>2</sub> by a novel insect cell  $\beta$ -N-acetylglucosaminidase (Licari *et al.*, 1993; Altmann *et al.*, 1995; Wagner *et al.*, 1996a). This final structure is found either with or without fucose linked to the chitobiose core (Butters and Hughes, 1981; Hsieh and Robbins, 1984; Ryan *et al.*, 1985; Nagao *et al.*, 1987; Kuroda *et al.*, 1990; Chen *et al.*, 1991; Wathen *et al.*, 1991; Williams *et al.*, 1991; Knepper *et al.*, 1992; Grabenhorst *et al.*, 1993; Yeh *et al.*, 1993; Kubelka *et al.*, 1994; Manneberg *et al.*, 1994).

The widely-used host cell lines for baculovirus vectors are Sf21 (Vaughn *et al.*, 1977), Sf9 (Summers and Smith, 1987), and High Five (Wickham *et al.*, 1992) and these are reported to have low levels of the glucosaminyltransferases I and II (Altmann *et al.*, 1993; Velardo *et al.*, 1993), but no galactosyl- or sialyltransferase activities. There are two reports of lectin blotting analyses which claim to demonstrate sialic acid on insect cell-expressed glycoproteins (Davis and Wood, 1995; Sridhar *et al.*, 1993), but these are completely invalid as controls were not included to show that the lectins were binding to sugars. There is one report of  $\beta$ 1,4-galactosyltransferase activity in insect cells (Ogonah *et al.*, 1996) and one group which has found penultimate galactose and terminal sialic acid on one human glycoprotein (Davidson *et al.*, 1990; Davidson and Castellino, 1991a). However, it is clear that this observation is peculiar to the glycoprotein used in that study as it has not been convincingly demonstrated by any other researchers for any other glycoprotein in the intervening five years even though this is a highly desirable result. Thus, although insect cells are theoretically capable of producing oligosaccharide structures similar to those produced in higher eukaryotes, this has yet to yield practical benefits. The unpredictability of the glycosylation pattern for any given protein, and the differences in the glycosylation pattern from protein to protein are clear limitations of the current system.

### B. Oligosaccharide Processing Genes

There are at least seven different enzymes responsible for the complete processing of N-linked oligosaccharides to form a complex biantennary structure containing penultimate galactose and terminal sialic acid residues (FIG. 13). A table containing

5 cloned glycosyltransferases, along with the source of the clone and the GenBank accession number is shown below (Field and Wainwright, 1995).

**TABLE 1**

Enzyme	EC designation	GenBank accession
<i>Sialyltransferases</i>		
$\alpha$ 2,3-sialyltransferase	<i>H.sapiens</i> : cDNA	X74570
$\alpha$ 2,3-sialyltransferase	<i>H.sapiens</i> : cDNA	L23768
$\alpha$ 2,3-sialyltransferase	<i>H.sapiens</i> : cDNA	L23767
$\alpha$ 2,3-sialyltransferase	<i>S.scrofa</i> : cDNA	M97753, M98463
$\alpha$ 2,3-sialyltransferase	<i>R.rattus</i>	M97754
$\alpha$ 2,3-sialyltransferase	<i>M.musculus</i> : cDNA	X73523
$\alpha$ 2,3-sialyltransferase	<i>M.musculus</i> : cDNA	X76988, X76988
$\alpha$ 2,3-sialyltransferase	<i>M.musculus</i> : cDNA	D28941
$\alpha$ 2,3-sialyltransferase	<i>G.gallus</i> : cDNA	X77775
$\alpha$ 2,3-sialyltransferase	<i>G.gallus</i> : cDNA	X74946
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i>	A17362
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	X17247
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	X62822
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	S55693, S55689
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	X54363
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	L11720
$\alpha$ 2,6-sialyltransferase	<i>H.sapiens</i> : cDNA	M38193
$\alpha$ 2,6-sialyltransferase	<i>R.rattus</i> : cDNA	M83142, M83143, M83141
$\alpha$ 2,6-sialyltransferase	<i>R.rattus</i> : cDNA	M73985, M73986, M73987



**TABLE 4 cont'd**

$\alpha$ 2,6-sialyltransferase	<i>R.rattus</i> : genomic	M54999
$\alpha$ 2,6-sialyltransferase	<i>R.rattus</i> : cDNA	M18769
$\alpha$ 2,6-sialyltransferase	<i>M.musculus</i> : cDNA	D16106
$\alpha$ 2,6-sialyltransferase	<i>G.gallus</i> : cDNA	X75558
$\alpha$ 2,8-sialyltransferase	<i>H.sapiens</i>	X77922
$\alpha$ 2,8-sialyltransferase	<i>H.sapiens</i>	D26360
Sialyltransferase	<i>H.sapiens</i> : cDNA	U14550
Sialyltransferase	<i>H.sapiens</i> : cDNA	D13972
<b><i>Fucosyltransferases</i></b>		
$\alpha$ 1,2fucosyltransferase	<i>H.sapiens</i> : cDNA	M35531
$\alpha$ 1,2fucosyltransferase	<i>R.norwegicus</i> : cDNA	L26009, L26010
$\alpha$ 1,3fucosyltransferase III	<i>H.sapiens</i> : cDNA	X53578
$\alpha$ 1,3fucosyltransferase IV	<i>H.sapiens</i> : genomic	S52967, S52968
$\alpha$ 1,3fucosyltransferase IV	<i>H.sapiens</i>	L01698
$\alpha$ 1,3fucosyltransferase VI	<i>H.sapiens</i> : cDNA	M98825
$\alpha$ 1,3fucosyltransferase VII	<i>H.sapiens</i> : cDNA	X78031
$\alpha$ 1,3fucosyltransferase VII	<i>H.sapiens</i> : cDNA	U08112, U11282
$\alpha$ 1,3fucosyltransferase	<i>H.sapiens</i>	M65030
$\alpha$ 1,3fucosyltransferase	<i>H.sapiens</i> : genomic	S65161
$\alpha$ 1,3fucosyltransferase	<i>H.sapiens</i>	M81485
$\alpha$ 1,3fucosyltransferase	<i>H.sapiens</i> : cDNA	M58596, M58597
<b><i>Galactosyltransferases</i></b>		
$\alpha$ 1,3galactosyltransferase	<i>H.sapiens</i> : genomic	J05421
$\alpha$ 1,3galactosyltransferase	<i>H.sapiens</i>	M65082
$\alpha$ 1,3galactosyltransferase	<i>H.sapiens</i>	M60263
$\alpha$ 1,3galactosyltransferase	<i>H.sapiens</i>	J05421
$\alpha$ 1,3galactosyltransferase	<i>B.taurus</i> : cDNA	J04989
$\alpha$ 1,3galactosyltransferase	<i>M.musculus</i>	M26925
$\alpha$ 1,3galactosyltransferase	<i>M.musculus</i> : cDNA	M85153
$\alpha$ 1,3galactosyltransferase	<i>C.aethiops</i>	M73307

**TABLE 1 cont'd**

$\alpha$ 1,3galactosyltransferase	<i>P.paniscus</i>	M72526
$\alpha$ 1,3galactosyltransferase	<i>E.patos</i>	M73308
$\alpha$ 1,3galactosyltransferase	<i>G. gorilla</i>	M73304
$\alpha$ 1,3galactosyltransferase	<i>M.mulatta</i>	M73306
$\alpha$ 1,3galactosyltransferase	<i>A.geoffrovi</i>	M73309
$\alpha$ 1,3galactosyltransferase	<i>P.pygmucus</i>	M73305
$\alpha$ 1,3galactosyltransferase	<i>S.scieureus</i>	M73310
$\alpha$ 1,3galactosyltransferase	<i>A.curaya</i>	M73311
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : cDNA	M22921, X14085
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : cDNA	X51589
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : cDNA	X55415
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : cDNA	X13223
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : cDNA	U10472, U10473, U10474
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i>	M14624
$\beta$ 1,4galactosyltransferase	<i>H.sapiens</i> : genomic	M70427, M70428, M70429, M70430, M70432, M70433
$\beta$ 1,4galactosyltransferase	<i>B.taurus</i>	J05217
$\beta$ 1,4galactosyltransferase	<i>B.taurus</i> : cDNA	M25398
$\beta$ 1,4galactosyltransferase	<i>B.taurus</i> : cDNA	M13569
$\beta$ 1,4galactosyltransferase	<i>B.taurus</i> : cDNA	X14558
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i>	L16840
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i> : cDNA	D00314, D00315
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i> : cDNA	D37790, D37791
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i> : genomic	M27917 through M27923
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i>	M36289
$\beta$ 1,4galactosyltransferase	<i>M.musculus</i>	J03880
$\beta$ 1,4galactosyltransferase	<i>G.gallus</i> : cDNA	L12565
$\beta$ 1,4galactosyltransferase	<i>G.gallus</i> : cDNA	X16336

**TABLE 1 cont'd**

Galactosyltransferase	<i>H.sapiens</i> : cDNA	M13701
Galactosyltransferase	<i>B.taurus</i> : cDNA	M13214
Galactosyltransferase	<i>R.norwegicus</i> : cDNA	L21698, S66862
Galactosyltransferase	<i>R.norwegicus</i> : cDNA	U07683
Galactosyltransferase	<i>C.elegans</i> : genomic	Z29095
Galactosyltransferase	<i>L.donovani</i> : genomic	L11348
<b><i>N-Acetylglucosaminyltransferases</i></b>		
GlcNAc transferaseNAG1PTase	<i>M.musculus</i> : genomic	U03603
GlcNAc transferaseNAG1PTase	<i>M.musculus</i> : cDNA	X65603, S41875
GlcNAc transferaseNAG1PTase	<i>C.longicaudatus</i> : cDNA	J05590, M22755
GlcNAc transferaseNAG1PTase	<i>L.mexicana</i>	M96635
GlcNAc transferaseNAG1PTase	<i>S.cerevisiae</i>	Y00126
GlcNAc transferaseNAG1PTase	<i>S.pombe</i>	U09454
$\beta$ 1,2GlcNAc transferase	<i>C.elegans</i> : genomic	Z46381
$\beta$ 1,4GlcNAc transferase	<i>L.stagnalis</i> : cDNA	X80228
$\beta$ 1,6GlcNAc transferase	<i>H.sapiens</i> cDNA	M97347
$\beta$ 1,6GlcNAc transferase	<i>H.sapiens</i> : cDNA	Z19550, L19656
$\beta$ 1,6GlcNAc transferase	<i>M.musculus</i> : cDNA	U19295
$\beta$ 1,6GlcNAc transferase	<i>C.elegans</i> : genomic	Z36752
$\beta$ 1,6GlcNAc transferase	<i>C.elegans</i> : genomic	Z37092
GlcNAc transferaseI	<i>H.sapiens</i> : cDNA	M55621
GlcNAc transferaseI	<i>H.sapiens</i> : cDNA	T08544
GlcNAc transferaseI	<i>H.sapiens</i>	M61829
GlcNAc transferaseI	<i>R.rattus</i> : cDNA	D16302
GlcNAc transferaseI	<i>M.musculus</i> : genomic	M73491
GlcNAc transferaseI	<i>M.musculus</i> : genomic	L07037
GlcNAc transferaseI	<i>O.cuniculus</i> : cDNA	M57301
GlcNAc transferaseI	<i>C.elegans</i>	Z46381

**TABLE 1 cont'd**

GlcNAc transferase II	<i>R. rattus</i> : cDNA	U21662
GlcNAc transferase II	<i>H. sapiens</i> : genomic	U15128, L36537
GlcNAc transferase III	<i>H. sapiens</i>	D13789
GlcNAc transferase III	<i>R. rattus</i> : cDNA	D10852
GlcNAc transferase V	<i>H. sapiens</i> : cDNA	D17716
GlcNAc transferase V	<i>R. rattus</i> : cDNA	L14284
<b><i>N-Acetylgalactosaminyltransferases</i></b>		
$\alpha$ 1,3GalNAc transferase	<i>H. sapiens</i> : cDNA	J05173
$\alpha$ 1,3GalNAc transferase	<i>H. sapiens</i> : cDNA	S44054
$\beta$ 1,4GalNAc transferase	<i>H. sapiens</i> : cDNA	M83651
Protein: GalNAc transferase	<i>B. taurus</i> : cDNA	L07780
Protein: GalNAc transferase	<i>B. taurus</i> : cDNA	L17437, L16925
<b><i>Mannosyltransferases</i></b>		
Mannosyltransferase	<i>C. elegans</i> : cDNA	M75918
Mannosyltransferase	<i>S. cerevisiae</i> : genomic	L19169, L19700
Mannosyltransferase	<i>S. cerevisiae</i> : genomic	L05146
Mannosyltransferase	<i>S. cerevisiae</i>	J04184
$\alpha$ 1,2mannosyltransferase	<i>S. cerevisiae</i> : cDNA	M81110
$\alpha$ 1,6mannosyltransferase	<i>S. cerevisiae</i> : genomic	D11095
$\beta$ 1,4mannosyltransferase	<i>S. cerevisiae</i>	J05416, Z35979
Mannosyltransferase	<i>S. cerevisiae</i> : genomic	L17083
Mannosyltransferase	<i>S. cerevisiae</i>	X62941
Mannosyltransferase	<i>S. cerevisiae</i>	X62647
Mannosyltransferase	<i>S. cerevisiae</i>	
Mannosyltransferase	<i>S. cerevisiae</i>	L23753
Mannosyltransferase	<i>S. cerevisiae</i>	L23752
Mannosyltransferase	<i>S. cerevisiae</i>	Z38059
Mannosyltransferase	<i>S. cerevisiae</i>	Z46728

The combination of  $\alpha$ -glucosidase I and  $\alpha$ -glucosidase II cleave the three glucose residues from the Glc<sub>3</sub>-Man<sub>9</sub>-GlcNAc<sub>2</sub> precursors.  $\alpha$ -glucosidase I and  $\alpha$ -glucosidase II

from eukaryotic sources are preferred for use in the present invention. The enzyme from *Aspergillus oryzae* (Minetoki *et al.*, 1995) is an example.

The next step in the pathway is catalyzed by "class I"  $\alpha$ -mannosidases, producing a  $\text{Man}_5\text{GlcNAc}_2$  structure. Eukaryotic  $\alpha$ -mannosidase genes or cDNAs are generally preferred for use in the present invention. Those from yeast (Camirand *et al.*, 1991), *Aspergillus* (Inoue *et al.*, 1995), *Penicillium* (Yoshida and Ichishima, 1995), *Drosophila* (Kerscher *et al.*, 1995), rabbit (Lal *et al.*, 1994), mouse (Herscovics *et al.*, 1994; Lal *et al.*, 1994) and human (Bause *et al.*, 1993) are examples. Particularly preferred is the  $\alpha$ -mannosidase cDNA from *Spodoptera* (Example 6; SEQ ID NO:1).

Next, N-acetylglucosaminyltransferase I catalyzes the addition of a single GlcNAc residue to  $\text{Man}_5\text{-GlcNAc}_2$ . Genes or cDNAs encoding N-acetylglucosaminyltransferase I from eukaryotic sources are preferred for use in the present invention. Those from rabbit (Sarkar *et al.*, 1991), mouse (Pownall *et al.*, 1992; Kumar *et al.*, 1992), rat (Fukada *et al.*, 1994) and human (Kumar *et al.*, 1990) are examples.

The next step in the pathway is the removal of two more mannose residues by  $\alpha$ -mannosidase II, a "class II" mannosidase to produce  $\text{GlcNAc-Man}_3\text{-GlcNAc}_2$ . Preferred for use in the present invention is  $\alpha$ -mannosidase II from eukaryotic sources. Examples are the yeast vacuolar mannosidase (Yoshihisa and Anraku, 1989; Accession no. M29146), rat ER  $\alpha$ -mannosidase (Bischoff *et al.*, 1990; Accession no. M57547), mouse  $\alpha$ -mannosidase II (Moremen and Robbins, 1991; Accession no. X61172), human  $\alpha$ -mannosidase II (Misago *et al.*, 1995; Accession no. U31520), human  $\alpha$ -mannosidase II<sup>x</sup> (Misago *et al.*, 1996; Accession no. D55649) and *Drosophila*  $\alpha$ -mannosidase II (Foster *et al.*, 1995; Accession no. X77652). Particularly preferred is the  $\alpha$ -mannosidase II cDNA from lepidopteran insect (Sf9) cells (Example 6; SEQ ID NO:3).

Concomitant with the removal of the two mannose residues is the addition of a fucose residue, catalyzed by fucosyltransferase. Eukaryotic genes or cDNAs which encode fucosyltransferase are preferred for use in the present invention. The human cDNA (Larsen *et al.*, 1990) is an example.

At this point, in insect cells, N-acetylglucosaminidase converts one of the intermediates in the oligosaccharide processing pathway to a structure which not a substrate for the enzymes which add the penultimate galactose and terminal sialic acid

- 72 -

residues. *Estigmene acrea* lacks this enzyme (Wagner, 1996a), which should lead to the accumulation of the intermediate which is a substrate for N-acetylglucosaminyltransferase II, the committed step in the production of complex oligosaccharide side chains containing penultimate galactose and terminal sialic acid residues. The inventor contemplates deleting the N-acetylglucosaminidase gene from a *Spodoptera* cell line using standard gene knockout techniques, or using antisense technology to reduce the levels of protein production in the insect cell.

The conversion of GlcNAc-Man<sub>3</sub>-GlcNAc<sub>2</sub> to GlcNAc<sub>2</sub>-Man<sub>3</sub>-GlcNAc<sub>2</sub> is catalyzed by N-acetylglucosaminyltransferase II. Eukaryotic genes or cDNAs encoding N-acetylglucosaminyltransferase II are generally preferred for use in the current invention. Those from rat (D'Agostaro *et al.*, 1995) and human (Tan *et al.*, 1995) are examples.

The next step in the pathway is the addition of a galactose residue to each branch of the oligosaccharide structure. This reaction is catalyzed by the enzyme  $\beta$ 1,4-galactosyltransferase.  $\beta$ 1,4-galactosyltransferase genes or cDNAs from eukaryotic sources are preferred for use in the present invention. Those from mouse (Nakazawa *et al.*, 1988), human (Masri *et al.*, 1988; Chatterjee *et al.*, 1995), rat (Bendiak *et al.*, 1993) and *Lymnaea stagnalis* (Bakker *et al.*, 1994) are examples. More preferred is the full-length cDNA encoding the short protein isoform of bovine  $\beta$ 1,4-galactosyltransferase (Harduin-Lepers *et al.*, 1993; Russo *et al.*, 1992).

The final processing step in the formation of complex biantennary oligosaccharide structures is the addition of sialic acid residues to each galactose residue at the end of the oligosaccharide branches. This reaction is catalyzed by various sialyltransferases. Eukaryotic cDNAs or genes encoding  $\alpha$ 2,6-sialyltransferase are preferred for use in the present invention. The human gene (Wang *et al.*, 1993) is an example.

### C. Oligosaccharide Gene Combinations

The present invention provides to insect cells high levels of one or more of the enzymes needed to produce the complex oligosaccharide found in higher eukaryotes. A preferred method is by providing eukaryotic cDNAs or genes encoding  $\alpha$ -glucosidase I,  $\alpha$ -glucosidase II,  $\alpha$ -mannosidase I, N-acetylglucosaminyltransferase I,  $\alpha$ -mannosidase II, fucosyltransferase, N-acetylglucosaminyltransferase II, a galactosyltransferase and a

sialyltransferase. A further embodiment is to provide various combinations of the coding sequences for these enzymes, to specifically design the oligosaccharide pattern of choice. A particularly preferred embodiment is to provide eukaryotic cDNAs or genes encoding the enzymes which are barely detectable or absent in insect cells, N-acetylglucosaminyltransferase I, N-acetylglucosaminyltransferase II,  $\beta$ 1,4-galactosyltransferase and sialyltransferase.

It will be understood that where the use of two or more oligosaccharide processing genes is contemplated, the genes may be combined in the vector in any desired combination. There is no requirement for any particular gene to be inserted before or after any other particular gene, when considering the DNA sequence in the 5' to 3' direction. One may therefore insert two or more genes into the vectors of the present invention in any order that is convenient, as may be determined by different cloning strategies or restriction enzyme sites.

In embodiments of the invention where different promoters are used to express two or more oligosaccharide processing genes, it may be preferred in certain embodiments to use a baculovirus early promoter to express genes that encode protein products that act at earlier steps in the glycosylation pathways. This may be useful in ensuring that the required partially processed recombinant polypeptide is available to act as a substrate for the processing enzymes that catalyze subsequent steps in the overall pathway. However, it will be understood that this is by no means a limitation of the present invention and is simply provided as one embodiment thereof.

#### **D. Assays for the Effects of Glycosylation on Protein Substrates**

While it is known that glycosylation of a protein in general can alter the functional aspects of the protein (Welply, 1991), delineation of the precise effects of individual glycosylation steps requires the use of enzyme inhibitors (Elbein, 1991), for example tunicamycin, castanospermine (which inhibits glucosidase I), deoxymannojirimycin (which inhibits  $\alpha$ -mannosidase I) or swainsonine (which inhibits  $\alpha$ -mannosidase II; Moremen *et al.*, 1994). However, some of the enzymes in the oligosaccharide processing pathway have no known inhibitors. The present invention provides a method for using conventional and modified baculovirus expression systems to study the influence of N-

linked oligosaccharide processing on glycoprotein function. Example 14 shows that there was no significant difference in the *in vitro* growth properties of wild type AcMNPV and an immediate early recombinant expressing  $\beta$ 1,4-galactosyltransferase, which contained nongalactosylated and galactosylated gp64, respectively. This approach can be used to produce nongalactosylated and galactosylated versions of any recombinant glycoprotein for interesting functional comparisons. This is an important application because there are no specific  $\beta$ 1,4-galactosyltransferase inhibitors that can be used to study the function of this late step in N-linked oligosaccharide processing.

The present invention provides for sequential addition of oligosaccharide residues to a protein of interest by adding additional processing enzyme coding units into the baculovirus expression vector. A preferred embodiment of the present invention is to use vectors that contain step-wise additions of N-acetylglucosaminyltransferase I, N-acetylglucosaminyltransferase II,  $\beta$ 1,4-galactosyltransferase and sialyltransferase expression units, to study the effect of adding N-acetylglucosamine, galactose and sialic acid on protein function.

It will be therefore understood that it is not a requirement of this invention to produce one or more recombinant proteins that are modified exactly in the manner that the counterpart mammalian or human protein appears in its natural environment. Even where a functional protein with complete or moderate biological activity is desired, it may still be the case that the glycosylation pattern does not have to directly correspond to that of the natural protein. Proteins that are modified to any degree further than those previously expressed in insect cells will naturally represent an advance in this technology. Proteins that more closely resemble the naturally occurring mammalian or human proteins will, of course, be preferred in many embodiments.

However, as outlined above, it is not always required or even desired to produce a protein with complete or even substantial biological activity. In fact, in terms of identifying inhibitors of particular glycosylation enzymes, all that is required is to produce a protein which may be analyzed to determine which sugar groups it contains. This provides a ready means for conducting screening assays to identify various inhibitors.

To conduct such a screening assay, one would generally provide to an insect cell a particular glycosylation enzyme and test the effect of the enzyme on a protein from the cell



- 75 -

that lends itself to ready analysis. The glycosylation enzyme for use in such embodiments will be chosen so that it catalyzes a glycosylation step that is not readily conducted in the natural insect cell. Expression of the enzyme will thus result in a protein with a different glycosylation pattern. Once this has been confirmed, the recombinant insect cell can then be exposed to a "candidate substance". A candidate substance that reduces the level of the newly modified protein, and results in the production of larger amounts of proteins that correspond to those produced in natural insect cells, will then be identified as having the ability to inhibit the expressed glycosylation enzyme and is therefore categorized as a "inhibitory substance".

#### IV. Genes Which Encode Accessory Proteins That Aid in Protein Folding

The proper folding of a protein into its correct three-dimensional structure is important for the proper function of the protein. For large, glycosylated proteins, folding *in vivo* is a complex process that requires other proteins. Many of these proteins belong to families which are evolutionarily conserved. These protein families fall into two major classes (Gething and Sambrook, 1992, incorporated herein by reference, including the incorporation of each of the references cited therein). The first class includes enzymes which catalyze isomerization reactions which are rate limiting in the folding process of some proteins. The second class includes chaperone proteins which associate with other proteins during the folding process to prevent the formation of incorrect intermediate structures.

There are two rate determining steps in the *in vitro* folding of proteins, thiol/disulphide interchange reactions and proline *cis-trans* isomerization. These reactions are catalyzed by protein disulphide isomerase and peptidyl prolyl *cis-trans* isomerase, respectively. Protein disulphide isomerase has been described from a number of sources, including *E. coli*, plants, yeast, *Drosophila* and higher eukaryotes. Likewise, peptidyl prolyl *cis-trans* isomerase has been detected in both prokaryotes and eukaryotes.

Protein chaperones generally fall into three major classes, which are all highly conserved between plants, prokaryotes and eukaryotes. These classes are referred to as chaperonin-60, stress-70 and stress-90 (Gething and Sambrook, 1992). Examples of proteins which belong to the chaperonin-60 class are *E. coli* GroEL and the yeast and

- 76 -

mammalian Hsp60. Representatives of the stress-70 class are *E. coli* DnaK and the BiP/GRP78 homologs from plants, yeast (Normington *et al.*, 1989), *Drosophila* (Rubin *et al.*, 1993), and higher eukaryotes such as rat (Munro and Pelham, 1986) and hamster (Ting *et al.*, 1987). The stress-90 class is represented by Hsp83 from *Drosophila*, yeast and mammals, and the Grp94 protein from mammals.

A potential method of improving protein processing in insect cells is by providing increased levels of proteins which assist in protein folding in the cell. For example, it has been demonstrated that coexpression of BiP (GRP78) resulted in an increase in the intracellular levels of functional immunoglobulin IgG (Hsu, 1994). However the promoter used in the previous example was the very late *polyhedrin* promoter.

The present invention contemplates the administration of proteins such as protein disulphide isomerase, peptidyl prolyl *cis-trans* isomerase and chaperone proteins, either alone or in conjunction with the oligosaccharide processing enzymes. A preferred method is by providing eukaryotic cDNAs or genes encoding eukaryotic protein disulphide isomerase, peptidyl prolyl *cis-trans* isomerase and chaperone proteins. Another preferred embodiment is a eukaryotic BiP/GRP78 gene. A particularly preferred embodiment is a eukaryotic BiP/GRP78 gene functionally positioned downstream from a baculovirus immediate-early promoter. The present invention further contemplates the cloning of the insect homolog of BiP/GRP78 (see section XI below). After identifying an appropriate DNA molecule, it may be inserted into any one of the many vectors in the present invention.

The present invention additionally contemplates the administration of additional protein modification enzymes, such as those involved in phosphorylation, acylation, acetylation, methylation and amidation, as described in Section I above.

## V. Promoters and Enhancers

The promoters and enhancers that control the transcription of protein encoding genes in eukaryotic cells are composed of multiple genetic elements. The cellular machinery is able to gather and integrate the regulatory information conveyed by each element, allowing different genes to evolve distinct, often complex patterns of transcriptional regulation.

- 77 -

The term promoter will be used here to refer to a group of transcriptional control modules that are clustered around the initiation site for RNA polymerase II. Much of the thinking about how promoters are organized derives from analyses of several viral promoters, including those for the HSV thymidine kinase (tk) and SV40 early transcription units. These studies, augmented by more recent work, have shown that promoters are composed of discrete functional modules, each consisting of approximately 7-20 bp of DNA, and containing one or more recognition sites for transcriptional activator proteins.

At least one module in each promoter functions to position the start site for RNA synthesis. The best known example of this is the TATA box, but in some promoters lacking a TATA box, such as the promoter for the mammalian terminal deoxynucleotidyl transferase gene and the promoter for the SV 40 late genes, a discrete element overlying the start site itself helps to fix the place of initiation.

Additional promoter elements regulate the frequency of transcriptional initiation. Typically, these are located in the region 30-110 bp upstream of the start site, although a number of promoters have recently been shown to contain functional elements downstream of the start site as well. The spacing between elements is flexible, so that promoter function is preserved when elements are inverted or moved relative to one another. In the tk promoter, the spacing between elements can be increased to 50bp apart before activity begins to decline. Depending on the promoter, it appears that individual elements can function either co-operatively or independently to activate transcription.

Enhancers were originally detected as genetic elements that increased transcription from a promoter located at a distant position on the same molecule of DNA. This ability to act over a large distance had little precedent in classic studies of prokaryotic transcriptional regulation. Subsequent work showed that regions of DNA with enhancer activity are organized much like promoters. That is, they are composed of many individual elements, each of which binds to one or more transcriptional proteins.

The basic distinction between enhancers and promoters is operational. An enhancer region as a whole must be able to stimulate transcription at a distance; this need not be true of a promoter region or its component elements. On the other hand, a promoter must have one or more elements that direct initiation of RNA synthesis at a particular site

- 78 -

and in a particular orientation, whereas enhancers lack these specificities. Aside from this operational distinction, enhancers and promoters are very similar entities.

5 Promoters and enhancers have the same general function of activating transcription in the cell. They are often overlapping and contiguous, often seeming to have a very similar modular organization. Taken together, these considerations suggest that enhancers and promoters are homologous entities and that the transcriptional activator proteins bound to these sequences may interact with the cellular transcriptional machinery in fundamentally the same way.

10 There are two basic procedures for expressing cloned genes from promoters, which are both useful in insect cell systems. In transient systems, the gene of interest is introduced into the insect cell by infection with a recombinant baculovirus. In the most widely used systems, the gene of interest is under the control of the *polyhedrin* promoter. The *polyhedrin* promoter is a very late promoter, which means that the expression of the gene of interest does not start until the late phase of the baculovirus infection. The expression levels are high, but transient as the baculovirus infection eventually leads to cell death.

15 The second method for expressing cloned genes from control regions is stable transfection. Stable transfection may allow for moderate expression levels from a transfected gene to be obtained in a long term continuous culture. In this method the recombinant DNA molecule and promoter/enhancer combination is introduced via transfection, with a gene encoding a selectable marker protein either on the same vector (transfection), or on a separate vector (co-transfection; Jarvis *et al.*, 1990). After selection for clones which express the marker protein, the cells are assayed for the presence of the gene of interest (for example by Southern analysis of the genomic DNA, northern analysis of the RNA or western analysis of the protein product). Cells which have the gene of interest incorporated into the genomic DNA of the host cell will stably express the gene.

20 In any event, it will be understood that promoters are DNA elements which when positioned functionally upstream of a gene leads to the expression of that gene. Each heterologous gene in the vector of the present invention is functionally positioned downstream of a promoter element. Promoters which are active in insect cells to drive transcription are intended for use in the present invention. Preferred are viral promoters,

30

more preferred are baculoviral promoters, and a particularly preferred embodiment uses immediate-early promoters.

#### A. Eukaryotic and Viral Promoters and Enhancers

Below are a list of viral promoters, cellular promoters/enhancers and inducible promoters/enhancers that could be used in combination with the present invention. Additionally any promoter/enhancer combination (as per the Eukaryotic Promoter Data Base EPDB) could also be used to drive expression of structural genes encoding oligosaccharide processing enzymes, protein folding accessory proteins, selectable marker proteins or a heterologous protein of interest.

**TABLE 2**

ENHANCER	REFERENCES
Immunoglobulin Heavy Chain	Hanerji <i>et al.</i> , 1983; Gilles <i>et al.</i> , 1983; Grosschedl and Baltimore, 1985; Atchinson and Perry, 1986, 1987; Imler <i>et al.</i> , 1987; Weinberger <i>et al.</i> , 1988; Kiledjian <i>et al.</i> , 1988; Porton <i>et al.</i> , 1990
Immunoglobulin Light Chain	Queen and Baltimore, 1983; Picard and Schaffner, 1984
T-Cell Receptor	Luria <i>et al.</i> , 1987, Winoto and Baltimore, 1989; Redondo <i>et al.</i> , 1990
HLA DQ $\alpha$ and DQ $\beta$	Sullivan and Peterlin, 1987
$\beta$ -Interferon	Goodbourn <i>et al.</i> , 1986; Fujita <i>et al.</i> , 1987; Goodbourn and Maniatis, 1985
Interleukin-2	Greene <i>et al.</i> , 1989
Interleukin-2 Receptor	Greene <i>et al.</i> , 1989; Lin <i>et al.</i> , 1990
MHC Class II 5	Koch <i>et al.</i> , 1989
MHC Class II HLA-DRA	Sherman <i>et al.</i> , 1989

**TABLE 2 cont'd**

$\beta$ -Actin	Kawamoto <i>et al.</i> , 1988; Ng <i>et al.</i> , 1989
Muscle Creatine Kinase	Jaynes <i>et al.</i> , 1988; Horlick and Benfield, 1989; Johnson <i>et al.</i> , 1989a
Prealbumin (Transthyretin)	Costa <i>et al.</i> , 1988
Elastase I	Omitz <i>et al.</i> , 1987
Metallothionein	Karin <i>et al.</i> , 1987; Culotta and Hamer, 1989
Collagenase	Pinkert <i>et al.</i> , 1987; Angel <i>et al.</i> , 1987
Albumin Gene	Pinkert <i>et al.</i> , 1987, Tronche <i>et al.</i> , 1989, 1990
$\alpha$ -Fetoprotein	Godbout <i>et al.</i> , 1988; Campere and Tilghman, 1989
t-Globin	Bodine and Ley, 1987; Perez-Stable and Constantini, 1990
$\beta$ -Globin	Trudel and Constantini, 1987
e-fos	Cohen <i>et al.</i> , 1987
c-HA-ras	Triesman, 1986; Deschamps <i>et al.</i> , 1985
Insulin	Edlund <i>et al.</i> , 1985
Neural Cell Adhesion Molecule (NCAM)	Hirsch <i>et al.</i> , 1990
$\alpha_1$ -Antitrypsin	Latimer <i>et al.</i> , 1990
H2B (TH2B) Histone	Hwang <i>et al.</i> , 1990
Mouse or Type I Collagen	Ripe <i>et al.</i> , 1989
Glucose-Regulated Proteins (GRP94 and GRP78)	Chang <i>et al.</i> , 1989
Rat Growth Hormone	Larsen <i>et al.</i> , 1986

**TABLE 2 cont'd**

Human Serum Amyloid A (SAA)	Edbrooke <i>et al.</i> , 1989
Troponin I (TN I)	Yutzey <i>et al.</i> , 1989
Platelet-Derived Growth Factor	Pech <i>et al.</i> , 1989
Duchenne Muscular Dystrophy	Klamut <i>et al.</i> , 1990
SV40	Banerji <i>et al.</i> , 1981; Moreau <i>et al.</i> , 1981; Sleight and Lockett, 1985; Firak and Subramanian, 1986; Herr and Clarke, 1986; Imbra and Karin, 1986; Kadesch and Berg, 1986; Wang and Calame, 1986; Ondek <i>et al.</i> , 1987; Kuhl <i>et al.</i> , 1987 Schaffner <i>et al.</i> , 1988
Polyoma	Swartzendruber and Lehman, 1975; Vasseur <i>et al.</i> , 1980; Katinka <i>et al.</i> , 1980, 1981; Tyndell <i>et al.</i> , 1981; Dandolo <i>et al.</i> , 1983; deVilliers <i>et al.</i> , 1984; Hen <i>et al.</i> , 1986; Satake <i>et al.</i> , 1988; Campbell and Villarreal, 1988
Retroviruses	Kriegler and Botchan, 1982, 1983; Levinson <i>et al.</i> , 1982; Kriegler <i>et al.</i> , 1983, 1984a,b, 1988; Bosze <i>et al.</i> , 1986; Miksicek <i>et al.</i> , 1986; Celander and Haseltine, 1987; Thiesen <i>et al.</i> , 1988; Celander <i>et al.</i> , 1988; Chol <i>et al.</i> , 1988; Reisman and Rotter, 1989
Papilloma Virus	Campo <i>et al.</i> , 1983; Lusky <i>et al.</i> , 1983; Spandidos and Wilkie, 1983; Spalholz <i>et al.</i> , 1985; Lusky and Botchan, 1986; Cripe <i>et al.</i> , 1987; Gloss <i>et al.</i> , 1987; Hirochika <i>et al.</i> , 1987, Stephens and Hentschel, 1987; Glue <i>et al.</i> , 1988

**TABLE 2 cont'd**

Hepatitis B Virus	Bulla and Siddiqui, 1986; Jameel and Siddiqui, 1986; Shaul and Ben-Levy, 1987; Spandau and Lee, 1988; Vannice and Levinson, 1988
Human Immunodeficiency Virus	Muesing <i>et al.</i> , 1987; Hauber and Cullan, 1988; Jakobovits <i>et al.</i> , 1988; Feng and Holland, 1988; Takebe <i>et al.</i> , 1988; Rowen <i>et al.</i> , 1988; Berkhout <i>et al.</i> , 1989; Laspia <i>et al.</i> , 1989; Sharp and Marciniak, 1989; Braddock <i>et al.</i> , 1989
Cytomegalovirus	Weber <i>et al.</i> , 1984; Boshart <i>et al.</i> , 1985; Foecking and Hofstetter, 1986
Gibbon Ape Leukemia Virus	Holbrook <i>et al.</i> , 1987; Quinn <i>et al.</i> , 1989

**TABLE 3**

Element	Inducer	References
MT II	Phorbol Ester (TFA) Heavy metals	Palmiter <i>et al.</i> , 1982; Haslinger and Karin, 1985; Searle <i>et al.</i> , 1985; Stuart <i>et al.</i> , 1985; Imagawa <i>et al.</i> , 1987; Karin @, 1987; Angel <i>et al.</i> , 1987b; McNeall <i>et al.</i> , 1989
MMTV (mouse mammary tumor virus)	Glucocorticoids	Huang <i>et al.</i> , 1981; Lee <i>et al.</i> , 1981; Majors and Varmus, 1983; Chandler <i>et al.</i> , 1983; Lee <i>et al.</i> , 1984; Fonta <i>et al.</i> , 1985; Sakai <i>et al.</i> , 1986
$\beta$ -Interferon	poly(rI)X poly(rc)	Tavernier <i>et al.</i> , 1983
Adenovirus 5 E2	Ela	Imperiale and Nevins, 1984



**TABLE 3 cont'd**

Collagenase	Phorbol Ester (TPA)	Angle <i>et al.</i> , 1987a
Stromelysin	Phorbol Ester (TPA)	Angle <i>et al.</i> , 1987b
SV40	Phorbol Ester (TFA)	Angel <i>et al.</i> , 1987b
Murine MX Gene	Interferon, Newcastle Disease Virus	
GRP78 Gene	A23187	Resendez <i>et al.</i> , 1988
a-2-Macroglobulin	IL-6	Kunz <i>et al.</i> , 1989
Vimentin	Serum	Rittling <i>et al.</i> , 1989
MHC Class I Gene H- 2kb	Interferon	Blonar <i>et al.</i> , 1989
HSP70	Ela, SV40 Large T Antigen	Taylor <i>et al.</i> , 1989; Taylor and Kingston, 1990a,b
Proliferin	Phorbol Ester-TPA	Mordacq and Linzer, 1989
Tumor Necrosis Factor	FMA	Hensel <i>et al.</i> , 1989
Thyroid Stimulating Hormone a Gene	Thyroid Hormone	Chatterjee <i>et al.</i> , 1989

### **B. Cellular Promoters and Enhancers**

Vector constructs incorporating insect cellular promoters have been used successfully, including *Drosophila* HSP70 (Vlak *et al.*, 1990; Zuidema *et al.*, 1990) and *Bombyx mori* actin (Johnson *et al.*, 1992). Multiple genes have also been successfully coexpressed in insect cells coinfecting with more than one recombinant baculovirus (O'Reilly and Miller, 1988; St Angelo *et al.*, 1987). Cellular promoter and enhancer elements which are active in insect cells are preferred for use in the present invention.

### C. Baculoviral Promoters and Enhancers

There are four distinct phases of a baculovirus infection, termed immediate-early, delayed-early, late and very late. Therefore, different baculovirus genes may be classified according to the phase of the viral infection during which they are expressed. Also there are a class of genes which have been defined as early genes, which have not been subcategorized as either immediate-early or delayed-early. Different classes of promoters control each class of gene.

#### 1. Immediate-Early Promoters

This class of promoters are distinguished by needing only host cell factors to drive expression. Examples are the *ie1* (Guarino and Summers, 1987), *ieN* (*ie2*; Carson *et al.*, 1991) and *ie0* promoters, with the *ie 1* promoter being particularly preferred for use in the present invention.

#### 2. Delayed-Early Promoters

This class of promoters are distinguished by needing only products of the immediate-early genes, in addition to host cell factors to drive expression. Examples are the 39K (Guarino and Smith, 1990) and gp64 (Blissard and Rohrmann, 1989; Whitford *et al.*, 1989) promoters, with the 39K promoter particularly preferred for use in the present invention.

#### 3. Early Promoters

This class of promoters have not been placed into the specific immediate-early of delayed-early class. Examples include the DA26, ETL and 35K promoters.

#### 4. Late Promoters

This class of promoters requires products of the delayed-early and immediate-early genes, as well as other host cell factors, to drive expression. Examples are the gp64 (Blissard and Rohrmann, 1989; Whitford *et al.*, 1989), p6.9 (Wilson *et al.*, 1987) and capsid (p39; Thiem and Miller, 1989) promoters.

### 5. Very Late Promoters

This class of promoters requires a number of baculovirus gene products, in addition to other host cell factors, to drive expression. Examples of promoters from this class are the *polyhedrin* (Hooft van Iddekinge *et al.*, 1983) and the p10 (Kuzio *et al.*, 1984) promoters. The best characterized and most often used baculoviral promoter is the *polyhedrin* promoter. The use of the *polyhedrin* promoter is a preferred embodiment of the present invention.

As mentioned, enhancers are DNA elements which can be positionally located to enhance transcription from a given promoter. Enhancers which are active in insect cells to drive transcription are preferred in the present invention. Preferred are viral enhancers, and most preferred are baculoviral enhancers.

Examples of baculoviral enhancers include hr1, hr2, hr3, hr4 and hr5 (Guarino *et al.*, 1986), with the use of the hr5 enhancer being a particularly preferred embodiment.

### VI. Selectable Marker Genes

The present invention also provides recombinant candidate screening methods which are based upon whole cell assays and which, preferably, employ a reporter gene that confers on its recombinant hosts a readily detectable phenotype that emerges only under conditions where a general DNA promoters positioned upstream of the reporter gene is functional.

Generally, reporter genes encode a polypeptide not otherwise produced by the host cell which is detectable by analysis of the cell culture, e.g., by fluorometric, radioisotopic or spectrophotometric analysis of the cell culture. Exemplary enzymes include esterases, phosphatases, proteases (tissue plasminogen activator or urokinase) and other enzymes capable of being detected by their activity, as will be known to those skilled in the art. Preferred examples are the enzyme chloramphenicol acetyltransferase (CAT) which may be employed with a radiolabelled substrate, firefly and bacterial luciferase, and even green fluorescent protein (GFP) as a marker for gene expression (Chalfie *et al.*, 1994). The use of GFP does not need exogenously added substrates, only irradiation by near UV or blue light, and thus has significant potential for use in monitoring gene expression in living cells.

Another class of reporter genes which confer detectable characteristics on a host cell are those which encode polypeptides, generally enzymes, which render their transformants

- 86 -

resistant against toxins. Examples of this class of reporter genes are the neo gene (Colberre-Garapin *et al.*, 1981) which protects host cells against toxic levels of the antibiotic G418, the gene conferring streptomycin resistance (U. S. Patent 4,430,434), the gene conferring hygromycin B resistance (Santerre *et al.*, 1984; U. S. Patents 4,727,028, 4,960,704 and 4,559,302), a gene encoding dihydrofolate reductase, which confers resistance to methotrexate (Alt *et al.*, 1978) along with many others well known in the art (Kaufman, 1990).

It is the genes or cDNAs encoding drug resistance proteins, which allow for the selection of recombinant clones in the preparation of stable cell lines, that are particularly preferred in the present invention.

## VII. Baculovirus Structural Genes and Flanking Baculovirus DNA

There are three main locations in the baculovirus genome into which recombinant expression cassettes can be transplaced. These are the gp64, the p10 and the *polyhedrin* loci. The baculovirus gp64 gene plays a central role in baculovirus infection, apparently mediating penetration of the virus into host cells during adsorptive endocytosis (Volkman and Goldsmith, 1985; Volkman *et al.*, 1984; Volkman, 1986; Blissard and Wenz, 1992; Charlton and Volkman, 1993). The present invention contemplates incorporating a functional copy of the baculovirus gp64 structural gene and promoter, as well as 5' and 3' flanking gp64 DNA segments, for constructs which use the gp64 locus of the baculovirus host for replacement of the recombinant baculovirus expression vector.

The *polyhedrin* gene can be used as a method for screening recombinant baculovirus constructs (Summers and Smith, 1987; Webb and Summers, 1990; Miller 1988). Further embodiments of the present invention comprise the 5' and 3' flanking *polyhedrin* DNA segments, for constructs which use the *polyhedrin* locus of the baculovirus host for replacement of the recombinant baculovirus expression vector. These recombinant vectors can be identified in plaque assays by their occlusion-negative phenotypes. A further embodiment would comprise the *polyhedrin* structural gene and promoter, enabling the recombinant viruses to be identified in plaque assays by their occlusion-positive phenotypes.

- 87 -

The present invention contemplates incorporating 5' and 3' flanking p10 DNA segments, either with or without a functional copy of the baculovirus p10 structural gene, for constructs which use the p10 locus of the baculovirus host for replacement of the recombinant baculovirus expression vector. Further embodiments of the present invention incorporate the necessary flanking DNA segments and structural genes and promoters into separate baculovirus expression vectors so that any combination of the three loci described above can be used for replacement of multiple recombinant baculovirus expression vectors.

The present invention also contemplates the use of immediate early and conventional baculovirus vectors as biocontrol agents, based on the idea that expression of appropriate foreign genes earlier in infection should allow immediate early recombinants to kill insect larvae faster or stop their feeding earlier than conventional *polyhedrin*- or *p10*-based recombinants. An immediate early vector designed to express an insect-specific toxin under *ie1* control failed to kill insect larvae faster than a conventional vector designed to express the same toxin under *p10* control, but the vector actually reduced feeding activity more effectively than the conventional vector. Infection of live insects or larvae require the products of the p10 and polyhedrin loci. This embodiment of the present invention contemplates incorporating a functional copy of the baculovirus p10 or polyhedrin structural gene and promoter when these loci are used for replacement of the recombinant vectors.

### VIII. Heterologous Structural Genes

A vast number of heterologous cDNAs have been expressed using the baculovirus expression system. Particularly preferred for use in the present invention is any heterologous coding region encoding for a protein in which oligosaccharide processing is desired. Below is a list of selected cloned structural genes that could be used in the present invention. The list is not in any way meant to be interpreted as limiting, only as exemplary of the types of structural genes contemplated for use in the present invention.

**TABLE 4**

## Selected Cloned Structural Genes

Gene	Clone Type*	Reference
activin	porcine-cDNA	Mason AJ, Nat, 318:659, 1985
adenosine deaminase	h-cDNA	Wiginton DA, PNAS, 80:7481, 1983
angiotensinogen I	r-cDNA	Ohkubo H, PNAS, 80:2196, 1983
	r-gDNA	Tanaka T, JBC, 259:8063, 1984
antithrombin III	h-cDNA	Bock SC, NAR 10:8113, 1982
	h-cDNA and gDNA	Prochownik EV, JBC, 258:8389, 1983
antitrypsin, alpha I	h-cDNA	Kurachi K, PNAS, 78:6826, 1981
	h-gDNA	Leicht M, Nat, 297:655, 1982
	RFLP	Cox DW, AJHG, 36:134S, 1984
apolipoprotein A-I	h-cDNA, h-gDNA	Shoulders CC, NAR, 10:4873, 1982
	RFLP	Karathanasis SK, Nat, 301:718, 1983
	h-gDNA	Kranthanas SK, PNAS, 80:6147, 1983
apolipoprotein A-II	h-cDNA	Sharpe CR, NAR, 12:3917, 1984
	Chr	Sakaguchi AY, AJHG, 36:207S, 1984
	h-cDNA	Knott TJ, BBRC, 120:734, 1984
apolipoprotein C-I	h-cDNA	Knott TJ, NAR, 12:3909, 1984
apolipoprotein C-II	h-cDNA	Jackson CL, PNAS, 81:2945, 1984
	h-cDNA	Mykelbost O, JBC, 259:4401, 1984
	h-cDNA	Fojo SS, PNAS, 81:6354, 1984
	RFLP	Humphries SE, C Gen, 26:389, 1984
apolipoprotein C-III	h-cDNA and gDNA	Karathanasis SK, Nat, 304:371, 1983
	h-cDNA	Sharpe CR, NAR, 12:3917, 1984
apolipoprotein E	h-cDNA	Breslow JL, JBC, 257:14639, 1982

**TABLE 4 cont'd**

atrial natriuretic	h-cDNA	Oikawa S, Nat, 309:724, 1984
factor	h-cDNA	Nakayama K, Nat, 310:699, 1984
	h-cDNA	Zivin RA, PNAS, 81:6325, 1984
	h-gDNA	Seidman CE, Sci, 226:1206, 1984
	h-gDNA	Nemer M, Nat, 312:654, 1984
	h-gDNA	Greenberg BI, Nat, 312:665, 1984
chorionic	h-cDNA	Fiddes JC, Nat, 281:351, 1981
gonadotropin,	RFLP	Boethby M, JBC, 256:5121, 1981
alpha chain		
chorionic	h-cDNA	Fiddes JC, Nat, 286:684, 1980
gonadotropin,	h-gDNA	Boorstein WR, Nat, 300:419, 1982
beta chain	h-gDNA	Talmadge K, Nat, 307:37, 1984
chymosin, pro	bovine-cDNA	Harris TJR, NAR, 10:2177, 1982
(rennin)		
complement, factor	h-cDNA	Woods DE, PNAS, 79:5661, 1982
B	h-cDNA and gDNA	Duncan R, PNAS, 80:4464, 1983
complement C2	h-cDNA	Bentley DR, PNAS, 81:1212, 1984
	h-gDNA (C2, C4, and B)	Carroll MC, Nat, 307:237, 1984
complement C3	m-cDNA	Domdey H, PNAS, 79:7619, 1983
	h-gDNA	Whitehead AS, PNAS, 79:5021, 1982
complement C4	h-cDNA and gDNA	Carroll MC, PNAS, 80:264, 1983
	h-cDNA	Whitehead AS, PNAS, 80:5387, 1983
complement C9	h-cDNA	DiScipio RC, PNAS, 81:7298, 1984
corticotropin	sheep - cDNA	Furutani Y, Nat, 301:537, 1983
releasing	h-gDNA	Shibahara S, EMBO J, 2:775, 1983
factor		

**TABLE 4 cont'd**

epidermal growth	m-cDNA	Gray A, Nat, 303:722, 1983
factor	m-cDNA	Scott J, Sci, 221:236, 1983
	h-gDNA	Brissenden JE, Nat, 310:781, 1984
epidermal growth	h-cDNA and Chr	Lan CR, Sci, 224:843, 1984
factor		
receptor, oncogene		
c-erb B		
epoxide dehydratase	r-cDNA	Gonzalez FJ, JBC, 256:4697, 1981
erythropoietin	h-cDNA	Lee-Huang S, PNAS, 81:2708, 1984
esterase inhibitor, Cl	h-cDNA,	Stanley KK, EMBO J, 3:1429, 1984
factor VIII	h-cDNA and gDNA	Gitschier J, Nat, 312:326, 1984
	h-cDNA	Toole JJ, Nat, 312:342, 1984
factor IX, Christmas	h-cDNA	Kutachi K, PNAS, 79:6461, 1982
factor	h-cDNA	Choo KH, Nat, 299:178, 1982
	RFLP	Camerino G, PNAS, 81:498, 1984
	h-gDNA	Anson DS, EMBO J, 3:1053, 1984
factor X	h-cDNA	Leytus SP, PNAS, 81:3699, 1984
fibrinogen A alpha,	h-cDNA	Kant JA, PNAS, 80:3953, 1983
B beta, gamma	h-gDNA (gamma)	Fornace AJ, Sci, 224:161, 1984
	h-cDNA (alpha	Imam AMA, NAR, 11:7427, 1983
	gamma)	Fornace AJ, JBC, 259:12826, 1984
	h-gDNA (gamma)	
gatrin releasing	h-cDNA	Spindel ER, PNAS, 81:5699, 1984
peptide		
glucagon, prepro	hamster-cDNA	Bell GI, Nat, 302:716, 1983
	h-gDNA	Bell GI, Nat, 304:368, 1983
growth hormone	h-cDNA	Martial JA, Sci, 205:602, 1979
	h-gDNA	DeNoto FM, NAR, 9:3719, 1981
	GH-like gene	Owerbach D, Sci, 209:289, 1980



**TABLE 4 cont'd**

growth hormone RF,	h-cDNA	Gubler V, PNAS, 80:4311, 1983
somatocrinin	h-cDNA	Mayo KE, Nat, 306:86:1983
hemopexin	h-cDNA	Stanley KK, EMBO J, 3:1429, 1984
inhibin	porcine-cDNA	Mason AJ, Nat, 318:659, 1985
insulin, prepro	h-gDNA	Ullrich a, Sci, 209:612, 1980
insulin-like growth	h-cDNA	Jansen M, Nat, 306:609, 1983
factor I	h-cDNA	Bell GI, Nat, 310:775, 1984
	Chr	Brissenden JE, Nat, 310:781, 1984
insulin-like growth	h-cDNA	Bell GI, Nat, 310:775, 1984
factor II	h-gDNA	Dull TJ, Nat, 310:777, 1984
	Chr	Brissenden JE, Nat, 310:781, 1984
interferon, alpha	h-cDNA	Maeda S, PNAS, 77:7010, 1980
(leukocyte), multiple	h-cDNA (8 distinct)	Goeddel DV, Nat, 290:20, 1981
	h-gDNA	Lawn RM, PNAS, 78:5435, 1981
	h-gDNA	Todokoro K, EMBO J, 3:1809, 1984
	h-gDNA	Torczynski RM, PNAS, 81:6451, 1984
interferon, beta	h-cDNA	Taniguchi T, Gene, 10:11, 1980
(fibroblast)	h-gDNA	Lawn RM, NAR, 9:1045, 1981
	h-gDNA (related)	Sehgal PB, PNAS, 80:3632, 1983
	h-gDNA (related)	Sagar AD, Sci, 223:1312, 1984
interferon, gamma	h-cDNA	Gray PW, Nat, 295:503, 1982
(immune)	h-gDNA	Gray PW, Nat, 298:859, 1982
interleukin-1	m-cDNA	Lomedico PT, Nat, 312:458, 1984
interleukin-2, T-cell	h-cDNA	Devos R, NAR, 11:4307, 1983
growth factor	h-cDNA	Taniguchi T, Nat, 302:305, 1983
	h-gDNA	Hollbrook NJ, PNAS, 81:1634, 1984
	Chr	Siegel LF, Sci, 223:175, 1984
interleukin-3	m-cDNA	Fung MC, Nat, 307:233, 1984
kininogen, two	bovine-cDNA	Nawa H, PNAS, 80:90, 1983
forms	bovine-cDNA and gDNA	Kitamura N, Nat, 305:545, 1983

**TABLE 4 cont'd**

luteinizing hormone, beta subunit	h-gDNA and Chr	Talmadge K, Nat, 207:37, 1984
luteinizing hormone releasing hormone	h-cDNA and gDNA	Seeburg PH, Nat, 311:666, 1984
lymphotoxin	h-cDNA and gDNA	Gray PW, Nat, 312:721, 1984
mast cell growth factor	m-cDNA	Yokoya T, PNAS, 81:1070, 1984
nerve growth factor, beta subunit	m-cDNA h-gDNA Chr	Scott J, Nat, 302:538, 1983 Ullrich A, Nat, 303:821, 1983 Franke C, Sci, 222:1248, 1983
oncogene, c-sis, PGDF chain A	h-gDNA h-cDNA	Dalla-Favera R, Nat, 295:31, 1981 Clarke MF, Nat, 208:464, 1984
pancreatic polypeptide and icosapeptide	h-cDNA	Boel E, EMBO J, 3:909, 1984
parathyroid hormone, prepro	h-cDNA h-gDNA	Hendy GN, PNAS, 78:7365, 1981 Vasicek TJ, PNAS, 80:2127, 1983
plasminogen	h-cDNA and gDNA	Malinowski DP, Fed P, 42:1761, 1983
plasminogen activator	h-cDNA h-cDNA h-gDNA	Edlund T, PNAS, 80:349, 1983 Pennica D, Nat, 301:214, 1983 Ny T, PNAS, 81:5355, 1984
prolactin	h-cDNA r-gDNA	Cook NE, JBC, 256:4007, 1981 Cooke NE, Nat, 297:603, 1982
proopiomelanocortin	h-cDNA h-gDNA	DeBold CR, Sci, 220:721, 1983 Cochet M, Nat, 297:335, 1982
protein C	h-cDNA	Foster D, PNAS, 81:4766, 1984
prothrombin	bovine-cDNA	MacGillivray RTA, PNAS, 77:5153, 1980
relaxin	h-gDNA h-cDNA (2 genes) Chr	Hudson P, Nat, 301:628, 1983 Hudson P, EMBO J, 3:2333, 1984 Crawford RJ, EMBO J, 3:2341, 1984

**TABLE 4 cont'd**

renin, prepro	h-cDNA	Imai T, PNAS, 80:7405, 1983
	h-gDNA	Hobart PM, PNAS 81:5026, 1984
	h-gDNA	Miyazaki H, PNAS, 81:5999, 1984
	Chr	Chirgwin JM, SCMG, 10:415, 1984
somatostatin	h-cDNA	Shen IP, PNAS, 79:4575, 1982
	h-gDNA and Ri-IP	Naylot SI, PNAS, 80:2686, 1983
tachykinin, prepro,	bovine-cDNA	Nawa H, Nat, 306:32, 1983
substances P&K	bovine-gDNA	Nawa H, Nat, 312:729, 1984
urokinase	h-cDNA	Verde P, PNAS, 81:4727, 1984
vasoactive intestinal	h-cDNA	Itoh N, Nat, 304:547, 1983
peptide, prepro		
vasopressin	r-cDNA	Schmale H, EMBO J, 2:763, 1983

Key to Table 4: \*cDNA - complementary DNA; Chr - chromosome; gDNA  
 - genomic DNA; RFLP - restriction fragment polymorphism; h - human; m -  
 5 mouse; r - rat

### IX. Cloning Site

Cloning sites allow for the insertion and proper orientation of a heterologous gene of interest. Cloning sites are DNA regions comprising a recognition site for a DNA  
 10 restriction endonuclease. Multiple cloning sites are DNA regions comprising two or more recognition sites for DNA restriction endonucleases, improving the utility of vectors which contain them. DNA fragments containing multiple cloning sites are commercially available or easily synthesized, and well known to practitioners in the art. A multiple cloning site comprising the recognition sites for five, six, seven, eight, nine, ten or more  
 15 DNA restriction endonucleases is preferred for use in the present invention. A multiple cloning site positioned downstream from a promoter element is a particularly preferred embodiment of the present invention.

## X. Insect Cell Lines

Insect cell lines which contain appropriate transcriptional factors to drive expression of the structural genes provided in the baculovirus expression vectors of the present invention are preferred for use. Examples include *Spodoptera frugiperda*, *Bombyx mori*, *Heliothis virescens*, *Heliothis zea*, *Mamestra brassicae*, *Estigmene acrea* and *Trichoplusia ni*.

## XI. Methods for Transfection, Infection, Cell Culture, and Protein Production and Purification

General methods involved in the use of the present invention, including methods for cell growth and maintenance, production of recombinant baculoviruses, infection of insect cells, and analysis of expressed proteins in insect cells are provided in detail in the Examples below. Also, good general references on the various techniques needed to practice the current invention are available (O'Reilly *et al.*, 1992).

## XII. $\alpha$ -Mannosidase I and $\alpha$ -Mannosidase II DNA Segments

Further aspects of the present invention concern isolated DNA segments and recombinant vectors encoding  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II, and the creation and use of recombinant host cells through the application of DNA technology, that express  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II.

The present invention concerns DNA segments, isolatable from uninfected *Spodoptera frugiperda* Sf-9 cells, that are free from total genomic DNA and are capable of conferring  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II activity to a recombinant host cell when incorporated into the recombinant host cell. As used herein, the term  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II activity indicates the ability to cleave mannose residues from  $\text{Man}_9\text{-GlcNAc}_2$  to produce  $\text{Man}_5\text{-GlcNAc}_2$  ( $\alpha$ -mannosidase I) and the ability to cleave two mannose residues from  $\text{Man}_5\text{-GlcNAc}_2$  to produce  $\text{Man}_3\text{-GlcNAc}_2$  ( $\alpha$ -mannosidase II).

As used herein, the term "DNA segment" refers to a DNA molecule that has been isolated free of total genomic DNA of a particular species. Therefore, a DNA segment encoding  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II refers to a DNA segment that contains  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II coding sequences yet is isolated away from, or

purified free from, total genomic DNA of *Spodoptera frugiperda*. Included within the term "DNA segment", are DNA segments and smaller fragments of such segments, and also recombinant vectors, including, for example, plasmids, cosmids, phage, viruses, and the like.

5 Similarly, a DNA segment comprising an isolated or purified  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II gene refers to a DNA segment including  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II gene coding sequences and, in certain aspects, regulatory sequences, isolated substantially away from other naturally occurring genes or protein encoding sequences. In this respect, the term "gene" is used for simplicity to refer to a functional  
10 protein, polypeptide or peptide encoding unit. As will be understood by those in the art, this functional term includes both genomic sequences, cDNA sequences and smaller engineered gene segments that express, or may be adapted to express, proteins, polypeptides or peptides.

"Isolated substantially away from other coding sequences" means that the gene of  
15 interest, in this case  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II gene, forms the significant part of the coding region of the DNA segment, and that the DNA segment does not contain large portions of naturally-occurring coding DNA, such as large chromosomal fragments or other functional genes or cDNA coding regions. Of course, this refers to the DNA segment as originally isolated, and does not exclude genes or coding regions later added to  
20 the segment by the hand of man.

In particular embodiments, the invention concerns isolated DNA segments and recombinant vectors incorporating DNA sequences that encode an  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II gene that includes within its amino acid sequence a contiguous amino acid sequence from SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:4 ( $\alpha$ -mannosidase II),  
25 corresponding to *Spodoptera frugiperda*.

Naturally, where the DNA segment or vector encodes a full length  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II protein, or is intended for use in expressing the  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II protein, the most preferred sequences are those that are essentially as set forth in the full length contiguous sequence of SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ  
30 ID NO:4 ( $\alpha$ -mannosidase II), and that encode a protein that retains  $\alpha$ -mannosidase I or  $\alpha$ -

mannosidase II activity, e.g., as may be determined by the  $\alpha$ -mannosidase assay, as disclosed herein (Example 10).

5 Sequence of the present invention will substantially correspond to a contiguous portion of SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:4 ( $\alpha$ -mannosidase II), and have relatively few amino acids that are not identical to, or a biologically functional equivalent of, the amino acids of SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:4 ( $\alpha$ -mannosidase II). The term "biologically functional equivalent" is well understood in the art and is further defined in detail herein (Section XVI).

10 Accordingly, sequences that have between about 70% and about 80%; or more preferably, between about 81% and about 90%; or even more preferably, between about 91% and about 99%; of amino acids that are identical or functionally equivalent to the amino acids of SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:4 ( $\alpha$ -mannosidase II) will be sequences that are "essentially as set forth in SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:4 ( $\alpha$ -mannosidase II).

15 In certain other embodiments, the invention concerns isolated DNA segments and recombinant vectors that include within their sequence a contiguous nucleic acid sequence from SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II). This definition is used in the same sense as described above and means that the nucleic acid sequence substantially corresponds to a contiguous portion of SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II) and has relatively few codons that  
20 are not identical, or functionally equivalent, to the codons of SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II). Again, DNA segments that encode proteins exhibiting  $\alpha$ -mannosidase I or  $\alpha$ -mannosidase II activity will be most preferred. The term "functionally equivalent codon" is used herein to refer to codons that encode the  
25 same amino acid, such as the six codons for arginine or serine, and also refers to codons that encode biologically equivalent amino acids. See Table 5 below.

- 97 -

**TABLE 5**

<b>Amino Acids</b>		<b>Codons</b>							
Alanine	Ala	A	GCA	GCC	GCG	GCU			
Cysteine	Cys	C	UGC	UGU					
Aspartic acid	Asp	D	GAC	GAU					
Glutamic acid	Glu	E	GAA	GAG					
Phenylalanine	Phe	F	UUC	UUU					
Glycine	Gly	G	GGA	GGC	GGG	GGU			
Histidine	His	H	CAC	CAU					
Isoleucine	Ile	I	AUA	AUC	AUU				
Lysine	Lys	K	AAA	AAG					
Leucine	Leu	L	UUA	UUG	CUA	CUC	CUG	CUU	
Methionine	Met	M	AUG						
Asparagine	Asn	N	AAC	AAU					
Proline	Pro	P	CCA	CCC	CCG	CCU			
Glutamine	Gln	Q	CAA	CAG					
Arginine	Arg	R	AGA	AGG	CGA	CGC	CGG	CGU	
Serine	Ser	S	AGC	AGU	UCA	UCC	UCG	UCU	
Threonine	Thr	T	ACA	ACC	ACG	ACU			
Valine	Val	V	GUA	GUC	GUG	GUU			
Tryptophan	Trp	W	UGG						
Tyrosine	Tyr	Y	UAC	UAU					

It will also be understood that amino acid and nucleic acid sequences may include additional residues, such as additional N- or C-terminal amino acids or 5' or 3' sequences, and yet still be essentially as set forth in one of the sequences disclosed herein, so long as the sequence meets the criteria set forth above, including the maintenance of biological protein activity where protein expression is concerned. The addition of terminal sequences particularly applies to nucleic acid sequences that may, for example, include various non-coding sequences flanking either of the 5' or 3' portions of the coding region or may include various internal sequences, i.e., introns, which are known to occur within genes.

- 98 -

Excepting intronic or flanking regions, and allowing for the degeneracy of the genetic code, sequences that have between about 70% and about 79%; or more preferably, between about 80% and about 89%; or even more preferably, between about 90% and about 99% of nucleotides that are identical to the nucleotides of SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II) will be sequences that are "essentially as set forth in SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II). Sequences that are essentially the same as those set forth in SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II) may also be functionally defined as sequences that are capable of hybridizing to a nucleic acid segment containing the complement of SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II) under relatively stringent conditions. Suitable relatively stringent hybridization conditions will be well known to those of skill in the art and are clearly set forth herein (Example 7).

Naturally, the present invention also encompasses DNA segments that are complementary, or essentially complementary, to the sequence set forth in SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II). Nucleic acid sequences that are "complementary" are those that are capable of base-pairing according to the standard Watson-Crick complementarity rules. As used herein, the term "complementary sequences" means nucleic acid sequences that are substantially complementary, as may be assessed by the same nucleotide comparison set forth above, or as defined as being capable of hybridizing to the nucleic acid segment of SEQ ID NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II) under relatively stringent conditions such as those described herein in Example 7.

The nucleic acid segments of the present invention, regardless of the length of the coding sequence itself, may be combined with other DNA sequences, such as promoters, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, other coding segments, and the like, such that their overall length may vary considerably. It is therefore contemplated that a nucleic acid fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol. For example, nucleic acid fragments may be prepared that include a short contiguous stretch identical to or complementary to SEQ ID



- 99 -

NO:1 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 ( $\alpha$ -mannosidase II), such as about 14 nucleotides, and that are up to about 10,000 or about 5,000 base pairs in length, with segments of about 3,000 being preferred in certain cases. DNA segments with total lengths of about 1,000, about 500, about 200, about 100 and about 50 base pairs in length (including all intermediate lengths) are also contemplated to be useful.

It will be readily understood that "intermediate lengths", in these contexts, means any length between the quoted ranges, such as 14, 15, 16, 17, 18, 19, 20, etc.; 21, 22, 23, etc.; 30, 31, 32, etc.; 50, 51, 52, 53, etc.; 100, 101, 102, 103, etc.; 150, 151, 152, 153, etc.; including all integers through the 200-500; 500-1,000; 1,000-2,000; 2,000-3,000; 3,000-5,000; 5,000-10,000 ranges, up to and including sequences of about 12,001, 12,002, 13,001, 13,002 and the like.

It will also be understood that this invention is not limited to the particular nucleic acid and amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 ( $\alpha$ -mannosidase I) and SEQ ID NO:3 and SEQ ID NO:4 ( $\alpha$ -mannosidase II), respectively. Recombinant vectors and isolated DNA segments may therefore variously include the  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II coding regions themselves, coding regions bearing selected alterations or modifications in the basic coding region, or they may encode larger polypeptides that nevertheless include  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II -coding regions or may encode biologically functional equivalent proteins or peptides that have variant amino acids sequences.

The DNA segments of the present invention encompass biologically functional equivalent  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II proteins and peptides. Such sequences may arise as a consequence of codon redundancy and functional equivalency that are known to occur naturally within nucleic acid sequences and the proteins thus encoded. Alternatively, functionally equivalent proteins or peptides may be created via the application of recombinant DNA technology, in which changes in the protein structure may be engineered, based on considerations of the properties of the amino acids being exchanged. Changes designed by man may be introduced through the application of site-directed mutagenesis techniques, e.g., to introduce improvements to the antigenicity of the protein or to test  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II mutants in order to examine  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II activity at the molecular level.

If desired, one may also prepare fusion proteins and peptides, e.g., where the  $\alpha$ -mannosidase I and  $\alpha$ -mannosidase II coding regions are aligned within the same expression unit with other proteins or peptides having desired functions, such as for purification or immunodetection purposes (e.g., proteins that may be purified by affinity chromatography and enzyme label coding regions, respectively).

### **XIII. Cloning Insect Oligosaccharide Processing and Protein Folding Accessory Genes**

The present inventor contemplates cloning oligosaccharide processing and protein folding accessory genes or cDNAs from insect cells, and particularly,  $\alpha$ -glucosidase I and  $\alpha$ -glucosidase II, N-acetylglucosaminyltransferase I, N-acetylglucosaminyltransferase II, protein disulphide isomerase, peptidyl prolyl *cis-trans* isomerase and BiP/GRP78. The insect cells contemplated for use include Sf-9, High Five and Ea cells.

A technique often employed by those skilled in the art of protein production today is to obtain a so-called "recombinant" version of the protein, to express it in a recombinant cell and to obtain the protein from such cells. These techniques are based upon the "cloning" of a DNA molecule encoding the protein from a DNA library, i.e., on obtaining a specific DNA molecule distinct from other portions of DNA. This can be achieved by, for example, cloning a cDNA molecule, or cloning a genomic-like DNA molecule.

The first step in such cloning procedures is the screening of an appropriate DNA library, such as, in the present case, a lambda ZAP II™ cDNA library from uninfected Sf-9 cells. The screening procedure may be an expression screening protocol employing antibodies directed against the protein, or activity assays. For example, antibody screening is very routinely employed. Alternatively, screening may be based on the hybridization of oligonucleotide probes, designed from a consideration of portions of the amino acid sequence of the protein, or from the DNA sequences of genes encoding related proteins. The operation of such screening protocols are well known to those of skill in the art and are described in detail in the scientific literature, for example, in Sambrook *et al.* (1989), incorporated herein by reference. Moreover, as the present invention encompasses the cloning of genomic segments as well as cDNA molecules, it is contemplated that suitable genomic cloning methods, as known to those in the art, may also be used.

#### XIV. Use in Insect Control

Baculoviruses have been used throughout this century for insect pest control. The present invention contemplates two novel uses of baculoviruses in this manner. The gp64 protein is involved in the infectivity and virulence of baculovirus, mainly through the oligosaccharide side chains. The current invention provides for a method of alteration of the oligosaccharides on gp64 (Example 13 and 14). An embodiment of the current invention is to use the vectors described herein to alter the glycoprotein structure, thereby altering the infectivity and virulence of the recombinant baculoviruses. A further embodiment includes delivering known insect toxins, such as *Bacillus thuringiensis* crystal toxin, protease inhibitor II, rice lectin, AaIT, LqhIT2 or juvenile hormone esterase, with juvenile hormone esterase particularly preferred.

#### XV. Site-Specific Mutagenesis

Site-specific mutagenesis is a technique useful in the preparation of individual peptides, or biologically functional equivalent proteins or peptides, through specific mutagenesis of the underlying DNA. The technique further provides a ready ability to prepare and test sequence variants, for example, incorporating one or more of the foregoing considerations, by introducing one or more nucleotide sequence changes into the DNA. Site-specific mutagenesis allows the production of mutants through the use of specific oligonucleotide sequences which encode the DNA sequence of the desired mutation, as well as a sufficient number of adjacent nucleotides, to provide a primer sequence of sufficient size and sequence complexity to form a stable duplex on both sides of the deletion junction being traversed. Typically, a primer of about 17 to 25 nucleotides in length is preferred, with about 5 to 10 residues on both sides of the junction of the sequence being altered.

In general, the technique of site-specific mutagenesis is well known in the art as exemplified by publications (Adelman *et al.*, 1983). As will be appreciated, the technique typically employs a phage vector which exists in both a single stranded and double stranded form. Typical vectors useful in site-directed mutagenesis include vectors such as the M13 phage (Messing *et al.*, 1981). These phage are readily commercially available

- 102 -

and their use is generally well known to those skilled in the art. Double stranded plasmids are also routinely employed in site directed mutagenesis which eliminates the step of transferring the gene of interest from a plasmid to a phage.

5 In general, site-directed mutagenesis in accordance herewith is performed by first obtaining a single-stranded vector or melting apart the two strands of a double stranded vector which includes within its sequence a DNA sequence which encodes an oligosaccharide processing enzyme. An oligonucleotide primer bearing the desired mutated sequence is prepared, generally synthetically, for example by the method of Crea  
10 *et al.* (1978). This primer is then annealed with the single-stranded vector, and subjected to DNA polymerizing enzymes such as *E. coli* polymerase I Klenow fragment, in order to complete the synthesis of the mutation-bearing strand. Thus, a heteroduplex is formed wherein one strand encodes the original non-mutated sequence and the second strand bears the desired mutation. This heteroduplex vector is then used to transform appropriate cells, such as *E. coli* cells, and clones are selected which include recombinant vectors bearing  
15 the mutated sequence arrangement.

The preparation of sequence variants of the selected oligosaccharide processing gene using site-directed mutagenesis is provided as a means of producing potentially useful oligosaccharide processing enzyme species and is not meant to be limiting as there are other ways in which sequence variants of the oligosaccharide processing enzyme may  
20 be obtained. For example, recombinant vectors encoding the desired oligosaccharide processing enzyme gene may be treated with mutagenic agents to obtain sequence variants (see, *e.g.*, a method described by Eichenlaub, 1979) for the mutagenesis of plasmid DNA using hydroxylamine.

## 25 XVI. Protein Purification

Further aspects of the present invention concern the purification, and in particular embodiments, the substantial purification, of a recombinant heterologous protein. The term "purified recombinant heterologous protein" as used herein, is intended to refer to a recombinant heterologous protein composition, isolatable from recombinant host insect  
30 cells, wherein the recombinant heterologous protein is purified to any degree relative to its naturally-obtainable state, *i.e.*, in this case, relative to its purity within a natural extract. A

purified recombinant heterologous protein therefore also refers to a recombinant heterologous protein free from the environment in which it may naturally occur.

Generally, "purified" will refer to a recombinant heterologous protein composition which has been subjected to fractionation to remove various non-insect cell components such as other cell components. Various techniques suitable for use in protein purification will be well known to those of skill in the art. These include, for example, precipitation with ammonium sulphate, PEG, antibodies and the like or by heat denaturation, followed by centrifugation; chromatography steps such as ion exchange, gel filtration, reverse phase, hydroxylapatite, lectin affinity and other affinity chromatography steps; isoelectric focusing; gel electrophoresis; and combinations of such and other techniques.

Methods exhibiting a lower degree of relative purification may have advantages in total recovery of protein product, or in maintaining the activity of an expressed protein. Inactive products also have utility in certain embodiments, such as, e.g., in antibody generation.

Partially purified recombinant heterologous protein fractions for use in such embodiments may be obtained by subjecting a insect cell extract to one or a combination of the steps described above. Substituting certain steps with improved equivalents is also contemplated to be useful. For example, it is appreciated that a cation-exchange column chromatography performed utilizing an HPLC apparatus will generally result in a greater - fold purification than the same technique utilizing a low pressure chromatography system.

## **XVII. Biological Functional Equivalents**

As mentioned above, modification and changes may be made in the structure of oligosaccharide processing enzymes and still obtain a molecule having like or otherwise desirable characteristics. For example, certain amino acids may be substituted for other amino acids in a protein structure without appreciable loss of oligosaccharide processing capabilities. Since it is the interactive capacity and nature of a protein that defines that protein's biological functional activity, certain amino acid sequence substitutions can be made in a protein sequence (or, of course, its underlying DNA coding sequence) and nevertheless obtain a protein with like (agonistic) properties. Equally, the same considerations may be employed to create a protein or polypeptide with countervailing

(e.g., antagonistic) properties. It is thus contemplated by the inventors that various changes may be made in the sequence of oligosaccharide processing proteins or peptides (or underlying DNA) without appreciable loss of their biological utility or activity.

5 In terms of functional equivalents, It is also well understood by the skilled artisan that, inherent in the definition of a biologically functional equivalent protein or peptide, is the concept that there is a limit to the number of changes that may be made within a defined portion of the molecule and still result in a molecule with an acceptable level of equivalent biological activity. Biologically functional equivalent peptides are thus defined herein as those peptides in which certain, not most or all, of the amino acids may be  
10 substituted. Of course, a plurality of distinct proteins/peptides with different substitutions may easily be made and used in accordance with the invention.

It is also well understood that where certain residues are shown to be particularly important to the biological or structural properties of a protein or peptide, e.g., residues in active sites, such residues may not generally be exchanged.

15 Conservative substitutions well known in the art include, for example, the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or  
20 isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; and valine to isoleucine or leucine.

In making such changes, the hydropathic index of amino acids may be considered. Each amino acid has been assigned a hydropathic index on the basis of their  
25 hydrophobicity and charge characteristics, these are: isoleucine (+4.5); valine (+4.2); leucine (+3.8); phenylalanine (+2.8); cysteine/cystine (+2.5); methionine (+1.9); alanine (+1.8); glycine (-0.4); threonine (-0.7); serine (-0.8); tryptophan (-0.9); tyrosine (-1.3); proline (-1.6); histidine (-3.2); glutamate (-3.5); glutamine (-3.5); aspartate (-3.5); asparagine (-3.5); lysine (-3.9); and arginine (-4.5).

30 The importance of the hydropathic amino acid index in conferring interactive biological function on a protein is generally understood in the art (Kyte & Doolittle, 1982,

incorporated herein by reference). It is known that certain amino acids may be substituted for other amino acids having a similar hydropathic index or score and still retain a similar biological activity. In making changes based upon the hydropathic index, the substitution of amino acids whose hydropathic indices are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

It is also understood in the art that the substitution of like amino acids can be made effectively on the basis of hydrophilicity. U.S. Patent 4,554,101, incorporated herein by reference, states that the greatest local average hydrophilicity of a protein, as governed by the hydrophilicity of its adjacent amino acids, correlates with its immunogenicity and antigenicity, i.e. with a biological property of the protein. use this shorter portion for non-immunological stuff It is understood that an amino acid can be substituted for another having a similar hydrophilicity value and still obtain a biologically equivalent, and in particular, an immunologically equivalent protein.

As detailed in U.S. Patent 4,554,101, the following hydrophilicity values have been assigned to amino acid residues: arginine (+3.0); lysine (+3.0); aspartate (+3.0  $\pm$  1); glutamate (+3.0  $\pm$  1); serine (+0.3); asparagine (+0.2); glutamine (+0.2); glycine (0); threonine (-0.4); proline (-0.5  $\pm$  1); alanine (-0.5); histidine (-0.5); cysteine (-1.0); methionine (-1.3); valine (-1.5); leucine (-1.8); isoleucine (-1.8); tyrosine (-2.3); phenylalanine (-2.5); tryptophan (-3.4).

In making changes based upon similar hydrophilicity values, the substitution of amino acids whose hydrophilicity values are within  $\pm 2$  is preferred, those which are within  $\pm 1$  are particularly preferred, and those within  $\pm 0.5$  are even more particularly preferred.

While discussion has focused on functionally equivalent polypeptides arising from amino acid changes, it will be appreciated that these changes may be effected by alteration of the encoding DNA; taking into consideration also that the genetic code is degenerate and that two or more codons may code for the same amino acid. A table of amino acids and their codons is presented herein for use in such embodiments, as well as for other uses, such as in the design of probes and primers and the like.

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed

- 106 -

in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

### EXAMPLE 1

#### Construction of pIE1HR1, 2, 3, and 4

These four plasmids are designed to facilitate the expression of foreign gene products under *iel* control in stably-transformed or transiently transfected lepidopteran insect cells. The *iel* 5' untranslated region and most of the open reading frame were deleted from the *Autographa californica* multicapsid nuclear polyhedrosis virus (AcMNPV) *iel* gene by digesting pAcIE1 (Guarino and Summers, 1986) with *Sma*I and *Hinc*II. The deleted fragment was replaced with a blunt-ended PCR<sup>TM</sup> amplicon containing the 5' end of the *iel* gene from -84 to +3. The primers used to produce this amplicon (IE1-84+: 5'-CAGTATAAATTGACGTTC-3' (SEQ ID NO:5); and IE1+3-: 5'-TTTGGATCCATAGTCACTTGGTTGTT-3' (SEQ ID NO:6)) were designed to add a *Bam*HI site just downstream of the initiation codon in the *iel* gene (the first base of this ATG is defined as position +1).

The sequence of the cloned PCR<sup>TM</sup> amplicon was checked by direct sequencing of double-stranded templates using a commercial sequencing kit (Sequenase<sup>TM</sup> 2.0; United States Biochemical Corp., Cleveland, OH). The resulting plasmid, pIE184*Bam*, was used to isolate a DNA fragment containing the 5' end of the *iel* gene from -38 to +2 followed immediately by a *Bam*HI site (GGATCC), a short cap sequence (AAAA) from the downstream PCR<sup>TM</sup> primer (IE1+3-; SEQ ID NO:6), a sequence from the 3' end of the *iel* gene (from position +1255 to +2491), and a short sequence from the pUC8 vector (from *Hind*III in the multiple cloning site to *Nar*I in the *lacZ'* gene). This 1431 bp fragment was used to replace the corresponding fragment in pAcIE1, which resulted in regeneration of the *iel* untranslated region from position -600 to -1, followed by the ATG, an overlapping



- 107 -

*Bam*HI site, the short cap sequence, the 3' end of the *ie1* gene from position +1255 to +2491, which includes a polyadenylation site, and the pUC8 vector.

This new plasmid, pIE1600Pre*Bam*, was linearized with *Bam*HI, the overhangs were removed with mung bean nuclease, and a blunt-ended *Mlu*I fragment from pHR5, which contains the AcMNPV hr5 enhancer element (Guarino *et al.*, 1986), was inserted. This produced pIE1600*Bam*HR, in which the enhancer element is oriented in the same direction as the *ie1* promoter at the upstream *Bam*HI site (position -600). A synthetic oligonucleotide encoding a multiple cloning site (mcs) was inserted into the single remaining *Bam*HI site of pIE1600*Bam*HR to produce pIE1HR1 and pIE1HR2 (FIG. 1A), which have the insert in opposite orientations with respect to the *ie1* promoter (mcs1 (SEQ ID NO:7) and mcs2 (SEQ ID NO:8)). This same linker also was inserted into the unique *Bam*HI site of pIE1600*Bam*HRDATG, in which the *ie1* translational initiation site (ACTATG) of pIE1600*Bam*HR had been changed to ACCGCG by site-directed mutagenesis (Kunkel, 1985). This produced pIE1HR3 and pIE1HR4 (FIG. 1A), which lack the *ie1* initiation codon and contain the mcs in opposite orientations with respect to the *ie1* promoter (mcs3 (SEQ ID NO:9) and mcs4 (SEQ ID NO:10)).

The pIE1HR plasmids (FIG. 1A) are designed to facilitate transient expression of a foreign gene in uninfected insect cells (Guarino and Summers, 1986) or isolation of transformed insect cell clones that can express a foreign gene constitutively, in the absence of baculovirus infection (Jarvis *et al.*, 1990; Jarvis, 1993; Jarvis and Guarino, 1995; Kleymann *et al.*, 1993; Joyce *et al.*, 1993; Vulsteke *et al.*, 1993; Cartier *et al.*, 1994). Each of these plasmids has the AcMNPV hr5 enhancer element (483 bp; Guarino *et al.*, 1986) positioned upstream and in the same orientation as the *ie1* promoter. In pIE1HR1 and 2, the *ie1* promoter sequence extends from position -600 to +3, with +1 defined as the first nucleotide of the *ie1* ATG (Guarino and Summers, 1987). In pIE1HR3 and 4, the promoter sequence extends from position -600 to -2. Thus, pIE1HR1 and 2 include the *ie1* translational initiation site and can be used to produce fusion proteins, while pIE1HR3 and 4 lack this site and can be used to produce native proteins. The *ie1* promoter in these four plasmids is followed by a mcs with several unique restriction sites. The mcs found in each plasmid is designated by a number (mcs1, mcs2, mcs3, or mcs4) that matches the number of the plasmid (pIE1HR1, pIE1HR2, pIE1HR3, or pIE1HR4) and the sequence of each

mcs region, beginning at position -6 of the *ie1* promoter, is shown in the brief description of FIG. 1 herein above. Each mcs is followed by the 3' end of the *ie1* gene (positions +1255 to +2491), which includes a polyadenylation site. These plasmids are all derivatives of pUC8 (Vieira and Messing, 1982), which carries an ampicillin resistance marker and has the pMB1 replicon.

The immediate early expression plasmids shown in FIG. 1A facilitate transient expression assays in insect cells or the production of stably-transformed insect cells by providing flexibility in cloning foreign genes under *ie1* control. These plasmids include all the promoter sequences that have been shown to be important for *ie1*-mediated gene expression in uninfected insect cells (Pullen and Friesen, 1995). They also include the hr5 enhancer element, which has been shown to stimulate *ie1*-mediated foreign gene expression (Pullen and Friesen, 1995; Rodems and Friesen, 1993; Guarino and Dong, 1994). Therefore, these plasmids provide optimal levels of foreign gene transcription in transiently-transfected or stably-transformed insect cells (Cartier *et al.*, 1994; Pullen and Friesen, 1995; Rodems and Friesen, 1993). In addition to their potential utility as a tool for foreign glycoprotein production, stably-transformed insect cells produced using these plasmids can be used as helper cells to facilitate studies on essential baculovirus, or as modified hosts to study insect cell biology and the baculovirus-host cell interaction (Cartier *et al.*, 1994; Jarvis, 1993).

#### **Construction of pAcP(-)IE1TV5 and 6 and pAcP(+)IE1TV1, 2, 3, and 4**

The pAcP(-)IE1TV5 and 6 plasmids are designed to facilitate the isolation of occlusion-negative recombinant baculoviruses in which a foreign gene of interest can be expressed under the control of the *ie1* promoter during the immediate early phase of infection. pAcP(-)IE1TV5 was constructed by replacing the *EcoRV-BamHI* fragment of pVL1393 (O'Reilly *et al.*, 1992) with the *SmaI-BamHI* fragment of pIE1600*BamHR*. This effectively replaced the *polyhedrin* sequence from -92 to +177 with the *ie1* sequence from -600 to +3, regenerated an overlapping unique *BamHI* site, and maintained some additional unique cloning sites immediately downstream (FIG. 1B). This same strategy was used to construct pAcP(-)IE1TV6, except the *EcoRV-BamHI* fragment from pVL1393

was replaced with the *Sma*I-*Bam*HI fragment of pIE1600*Bam*HRDATG, in which the *ie1* ATG had been eliminated by site-directed mutagenesis.

The pAcP(+)*IE1TV1*, 2, 3, and 4 plasmids are designed for the isolation of occlusion-positive recombinants that can express a foreign gene under *ie1* control during the immediate early phase of infection. First pAcPolh was constructed, which contained the full-length AcMNPV *polyhedrin* gene with about 2 Kb and 1.5 Kb of 5' and 3' flanking sequences, respectively, and ultimately served as the target for inserting a DNA fragment encoding the hr5 enhancer, *ie1* promoter, and mcs. A precursor, pAcPolh-5', was constructed by inserting the *Xho*I-*Bam*HI fragment of pAcPstI-D into the *Sa*II-*Bam*HI sites of pUC18 (Yanisch-Perron *et al.*, 1985), then the 1.94 Kb *Bam*HI fragment of pAcPstI-D was inserted into the unique *Bam*HI site of pAc-Polh-5' to produce pAcPolh. pAcP(+)*IE1TV1*, 2, 3, or 4 (FIG. 1C) were constructed by inserting the hr5-*ie1*-mcs fragments from pIE1HR1, 2, 3, or 4, respectively, into the unique *Eco*RV site of pAcPolh. pAcP(+)*IE1TV1* and 2 contain the hr5 enhancer element, the *ie1* promoter from -600 to -1, and the *ie1* ATG, followed by mcs1 or mcs2. pAcP(+)*IE1TV3* and 4 have the enhancer and the *ie1* promoter from -600 to -2, followed by mcs3 or mcs4, but lack the *ie1* ATG.

The pAcP(-)*IE1TV* (FIG. 1B) and pAcP(+)*IE1TV* (FIG. 1C) transfer plasmids are designed for the production of occlusion-negative or -positive recombinant baculovirus vectors, respectively, that can express a foreign gene beginning immediately after infection. Each of these plasmids has the hr5 enhancer and *ie1* promoter from positions -600 to +3 or -600 to -2, as described above. Thus, some include the *ie1* translational start site and can be used to express fusion proteins, whereas others lack it and can be used to express native proteins. The *ie1* promoter in each plasmid is followed by a mcs with several unique restriction sites; as above, the number following the name of the plasmid indicates which mcs it contains and the various mcs sequences are shown in the brief description of FIG. 1 herein above.

In the pAcP(-)*IE1TV* plasmids, the mcs is followed by sequences which begin in the middle of the *polyhedrin* open reading frame (at position +177 with respect to the *polyhedrin* ATG) and extend about 2.8 Kb downstream through the *polyhedrin* polyadenylation site. The sequence on the other side of the hr5-*ie1*-mcs complex in the pAcP(-)*IE1TV* plasmids begins at the *Eco*RV site in the *polyhedrin* promoter region

- 110 -

(position -92 with respect to the *polyhedrin* ATG) and extends about 4.0 kb in the 5' direction with respect to the *polyhedrin* ATG. Thus, as in conventional *polyhedrin*-based baculovirus transfer plasmids, these long flanking sequences will target the foreign gene to the *polyhedrin* locus where it can be inserted by homologous recombination. This produces *polyhedrin*-negative recombinants, which can be identified in plaque assays by their occlusion-negative phenotypes.

By contrast, the mcs in the pAcP(+)IE1TV plasmids is followed by sequences that begin at the *EcoRV* site in the promoter region of the *polyhedrin* gene (position -92) and extend about 2.1 kb in the 5' direction with respect to the *polyhedrin* ATG (FIG. 1C). The sequences preceding the hr5-*ie1*-mcs complex in the pAcP(+)IE1TV plasmids begin at the *EcoRV* site and extend about 2.2 Kb in the 3' direction with respect to the *polyhedrin* ATG. Thus, these plasmids have an intact *polyhedrin* promoter, open reading frame, and 3' flanking sequence positioned upstream and in opposite orientation to the hr5-*ie1*-mcs and a long flanking sequence from the 5' side of the *polyhedrin* gene positioned downstream and in opposite orientation to the hr5-*ie1*-mcs. As with the pAcP(-)IE1TV plasmids, the pAcP(+)IE1TV plasmids can be used to insert the foreign gene into the *polyhedrin* locus by homologous recombination. However, these latter transfer plasmids will produce occlusion-positive recombinants that can be distinguished by their plaque phenotypes only if genomic DNA from an occlusion-negative virus is used as the target for homologous recombination.

The immediate early baculovirus transfer plasmids shown in FIG. 1B and FIG. 1C are designed to facilitate the isolation of either occlusion-negative or -positive recombinant baculoviruses that can be used to express foreign genes during the early phase of infection. The availability of multiple plasmids designed to produce recombinants with either plaque phenotype provides flexibility in the choice of screening techniques and allows one to produce either environmentally labile (occlusion-negative) or stable (occlusion-positive) recombinants for use as biopesticides (Section XIII). It should be noted that the pAcP(-)IE1TV and pAcP(+)IE1TV transfer plasmids will target the *ie1*-driven foreign gene for insertion into the viral genome in opposite orientations and the sequences, including potential polyadenylation sites, downstream of the inserts will be completely different. These differences might influence the levels of expression that can be obtained with

- 111 -

immediate early baculovirus vectors produced with these different types of transfer plasmids.

## EXAMPLE 2

### 5                    Isolation and analysis of immediate early baculovirus vectors    that express *E. coli* $\beta$ -gal.

10                    The *E. coli lacZ* gene was inserted into pAcP(-)IE1TV1 or pAcP(+)IE1TV1 and the resulting plasmids were used to isolate immediate early baculovirus vectors. The *Bam*HI fragment of pVL1393- $\beta$ gal was inserted into the unique *Bam*HI site of pAcP(-)IE1TV5 or *Bgl*II site of pAcP(+)IE1TV1 to produce pAcP(-)IE1 $\beta$ gal or pAcP(+)IE1 $\beta$ gal, respectively. pAcP(-)IE1 $\beta$ gal is designed to express a fusion protein under the influence of the hr5 enhancer and *ie1* promoter which initiates at the *ie1* ATG and has two linker amino acids (D-P) fused to amino acids 10-1024 of  $\beta$ -gal. pAcP(+)IE1 $\beta$ gal is identical, except it encodes a fusion protein with four linker amino acids (D-L-D-P) fused to  $\beta$ -gal  
15                    and also has an intact *polyhedrin* gene oriented in the opposite direction.

Working stocks of these viruses were prepared, titered, and used as follows. Occlusion-negative or -positive recombinant viruses were isolated after calcium phosphate-mediated cotransfection of Sf9 cells with a mixture of the appropriate transfer plasmid and viral DNA, as described previously (Summers and Smith, 1987). The transfer  
20                    plasmids used to isolate occlusion-negative recombinants expressing  $\beta$ -gal, CAT (Example 3), or t-PA (Example 4) were pAcP(-)IE1 $\beta$ gal, pAcP(-)IE1CAT, and pAcP(-)IE1tPA, respectively. The viral DNA was from wild-type AcMNPV and recombinants were identified by their occlusion-negative blue ( $\beta$ -gal) or white (CAT and t-PA; Examples 3 and 4) phenotypes in plaque assays containing X-gal (Research Organics  
25                    Inc., Cleveland, OH). The transfer plasmids used to isolate occlusion-positive recombinants were pAcP(+)IE1 $\beta$ gal, pAcP(+)IE1CAT, pAcP(+)IE1tPA, or pAcP(+)IE1SfManII, respectively. The viral DNA was Bsu36I-linearized BAKPAK6 (32), and recombinants were identified by their occlusion-positive blue ( $\beta$ -gal) or white (CAT, t-PA, and SfManII; Examples 3, 4 and 5) phenotypes in plaque assays containing  
30                    X-gal. Once the desired recombinants were identified, well-isolated plaques were picked,

- 112 -

taken through one additional round of plaque purification, and working virus stocks were prepared and titered in Sf9 cells, as described below.

Sf9 cells were routinely maintained as a spinner culture in TNM-FH medium supplemented with fetal bovine serum, antibiotics, and pluronic F68, as previously described (Summers and Smith, 1987). The E2 strain of wild-type AcMNPV and the recombinant baculoviruses used were routinely propagated and titrated by plaque assay in Sf9 cells and working virus stocks were stored frozen in the dark at -85°C (Summers and Smith, 1987, Jarvis and Garcia, 1994). The recombinant viruses used as controls for this study, which express  $\beta$ -gal (VL941- $\beta$ gal), CAT (Ac360CAT; Example 3), t-PA (PreProTPA; Example 4), or the Sf9  $\alpha$ -mannosidase II protein (AcSfManII; Example 5) under the influence of the *polyhedrin* promoter, have been described previously (Jarvis *et al.*, 1993; Luckow and Summers, 1988, 1989; Example 6-10).

Working stocks of these viruses were used to compare the kinetics and levels of  $\beta$ -gal expression obtained in infected Sf9 cells to those obtained with a conventional *polyhedrin*-based baculovirus vector. Sf9 cells were grown in suspension to a density of  $1 \times 10^6$  cells per ml and infected with the appropriate virus at a multiplicity of infection of 5 plaque-forming units per cell. The virus was allowed to adsorb for one hr at 28°C, then the inoculum was removed and the cells were washed twice with TN-MFH medium supplemented with 10% serum, antibiotics, and pluronic F68 and twice with Grace's medium (Summers and Smith, 1987) supplemented with 0.5% serum, antibiotics, and pluronic F68. The infected cells were resuspended in the latter medium at a density of  $1 \times 10^6$  per ml, returned to the spinner, and samples containing  $5 \times 10^7$  or  $5 \times 10^6$  cells were removed at various times after infection for extraction of total RNA or protein, respectively.

Total RNA was prepared (Chirgwin *et al.*, 1979) and 20  $\mu$ g, 10  $\mu$ g and 5  $\mu$ g aliquots were analyzed by dot blot assays on nitrocellulose filters (Schleicher and Schuell, Inc.; Keene, NH; Luckow and Summers, 1988), as described previously. The probe was a 625 bp internal HincII fragment of the *E. coli lacZ* gene that was twice gel-purified and radiolabeled by the random primer method (Feinberg and Vogelstein, 1983).

For analysis of  $\beta$ -gal, CAT (Example 3), and SfManII (Example 5) expression, total protein was extracted from infected cell pellets by trituration in protein disruption

buffer (50 mM Tris-HCl, pH 6.8; 4% sodium dodecyl sulfate; 4%  $\beta$ -mercaptoethanol) through a syringe equipped with a 22 ga needle followed by boiling for 3 min. For t-PA (Example 4), extracellular medium was harvested, clarified, freeze-dried, and redissolved by boiling in protein disruption buffer. Proteins were subsequently resolved by sodium dodecyl sulfate polyacrylamide gel electrophoresis using the discontinuous buffer system (Laemmli 1970), and either stained with Coomassie Brilliant Blue or transferred to Immobilon™ PVDF filters (Millipore Corporation, Bedford, MA) using a standard wet electrophoretic transfer method (Towbin *et al.*, 1979). The filters were incubated overnight at 40°C with blocking buffer (50 mM Tris-HCl, pH 7.5; 150 mM NaCl; 1% NP40; 5% nonfat dry milk), then probed in the same buffer containing appropriately diluted rabbit anti- $\beta$ -gal, rabbit anti-CAT (Example 3), or goat anti-t-PA (Example 4). After washing away the unbound primary antibodies, the filters were incubated with appropriately diluted goat or rabbit secondary antibody conjugated to alkaline phosphatase. The unbound secondary antibody was washed away, then the immunoblots were rinsed and developed using a standard color reaction (Blake *et al.*, 1984).

$\beta$ -gal, CAT (Guarino and Summers, 1986; Example 3), and Sf9  $\alpha$ -mannosidase II (Example 5) activities were measured by biochemical assays done on cytosolic extracts of infected cells prepared by freeze-thaw or detergent lysis at various times after infection, as described previously. Human t-PA activity (Example 4) was measured by a fibrin agar plate lysis assay done on clarified extracellular medium from infected cells isolated at various times after infection, as described previously (Jarvis *et al.*, 1993).

Immunoblotting analysis showed that  $\beta$ -gal could be detected in cells infected with either immediate early vector (AcP(+))IE1 $\beta$ gal or AcP(-))IE1 $\beta$ gal) as early as 4 hr postinfection. In both cases, the  $\beta$ -gal protein accumulated with increasing time of infection and reached peak steady-state levels at 24 hr postinfection. The occlusion-positive immediate early vector produced larger amounts of  $\beta$ -gal than the occlusion-negative vector, particularly at earlier times after infection.  $\beta$ -gal was not detected in cells infected with a conventional baculovirus vector (941 $\beta$ gal; polyhedrin promoter) until 24 hr postinfection and, at that time point, the amount of accumulated  $\beta$ -gal produced by that vector was lower than the amount produced by the immediate early vectors. However, at later times after infection, the conventional baculovirus vector provided higher levels of

accumulated  $\beta$ -gal protein. It was previously demonstrated that immunoblotting provided reasonably quantitative estimates of the relative levels of total  $\beta$ -gal protein in insect cell lysates (Jarvis *et al.*, 1990), but it is possible that the difference in the amounts observed at 48 hr postinfection is underrepresented by this analysis.

5           The amounts of  $\beta$ -gal enzyme activity produced by the immediate early or conventional baculovirus vectors were also compared and the results, which were consistent with the immunoblotting results, are shown on a log scale plot in FIG. 2. The immediate early vectors produced  $\beta$ -gal activity earlier, with a peak at 24 hr postinfection, and the occlusion-positive vector produced more activity than the occlusion-negative  
10       vector. The occlusion-positive immediate early vector produced about twice as much  $\beta$ -gal activity as the conventional vector by 24 hr postinfection, but about 25-fold and 50-fold lower activity by 36 and 48 hr postinfection, respectively. The reason for the difference in RNA levels was unclear, but a major difference between the two types of immediate early vector was the orientation of the *iel*-controlled foreign gene with respect  
15       to the rest of the viral genome. Whereas the foreign genes in the occlusion-positive vectors are oriented from right to left on the AcMNPV map (Summers and Smith, 1987; O'Reilly *et al.*, 1992), the same genes are oriented from left to right in the occlusion-negative vectors. This was not a specifically designed difference between the two different types of immediate early vectors; rather, it was a by-product of the desire to  
20       position the *iel* and *polyhedrin* promoters in the occlusion-positive vectors in back-to-back orientation.

Transcriptional analysis of *lacZ* expression by dot blot assays showed that *lacZ*-specific RNA was detectable as early as 4 hr postinfection in cells infected with either immediate early baculovirus vector. Cells infected with the occlusion-positive vector  
25       contained more *lacZ* RNA than cells infected with the occlusion-negative vector. In both cases, *lacZ* RNA levels reached plateaus at 24 hr postinfection and, at this time point, cells infected with the immediate early vectors contained more *lacZ* RNA than cells infected with a conventional vector. *LacZ* RNA was first detected in cells infected with a conventional vector at 24 hr postinfection and the levels continued to rise to 48 hr  
30       postinfection. These results were consistent with the results observed for expression of  $\beta$ -gal protein and enzymatic activity.



- 115 -

**EXAMPLE 3****Isolation and analysis of immediate early baculovirus vectors  
that express *E. coli* CAT.**

Occlusion-negative and -positive immediate early baculovirus vectors containing  
5 the *E. coli* CAT gene were produced. The *Bam*HI fragment of pCAT#3 was inserted into  
the unique *Bam*HI site of pAcP(-)IE1TV5 or the *Bgl*II site of pAcP(+)IE1TV1 to produce  
pAcP(-)IE1CAT or pAcP(+)IE1CAT, respectively. pAcP(-)IE1CAT is designed to  
express CAT as a fusion protein which initiates at the *ie1* ATG and has twelve linker  
10 amino acids (D-P-S-R-F-S-G-A-K-E-A-K; SEQ ID NO:16) fused to amino acids 1-219 of  
the CAT protein. pAcP(+)IE1CAT encodes a fusion protein which initiates at the *ie1*  
ATG and has fourteen linker amino acids (D-L-D-P-S-R-F-S-G-A-K-E-A-K; SEQ ID  
NO:17) joined to the CAT sequence and also includes the intact *polyhedrin* gene oriented  
in the opposite direction.

The kinetics and levels of CAT protein expression provided by these vectors was  
15 compared to those provided by a conventional baculovirus vector (Ac360CAT; polyhedrin  
promoter). The immediate early vectors produced the foreign protein at earlier times after  
infection, with a plateau at 24 hr postinfection, and the occlusion-positive recombinant  
produced larger amounts than the occlusion-negative recombinant. CAT protein was first  
detected in cells infected with a conventional baculovirus vector at 24 hr postinfection and,  
20 even at that time point, the conventional vector produced more CAT than either of the  
immediate early vectors. These results were consistent with the results of CAT activity  
assays, which showed that the immediate early vectors produced about 10-fold less  
activity at 24 hr postinfection and about 80-fold less activity by 36 hr postinfection (FIG.  
3). These results also were consistent with previous results (Morris and Miller, 1992),  
25 which indicated that CAT activity was expressed at very low levels under *ie1* control.

**EXAMPLE 4****Isolation and analysis of immediate early baculovirus vectors  
that express human t-PA.**

30 The results in Examples 2 and 3 showed that immediate early baculovirus vectors  
could produce two different prokaryotic enzymes earlier in infection, but that conventional

5 baculovirus vectors containing the *polyhedrin* promoter could ultimately provide higher levels of both protein and enzymatic activity. Previous findings had indicated that earlier expression would probably be advantageous for foreign glycoprotein expression (Jarvis and Summers, 1989; Jarvis *et al.*, 1990; Murphy *et al.*, 1990; Sridhar *et al.*, 1993), but this idea had never been tested by using the *ie1* promoter to express a foreign glycoprotein gene in baculovirus-infected insect cells. Therefore, immediate early recombinants capable of expressing human t-PA, a foreign secreted glycoprotein, under *ie1* control were produced. This also provided a test of immediate early baculovirus vectors designed to express unfused, native proteins.

10 The native t-PA gene was inserted into pAcP(-)IE1TV6 and pAcP(+)IE1TV3 and the resulting plasmids were used to isolate immediate early baculovirus vectors. The *Bam*HI-*Kpn*I fragment of pPrePro-t-PA (Jarvis *et al.*, 1993) was inserted into the *Bam*HI-*Kpn*I sites of pAcP(-)IE1TV6 to produce pAcP(-)IE1tPA, which is designed to express the native t-PA protein under the influence of the hr5 enhancer and *ie1* promoter. A similar strategy was used to produce pAcP(+)IE1tPA, except the *Kpn*I site was blunt-ended with T4 DNA polymerase and the *Bam*HI-*Kpn*I (blunt) fragment was inserted into the *Bgl*II-*Sst*I sites of pAcP(+)IE1TV3.

20 These vectors were used to infect Sf9 cells and the amounts of t-PA protein in the extracellular fraction of these cells were monitored by immunoblotting. As had been observed with  $\beta$ -gal and CAT, the immediate early vectors produced extracellular t-PA starting at 4 hr postinfection, with a peak at 24 hr postinfection, and the occlusion-positive vector produced larger amounts than the occlusion-negative vector. The conventional baculovirus vector (PreProTPA; polyhedrin promoter) first produced extracellular t-PA at 24 hr postinfection and, at that time point, the amount was similar to the amount produced by the occlusion-negative immediate early vector and lower than that produced by the occlusion-positive immediate early vector. At 36 hr postinfection, the medium from cells infected with the occlusion-positive immediate early vector still contained more t-PA than medium from cells infected with the conventional vector. By 48 hr postinfection, there was a clear reduction in the amount of extracellular t-PA in the medium of cells infected by either immediate early vector, which probably reflected turnover of the extracellular t-

25

30

- 117 -

PA product, and, at that time, the medium from cells infected with the conventional baculovirus vector contained more immunoreactive t-PA protein.

The results of t-PA activity assays showed that the immediate early vectors produced t-PA activity earlier than the conventional vectors and that the levels of activity produced by the former were about equal to those produced by the latter, even at 48 hr postinfection. Thus, unlike  $\beta$ -gal and CAT, a conventional baculovirus vector was unable to produce significantly more extracellular human t-PA protein or activity than the immediate early vectors described herein.

## EXAMPLE 5

### Isolation and analysis of immediate early baculovirus vectors that express Sf9 $\alpha$ -mannosidase II.

An occlusion-positive immediate early baculovirus vector capable of expressing a membrane-bound secretory pathway glycoprotein,  $\alpha$ -mannosidase II, was isolated. The *BglII-NotI* fragment of pSfManII (Example 6) was inserted into the *BglII-NotI* sites of pAcP(+)IE1TV3 to produce pAcP(+)IE1SfManII, which is designed to express the native Sf9 cell  $\alpha$ -mannosidase II protein under the influence of the hr5 enhancer and *iel* promoter. Since no antibody is available, a comparison of the amounts of total Sf9  $\alpha$ -mannosidase II protein expressed by immediate early or conventional baculovirus vectors (AcSfManII; polyhedrin promoter) was limited to SDS-PAGE and Coomassie Brilliant Blue staining of infected cell lysates.

The results showed that the Sf9  $\alpha$ -mannosidase II protein, which has an  $M_r$  of approximately 131,000, could only be seen against the background of other infected cell proteins in lysates from cells infected for 48 hr with the conventional vector. However, when  $\alpha$ -mannosidase II activity in these same lysates was measured, the immediate early baculovirus vector produced activity earlier, with a peak at 24 hr postinfection, and at higher levels than the conventional vector at all time points examined (FIG. 4). Thus, the immediate early baculovirus vector produced less total Sf9  $\alpha$ -mannosidase II protein, but more enzymatically active protein than the conventional vector, even as late as 48 hr postinfection. This might be related to adverse effects of baculovirus infection on the host cell secretory pathway at late times of infection (Jarvis and Summers, 1989; Jarvis *et al.*,

1990; Murphy *et al.*, 1990). Alternatively, it might indicate that the levels of newly synthesized protein expressed under *polyhedrin* control at late times of infection exceed the capabilities of the host protein processing machinery and only a relatively small proportion can be processed to an enzymatically active form.

## EXAMPLE 6

### Isolation and characterization of $\alpha$ -mannosidase II and $\alpha$ -mannosidase I cDNAs from Sf9 cells.

An  $\alpha$ -mannosidase II cDNA from lepidopteran insect (Sf9) cells was isolated using a degenerate oligonucleotide PCR<sup>TM</sup> approach (Moremen, 1989). Genomic DNA was isolated from Sf9 cells by a standard method (Sambrook *et al.*, 1989) and used for PCR<sup>TM</sup> (Saiki *et al.*, 1985) with degenerate oligonucleotide primers (GGITGGIIIATHGAYCCITTYGGNCA; SEQ ID NO:13, and GGNCKISWIIIRAA RTAICCISDCCARTA; SEQ ID NO:14) designed against conserved amino acid sequences in two class II  $\alpha$ -mannosidases (Moremen *et al.*, 1994), namely, murine Golgi  $\alpha$ -mannosidase II (Moremen and Robbins, 1991) and the lysosomal  $\alpha$ -mannosidase from *Dictyostelium discoideum* (Schatzle *et al.*, 1992). PCRs<sup>TM</sup> were done in a total volume of 25 ml containing 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2.5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 0.2 mM dNTP's, 1 mM primers, 1 mg of genomic DNA, and 2.5 U of *Taq* polymerase (Perkin-Elmer Corp., Norwalk, CT). After 40 cycles of denaturation (45 sec at 92°C), annealing (45 sec at 45°C), and extension (3 min at 72°C) in a Perkin-Elmer thermal cycler, a final extension was done for 5 min at 72°C and the amplification products were analyzed on 1% agarose gels.

The resulting 669 bp amplification product was identical in size to a positive control RT-PCR<sup>TM</sup> product derived from murine liver mRNA. Similar RT-PCR<sup>TM</sup> products were obtained using mRNA isolated from either uninfected or baculovirus-infected Sf9 cells. The PCR<sup>TM</sup> product from Sf9 genomic DNA was cloned a plasmid vector designed to facilitate direct cloning of PCR<sup>TM</sup> products (pCRII<sup>TM</sup>; Invitrogen, San Diego, CA), and its sequence was determined by the chain termination method (Sanger *et al.*, 1977). The translation of the ampimer sequence was compared to a translation of the GenBank sequence database.

The cDNA sequence was assembled using the sequence assembly package of Staden (1987). The sequence of the amplicon translation was compared to the six frame translation of the GenBank non-redundant DNA sequence database (version 91) using the TFASTA subroutine of the University of Wisconsin Genetics Computer Group (GCG) software package (Program Manual for the Wisconsin Package, Version 8.1, Genetics Computer Group, Madison, WI). The pairwise sequence comparisons were performed using the Bestfit subroutine and multiple sequence alignments and dendrograms were prepared using the Pileup and Boxshade subroutines of the GCG software package.. Only class II mannosidases, including murine and human  $\alpha$ -mannosidase II (42.3% and 43.3% identity, respectively) and *D. discoideum* and human lysosomal  $\alpha$ -mannosidase (29.4% and 26.1% identity, respectively), were identified by this analysis. This suggested that the Sf9 amplicon was derived from a gene that is related to the class II mannosidases and is more similar to the Golgi processing than the lysosomal mannosidases.

The Sf9 amplicon DNA sequence was used to design exact-match primers against the putative Sf9  $\alpha$ -mannosidase II coding region and these primers were used for PCRs<sup>TM</sup> with total  $\lambda$  DNA from an unfractionated Sf9 cDNA library. Electrophoretic analysis of the reaction products revealed one major DNA fragment of about the same size as the RT-PCR<sup>TM</sup> product. The same result was obtained with total  $\lambda$  DNA from an unfractionated Sf9 genomic DNA library or with the pCRII clone containing the Sf9 amplicon, but not in negative controls which lacked template DNA or contained one specific and one nonspecific primer. These results indicated that the uninfected Sf9 cell cDNA library included a clone containing the putative Sf9  $\alpha$ -mannosidase II coding region. This cDNA was isolated by using a sibling selection and PCR<sup>TM</sup> screening approach (Moremen, 1989).

Briefly, an Sf9 cDNA library in  $\lambda$ ZAPII<sup>TM</sup> (Short *et al.*, 1988; Stratagene, La Jolla, CA) was split into 43 pools of 50,000 clones, each pool was amplified in *E. coli*, and total  $\lambda$  DNA was prepared from  $2 \times 10^6$  progeny using a commercial anti-lambda phage immunosorbent (Lambdasorb), according to the manufacturer's instructions (Promega Corp., Madison, WI). These DNAs were used as templates for PCRs<sup>TM</sup> with the exact-match primers to determine which pools included an Sf9  $\alpha$ -mannosidase II clone. One positive pool was split into eight subpools of 10,000 clones, each subpool was reamplified in *E. coli*, total  $\lambda$  DNA was isolated, and the PCR<sup>TM</sup> screening process was repeated.

- 120 -

Finally, one positive subpool, which theoretically included an Sf9  $\alpha$ -mannosidase II clone at a frequency of at least 1 in 10,000, was screened by plaque hybridization (Benton and Davis, 1977; Sambrook, 1989). The hybridization probe, which was the original Sf9  $\alpha$ -mannosidase II PCR<sup>TM</sup> amplimer that had been cloned into pCRII<sup>TM</sup>, was excised with  
5 *Eco*RI, gel-purified twice, and uniformly labeled by the random primer method (Feinberg and Vogelstein, 1983).

Positive plaques from high-density plates were taken through two additional rounds of low density plaque hybridization for further purification and screening. The cDNA inserts in two  $\lambda$ ZAPII<sup>TM</sup> clones that remained positive through all three rounds of  
10 screening were excised as Bluescript<sup>TM</sup>-based plasmid subclones by coinfection with M13R408 helper phage, as described previously (Short *et al.*, 1988). The resulting plasmids were isolated by standard alkaline lysis extraction and CsCl-EtBr gradient centrifugation procedures (Sambrook *et al.*, 1989) and used as templates to sequence the  
15 cDNA inserts with universal and gene-specific primers (Sanger *et al.*, 1977). The largest cDNA (about 6.5 Kb) was sequenced with universal and gene-specific primers and compared to mammalian  $\alpha$ -mannosidase II DNA sequences. This analysis revealed extensive similarities, but indicated that the cDNA clone lacked the 5' end of the  $\alpha$ -mannosidase II coding region.

The 5' end of the Sf9  $\alpha$ -mannosidase II cDNA was isolated by using ligation-  
20 anchored PCR<sup>TM</sup> (Troutt *et al.*, 1992) as outlined in FIG. 5A. Total RNA was prepared from a log phase culture of uninfected Sf9 cells by the method of Chirgwin and coworkers (1979) and used to prepare poly A<sup>+</sup> RNA by oligo-dT cellulose column chromatography (Aviv and Leder, 1972). One microgram of the poly A<sup>+</sup> RNA was used for first-strand  
25 cDNA synthesis with random hexamer primers and an RNase H-minus form of MoMuLV reverse transcriptase (Superscript<sup>TM</sup> II; Life Technologies, Gaithersburg, MD). After reverse transcription, the RNA was digested with RNase H and the reaction mixture was diluted and desalted by ultrafiltration in a Microcon<sup>TM</sup> 100 filter (Amicon, Inc., Beverly, MA). The single-stranded cDNA was recovered and a 5'-phosphorylated, 3'-blocked  
30 primer complementary to the T3 primer (5'-TCCCTTTAGTGAGGGTTAATTT-NH<sub>2</sub>-3' SEQ ID NO:15) was ligated to its 3' end with T4 RNA ligase (New England Biolabs, Beverly, MA).

The resulting anchored first-strand cDNA product was used as the template for a PCR<sup>TM</sup> with T3 as the upstream primer and an Sf9  $\alpha$ -mannosidase II-specific oligonucleotide (Sf31+92- in FIG. 5A) as the downstream primer, under the conditions described by Apte and Siebert (1993). The amplification product was extracted with phenol-chloroform and a fraction was used as the template for a secondary PCR<sup>TM</sup> under the same conditions as the primary PCR<sup>TM</sup> with T3 as the upstream primer and a different Sf9  $\alpha$ -mannosidase II-specific oligonucleotide (SfManII+157- in FIG. 5A) as the downstream primer. The secondary products were extracted with phenol-chloroform, gel-purified on a 1% agarose gel, and a band of interest identified by Southern blotting with the gene-specific 5' end probe shown in FIG. 5A. After the second round of PCR<sup>TM</sup> amplification, several products were observed by ethidium bromide staining, but only two (175 and 750 bp) hybridized with the 5' end probe. The 750 bp product was cloned into pCRII<sup>TM</sup>, sequenced, and the results showed that it overlapped and extended the 5' end of the Sf9  $\alpha$ -mannosidase cDNA clone by an additional 681 bp.

The resulting sequence information was used to design exact-match primers for amplification of the 5' end of the putative  $\alpha$ -mannosidase II cDNA from the original Sf9 cell cDNA preparation, as diagrammed in FIG. 5B. The 5' primer (*Bgl*II...-20 in FIG. 5B) was designed to incorporate a unique *Bgl*II site at position -20, with respect to the putative translational initiation site, and the 3' primer (SfManII-A1 in FIG. 5B) was located downstream of a unique *Xho*I site. This amplification product was cloned into pCRII<sup>TM</sup> to produce pSfManII-5', several independent transformants were sequenced, and the *Bgl*II-*Xho*I fragment from a representative clone was excised and gel-purified. In parallel, the *Xho*I-*Dra*I fragment of the partial  $\alpha$ -mannosidase II cDNA clone from the Sf9 library was subcloned into a modified form of pBSKS<sup>TM</sup>+ (pBSDK/BS in FIG. 5B) to produce pSfManII-3'. Finally, the full-length Sf9  $\alpha$ -mannosidase II cDNA was assembled by inserting the *Bgl*II-*Xho*I fragment of pSfManII-5' into *Bgl*II-*Xho*I-digested pSfManII-3' to produce pSfManII, as shown in FIG. 5B. The complete sequence of the Sf9  $\alpha$ -mannosidase II cDNA was assembled and analyzed using version 8.1 of the University of Wisconsin Genetics Computer Group software package (Program Manual for the Wisconsin Package, Version 8.1, Genetics Computer Group, Madison, WI).

The assembled full-length open reading frame of the Sf9  $\alpha$ -mannosidase II cDNA, together with 176 bp of 5' and 179 bp of 3' sequence, is shown in SEQ ID NO:3. The 3393 bp open reading frame encodes a polypeptide of 1130 amino acids (SEQ ID NO:4) with a 37% identity to murine Golgi  $\alpha$ -mannosidase II (Moremen and Robbins, 1991).

5 The first in-frame ATG in the long open reading frame is preceded by a purine at the critical -3 position, suggesting that it serves as the translation initiation site (Kozak, 1983, 1986a). Hydropathy analysis (Kyte and Doolittle, 1982) revealed a potential transmembrane domain between amino acids 14 and 34 and predicted a type II transmembrane topology similar to all other cloned Golgi processing hydrolases and  
10 glycosyltransferases (Paulson and Colley, 1989, Lowe, 1991; Moremen *et al.*, 1994). In addition, the putative Sf9  $\alpha$ -mannosidase protein would have seven potential N-glycosylation sites.

The protein encoded by the Sf9  $\alpha$ -mannosidase cDNA was compared to the protein sequences of other class II  $\alpha$ -mannosidases. An optimized multiple sequence alignment  
15 was generated using the Pileup and Boxshade subroutines, as described above. Protein sequences included in the alignment were the yeast vacuolar mannosidase (Yoshihisa and Anraku, 1989; Accession no. M29146), rat ER  $\alpha$ -mannosidase (Bischoff *et al.*, 1990; Accession no. M57547), *Dictyostelium discoideum* lysosomal  $\alpha$ -mannosidase (Schatzle  
20 *et al.*, 1992; Accession no. M82822), human lysosomal  $\alpha$ -mannosidase (Nebes and Schmidt, 1994, Accession no. U05572), mouse  $\alpha$ -mannosidase II (Moremen and Robbins, 1991; Accession no. X61172), human  $\alpha$ -mannosidase II (Misago *et al.*, 1995; Accession no. U31520), human  $\alpha$ -mannosidase II<sup>x</sup> (Misago *et al.*, 1996; Accession no. D55649), *Drosophila*  $\alpha$ -mannosidase II (Foster *et al.*, 1995; Accession no. X77652), and Sf9  $\alpha$ -mannosidase II (SEQ ID NO:4).

25 The protein encoded by the Sf9  $\alpha$ -mannosidase cDNA has extensive amino acid sequence similarity to a subclass of the class II mannosidases (Moremen *et al.*, 1994). This subclass is typified by the mammalian Golgi glycoprotein processing enzyme,  $\alpha$ -mannosidase II, and a recently cloned homolog,  $\alpha$ -mannosidase II<sup>x</sup> (Misago *et al.*, 1995; FIG. 6). The regions of lowest sequence similarity are localized to the NH<sub>2</sub> terminal 124  
30 amino acids of the Sf9  $\alpha$ -mannosidase polypeptide, which encode the putative cytoplasmic tail, transmembrane domain, and "stem region". These regions were previously shown to



be unessential for the catalytic activity of mammalian  $\alpha$ -mannosidase II (Moremen *et al.*, 1991), indicating that there would be little selective pressure to maintain their primary sequences during evolution. Surprisingly, the predicted Sf9  $\alpha$ -mannosidase protein is more similar to the mammalian  $\alpha$ -mannosidase II proteins than to the putative  $\alpha$ -mannosidase II protein encoded by a cDNA recently isolated from *Drosophila* (Foster *et al.*, 1995).

Using the same general methodology described above, an  $\alpha$ -mannosidase I cDNA was isolated from Sf9 cells (Examples 15 through 19 below). The nucleic acid sequence is shown in SEQ ID NO:1, and the amino acid sequence is shown in SEQ ID NO:2.

#### EXAMPLE 7

##### Southern blotting analysis of the Sf9 $\alpha$ -mannosidase II gene.

Southern blotting analyses were done to examine the structure of the Sf9  $\alpha$ -mannosidase II gene and its relationship to  $\alpha$ -mannosidase II genes from other insects and higher eukaryotes. Genomic DNA from the lepidopteran insect cell lines Sf9, Sf21, High Five, Ea, Bm, and Md and from a mammalian cell line COS was isolated by a standard method (Sambrook *et al.*, 1989). Twenty micrograms of the genomic DNA samples were digested with *HindIII*, which does not cut the Sf9  $\alpha$ -mannosidase II cDNA, or with *PstI*, which cuts this cDNA five times, and the digests were resolved on a 1% agarose gel.

The DNA was transferred to a positively charged nylon filter (Zetaprobe™; Bio-Rad Laboratories, Hercules, CA) under alkaline conditions (Southern, 1975; Reed and Mann, 1985) and the filter was prehybridized for at least one hour at 68°C in a buffer containing 1.5 × SSPE (15 mM NaPO<sub>4</sub>, pH 7.0; 270 mM NaCl, and 15 mM EDTA), 1% (w/v) sodium dodecyl sulfate (SDS), 0.5% (w/v) nonfat dry milk, and 150 µg/ml of sheared salmon sperm DNA (Sigma). High stringency hybridizations were done overnight at 68°C in the same buffer with a twice gel-purified, random primer-labeled (Feinberg and Vogelstein, 1983), *XhoI-DraI* fragment of the Sf9  $\alpha$ -mannosidase II cDNA clone (FIG. 5A). After hybridization, the filters were washed for 15 min at room temperature with 2 × SSC plus 0.1% SDS, then with 0.5 × SSC plus 0.1% SDS, then with 0.1 × SSC plus 0.1% SDS, and finally, for 30 min with 0.1 × SSC plus 1% SDS that had been prewarmed to

- 124 -

50°C. For low stringency hybridizations, the hybridization temperature was reduced to 55°C and the last wash was done at room temperature. After washing, the filters were sealed in plastic bags and exposed to Kodak (Rochester, N.Y.) X-OMAT AR™ film with Fisher (Pittsburgh, PA) intensifying screens for various times at -85°C.

5           The *Hind*III digests of DNA from Sf9, Sf21, Bm, and Md cells produced single bands with similar hybridization intensities, suggesting that these cells have single copy, closely related  $\alpha$ -mannosidase II genes. *Pst*I digests of DNA from these four cell lines produced identical multiple banding patterns (there were only four bands because two of the six expected *Pst*I fragments were too small to be retained by the gel) with similar  
10       hybridization intensities, supporting the idea that they all have closely related  $\alpha$ -mannosidase II genes. By contrast, *Hind*III and *Pst*I digests of genomic DNA from High 5 and Ea cells produced different banding patterns and weaker hybridization signals, suggesting that the  $\alpha$ -mannosidase II genes in these cell lines differ from the  $\alpha$ -mannosidase II genes in the former cell lines. This conclusion was supported by the  
15       Southern blotting results obtained after digesting genomic DNA from Sf9, High 5, and Ea cells with six different enzymes (*Eco*RI, *Hind*III, *Pst*I, *Ssp*I, *Sty*I and *Xba*I), which revealed significant differences in the restriction maps of the  $\alpha$ -mannosidase II genes in these cell lines. The Sf9 probe failed to hybridize with DNA from COS cells, indicating that the Sf9  $\alpha$ -mannosidase II gene is less closely related to the  $\alpha$ -mannosidase II genes in  
20       these mammalian cells than it is to the  $\alpha$ -mannosidase II genes in the various lepidopteran insect cell lines. When the blots were stripped and rehybridized under lower stringency, the hybridization signals obtained with DNA from the various lepidopteran insect cells were approximately equal, but no hybridization was detected with COS cell DNA.

          The nearly full-length Sf9  $\alpha$ -mannosidase II probe also was used for low  
25       stringency hybridizations on Southern blots of *Hind*III and *Pst*I digests of genomic DNA from insects belonging to the Orders Lepidoptera (*H. virescens* and *H. zea*), Coleoptera (*T. molitor*), Orthoptera (*S. gregaria*), Blattaria (*B. discoidalis*), and Diptera (*D. melanogaster*), and from *Xenopus laevis*. The results showed that the probe hybridized with DNA from two different lepidopteran insects, *Heliothis virescens* (tobacco budworm)  
30       and *Helicoverpa zea* (corn earworm), but the hybridization signal was weaker and the digestion patterns were different, when compared to the Sf9 cell controls. The Sf9  $\alpha$ -

mannosidase II probe failed to detectably hybridize to any non-lepidopteran insect DNA, including beetle (*Coleoptera*), locust (*Orthoptera*), cockroach (*Blattaria*), and fruitfly (*Diptera*), or to frog (*Xenopus*) DNA. These results supported the idea that the Sf9  $\alpha$ -mannosidase II gene is more closely related to the  $\alpha$ -mannosidase II genes of other lepidopteran insects than to these same genes in animals outside of the Order *Lepidoptera*.

### EXAMPLE 8

#### Transcription of the Sf9 $\alpha$ -mannosidase II gene.

Initially, Northern blotting was used to try to examine transcription of the Sf9  $\alpha$ -mannosidase II gene in uninfected and baculovirus-infected Sf9 cells, but this approach failed even using 20 mg of poly A+ RNA, despite being able to obtain specific RT-PCR™ products from these RNAs. Therefore, the inventors turned to the use of a more sensitive technique, ribonuclease protection (Lee and Costlow, 1987), with a 431 bp antisense riboprobe consisting of 19 bp of vector sequence followed by 412 bp of sequence from the middle of the Sf9  $\alpha$ -mannosidase II cDNA (positions 966-1384 in SEQ ID NO:3).

Sf9 cells were grown in 500 ml spinner flasks (Bellco Glass Co., N.J.) to a density of  $1 \times 10^6$  cells per ml and either mock-infected or infected with wild-type baculovirus (*Autographa californica* multicapsid nuclear polyhedrosis virus) at a multiplicity of five plaque-forming units per cell. After adsorption for one hour at 28°C, the cells were separated from the inoculum by low speed centrifugation, gently resuspended in 500 ml of TN-MFH medium supplemented with 10% serum, antibiotics, and pluronic F68, and returned to the spinner flask. Total RNA either was extracted immediately from the mock-infected cells or was extracted 12, 24, or 48 h later from the infected cells and used to isolate poly A+ RNA, as described in Example 6.

Twenty microgram samples of each mRNA preparation were analyzed by RNase protection assays using a commercial kit according to the manufacturer's instructions (Ambion, Inc., Austin TX). The riboprobe for these assays was synthesized *in vitro* with T7 RNA polymerase (Melton *et al.*, 1984) and [ $\alpha$ -<sup>32</sup>P]-GTP (800 Ci/mmol; DuPont NEN, Boston, MA) using a commercial kit (Ambion) according to the manufacturer's instructions. The DNA template for the transcription reactions was pSfManIIDBst, a derivative of pSfManII (FIG. 5B), linearized at the *Pm*II site. Transcription of this

- 126 -

template produced a 431 bp antisense RNA consisting of 19 bp from the vector followed by 412 bp beginning at the *Bst*XI site and ending at the *Pml*I site of the Sf9  $\alpha$ -mannosidase II cDNA (positions 1384 and 966, respectively, in SEQ ID NO:3). Protected fragments were analyzed on 5% acrylamide-7M urea gels, as described previously (Jarvis, 1993b), and the gels were dried and exposed to Kodak X-OMAT AR™ film with intensifying screens for various times at -85°C.

The results showed that RNA from mock-infected Sf9 cells protected a 412 bp fragment of the probe, indicating that the  $\alpha$ -mannosidase II gene is expressed in these cells. The steady state levels of  $\alpha$ -mannosidase II-specific RNA must be very low, since no protection was detected in assays with 20  $\mu$ g of total RNA and large amounts (10  $\mu$ g) of poly A+ RNA produced only a relatively weak signal. The signals observed with poly A+ RNA from infected cells were even weaker than the signal obtained from uninfected cells and little, if any, protection was observed with RNA from cells infected for 48 hours. Ethidium bromide staining of the poly A+ RNA samples used for this study indicated that equal amounts had been loaded, suggesting that steady state levels of Sf9  $\alpha$ -mannosidase II RNA are reduced by baculovirus infection.

### EXAMPLE 9

#### *in vitro* translation and processing of the Sf9 $\alpha$ -mannosidase II protein.

To obtain further evidence that the Sf9  $\alpha$ -mannosidase II open reading frame encodes a protein, a plasmid construct containing the Sf9  $\alpha$ -mannosidase II cDNA was linearized, transcribed *in vitro*, and the resulting RNA was used for *in vitro* translation studies. For these studies, the full-length Sf9  $\alpha$ -mannosidase II open reading frame was subcloned downstream of an SP6 promoter in the plasmid pGem7Zf+™ (Promega) to produce pGemSfManII. RNA was synthesized *in vitro* from *Xba*I-linearized pGemSfManII as described above, except SP6 RNA polymerase was used instead of T7 RNA polymerase and the [ $\alpha$ -<sup>32</sup>P]-GTP was replaced by nonradioactive rGTP.

A portion of the *in vitro* transcribed RNA was used for *in vitro* translation reactions in a rabbit reticulocyte lysate (Promega) in the presence or absence of canine pancreatic microsomal membranes (Blobel and Dobberstein, 1975; Promega), as described previously (Moremen and Robbins, 1991). Subsequently, translation reactions were treated with

water, 100 mg/ml trypsin, or trypsin plus 0.1% (v/v) Nonidet-P40 (Zilberstein *et al.*, 1980), as described previously (Moremen and Robbins, 1991). The reaction products were acetone-precipitated and the precipitates were dried, redissolved in protein disruption buffer [50 mM Tris-HCl, pH 6.8; 4% (w/v) SDS; 4% (v/v)  $\beta$ -mercaptoethanol], and heated at 65°C for 10 min. Total solubilized proteins were analyzed by SDS-PAGE using the discontinuous buffer system (Laemmli 1970) and the gels were fluorographed with Autofluor (National Diagnostics, Atlanta, GA), dried, and exposed to Kodak X-OMAT AR™ film at -85°C.

The results showed that a protein of about the expected size was produced when a rabbit reticulocyte lysate was primed with Sf9  $\alpha$ -mannosidase II RNA. Several additional lower molecular weight proteins were also observed, which had been seen previously in translations of murine  $\alpha$ -mannosidase II cDNA (Moremen and Robbins, 1991), and might be explained by premature translational termination or degradation of the full-length product. When translations were done in the presence of canine pancreatic microsomal membranes, a new product was observed that was larger than the largest product translated in the absence of microsomes. Unlike the smaller products, this one was not degraded by subsequent trypsin treatment, but was converted to a slightly smaller form.

This result indicated that the majority of the protein was oriented towards the lumen of the microsomes, where it was protected from trypsin as a result of co-translational translocation during synthesis. In support of this conclusion, this product was completely degraded when trypsin treatments were performed in the presence of a nonionic detergent to solubilize the membranes. The larger size of the translation product prior to proteolysis also suggested that one or more of the potential N-glycosylation sites are utilized during synthesis. Together, these results indicate that the Sf9  $\alpha$ -mannosidase II cDNA encodes a protein with the characteristics of a type II membrane glycoprotein.

#### EXAMPLE 10

##### Expression of the Sf9 $\alpha$ -mannosidase II protein in the baculovirus system.

*In vivo* evidence that the Sf9  $\alpha$ -mannosidase II cDNA encodes a protein was obtained by using a recombinant baculovirus to express the cDNA under the control of the strong *polyhedrin* promoter in infected Sf9 cells. A standard method was used to isolate a

recombinant baculovirus containing the Sf9  $\alpha$ -mannosidase II cDNA (Summers and Smith, 1987; O'Reilly *et al.*, 1992). The intact Sf9  $\alpha$ -mannosidase II open reading frame was excised from pSfManII and subcloned into the baculovirus transfer vector, pVL1392 (Webb and Summers, 1990). The resulting plasmid, in which the Sf9  $\alpha$ -mannosidase II cDNA was positioned downstream of the strong *polyhedrin* promoter, was mixed with wild type viral DNA and the mixture was used to cotransfect Sf9 cells by a modified calcium phosphate precipitation method (Summers and Smith, 1987). Viral progeny were harvested five days after transfection and resolved by plaque assay in Sf9 cells, as described previously (Summers and Smith, 1987). Recombinants were identified by their occlusion-negative plaque phenotypes and taken through two additional rounds of plaque-purification. Virus stocks were prepared and titered by plaque assay in Sf9 cells and stored frozen in the dark at  $-85^{\circ}\text{C}$  (Jarvis and Garcia, 1994).

The procedures used for baculovirus infections and analysis of recombinant protein biosynthesis have been described previously (Jarvis and Summers, 1989; Jarvis *et al.*, 1991). Briefly, Sf9 cells were seeded into 6-well plates (Corning Glass Works, Corning, NY) at a density of  $1 \times 10^6$  cells per well, mock-infected or infected at a multiplicity of about 5 plaque-forming units per cell, and incubated at  $28^{\circ}\text{C}$  until 24, 36, 48, or 72 h postinfection. At these time points, the cells were gently squirted off the plastic into the medium, pelleted, 0.5 ml of protein disruption buffer was added, and the cell pellets were triturated through a 1 ml syringe equipped with a 22 ga needle. The sheared lysates were boiled for 3 min, total solubilized proteins were resolved by SDS-PAGE, and the gels were stained with Coomassie Brilliant Blue, destained, and photographed.

SDS-PAGE analysis of total protein lysates of Sf9 cells infected for 48 or 72 h with this recombinant virus revealed large amounts of a new protein of about the expected size, which was not detected in mock or wild-type virus-infected lysates at any time after infection. This result, together with the kinetics of appearance and accumulation of this protein during recombinant baculovirus infection, suggested that this protein is the product of the Sf9  $\alpha$ -mannosidase II cDNA. Evidence that the protein encoded by the Sf9  $\alpha$ -mannosidase II cDNA is actually an  $\alpha$ -mannosidase II was obtained by biochemical activity assays with p-nitrophenyl- $\alpha$ -D-mannopyranoside as the substrate (FIG. 7A and FIG. 7B).

Sf9 cells were infected with wild-type or recombinant baculoviruses were harvested by centrifugation at various times after infection, and pellets containing  $1 \times 10^6$  cells were resuspended in 100  $\mu$ l of assay buffer (0.1 M MES, pH 6.3; 0.5% Triton- X-100). The cell suspensions were assayed for  $\alpha$ -mannosidase activity by mixing 25  $\mu$ l of the cell extracts with 25  $\mu$ l of 10 mM p-nitrophenyl  $\alpha$ -D-mannopyranoside in the presence or absence of various concentrations of swainsonine. The reaction mixtures were incubated in a microtiter plate for 1 hr at 37°C with gentle agitation, then quenched by the addition of 200  $\mu$ l of stop solution (133 mM glycine, 67 mM NaCl, 83 mM Na<sub>2</sub>CO<sub>3</sub>). Absorbance was measured at 410 nm on a plate reader (Dynatech Model MR 5000), corrected for light scattering at 570 nm, and the corrected absorbance values were converted to nmol p-nitrophenol using a standard curve produced on the same plate reader.

Extracts from Sf9 cells infected with the recombinant baculovirus clearly contained higher levels of pNP- $\alpha$ -mannosidase activity than extracts from wild-type virus-infected controls. The levels of  $\alpha$ -mannosidase activity increased with increasing time of infection with the recombinant, but not the wild type virus. The putative SfManII protein accumulated in the recombinant virus-infected cells to levels that could be detected by SDS-PAGE and Coomassie blue staining of total cell lysates prepared at 48 hr postinfection. At this very late time after infection, the overexpressed protein had low specific activity. However, this was not unexpected, as previous studies have shown that production of enzymatically active secretory pathway proteins in the baculovirus system is inefficient due to adverse effects of virus infection on host cell secretory pathway function (Jarvis and Summers, 1989; Example 5). Finally, the  $\alpha$ -mannosidase activity detected in the recombinant baculovirus-infected cell extracts was sensitive to swainsonine, a known inhibitor of class II  $\alpha$ -mannosidases (Moremen *et al.*, 1994).

## EXAMPLE 11

### **Construction of immediate early baculovirus vectors containing a $\beta$ 1,4-galactosyltransferase cDNA.**

A bovine  $\beta$ 1,4-galactosyltransferase cDNA was subcloned into two different immediate early baculovirus transfer vectors. A full-length cDNA encoding the short protein isoform of bovine  $\beta$ 1,4-galactosyltransferase (Harduin-Lepers *et al.*, 1993; Russo

- 130 -

*et al.*, 1992) was excised from pSP65 (Promega Corp., Madison, WI) and the resulting 1.5 Kb *Bam*HI fragment was gel-purified, recovered, and inserted into the unique *Bam*HI or *Bgl*II sites of the immediate early transfer vectors pAcP(-)IE1TV2 and pAcP(+)IE1TV3, respectively (Example 1).

5       The resulting plasmids (FIG. 8A and FIG. 8B) contained the  $\beta$ 1,4-galactosyltransferase cDNA under the control of the viral *ie1* promoter, which is active immediately after the virus enters the cell. These plasmids also included the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) hr5 enhancer to maximize *ie1*-mediated transcription (Guarino *et al.*, 1986; Rodems and Friesen, 1993) and upstream and  
10       downstream flanking sequences from the AcMNPV *polyhedrin* gene to target the new DNA sequences to this nonessential region of the viral genome (Smith *et al.*, 1983a). The major differences between these two plasmids were the presence or absence of the *polyhedrin* open reading frame, which determines whether recombinant viruses will be occlusion positive or negative, and the orientation of the *ie1*- $\beta$ 1,4-galactosyltransferase  
15       sequence with respect to other viral DNA sequences.

## EXAMPLE 12

### Expression of $\beta$ 1,4-galactosyltransferase activity.

20       The two plasmids shown in FIG. 8A and FIG. 8B were used to produce recombinant baculoviruses and the ability of these viruses to produce  $\beta$ 1,4-galactosyltransferase activity during infection of Sf9 cells was examined as described below. The resulting plasmids, pAcP(-)IE1GalT and pAcP(+)IE1GalT (FIG. 8A and FIG. 8B), were mixed with AcMNPV viral DNA or Bsu36I-digested BakPak6 viral DNA (Kitts and Possee, 1993), respectively, and the mixtures were cotransfected onto Sf9 cells using a  
25       modified calcium phosphate precipitation method (Summers and Smith, 1987; O'Reilly *et al.*, 1992). Several days later, the growth media were recovered from the cotransfected cells, progeny viruses were resolved by plaque assay on Sf9 cells, and recombinant viruses were visually identified by their distinctive plaque phenotypes. This was straightforward because the occlusion negative recombinant, AcP(-)IE1GalT, was derived from an occlusion-positive parent (AcMNPV) and the occlusion positive recombinant,  
30       AcP(+)IE1GalT, was derived from an occlusion-negative parent (BakPak6). Putative



- 131 -

recombinants were plaque-purified twice more, passaged once, and screened for the production of  $\beta$ 1,4-galactosyltransferase activity.

Cell extracts were assayed for  $\beta$ 1,4-galactosyltransferase activity by adapting previously described methods (Berger *et al.*, 1986; Whiteheart *et al.*, 1989). Briefly, Sf9  
5 cells were grown to a density of about  $2.5 \times 10^6$  in 25 cm<sup>2</sup> flasks (Corning Glass Works, Corning, NY) and mock-infected or infected at a multiplicity of about 5 plaque-forming units per cell. After a 1 hr adsorption period at 28°C, the inocula were removed and the cells were rinsed and fed with fresh medium. The flasks were incubated for various times at 28°C, then the cells were dislodged and pelleted in a clinical centrifuge (IEC Model  
10 HN-SII; Needham Heights, MA). The cells were washed with cold Tris-buffered saline (25 mM Tris-HCl, pH 7.4; 140 mM NaCl), resuspended in cold assay buffer (10 mM HEPES, pH 7.4; 140 mM NaCl; 5 mM MnCl<sub>2</sub>, and 0.5% NP40), and frozen at -85°C. The frozen extracts were slow-thawed, clarified for 10 min in a microcentrifuge (Fisher Model 235C; Fisher Scientific Co., Pittsburgh, PA), and total protein concentrations in the  
15 supernatants were measured using the bicinchoninic acid method (Smith *et al.*, 1985; Pierce Chemical Company; Rockford, IL) with BSA as the standard.

Triplicate samples of the clarified extracts, each containing 100  $\mu$ g of protein, were assayed for  $\beta$ 1,4-galactosyltransferase activity in a total volume of 0.11 ml of fresh assay buffer containing 0.3  $\mu$ Ci of uridine diphosphate [ $6\text{-}^3\text{H}$ ] Gal (15 Ci/mmol; American  
20 Radiolabeled Chemicals, Inc.; St. Louis, MO) and 450  $\mu$ g/ml of ovalbumin (Grade V, Sigma). After 1 hr at 37°C, the reaction mixtures were quenched with 0.4 ml of cold assay buffer and spotted onto glass fiber filters (Whatman GF/D; Hillsboro, OR). The filters were dried and washed once with cold 10% (w/v) trichloroacetic acid, twice with cold 5% (w/v) trichloroacetic acid, and once with cold 95% (v/v) ethanol, then the filters were  
25 redried, placed in vials containing liquid scintillation cocktail (Packard UltimaGold; Meriden, CT), and radioactivity was measured in a liquid scintillation counter (Beckman Model LS6000-IC; Fullerton, CA).

No activity was detected in extracts from mock- or wild type AcMNPV-infected cells, but activity was detected in extracts from recombinant virus-infected cells beginning  
30 at 4 hr postinfection and rising to a plateau at 12 hr postinfection (FIG. 9). These results were similar to those observed with analogous recombinants expressing *E. coli*  $\beta$ -

galactosidase, chloramphenicol acetyltransferase, human tissue plasminogen activator, or Sf9  $\alpha$ -mannosidase II under *iel* control (Examples 2-5).

### EXAMPLE 13

#### 5                    Modification of the insect cell N-glycosylation pathway.

The inventor contemplated that the novel immediate early recombinant baculoviruses could be used to modify the N-linked oligosaccharide processing capabilities of lepidopteran insect cells. The strategy was to use the viral *iel* promoter (Jarvis *et al.*, 1996) to express a bovine  $\beta$ 1,4-galactosyltransferase cDNA (Harduin-Lepers  
10 *et al.*, 1993; Russo *et al.*, 1992) early in infection and determine if this enzyme could contribute to the insect cell N-glycosylation pathway and modify a foreign glycoprotein synthesized later in infection.

The gp64 protein is the major structural glycoprotein in progeny virions that bud from the surface of AcMNPV-infected cells (Volkman, 1986). Biosynthesis of AcMNPV  
15 gp64 peaks at 24 hr postinfection and at least one of its N-linked oligosaccharide side chains is processed to an endo- $\beta$ -D-N-acetylglucosaminidase H-resistant form (Jarvis and Garcia, 1994), but it contains no galactose (Jarvis and Finn, 1995). Thus, if gp64 from recombinant virions contained galactose, this would indicate that the  $\beta$ 1,4-galactosyltransferase encoded by the recombinant virus had contributed to the host cell  
20 processing pathway and extended one or more of the N-linked oligosaccharide side chains on gp64.

Sf9 cells were grown to a density of about  $1 \times 10^6$  cells per ml in 100 ml spinner flasks (Bellco Glass Inc., Vineland, N.J.) and infected with wild-type or recombinant baculovirus at a multiplicity of about 4 plaque-forming units per cell. At 48 hr  
25 postinfection, the infected cells were harvested, pelleted, and progeny budded virus particles were partially purified from the cell-free supernatant as described previously (Jarvis and Garcia, 1994). The budded virus preparations were treated for 10 min on ice with cold extraction buffer [50 mM Tris, pH 8.0; 100 mM NaCl, 1% (v/v) NP40, 0.2 mM leupeptin], the extracts were clarified in a microcentrifuge (Fisher Model 235C).

30                    The gp64 protein was immunoprecipitated from the supernatants with a monoclonal antibody (AcV1; 54) as described previously (Jarvis and Summers, 1989).

- 133 -

The immunoprecipitates were washed, disrupted, resolved by discontinuous SDS-PAGE (Laemmli, 1970), and proteins were transferred to Immobilon™ membranes (Millipore Corp.; Bedford, MA). The membranes were cut into strips corresponding to individual lanes and the strips were probed with either digoxigenylated lectins (Boehringer Mannheim Biochemicals; Indianapolis, IN) or rabbit anti-gp64, as described previously (Jarvis and Finn, 1995). Bound lectins or antibodies were detected by secondary reactions with alkaline phosphatase-conjugated anti-digoxigenin (Boehringer) or alkaline phosphatase-conjugated goat anti-rabbit IgG (Sigma), respectively, followed by an alkaline phosphatase color reaction (Blake *et al.*, 1984). For some lectin blotting studies, gp64 was pretreated with peptide:N-glycosidase F (New England Biolabs, Beverly, MA) as described previously (Jarvis and Finn, 1995).

Lectin blotting analyses showed that *Ricinus communis* agglutinin (RCA), which binds to  $\beta$ -linked galactose, bound strongly to gp64 from recombinant virions (FIG. 10B). Binding was carbohydrate-specific, as indicated by the inability of RCA to bind to gp64 from wild type virions (FIG. 10A) or to gp64 from recombinant virions when the reaction was done in the presence of competing galactose (FIG. 10B). RCA binding was not observed after pretreatment of gp64 from recombinant virions with peptide:N-glycosidase F, which showed that the galactose on gp64 was part of an N-linked oligosaccharide side chain (FIG. 11).

#### EXAMPLE 14

##### Influence of galactose addition on glycoprotein function.

The AcMNPV gp64 protein plays a key role in baculovirus infection, serving as a fusogen which apparently mediates penetration of budded virus particles into the host cell during adsorptive endocytosis (Volkman, 1986; Blissard and Wenz, 1992; Volkman and Goldsmith, 1985; Volkman *et al.*, 1986). This led to the question of whether galactosylation of gp64 and/or other virion glycoproteins influenced the growth of the immediate early recombinant virus.

To address this question, the one-step growth curves of wild type AcMNPV and immediate early recombinants expressing  $\beta$ 1,4-galactosyltransferase or  $\beta$ -galactosidase under *iel* control were compared. For the one-step growth studies, viral titers were

determined by TCID<sub>50</sub> assays and the results were converted to plaque-forming units per ml using a Microsoft® Excel spreadsheet (Summers and Smith, 1987; O'Reilly *et al.*, 1992). The results showed that there was no significant difference in the growth rates or numbers of infectious progeny produced by any of these viruses during *in vitro* infection of cultured Sf9 cells (FIG. 12).

## EXAMPLE 15

### Isolation and Characterization of an $\alpha$ 1,2-Mannosidase cDNA from Sf9 Cells

The presence of different types of oligosaccharide side-chains is one source of functional and structural diversity in glycoproteins. During the past ten years, a large number of genes encoding the enzymes that modify N-linked glycans have been cloned and characterized (Moremen *et al.*, 1994; Field and Wainwright, 1995). Glycoproteins acquire their N-linked oligosaccharide side-chains in the lumen of the endoplasmic reticulum (ER) by the transfer of a preassembled Glc<sub>3</sub>Man<sub>9</sub>GlcNAc<sub>2</sub> precursor from dolichol pyrophosphate to specific asparagine residues in the nascent polypeptide. These side-chains are then remodeled by the action of processing enzymes. In mammals, this involves trimming of the glucose residues and up to six of the nine mannose residues followed by the addition of fucose, N-acetylglucosamine, galactose, and sialic acid residues (reviewed by Kornfeld and Kornfeld, 1985). One part of this pathway that is being intensively investigated is trimming of the  $\alpha$ 1,2-linked mannose residues. Studies have shown that this is accomplished by a family of  $\alpha$ 1,2-mannosidases that act on glycoproteins in both the ER and Golgi apparatus (Moremen *et al.*, 1994).

It is generally accepted that insect cells, like mammalian cells, can trim N-linked glycans and extend them by adding fucose and N-acetylglucosamine. However, data suggest that insect cells differ from higher eukaryotes by their inability to add antennary galactose or sialic acid to these side-chains (Marz *et al.*, 1995). Insect cells clearly have  $\alpha$ 1,2-mannosidase activity involved in the trimming of N-linked glycans. This was demonstrated by the ability of 1-deoxymannojirimycin (dMNJ), a specific inhibitor of class I  $\alpha$ -mannosidases, to block the processing of N-linked glycans on gp64, the major virion glycoprotein produced in baculovirus-infected lepidopteran cells (Jarvis and Garcia, 1994). More direct evidence was provided by Ren and coworkers (1995), who purified an

enzymatically active  $\alpha$ 1,2-mannosidase from a membrane fraction of baculovirus-infected lepidopteran insect cells (Ren *et al.*, 1995). Finally, a putative  $\alpha$ 1,2-mannosidase gene was recently cloned from *Drosophila* (Kerscher *et al.*, 1995), although it was not proven that this gene actually encodes an active enzyme. Cloning and characterization of the genes encoding these enzymes from various organisms will help to elucidate the structural and functional relationships among these enzymes. The present Example details the cloning of an  $\alpha$ 1,2-mannosidase cDNA homolog from a lepidopteran insect cell-line Sf9 cDNA library.

This cDNA contains an open reading frame which encodes a 670 amino acid protein with a calculated molecular weight of 75,225 Da and, like other  $\alpha$ 1,2-mannosidases, is predicted to be a type II integral membrane protein with a short N-terminal cytoplasmic domain and a large C-terminal catalytic domain. This protein has two potential N-glycosylation sites, two consensus calcium binding sequences, and is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31 to 52). The amino acid sequence of this protein is 35-57% identical to *Drosophila*, human, murine and yeast  $\alpha$ 1,2-mannosidases. A transcript of approximately six kilobases was detected by Northern blot analysis of Sf9 mRNA. Genomic Southern blots probed with an intron-free fragment of the  $\alpha$ 1,2-mannosidase gene indicated that there are at least two copies or cross-hybridizing variants of this gene in the Sf9 genome. *In vivo* expression of the cDNA using a recombinant baculovirus produced a protein which released [ $^3$ H]mannose from [ $^3$ H]Man9GlcNAc. This activity required calcium, but not magnesium, and was inhibited by 1-deoxymannojirimycin. These results indicate that Sf9 cells encode and express an  $\alpha$ 1,2-mannosidase with properties similar to those of other eukaryotic processing  $\alpha$ 1,2-mannosidases.

A 675 bp fragment of an  $\alpha$ 1,2-mannosidase homolog was amplified by polymerase chain reaction (PCR<sup>TM</sup>) from an Sf9 cDNA library in  $\lambda$  ZapII. Degenerate oligonucleotide 1 (GAYWSITTYTAYGARTAYYTIYTNA; SEQ ID NO:18) and degenerate oligonucleotide 2 (RTGNGCYTCNGTRTTTAA; SEQ ID NO:19), corresponding to conserved amino acid sequences in yeast (Camirand *et al.*, 1991) and rabbit (Lal *et al.*, 1994)  $\alpha$ 1,2-mannosidases (Herscovics *et al.*, 1994) were used to amplify a putative  $\alpha$ 1,2-mannosidase fragment from an Sf9 cDNA library in  $\lambda$ -ZAPII (Short *et al.*, 1988;

- 136 -

Stratagene, La Jolla, CA). The template for the polymerase chain reactions (PCRs<sup>TM</sup>; Saiki *et al.*, 1985) was 2.5 ml of a clarified  $\lambda$ -ZAPII plate lysate ( $5 \times 10^7$  pfu/ml) prepared in SM buffer (50 mM Tris-HCl pH 7.5, 100 mM NaCl, 8 mM MgSO<sub>4</sub>) and the reactions were done in a total volume of 50 ml containing final concentrations of 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 1.5 mM MgCl<sub>2</sub>, 0.2 mM dNTP's, 1.25 units of Taq polymerase, and 1 mM of each primer. PCRs<sup>TM</sup> were performed in a Perkin-Elmer thermal cycler (Perkin-Elmer Corp., Norwalk, CT) programmed for 5 min at 94°C followed by 40 cycles of 1 min at 94°C, 1 min at 45°C, 3 min at 72°C, and a final extension of 7 min at 72°C.

The identity of the PCR<sup>TM</sup> amplicon as a putative  $\alpha$ 1,2-mannosidase fragment was confirmed by Southern blotting (Southern, 1975; Sambrook *et al.*, 1989), with an end-labeled degenerate oligonucleotide (RTAIARRTAYTTIARIGTYTCIGCNA; SEQ ID NO:20) designed against a third conserved amino acid sequence located between the two conserved regions used to design the PCR<sup>TM</sup> primers. The PCR<sup>TM</sup> amplicon was gel-purified, cloned into pBSKS+ (Stratagene), and sequenced using the chain termination method (Sanger *et al.*, 1977).

The sequencing results were used to design exact-match oligonucleotide primers (*Sf ManI* +1310+ (GCATCATGTTTCGACACG; SEQ ID NO:21) and *Sf ManI* +1791- (GTGGTAGACGTTTCACGAGAC; SEQ ID NO:22); the numbers identify the position of the 5' end of the oligo with respect to the start of the Sf9  $\alpha$ 1,2-mannosidase ORF, and the signs following these numbers indicate sense (+) or anti-sense (-) to isolate an  $\alpha$ 1,2-mannosidase clone from the Sf9 cDNA library by sibling selection and PCR<sup>TM</sup>, as described previously (Moremen, 1989; Example 6 above). The PCR<sup>TM</sup> reaction conditions were as described above except the annealing step was done at 54°C instead of 45°C. The library was initially split into 22 subpools of 50,000 clones. A positive subpool of 50,000 was further split into 15 "daughter" subpools of 5,000 clones, and a positive subpool of 5,000 was finally split into 12 daughter subpools of 2,000 clones. A positive subpool of 2,000 was then screened by plaque hybridization (Benton and Davis, 1977) with the cloned PCR<sup>TM</sup> amplicon, which had been excised from the vector, gel-purified twice, and uniformly labeled with [ $\alpha$ -<sup>32</sup>P]dATP (Feinberg and Vogelstein, 1983).

A positive clone was identified and plaque purified once more. The cDNA was excised *in vivo* as a pBluescript-based subclone by coinfecting *E. coli* XLI-Blue

- 137 -

(Stratagene) with this  $\lambda$ -ZAPII isolate plus M13-R408 helper phage. Double-stranded plasmid DNA was prepared and sequenced using the ABI PRISM™ Dye Terminator cycle sequencing method with AmpliTaq® DNA polymerase (Perkin-Elmer Corp.).

5 This initial cDNA clone lacked about 600 bp from the 5' end of the putative  $\alpha$ 1,2-mannosidase ORF. Hence, the 22 subpools (50,000 clones each) of the cDNA library were re-screened for a full-length clone using a modified 5' rapid amplification of cDNA ends (5'-RACE) procedure (Frohman *et al.*, 1988), as outlined in FIG. 14. Briefly, a T7-adapter primer (TTGCGTCTACTGCAGTCTACGACTCACTATAGGGC; SEQ ID NO:23) was designed to be complementary to the T7 promoter sequence in the  $\lambda$ -ZAP II  
10 vector and to include a 17-base adapter sequence at its 5' end. This primer could anneal to the T7 promoter sequence of every cDNA clone in the library. The other primers in the reaction were an Sf9  $\alpha$ 1,2-mannosidase-specific primer (AAGTGAGCTCGCTTCGACAT; SEQ ID NO:30) complementary to an internal sequence near the 5' end of the partial cDNA clone and a primer corresponding to the  
15 adapter sequence at the 5' end of the T7-adapter-primer. These two primers could anneal only to clones containing the Sf9  $\alpha$ 1,2-mannosidase cDNA. The size of the amplicon produced by this procedure reveals the length of the cDNA sequence located upstream of the Sf9  $\alpha$ 1,2-mannosidase-specific primer in the clone being amplified.

20 PCR<sub>s</sub>™ were done as described above with 54°C for annealing and the following primer concentrations: 70 nM of the T7-adapter-primer (SEQ ID NO:23), 1 mM of the 17-base adapter primer (TTGCGTCTACTGCAGTC; SEQ ID NO:24), and 1 mM of the sequence-specific primer. A subpool that included a putative full-length  $\alpha$ 1,2-mannosidase clone was identified and the clone was isolated by sibling selection and plaque hybridization as described above except the modified RACE procedure was used to  
25 screen the various subpools. Finally, the cDNA was excised and sequenced as described above and was found to contain a complete ORF encoding a putative  $\alpha$ 1,2-mannosidase. Computer analyses of the cDNA sequence were carried out using the Fragment Assembly System, Peptide structure, and GAP subroutines of the University of Wisconsin Genetics Computer Group software package (Program Manual for the Wisconsin Package, Version  
30 8, September 1994, Genetics Computer Group, 575 Science Drive, Madison, Wisconsin, USA 53711).

- 138 -

This screening procedure identified a full-length  $\alpha$ 1,2-mannosidase cDNA clone which contains an ORF that begins with an ATG in a favorable sequence for translational initiation (SEQ ID NO:1; Kozak, 1984, 1986; Cavener and Ray, 1991). This ORF encodes a 670 amino acid protein (SEQ ID NO:2) with a calculated molecular weight of 75,225 Da. The amino acid sequence of this putative Sf9  $\alpha$ 1,2-mannosidase is 57%, 47%, 46%, 46%, and 35% identical to *Drosophila* (Kerscher *et al.*, 1995; GenBank Accession # X82640), mouse 1A (Lal *et al.*, 1994; GenBank Accession # U04299), mouse 1B (Herscovics *et al.*, 1994; GenBank Accession # U03458), human (Bause *et al.*, 1993; GenBank Accession # X74837), and yeast (Camirand *et al.*, 1991; GenBank Accession # M63598) processing  $\alpha$ 1,2-mannosidases, respectively. The putative Sf9  $\alpha$ 1,2-mannosidase is predicted to be a type II integral membrane protein with a 22 amino acid transmembrane domain (residues 31 to 52). It contains two potential N-glycosylation sites (residues 61 and 332) and two putative calcium binding sequences (residues 258 to 269 and 273 to 284) as defined by Marsden and coworkers (1990). In addition, there are several other potential calcium binding sequences, but these have less than three acidic residues available for binding calcium and are therefore less likely to be significant (Marsden *et al.*, 1990).

The N-glycosylation pathway in insects is thought to be a truncated version of the mammalian pathway, lacking the ability to add antennary galactose or sialic acid to oligosaccharide side-chains (reviewed in Marz *et al.*, 1995). On the other hand, there have been a few reports which indicate that baculovirus-infected lepidopteran insect cells can produce N-linked glycans containing penultimate galactose and terminal sialic acid (Davidson *et al.*, 1990) and that this process might be facilitated by baculovirus induction of an  $\alpha$ 1,2-mannosidase with preferential activity toward  $\text{Man}_6\text{GlcNAc}_2$  (Davidson *et al.*, 1991). An enzyme with this activity was recently purified from a membrane fraction of baculovirus-infected lepidopteran insect cells by Ren and coworkers (1995). However, since the gene encoding this enzyme has not been isolated, the relationship, if any, between this enzyme and the instant  $\alpha$ 1,2-mannosidase is unclear.



**EXAMPLE 16****PCR<sup>TM</sup> screening of introns within the Sf9  $\alpha$ 1,2-mannosidase gene  
and genomic Southern blotting**

Preliminary PCR<sup>TM</sup> studies using primers corresponding to selected regions in the  
5 Sf9  $\alpha$ 1,2-mannosidase sequence were done to identify an intron-free region in the Sf9  
 $\alpha$ 1,2-mannosidase gene that could be used as an unambiguous probe for genomic Southern  
blots. Several pairs of exact-match primers corresponding to various regions in the Sf9  
 $\alpha$ 1,2-mannosidase cDNA were used for PCR's<sup>TM</sup> on Sf9 genomic DNA to determine if it  
contained any introns. The primer pairs were: pair 1, Sf MI +1310+ (SEQ ID NO:21) and  
10 Sf MI +2123- (CCTTGCTATTTACTCTCGTC; SEQ ID NO:25); pair 2, Sf MI +843+  
(TGTGTTTCGAGACGACGATC; SEQ ID NO:26) and Sf MI +1492-  
(GACATCGAGTTGTCCAGG; SEQ ID NO:27); and finally pair 3, Sf MI -25+  
(GTGTAGGTTCTGTGTTTACG; SEQ ID NO:28) and Sf MI +306-  
(TTCACCATGGTGAGCGATC; SEQ ID NO:29). PCR's<sup>TM</sup> were done as described  
15 above, except the template was 100 ng of Sf9 genomic DNA isolated as described  
previously (Sambrook, 1989). The presence of introns was indicated by an increase in the  
size of the product amplified from the genomic DNA template relative to the size of the  
product amplified from the cDNA clone. The identity of the PCR<sup>TM</sup> products as fragments  
of the  $\alpha$ 1,2-mannosidase gene was confirmed by Southern blotting (Southern, 1975) with  
20 the full-length Sf9  $\alpha$ 1,2-mannosidase cDNA, which had been excised from the vector, gel  
purified twice, and uniformly labeled with [ $\alpha$ -<sup>32</sup>P]dATP (Feinberg and Vogelstein, 1983).

These studies identified two regions containing introns, as indicated by an increase  
in the size of the product amplified from Sf9 genomic DNA relative to the size of the  
product amplified from the cDNA. It is important to note that there could be other intron-  
25 containing regions within the gene, since the PCR<sup>TM</sup> screening was not comprehensive.  
However, one region of this gene, corresponding to positions -25 to +306 contained no  
detectable introns. Therefore, the inventors used a 302 bp *Sna*BI (position -6)-*Nco*I  
(position +296) fragment from this region as a probe for genomic Southern blotting  
analyses.

30 Genomic DNA from Sf9, Bm, High Five, Ea, or COS cells was digested with  
either *Nco*I alone, or with both *Sna*BI and *Nco*I, and analyzed by Southern blotting under

high stringency conditions. Sf9 cells are derived from the IPLB-Sf21-AE cell line, which was originally isolated from *Spodoptera frugiperda* (fall armyworm) ovaries (Vaughn *et al.*, 1977). Sf9 cells were maintained as a suspension culture at densities between 0.3 and  $3.0 \times 10^6$  cells per ml in TNM-FH medium (Summers and Smith, 1987) supplemented with 10% (v/v) heat-inactivated fetal bovine serum (Sigma Chemical Co., St. Louis, MO), 1.25 mg/ml amphotericin B (Sigma), 25 mg/ml gentamicin (Sigma), and 0.1% (w/v) pluronic F68 (BASF Wyandotte Corp., Parsippany, NJ; Murhammer and Goochee, 1988). The other lepidopteran insect cell lines used in this study were BTI-Tn-5B1-4 (High Five; Wickham *et al.*, 1992), derived from *Trichoplusia ni* (cabbage looper) eggs; Bm 5 (Bm; Grace, 1967), derived from *Bombyx mori* (silkworm) ovaries; and BTI-EaA (Ea; Granados and Naughton, 1975), derived from *Estigmene acrea* (saltmarsh caterpillar). COS-1 (Gluzman, 1981) is an SV40-transformed monkey kidney cell line.

Approximately seven mg of genomic DNA from Sf9, Bm, High Five, Ea, and COS cells were digested with either *NcoI* only or with both *SnaBI* and *NcoI*. The DNA's were resolved on 1% agarose gels, depurinated by soaking in 0.25 M HCl for 10 min, and transferred to positively charged nylon membranes (Zeta-Probe<sup>®</sup>; Bio-Rad Laboratories, Hercules, CA) in 0.4 M NaOH (Southern, 1975; Reed and Mann, 1985).

The membranes were prehybridized for one hour in a solution of 7%(w/v) SDS, 0.12 M Na<sub>2</sub>HPO<sub>4</sub> (pH 7.2), 0.25 M NaCl, 1 mM EDTA, and a formamide concentration of 50%, 42%, or 35% for decreasing levels of stringency. Hybridization was carried out overnight at 43°C in the same solution using a fragment of the Sf9  $\alpha$ 1,2-mannosidase cDNA prepared as described above. For these analyses, however, the probe was an internal 302 bp, *SnaBI-NcoI* fragment corresponding to positions -6 (*SnaBI*) to +296 (*NcoI*) of the cDNA with respect to the start of the ORF. PCR<sup>™</sup> analysis of Sf9 genomic DNA had shown that there were no introns within this region of the genomic copy of the  $\alpha$ 1,2-mannosidase gene. After hybridization, the membranes were rinsed in 2X SSC then washed successively with vigorous agitation for 15 min in each of the following solutions: 2X SSC/0.1% SDS at room temperature; 0.5X SSC/0.1% SDS at room temperature; 0.1X SSC/0.1% SDS at either 65°C for high stringency (50% formamide) or room temperature for low stringency (42% or 35% formamide). The membranes were then blotted dry and

- 141 -

exposed to Kodak (Rochester, N.Y.) BioMax MS film for 24 hours with an intensifying screen.

The probe hybridized with two fragments from the *NcoI*-digested Sf9 DNA, suggesting that there are two copies or two cross-hybridizing variants of the  $\alpha$ 1,2-mannosidase gene in the Sf9 genome. The same probe hybridized with a single 302 bp  
5 fragment of the *SnaBI* and *NcoI* doubly-digested Sf9 DNA, indicating that the two  $\alpha$ -mannosidase genes differ with respect to the positions of their upstream *NcoI* sites, and that the positions of the *SnaBI* and downstream *NcoI* sites are conserved. Similar results were obtained with genomic DNA from Bm cells, except the upper fragment detected in  
10 the *NcoI* digest was lighter. Very light hybridization was detected with DNA from High Five cells, and no hybridization was detected with DNA from Ea or COS cells. These results indicated that the  $\alpha$ 1,2-mannosidase genes present in High Five, Ea, and COS cells are significantly different from those present in Sf9 and Bm cells. This might help to explain why these cell lines have differing N-glycan processing capabilities (Davis *et al.*,  
15 1993; Ogonah *et al.*, 1996).

To further investigate these differences, the Southern blotting analyses of Sf9, High Five, and Ea genomic DNA were repeated under less stringent conditions (42% formamide and 35% formamide). Under these conditions, the probe hybridized with three major fragments of *NcoI*-digested Sf9 DNA, one major fragment of *NcoI*-digested High Five cell  
20 DNA, and several fragments of *NcoI*-digested DNA from Ea cells. The probe hybridized with multiple fragments of various sizes with *SnaBI* and *NcoI* double-digests of the DNA from these three insect cell lines.

## EXAMPLE 17

### 25 Expression of the $\alpha$ 1,2-mannosidase gene

To study the expression of the  $\alpha$ -1,2-mannosidase gene, Northern blotting analysis of Sf9 mRNA was conducted with the full-length Sf9  $\alpha$ 1,2-mannosidase ORF as a probe. Total RNA from approximately  $2 \times 10^8$  Sf9 cells was prepared by the method of Chirgwin and coworkers (1979) and messenger RNA was isolated on an oligo-dT cellulose column  
30 (Aviv and Leder, 1972). Ten mg of the Sf9 mRNA were resolved on a 1.2% agarose/0.66 M formaldehyde gel and transferred to a positively charged nylon membrane (Zeta-

- 142 -

Probe<sup>®</sup>; Bio-Rad) in 50 mM NaOH. Prehybridization, hybridization, washing, and autoradiography were done as described in Example 16, except 10% (w/v) PEG-8000 (Sigma) was used in the hybridization solution and the probe contained the complete ORF of the Sf9  $\alpha$ 1,2-mannosidase gene.

5 Northern blotting analysis of Sf9 mRNA with the full-length Sf9  $\alpha$ 1,2-mannosidase ORF as a probe revealed a single transcript of about 6 kb. Since the  $\alpha$ 1,2-mannosidase ORF is only about 2 kb in length, most of the remaining 4 kb is probably 3' untranslated region in the mRNA transcript. This speculation is supported by the fact that the initial (partial) Sf9  $\alpha$ 1,2-mannosidase cDNA clone contained about 3 kb of 3' untranslated sequence.

10

### EXAMPLE 18

#### Baculovirus-mediated overexpression of the Sf9 $\alpha$ 1,2-mannosidase

A recombinant baculovirus was produced that encoded the Sf9  $\alpha$ 1,2-mannosidase cDNA under the control of the strong polyhedrin promoter and used to express the Sf9  $\alpha$ 1,2-mannosidase protein. The Sf9  $\alpha$ 1,2-mannosidase ORF was subcloned into a baculovirus transfer plasmid (pVL1393; Webb and Summers, 1990) downstream of the polyhedrin promoter. The resulting plasmid was used to produce a baculovirus expression vector encoding the Sf9  $\alpha$ 1,2-mannosidase gene under polyhedrin control by using standard methods (Summers and Smith, 1987; O'Reilly *et al.*, 1992). The viral DNA used as the target for homologous recombination was BacPAK6 (Kitts and Possee, 1993) that had been digested with *Bsu36I* (New England Biolabs, Beverly, MA). Recombinant viruses were plaque purified twice, titered by plaque assay, and used to infect Sf9 cells. Expression of the  $\alpha$ 1,2-mannosidase protein was assessed by discontinuous SDS-polyacrylamide gel electrophoresis (PAGE) and Coomassie-blue staining of total protein lysates, as described previously (Laemmli, 1970; Jarvis *et al.*, 1996).

15

20

25

A protein with an apparent molecular weight of about 68 kDa was observed in total lysates from cells infected with the recombinant baculovirus, but not in lysates from mock-infected or wild-type baculovirus-infected cells at 48 and 72 hours postinfection. The 29 kDa polyhedrin protein was detected only in lysates from wild-type baculovirus-infected cell lysates at 48 and 72 hours postinfection. These results are consistent with those

30

expected of a recombinant baculovirus encoding a foreign protein under the control of the polyhedrin promoter.

### EXAMPLE 19

5

#### $\alpha$ -mannosidase activity assays

Sf9 cell lysates were used for  $\alpha$ 1,2-mannosidase activity assays with [ $^3$ H]Man<sub>6</sub>GlcNAc as described previously (Herscovics and Jelinek-Kelly, 1987) with some modifications. The cells were seeded into 25 cm<sup>2</sup> tissue culture flasks (Corning Glass Works, Corning, NY) at a density of 3 million cells per flask and infected at a multiplicity of infection of 10 plaque forming units per cell with either a recombinant baculovirus encoding the Sf9  $\alpha$ 1,2-mannosidase cDNA under the control of the polyhedrin promoter, or wild type baculovirus as a control. The cells were harvested by centrifugation at selected times after infection, washed with 100 mM Na<sup>+</sup>MES (pH 6.0), and lysed using 1 ml per 30,000 cells of the same buffer containing 0.5% Triton X-100 with or without 80 mM EDTA.

15

Five ml of the lysates were used in each reaction of the  $\alpha$ 1,2-mannosidase activity assays. Cell lysates for negative control reactions were boiled for 3 min prior to being added to the reactions. All reactions were carried out in a total volume of 40 ml containing 75 mM Na<sup>+</sup>MES (pH 6.0), 0.0625% Triton X-100, and 6000 cpm of [ $^3$ H]Man<sub>6</sub>GlcNAc. In addition, some reactions contained CaCl<sub>2</sub>, MgCl<sub>2</sub>, EDTA, or dMNJ. The reactions were incubated at 37°C for 2.5 hours, boiled for 2 min, and 250  $\mu$ l of a 5 mM solution of CaCl<sub>2</sub>, MgCl<sub>2</sub>, and MnCl<sub>2</sub>, and 175  $\mu$ l of a 2.25 mg/ml solution of concanavalin A (Boehringer-Mannheim, Indianapolis, IN) in 3.8 M NaCl were added to each reaction. The solutions were vortexed gently and incubated at room temperature for two minutes, then 1 ml of 25% PEG-8000 was added and the solutions were vortexed and incubated for another 5 min at room temperature. The solutions were then centrifuged for 2 min at 10,000 X g, 1 ml of the supernatant was added to 4 ml of a scintillation cocktail (Ultima Gold<sup>TM</sup>; Packard Instrument Company, Meriden, CT), and radioactivity was measured using a Beckman liquid scintillation counter (Model LS 6000IC; Beckman Instruments, Inc., Fullerton, CA).

20

25

30

Using this assay, there was no difference in the levels of  $\alpha$ -mannosidase activity detected in lysates from wild-type virus-infected cells or in boiled lysates (FIG. 15A). This result indicated that the endogenous activity in wild type virus-infected cells was too low to be detected by this assay. By contrast, recombinant virus-infected cells contained significantly higher levels of activity than boiled lysates. Activity was detected at 24, 36, and 48, but not at 12 hours postinfection, and more activity was detected at 36 and 48 than at 24 hours postinfection (FIG. 15A). Like the protein profiles, these results were consistent with those expected of a recombinant baculovirus encoding a foreign enzyme under the control of the polyhedrin promoter. The  $\alpha$ -mannosidase activity observed in recombinant baculovirus-infected cells was strongly inhibited by dMNJ, an inhibitor of class I  $\alpha$ -mannosidases, and by EDTA (FIG. 15B). The inhibition by EDTA could be reversed by the addition of calcium, but not magnesium. These properties are identical to those of  $\alpha$ 1,2-mannosidases from other eukaryotes (Moremen *et al.*, 1994).

## EXAMPLE 20

### Isolation and Characterization of Stably-transformed Sf9 Cells that Express Mammalian $\beta$ 1.4-galactosyltransferase

Expression plasmids and methods have been described that can be used to produce stably-transformed insect cell subclones that express foreign genes constitutively (Jarvis *et al.*, 1990; Jarvis and Guarino, 1995; Examples 1-5 above). Briefly, various expression plasmids were constructed containing a baculovirus IE1 promoter and hr5 enhancer that can be used to express any gene of interest or selectable marker in uninfected insect cells. Sf9 cells were cotransfected with derivatives of these constructs containing various genes of interest, selected for neomycin resistance, and subclones were produced by limiting dilution. After amplification, the subclones were screened for their ability to express the gene of interest.

This general procedure was used to successfully produce a variety of stably-transformed Sf9 subclones that express different gene products, including *E. coli*  $\beta$ -galactosidase, human tissue plasminogen activator, and the baculovirus IE2, pp31, and gp64 proteins (Jarvis *et al.*, 1990, Examples 1-5 above). Other labs also have used this approach to produce stably-transformed insect cells that express various foreign gene

products (Cartier *et al.*, 1994; Henderson *et al.*, 1995; Joyce *et al.*, 1993). As described above, it has been demonstrated that IE1-based recombinant baculovirus vectors could be used to express a bovine  $\beta$ 1,4-galactosyltransferase ( $\beta$ 4-GT) cDNA and modify the Sf9 cell N-glycosylation pathway, as detailed above (Examples 11-14 above). The present  
5 Example describes the isolation of a stably-transformed Sf9 cell subclone that constitutively expresses  $\beta$ 4-GT.

Sf9 cells were cotransfected with immediate-early expression plasmids containing the  $\beta$ 4-GT or neo genes positioned under IE1 control. The cotransfected cells were selected in neo, as described above, and extracts from ten independent subclones were  
10 screened for  $\beta$ 4-GT activity, as previously described (Examples 11-14 above). The results showed that all ten of these subclones produced  $\beta$ 4-GT activity, though expression levels were quite variable. Subclone 9, which expressed the highest levels of activity was designated SfGalT and further characterized by genomic Southern blotting. The results showed that these cells have multiple tandem duplications of the expression plasmid  
15 integrated at one site and a single copy inserted at one additional site.

The ability of these cells to modify a foreign glycoprotein was demonstrated by comparing the lectin blotting profiles of gp64 isolated from progeny virions from either Sf9 or SfGalT cells infected with wild-type baculovirus. The results of the lectin blots showed that RCA failed to bind specifically to gp64 from the progeny from Sf9 cells,  
20 whereas it clearly bound to gp64 from the progeny from SfGalT cells (FIG. 16A and FIG. 16B). These results indicated that gp64 produced by Sf9 cells lacks  $\beta$ -linked galactose, while gp64 produced by SfGalT cells contains  $\beta$ -linked galactose. Thus, a stably-transformed insect cell subclone has been successfully produced which has an N-glycosylation pathway that has been genetically and biochemically engineered to  
25 include mammalian  $\beta$ 4-GT activity.

Lectin blotting results also showed that the SfGalT cells differentially modified human tissue plasminogen activator, which was expressed when these cells were infected with a conventional recombinant baculovirus expression vector. Tissue plasminogen activator produced under the control of the polyhedrin promoter in Sf9 cells failed to bind  
30 to RCA, whereas the same protein produced by the same virus in SfGalT cells bound to RCA (FIG. 17A and FIG. 17B). These results indicate that SfGalT cells can be used to

produce more extensively N-glycosylated foreign glycoproteins when used in conjunction with conventional baculovirus expression vectors.

### EXAMPLE 21

5     **Isolation and characterization of stably-transformed Sf9 cells that express mammalian  $\beta$ 1,4-galactosyltransferase and  $\alpha$ 2,6-sialyltransferase**

10     This example describes the production of a new Sf9 cell subclone that has both mammalian  $\beta$ 4-GT and  $\alpha$ 2,6-sialyltransferase ( $\alpha$ 2,6-ST) activity. A new immediate early expression plasmid was constructed that contains two copies of the IE1 promoter. The starting materials were pIE1HR4 and pAcP(-)IE1TV6 (Examples 1-5 above), which were recombined to produce an expression plasmid with two back-to-back IE1 promoters separated by the hr5 enhancer element. Each promoter is followed by at least one unique restriction site, which was used for the subsequent insertion of bovine  $\beta$ 4-GT (Shaper *et al.*, 1988) and rat  $\alpha$ 2,6-ST (Weinstein *et al.*, 1987) cDNAs.

15     The ability of the resulting plasmid to express  $\beta$ 4-GT and rat  $\alpha$ 2,6-ST is tested by transient transfection assays. Briefly, Sf9 cells are transfected with 10  $\mu$ g of plasmid DNA, detergent extracts are prepared at 24 hr after transfection, and  $\beta$ 4-GT and rat  $\alpha$ 2,6-ST activities are measured. Cell extraction and radioassay methods for both enzyme activities have been described (Examples 11-14 above; Paulson *et al.*, 1977). Control transfections are done using the dual expression plasmid with no inserts, or IE1 expression plasmids containing the individual  $\beta$ 4-GT and rat  $\alpha$ 2,6-ST cDNAs.

20     Next, the plasmid was used for coselection of an Sf9 cell subclone, as described in Example 19 above. Sf9 cells were cotransfected with the dual IE1 expression plasmid plus IE1Neo, and transformants were isolated by selection in neomycin followed by limiting dilution. Subclones are amplified and screened for both activities. Subclones that have both activities are characterized by genomic Southern blotting to evaluate the nature of the genetic modification. The ability of these cells to differentially glycosylate gp64 is assessed first by lectin-blotting assays designed to specifically detect  $\beta$ -linked galactose or  $\alpha$ 2,6-linked sialic acid. The same proteins expressed in untransformed Sf9 cells with the same recombinant viruses and lectins preincubated in the presence of competing sugars are used as controls.

25

30



**EXAMPLE 22****Recombinant Baculoviruses and Transfer Plasmids****1. AcP(+)DIE-GTST**

5 AcP(+)DIE-GTST (FIG. 20A) is a recombinant baculovirus that contains early-promoted and hr-enhanced galactosyltransferase (GT) and sialyltransferase (ST) genes in the polyhedrin region. This virus is used together with a conventional recombinant baculovirus to coinfect conventional host cell lines. AcP(+)DIE-GTST expresses GT and ST early in infection and extends the insect cell N-glycosylation pathway. This occurs  
10 before the protein of interest is expressed, preferably under the control of a late or very late baculovirus promoter by the conventional recombinant baculovirus. The protein of interest is more extensively processed by the modified N-glycosylation pathway, resulting in the production of a more authentic recombinant protein.

The inventor contemplates a number of variations for use with this novel  
15 recombinant baculovirus. First, any early viral or constitutive cellular promoter may be used to express GT and ST. Second, any enhancer may be used to increase expression of GT and ST. Third, the relative positions of the GT, ST, and polh genes are unimportant. Fourth, similar embodiments provide other types of protein processing (*e.g.*, folding, phosphorylation, acylation, acetylation, methylation or amidation).

20

**2. pAcP(-)DIE-GTST**

pAcP(-)DIE-GTST (FIG. 20B) is a recombinant transfer plasmid that contains early-promoted and hr-enhanced GT and ST genes and a late-promoted gene encoding any protein of interest, all embedded within polyhedrin flanking sequences. This plasmid is  
25 used to produce recombinant baculoviruses that are used, in turn, to infect conventional host cell lines. These recombinant viruses express GT and ST earlier in infection, extending the insect N-glycosylation pathway. These same recombinants also express the protein of interest, preferably later in infection. This design provides more extensive processing of the protein of interest and produces a more authentic recombinant protein  
30 without having to resort to coinfection.

- 148 -

The inventor additionally contemplates a number of variations for use with this novel recombinant transfer plasmid. First, any early viral or constitutive cellular promoter may be used to express GT and ST. Second, any enhancer may be used to increase expression of GT and ST. Third, any promoter, preferably a late or very late viral promoter, may be used to express protein of interest. Fourth, the relative positions of the GT, ST, and polh genes are unimportant. Fifth, the precise nature of the multiple cloning site is unimportant. And sixth, similar embodiments provide other types of protein processing, as detailed above.

### 3. AcSWT-1

AcSWT-1 (FIG. 20C) is a recombinant baculovirus that contains early-promoted and hr-enhanced GT and ST genes inserted into the gp64 region of the baculoviral genome together with multiple Bsu36I sites in ORF-603, polh-LacZ, and ORF-1629. The genes are inserted into the gp64 locus using the transfer plasmid (pAc64DIE-GTST). This recombinant viral DNA is used as a target for the insertion of one or more genes encoding any protein of interest, under the control of a promoter, preferably a late or very late promoter. The insertion is carried out using conventional baculovirus transfer plasmids and a conventional method involving linearization of the viral DNA by digestion with Bsu36I. The resulting recombinants are used to express the protein of interest during infection of conventional insect cell lines. Unlike existing baculoviral vectors, however, recombinant baculoviruses produced with AcSWT-1 viral DNA express GT and ST early in infection, which extends the insect cell N-glycosylation pathway. Thus, the protein of interest that is expressed, preferably later in infection, is more authentic due to virus-mediated modification of the host protein processing machinery.

The inventor also contemplates a number of variations for use with this novel recombinant baculovirus. First, any early viral or constitutive cellular promoter may be used to express GT and ST. Second, any enhancer may be used to increase expression of GT and ST. Third, the GT and ST genes may be inserted into other nonessential locations in viral genome (*e.g.*, p10, see below). Fourth, any promoter, preferably a late or very late viral promoter, may be used to express the protein of interest. Fifth, the relative positions

of the GT and ST genes are unimportant. And sixth, as above, similar embodiments provide other types of protein processing.

#### 4. AcSWT-2

5 AcSWT-2 (FIG. 20D) is a recombinant baculovirus that contains early-promoted and hr-enhanced GT and ST genes inserted into the gp64 region of the baculovirus genome, early-promoted and enhanced N-acetylglucosaminyltransferase (GlcNAc-T) I and II genes inserted into the p10 region of the baculovirus genome, and multiple Bsu36I sites in ORF-603, polh-LacZ, and ORF-1629. This recombinant viral DNA is used exactly as  
10 described above for AcSWT-1. However, in addition to providing GT and ST, which are believed to be absent in insect cells, AcSWT-2 also provides GlcNAc-TI and GlcNAc-TII, which are present only at very low levels in insect cells. Thus, recombinant baculoviruses produced with AcSWT-2 viral DNA express GlcNAc-TI, GlcNAc-TII, GT, and ST early in infection, which increase the levels of existing activities and add new activities to the  
15 insect cell N-glycosylation pathway. The protein of interest that is expressed, preferably later in infection, is more authentic due to virus-mediated enhancement and extension of host protein processing machinery.

As with the embodiments above, any early viral or constitutive cellular promoter may be used to express processing enzymes, and any enhancer may be used to increase  
20 expression of processing enzymes. The GT and ST genes may be inserted into other nonessential locations in viral genome, and the relative positions of the GT, ST, GlcNAc-TI and GlcNAc-TII genes are unimportant. Any promoter, preferably a late or very late viral promoter, may be used to express the protein of interest, and similar embodiments provide other types of protein processing.

25

### EXAMPLE 23

#### Production and Use of Insect Cells With Stably Integrated Glycosylation Genes

##### 1. SfGalT plus AcP(+)/IE1ST

This is a combination of an Sf9 cell subclone that contains an early-promoted and  
30 hr-enhanced GT gene stably integrated into the genome of the cell, and a novel recombinant baculovirus that contains an early-promoted and enhanced ST gene (FIG.

- 150 -

21C). The SfGalT cells, which were isolated and characterized as described above in Example 20, contain stably-integrated copies of the expression plasmid, pIE1GT, and constitutively express GT activity. AcP(+)/IE1ST contains an early-promoted and enhanced ST gene in the polyhedrin region of the baculovirus genome. The infection of SfGalT cells with AcP(+)/IE1ST results in terminal sialylation of gp64 (FIG. 18A and FIG. 18B). This does not occur when SfGalT cells are infected with wild-type baculovirus, nor when Sf9 cells are infected with the AcP(+)/IE1ST recombinant. The presence of terminal sialic acid residues was confirmed by linkage analysis of the oligosaccharides on gp64 (FIG. 19). Thus, the constitutive GT activity and the ST activity expressed by the virus early in infection collaborate to modify gp64, which is a natural virus-encoded product expressed predominantly during the late phase of infection.

As discussed above for the recombinant baculoviruses, any early viral or constitutive cellular promoter may be used to express the processing enzymes, and any enhancer may be used to increase expression of processing enzymes. Additionally, any promoter may be used to express the protein of interest. The ST gene may be inserted into other nonessential locations in viral genome. Further, any insect cell line may be used as the parent for stable transformation. Also, similar embodiments provide other types of protein processing, as discussed above.

## 2. SfGalT plus AcP(-)/IE1ST

This is a combination of an Sf9 cell subclone that contains an early-promoted and hr-enhanced GT gene stably integrated into the genome of the cell, and a novel recombinant baculovirus that contains an early-promoted and enhanced ST gene and also encodes a late-promoted gene of interest (FIG. 21D). The SfGalT cells, which were isolated and characterized as described above, contain stably-integrated copies of the expression plasmid, pIE1GT, and constitutively express GT activity. AcP(-)/IE1ST contains an early-promoted and enhanced ST gene and a late-promoted protein of interest in the polyhedrin region. Infection of SfGalT cells with AcP(+)/IE1ST results in terminal sialylation of the protein of interest.

With this system, as described above, any early viral or constitutive cellular promoter may be used to express processing enzymes, and any enhancer may be used to

- 151 -

increase expression of processing enzymes. The relative positions of the ST gene and the gene of interest are unimportant, and the ST gene may be inserted into other nonessential locations in the viral genome. Any promoter may be used to express the protein of interest, and any insect cell line may be used as the parent for stable transformation. As with all of these recombinant baculoviruses and cell lines, similar embodiments provide other types of protein processing.

### 3. SfSWT-1

SfSWT-1 (FIG. 21A) is an Sf9 cell subclone that contains early-promoted and hr-enhanced GT and ST genes. The cells were produced by cotransfecting Sf9 cells with pDIE-GTST plus pIE1Neo, followed by selection with G418 and limiting dilution. These cells contain stably-integrated copies of the expression plasmid and constitutively express GT and ST activities. Thus, these cells have a modified N-glycosylation pathway that can process a protein of interest more extensively. The protein of interest is expressed by infecting the cells with a conventional baculovirus expression vector, which contains the gene of interest under the control of any promoter.

As described above, any early viral or constitutive cellular promoter may be used to express processing enzymes, any enhancer may be used to increase expression of processing enzymes, and any promoter may be used to express the protein of interest. The relative positions of the GT and ST genes are unimportant. Again, any insect cell line may be used as the parent for stable transformation, and similar embodiments provide other types of protein processing.

### 4. SfSWT-2

SfSWT-2 (FIG. 21B) is an Sf9 cell subclone that contains early-promoted and hr-enhanced GT, ST, GlcNAc-TI, and GlcNAc-TII genes. These cells are produced by cotransfecting the SfSWT-1 cells from above with pDIE-GNTI-II plus pIE1Hygro, followed by selection with G418 plus hygromycin and limiting dilution. These cells contain stably-integrated copies of both expression plasmids (pDIE-GTST and pDIE-GNTI-II) and thus constitutively express not only GT and ST activities, as with the

- 152 -

SfSWT-1 cells, but also express GlcNAc-TI and GlcNAc-TII, which are present only at very low levels in insect cells.

As described above for SfSWT-1, any early viral or constitutive cellular promoter may be used to express processing enzymes, any enhancer may be used to increase expression of processing enzymes, and any promoter may be used to express the protein of interest. Any insect cell line may be used as the parent for stable transformation, and the relative positions of the GT, ST, GlcNAc-TI and GlcNAc-TII genes are unimportant. Similar embodiments provide other types of protein processing.

\* ..... \*

All of the compositions and methods disclosed and claimed herein can be made and executed without undue experimentation in light of the present disclosure. While the compositions and methods of this invention have been described in terms of preferred embodiments, it will be apparent to those of skill in the art that variations may be applied to the compositions, and in the steps or in the sequence of steps of the methods described herein without departing from the concept, spirit and scope of the invention. More specifically, it will be apparent that certain agents which are both chemically and physiologically related may be substituted for the agents described herein while the same or similar results would be achieved. All such similar substitutes and modifications apparent to those skilled in the art are deemed to be within the spirit, scope and concept of the invention as defined by the appended claims.

**REFERENCES**

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

- Ackermann *et al.*, *Baculovirus and Insect Cell Gene Expr. Conf. Abstr.*, ST13, 1995.
- Adams and McClintock, *In: Atlas of Invertebrate Viruses*, Adams, J.R. and Bonami, J.R., eds., CRC Press, Inc., Boca Raton, Florida, 87-204, 1991.
- Adang and Miller, *J. Virol.*, 44:782, 1982.
- Adelman *et al.*, *DNA* 2:183, 1983.
- Aeed and Elhammer, *Biochemistry*, 33:8793, 1994.
- Agarwal *et al.*, *Oncogene*, 11:427, 1995.
- Agbandje *et al.*, *Virology*, 184:170, 1991.
- Alnemri and Litwack, *Biochemistry*, 32:5387, 1993.
- Alt *et al.*, *J. Biol. Chem.*, 253:1357, 1978.
- Altmann *et al.*, *Glycobiology*, 3:619-625, 1993.
- Altmann *et al.*, *J. Biol. Chem.*, 270:17344-17349, 1995.
- Andersons *et al.*, *Biochem. J.*, 280:219, 1991.
- Apte and Siebert, *Biotechniques*, 15:890-893, 1993.
- Arp *et al.*, *J. Gen. Virol.*, 74:211, 1993.
- Aviv and Leder, *Proc. Nat. Acad. Sci. U.S.A.*, 69:1408-1412, 1972.
- Ayres *et al.*, *Virology*, 202:586, 1994.
- Bailer *et al.*, *Prot. Expr. Pur.*, 6:546, 1995.
- Bakker *et al.*, *J Biol. Chem.*, 269(48):30326-33, 1994.
- Bause *et al.*, *Eur. J. Biochem*, 217:535-540, 1993.
- Beames *et al.*, *Biotechniques*, 11:378, 1991.

- 154 -

- Becker *et al.*, *Bio/Technology*, 12:69, 1994.
- Belyaev and Roy, *Virology*, 190:840, 1992.
- Belyaev *et al.*, *Gene*, 156:229, 1995.
- Bendiak *et al.*, *Eur. J. Biochem.* 216(2):405-17, 1993.
- 5 Beniya *et al.*, *Virology*, 216:12, 1996.
- Benton and Davis, *Science*, 196:180-182, 1977.
- Berger *et al.*, *FEBS Letters*, 203:64-68, 1986.
- Bischoff *et al.*, *J. Biol. Chem.*, 165:17110-17117, 1990.
- Bishop *et al.*, *inNovations*, 4:1, 1995.
- 10 Blake *et al.*, *Anal. Biochem.*, 36:175-179, 1984.
- Blissard and Rohrmann, *Virology*, 170:537-555, 1989.
- Blissard and Rohrmann, *Ann. Rev. Entomol.*, 35:127, 1990.
- Blissard and Wenz, *J. Virol.*, 66:6829-6835, 1992.
- Blobel and Dobberstein, *J. Cell Biol.*, 67:852-862, 1975.
- 15 Bonning *et al.*, *J. Gen. Virol.*, 75:1551, 1994.
- Boose *et al.*, *Prot. Expr. Pur.*, 1:111, 1990.
- Boublik *et al.*, *Bio/Technology*, 13:1079, 1995.
- Bozon *et al.*, *J. Mol. Endocrinol.*, 14:277, 1995.
- Broussard *et al.*, *Virology*, 222:318, 1996.
- 20 Buss *et al.*, *Mol. Cell. Biol.*, 11:1523, 1991.
- Butters and Hughes, *Biochim. Biophys. Acta*, 640:655-671, 1981.
- Camirand *et al.*, *J. Biol. Chem.*, 266:15120-15127, 1991.
- Capone, *Gene Anal. Tech.*, 6:62, 1989.
- Carson *et al.*, *Virology*, 182:279-286, 1991.
- 25 Cartier *et al.*, *J. Virol.*, 68:7728-7737, 1994.
- Cavener and Ray, *Nuc. Acids Res.*, 19:3185-3192, 1991.



- Chalfie *et al.*, *Science*, 263:802-805, 1994.
- Chatterjee *et al.*, *Int. J. Biochem. Cell Biol.* 27(3):329-36, 1995.
- Chazenbalk and Rapoport, *J. Biol. Chem.*, 270:1543, 1995.
- Chen *et al.*, *J. Biol. Chem.*, 266:4081-4087, 1991.
- 5 Chirgwin *et al.*, *Biochemistry*, 18:5294-5299, 1979.
- Chisholm and Henner, *J. Virol.*, 62:3193, 1988.
- Chou *et al.*, *Proc. Natl. Acad. Sci. USA*, 92:4417, 1995.
- Choudary *et al.*, in: *Baculovirus Expression Protocols*, (C. D. Richardson ed.), Humana Press, Clifton, N.J, pp. 243-264, 1995.
- 10 Colberre-Garapin *et al.*, *J. Mol. Biol.*, 150:1, 1981
- Cooney *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:1882, 1993.
- D'Agostaro *et al.*, *J. Biol. Chem.* 270(25):15211-21, 1995.
- Davidson and Castellino, *Biochemistry*, 30:6167-6174, 1991a.
- Davidson *et al.*, *Biochemistry*, 30:9811-9815, 1991.
- 15 Davidson *et al.*, *Biochemistry*, 29:5584-5590, 1990.
- Davies and Morgan, *Biochem. J.*, 295:889, 1993.
- Davis and Wood, *In Vitro Cellular & Developmental Biology, Animal* 31:659-663, 1995.
- Davis *et al.*, *In Vitro Cellular and Developmental Biology. Animal*, 29A:842-846, 1993.
- Davrinche *et al.*, *Biochem. Biophys. Res. Comm.*, 195:469, 1993.
- 20 Delchambre *et al.*, *EMBO J.*, 8:2653, 1989.
- Deutschmann and Jager, *Enz. Microb. Tech.*, 16:506, 1994.
- Domingo and Trowbridge, *J. Biol. Chem.*, 263:13386, 1988.
- Eichenlaub, *J. Bacteriol* 138:559-566, 1979.
- Elbein, *FASEB J.*, 5:3055-3063, 1991.
- 25 Emery and Bishop, *Prot. Engr.*, 1:359, 1987.
- Engelhard *et al.*, *Proc. Natl. Acad. Sci. USA*, 91:3224, 1994.

- Ernst *et al.*, *Nuc. Acids Res.*, 22:2855, 1994.
- Estes *et al.*, *J. Virol.*, 61:1488, 1987.
- Feinberg and Vogelstein, *Analyt. Biochem.*, 132:6-13, 1983.
- Field and Wainwright, *Glycobiology*, 5:463-472, 1995.
- 5 Ford *et al.*, *Prot. Expr. Pur.*, 2:95, 1991.
- Forstova *et al.*, *Human Gene Therapy*, 6:297, 1995.
- Foster *et al.*, *Gene*, 154:183-186, 1995.
- Frohman *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:8998-9002, 1988.
- Fuchs *et al.*, *Eur. J. Biochem.*, 228:625, 1995.
- 10 Fuchs *et al.*, *J. Virol.*, 48:641, 1983.
- Fukada *et al.*, *Biosci. Biotechnol. Biochem.* 58(1):200-1, 1994.
- Furlong *et al.*, *Biotech. Appl. Biochem.*, 10:454, 1988.
- Garnier *et al.*, *Bio/Technology*, 13:1101, 1995a.
- Garnier *et al.*, *J. Virol.*, 69:4060, 1995b.
- 15 Gething and Sambrook, *Nature*, 355:33-45, 1992.
- Giese *et al.*, *J. Virol.*, 63:3080, 1989.
- Gluzman, *Cell*, 23:567-572, 1981.
- Godeau *et al.*, *Nuc. Acids Res.*, 20:6239, 1992.
- Grabenhorst *et al.*, *Eur. J. Biochem.*, 215: 189-197, 1993.
- 20 Grabenhorst *et al.*, *Eur. J. Biochem.*, 232:718-725, 1995.
- Grace, *Nature* (London), 216:613, 1967.
- Graham *et al.*, The NIAID AIDS Vaccine Clinical Trials Network, *J. Inf. Dis.*, 167:533, 1993.
- Granados and Naughton, *Intervirology*, 5:62-68, 1975.
- 25 Guarino and Dong, *Virology*, 200:328-335, 1994.
- Guarino and Smith, *Virology*, 179:1-8, 1990.

- Guarino and Summers, *J. Virol.*, 57:563-571, 1986.
- Guarino and Summers, *J. Virol.*, 61:2091-2099, 1987.
- Guarino *et al.*, *J. Virol.*, 60:224-229, 1986.
- Guarino *et al.*, *J. Virol.*, 60:224-229, 1986.
- 5 Han *et al.*, *Biochemistry*, 34:10835, 1995.
- Harduin-Lepers *et al.*, *J. Biol. Chem.*, 268:14348-14359, 1993.
- Hart, *Curr. Op. Cell Biol.*, 4:1017, 1992.
- Hartig *et al.*, *Dev. Biol. Std.*, 76:313, 1992.
- Hasemann and Capra, *Proc. Natl. Acad. Sci. USA*, 87:3942, 1990.
- 10 Hawtin *et al.*, *Virology*, 212:673, 1995.
- Hellers *et al.*, *Eur. J. Biochem.*, 199:435, 1991.
- Henderson *et al.*, *FEBS Letters*, 371(3):293-6, 1995.
- Herscovics and Jelinek-Kelly, *Anal. Biochem.*, 166:85-89, 1987.
- Herscovics *et al.*, *J. Biol. Chem.*, 269:9864-9871, 1994.
- 15 Hill-Perkins and Possee, *J. Gen. Virol.*, 71:971, 1990.
- Hills and Crane-Robinson, *Biochim. Biophys. Acta*, 1260:14, 1995.
- Hink *et al.*, *Biotech. Progr.*, 7:9, 1991.
- Hooft van Iddekinge *et al.*, *Virology*, 131:561-565, 1983.
- Hopp, U.S. Patent 4,554,101.
- 20 Hoss *et al.*, *J. Virol.*, 64:4799, 1990.
- Hsieh and Robbins, *J. Biol. Chem.*, 259:2375-2382, 1984.
- Hsu *et al.*, *Prot. Expr. Pur.*, 5:595, 1994.
- Hu *et al.*, *J. Virol.*, 61:3617, 1987.
- Huh and Weaver, *J. Gen. Virol.*, 71:195-202, 1990.
- 25 Iatrou *et al.*, *Proc. Natl. Acad. Sci. USA*, 86:9129, 1989.
- Jarvis and Finn, *Virology*, 212:500-511, 1995.

- 158 -

- Jarvis and Garcia, *BioTechniques*, 16:508-513, 1994.
- Jarvis and Garcia, Jr., *Virology*, 205:300-313, 1994.
- Jarvis and Guarino, In: *Methods in Molecular Biology*, C.D. Richardson (ed.),  
Baculovirus Expression Protocols., Humana Press, Clifton, N.J, 39:187-202,  
5 1995.
- Jarvis and Summers, In: *Recombinant DNA vaccines: rationale and strategies*, R.E.  
Isaacson (ed.), Marcel Dekker, Inc., New York, 265-291, 1992.
- Jarvis and Summers, *Mol. Cell. Biol.*, 9:214-223, 1989.
- Jarvis, In: *Insect cell culture engineering*, M.F.A Goosen, A. Daugulis, and P.Faulkner  
10 (eds.), Marcel Dekker, Inc., New York, 193-217, 1993a
- Jarvis, *J. Virol.*, 67:2583-2591, 1993b.
- Jarvis, *J. Virol.*, 67:2583, 1993.
- Jarvis et al., *Virology*, 185:795-810, 1991.
- Jarvis et al., *Bio/Technology*, 8:950-955, 1990.
- Jarvis et al., *Biol. Control*, 7:228, 1996.
- 15 Jarvis et al., *J. Biol. Chem.*, 268:16754-16762, 1993.
- Jeang et al., *J. Virol.*, 61:1761, 1987.
- Johnson et al., *Virology*, 190:815-823, 1992.
- Joyce et al., *FEBS Lett.*, 335:61-64, 1993.
- Kalman et al., *J. Biol. Chem.*, 270:14835, 1995.
- 20 Kalsner et al., *Glycoconjugate J.*, 12:360-370, 1995.
- Kang et al., *J. Gen. Virol.*, 68:2607, 1987.
- Kaufman, *Methods in Enzymology*, 185:537-566, 1990.
- Keddie et al., *Science*, 243:1728, 1989.
- Kerscher et al., *Dev. Biol.*, 168:613-626, 1995.
- 25 Kim and Weaver, *Virology*, 195:587, 1993.
- King and Possee, "The baculovirus system: a laboratory guide," Chapman and Hall,  
London, 1992.

- Kitts and Possee, *Biotechniques*, 14:810-817, 1993.
- Kitts *et al.*, *Nuc. Acids Res.*, 18:5667, 1990.
- Kleymann *et al.*, *Eur. J. Biochem.*, 213:797-804, 1993.
- Knepper *et al.*, *Biochemistry*, 31:11651-11659, 1992.
- 5 Kornfeld and Kornfeld, *Ann. Rev. Biochem.*, 54:631-664, 1985.
- Kovacs *et al.*, *Virology*, 185:633, 1991.
- Kozak, *Microbiol. Rev.*, 47:1-45, 1983.
- Kozak, *J. Cell Biol.*, 108:229-241, 1986a.
- Kozak, *Nuc. Acids Res.*, 12:857-872, 1984.
- 10 Kozak, *Cell*, 44:283-292, 1986b.
- Kozma *et al.*, *J. Biol. Chem.*, 268:7134, 1993.
- Kretzschmar *et al.*, *Biol. Chem. Hoppe-Seyler*, 375:23, 1994.
- Ku and Omary, *Exp. Cell Res.*, 211:24, 1994.
- Kubelka *et al.*, *Arch. Bioch. Biophys.*, 308:148-157, 1994.
- 15 Kuhn and Zipfel, *Gene*, 162:225, 1995.
- Kumar *et al.*, *Glycobiology* 2(4):383-93, 1992.
- Kumar *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 87:9948-9952, 1990.
- Kunkel, *Proc. Natl. Acad. Sci. U.S.A.*, 82:488-492, 1985.
- Kuroda *et al.*, *Virology*, 174:418-429, 1990.
- 20 Kuroda *et al.*, *J. Virol.*, 63:1677, 1989.
- Kuroda *et al.*, *EMBO J.*, 5:1359, 1986.
- Kuroda *et al.*, *Virology*, 180:159, 1991.
- Kuzio *et al.*, *Virology*, 139:414-418, 1984.
- Kyte and Doolittle, *J. Mol. Biol.*, 157:105-132, 1982.
- 25 Laemmli, *Nature*, 227:680-685, 1970.
- Lal *et al.*, *J. Biol. Chem.*, 269:9872-9881, 1994.

- 160 -

- Lanford, *Virology*, 167:72, 1988.
- Larsen *et al.*, *Proc Natl Acad Sci USA* 87(17):6674-8, 1990.
- Lawrie *et al.*, *J. Biotech.*, 39:1, 1995.
- Lebacqz-Verheyden *et al.*, *Mol. Cell. Biol.*, 8:3129, 1988.
- 5 Lee and Costlow, *Meth. Enzymol.*, 152:633-648, 1987.
- Lee and Miller, *J. Virol.*, 27:754, 1978.
- Lee *et al.*, *J. Biol. Chem.*, 264:13848-13855, 1989.
- Lerch and Friesen, *Nuc. Acids Res.*, 21:1753, 1993.
- Leusch *et al.*, *Gene*, 160:191, 1995.
- 10 Licari *et al.*, *Biotech. Prog.*, 9:146-152, 1993.
- Lowe, *Sem. Cell Biol.*, 2:289-307, 1991.
- Lowe *et al.*, *J. Biol. Chem.*, 266:1672, 1991.
- Lowe *et al.*, *Biochem. Soc. Trans.*, 20:484, 1992.
- Lu and Miller, *J. Virol.*, 69:975-982, 1995.
- 15 Lu and Miller, *Biotechniques*, 21:63, 1996.
- Luckow and Summers, *Virology* 170:31-39, 1989
- Luckow and Summers, *Virology* 167:56-71, 1988
- Luckow and Summers, *Bio/Technology*, 6:47, 1988.
- Luckow, In: *Recombinant DNA technology and applications*, (A. Prokop, R. K. Bajpai  
20 and C. S. Ho, eds.), McGraw-Hill, Inc., New York, pp. 97-152, 1991.
- Luckow *et al.*, *J. Virol.*, 67:4566, 1993.
- Maeda, *Ann. Rev. Entomol.*, 34:351, 1989.
- Maeda *et al.*, *Nature*, 315:592, 1985.
- Maiorella *et al.*, *Bio/Technology*, 6:1406, 1988.
- 25 Malitschek and Scharl, *Biotechniques*, 11:177, 1991.
- Manneberg *et al.*, *Protein Science*, 3:30-38, 1994.

- 161 -

- Manns and Grosse, *Biotechniques*, 10:154, 1991.
- Marsden *et al.*, *Biochem. Cell Biol.*, 68:587-601, 1990.
- Martens, *et al.*, *J. Virol. Meth.*, 52:15, 1995.
- Martin *et al.*, *DNA*, 7:99, 1988.
- 5 Marz *et al.*, In: *Glycoproteins*, Montreuil, J., Vliegenthart, J.F.G. and Schachter, H. (eds), Elsevier, Amsterdam, Vol. 29a, pp. 543-563, 1995.
- Marz *et al.*, In: *Glycoproteins*, (J. Montreuil, J. F. G. Vliegenthart and H. Schachter, eds.), Elsevier, Amsterdam, Vol. 29a, pp. 543-563, 1995.
- Masri *et al.*, *Biochem. Biophys. Res. Commun.* 157(2):657-63, 1988.
- 10 Matsuura *et al.*, *J. Gen. Virol.*, 68:1233, 1987.
- McCutchen *et al.*, *Bio/Technology*, 9:848, 1991.
- McLachlin and Miller, *J. Virol.*, 68:7746-7756, 1994.
- Melton *et al.*, *Nuc. Acids Res.*, 12:7035-7055, 1984.
- Merryweather *et al.*, *J. Gen. Virol.*, 71:1535, 1990.
- 15 Messing *et al.*, Third Cleveland Symposium on Macromolecules and Recombinant DNA, Editor A. Walton, Elsevier, Amsterdam, 1981.
- Miller, *Ann. Rev. Microbiol.*, 42:177-199, 1988.
- Miller, *J. Virol.*, 39:973, 1981.
- Min and Bishop, *J. Gen. Virol.*, 72:2551, 1991.
- 20 Minch *et al.*, *Biotechnol. Prog.*, 11:348-351, 1995.
- Minetoki *et al.*, *Biosci. Biotechnol. Biochem.* 59(8):1516-21, 1995.
- Misago *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 92:11766-11770, 1995.
- Montreuil *et al.*, In: *New Comprehensive Biochemistry*, (A. Neuberger and L. L. M. Van Deenen, series eds.), Elsevier, Amsterdam, 1995.
- 25 Moremen and Robbins, *J. Cell Biol.*, 115:1521-1534, 1991.
- Moremen, *Proc. Natl. Acad. Sci. U.S.A.*, 86:5276-5280, 1989.
- Moremen *et al.*, *J. Biol. Chem.*, 266:16876-16885, 1991.
- Moremen *et al.*, *Glycobiology*, 4:113-125, 1994.

- 162 -

- Morris and Miller, *J. Virol.*, 66:7397-7405, 1992.
- Mouillac *et al.*, *J. Biol. Chem.*, 267:21733, 1992.
- Mroczkowski *et al.*, *J. Biol. Chem.*, 269:13522, 1994.
- Munro and Pelham, *Cell*, 46:291-300, 1986.
- 5 Murhammer and Goochee, *Bio/Technology*, 6:1411-1418, 1988.
- Murphy *et al.*, *Gen. Anal. Tech. Appl.*, 7:160-171, 1990.
- Murphy *et al.*, *Prot. Expr. Pur.*, 4:349, 1993.
- Nagao *et al.*, *Insect Biochem.*, 17:531-538, 1987.
- Nakazawa *et al.*, *J Biochem* 104(2):165-8, 1988.
- 10 Nebes and Schmidt, *Biochem. Biophys. Res. Comm.*, 200:239-245, 1994.
- Normington *et al.*, *Cell*, 57:1223-1236, 1989.
- Numata *et al.*, *J. Clin. Micro.*, 32:121, 1994.
- O'Reilly and Miller, *J. Virology*, 62:3109-3119, 1988.
- O'Reilly *et al.*, In *Baculovirus expression vectors*, W.H. Freeman and Company, N.Y,  
15 1992.
- Ogonah *et al.*, *Bio/Technology*, 14:197-202, 1996.
- Ohkawa *et al.*, *J. Virol.*, 68:6619, 1994.
- Oker-Blom *et al.*, *Biochim. Biophys. Acta*, 1176:269, 1993.
- Ooi and Miller, *Virology*, 166:515, 1988.
- 20 Ooi *et al.*, *J. Mol. Biol.*, 210:721, 1989.
- Page *et al.*, *J. Biol. Chem.*, 264:19147, 1989.
- Pajot-Augy *et al.*, *J. Mol. Endocrinol.*, 14:51, 1995.
- Parekh *et al.*, *Prot. Expr. Pur.*, 6:537, 1995.
- Park *et al.*, *J. Virol. Meth.*, 45:303, 1993.
- 25 Passarelli and Miller, *J. Virol.*, 67:2149-2158, 1993.
- Passarelli *et al.*, *J. Virol.*, 68:4673, 1994.



- 163 -

- Patel *et al.*, *Nuc. Acids Res.*, 20:97, 1992.
- Paulson and Colley, *J. Biol. Chem.*, 264:17615-17618, 1989.
- Paulson *et al.*, *J. Biol. Chem.*, 252(2356-2362), 1977.
- Peakman *et al.*, *Nuc. Acids Res.*, 20:6111, 1992a.
- 5 Peakman *et al.*, *Nuc. Acids Res.*, 20:495, 1992b.
- Pearson and Roy, *Immunol. Cell Biol.*, 71:381, 1993.
- Pen *et al.*, *Nuc. Acids Res.*, 17:451, 1989.
- Peng *et al.*, *Biotechniques*, 14:274, 1993.
- Pennock *et al.*, *Mol. Cell. Biol.*, 4:399, 1984.
- 10 Possee and Howard, *Nuc. Acids Res.*, 15:10233, 1987.
- Pownall *et al.*, *Genomics* 12(4):699-704, 1992.
- Prasad *et al.*, *J. Virol.*, 68:5117, 1994.
- Pullen and Friesen, *J. Virol.*, 69:156-165, 1995.
- Qin *et al.*, *J. Gen. Virol.*, 70:1273, 1989.
- 15 Ranjan and Hasnain, *Virus Genes*, 9:149, 1995.
- Rankin *et al.*, *Gene*, 70:39, 1988.
- Rankl *et al.*, *Prot. Expr. Pur.*, 5:346, 1994.
- Redfield *et al.*, *New Engl. J. Med.*, 324:1677, 1991.
- Reed and Mann, *Nuc. Acids Res.*, 13, 7207-7221, 1985.
- 20 Reed and Muench, *Am. J. Hyg.*, 27:493, 1938.
- Ren *et al.*, *Biochemistry*, 34:2489-2495, 1995.
- Richardson, ed., "Baculovirus expression protocols," Vol 39 *In: Methods in Molecular Biology*, (J. M. Walker, series ed.), Humana Press, Totowa, New Jersey, 1995.
- Risinger *et al.*, *J. Biol. Chem.*, 267:5680, 1992.
- 25 Rodems and Friesen, *J. Virol.*, 67:5776-5785, 1993.
- Roelvink, *et al.*, *J. Gen. Virol.*, 73:1481, 1992.

- 164 -

- Rohrmann, *J. Gen. Virol.*, 67:1499, 1986.
- Roy, *Virology*, 216:1, 1996.
- Rubin *et al.*, *Gene*, 128:155-163, 1993.
- Russo *et al.*, *J. Biol. Chem.*, 267:9241-9247, 1992.
- 5 Ryan *et al.*, *Arch. Biochem. Biophys.*, 243:115-124, 1985.
- Saiki *et al.*, *Science*, 230:1350-1354, 1985.
- Saint Angelo *et al.*, *J. Virology*, 61:361-365.
- Sambrook *et al.*, *In Molecular Cloning: A Laboratory Manual*, Second edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989.
- 10 Sanger *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 74:5463-5467, 1977.
- Santerre, *et al.*, *Gene*, 30:147, 1984.
- Sareneva *et al.*, *J. Interf. Res.*, 13:267, 1993.
- Sarkar *et al.*, *Proc Natl Acad Sci USA*, 88(1):234-8, 1991.
- Schatzle *et al.*, *J. Biol. Chem.*, 267:4000-4007, 1992.
- 15 Shaper *et al.*, *J. Biol. Chem.*, 263:10420-10428, 1988.
- Short *et al.*, *Nuc. Acids. Res.*, 16:7583-7600, 1988.
- Shuler *et al.*, "Baculovirus expression systems and biopesticides," Wiley-Liss, Inc., New York, 1995.
- Sisk *et al.*, *Biotechniques*, 13:186, 1992.
- 20 Slightom and Sieu, *Biotechniques*, 13:94, 1992.
- Smith *et al.*, *J. Virol.*, 46:584-593, 1983a.
- Smith *et al.*, *Anal. Biochem.*, 150:76-85, 1985.
- Smith *et al.*, *J. Biol. Chem.*, 265:6225-6234, 1990.
- Smith *et al.*, *Mol. Cell. Biol.*, 3:2156, 1983b.
- 25 Smith *et al.*, *J. Virol.*, 45:215, 1983c.
- Southern, *J. Mol. Biol.*, 98:503-517, 1975.
- Sridhar *et al.*, *FEBS Lett.*, 315:282-286, 1993.

- 165 -

- Sridhar *et al.*, *FEBS Lett.*, 315:282, 1993.
- St. Angelo *et al.*, *J. Virol.*, 61:361, 1987.
- Staden, In: *Nucleic acid and protein sequence analysis, a practical approach*, M.J. Bishop and C.J. Rawlings (eds.), IRL Press Limited, Eynsham, Oxford, England, 173-217, 1987.
- 5 Staudacher *et al.*, *Eur. J. Biochem.*, 207:987-993, 1992.
- Stewart *et al.*, *Nature*, 352:85, 1991.
- Stoltz *et al.*, *J. Gen. Virol.*, 19:145, 1973.
- Summers and Smith, *Texas Agricultural Experiment Station Bulletin No. 1555*, 1987.
- 10 Suzuki *et al.*, *EMBO J.*, 9:4259, 1990.
- Takagi *et al.*, *Biochem. Biophys. Res. Comm.*, 184:471, 1992.
- Tan *et al.*, *Eur J Biochem*, 231(2):317-28, 1995.
- Taticek *et al.*, *Curr. Op. Biotech.*, 5:165, 1994.
- Tessier *et al.*, *Gene*, 98:177, 1991.
- 15 Thiem and Miller, *J. Virology*, 63:2008-18, 1989.
- Thiem and Miller, *et al.*, *Gene*, 91:87, 1990.
- Thompson *et al.*, *J. Cell. Biochem.*, 43:67, 1990.
- Ting *et al.*, *Gene*, 55:147-152, 1987.
- Todd *et al.*, *J. Virol.*, 69:968-974, 1995.
- 20 Tomita *et al.*, *Cytotechnology*, 17:65, 1995.
- Towbin *et al.*, *Proc. Natl. Acad. Sci. U.S.A.* 76:4350-4353, 1979.
- Tramper *et al.*, *Bioproc. Tech.*, 17:139, 1993.
- Troutt *et al.*, *Proc. Natl. Acad. Sci. U.S.A.*, 89:9823-9825, 1992.
- Tsao *et al.*, *J. Biol. Chem.*, 265:5188, 1990.
- 25 Urakawa and Roy, *J. Virol.*, 62:3919, 1988.
- Urakawa *et al.*, *J. Gen. Virol.*, 70:1453, 1989.
- Urbancikova and Hitchcock-DeGregori, *J. Biol. Chem.*, 269:24310, 1994.

- 166 -

- Vail *et al.*, *J. Invert. Path.*, 17:383, 1971.
- Vakharia *et al.*, *Insect Biochem. Mol. Biol.*, 25:583, 1995.
- van Lier *et al.*, *Biotech. Progr.*, 10:60, 1994.
- Vaughn *et al.*, *In Vitro*, 13:213-217, 1977,
- 5 Veit *et al.*, *FEBS Lett.*, 339:160, 1994.
- Velardo *et al.*, *J. Biol. Chem.* 268:17902-7, 1993.
- Vialard and Richardson, *J. Virol.*, 67:5859, 1993.
- Vialard *et al.*, *J. Virol.*, 64:37, 1990.
- Vieira and Messing, *Gene*, 19:259-268, 1982.
- 10 Vihko *et al.*, *Proc. Natl. Acad. Sci. USA*, 90:799, 1993.
- Vlak *et al.*, *Virology*, 179:312-320, 1990.
- Vlak *et al.*, *J. Virol.*, 40:762, 1981.
- Volkman and Goldsmith, *Virology*, 143:185-195, 1985.
- Volkman and Goldsmith, *Virology*, 143:185-195, 1985.
- 15 Volkman and Summers, *J. Invert. Path.*, 30:102, 1977.
- Volkman, *Curr. Top. Microbiol. Immunol.*, 131:103-118, 1986.
- Volkman *et al.*, "Virus Taxonomy, in: Sixth Report of the International Committee on Taxonomy of Viruses, (F. A. Murphy, C. M. Fauquet, D. H. L. Bishop, S. A. Ghabrial, A. W. Jarvis, G. P. Martelli, M. A. Mayo and M. D. Summers, eds.), Springer-Verlag, Wien, pp. 104, 1995.
- 20 Volkman *et al.*, *Virology*, 133:354-362, 1984.
- Volkman *et al.*, *J. Virol.*, 19:820, 1976.
- Vulsteke *et al.*, *Insect Mol. Biol.*, 2:195-204, 1993.
- Wagner *et al.*, *J. Virol.*, 70:4103-4109, 1996a.
- 25 Wagner *et al.*, *Glycobiology*, 6:165-175, 1996b.
- Wang and Fraser, *J. Virol. Meth.*, 31:113, 1991.
- Wang *et al.*, *J Biol Chem*, 268(6):4355-61, 1993.

- Wang *et al.*, *Gene*, 100:131, 1991.
- Wathen *et al.*, *Biochemistry*, 30:2863-2868, 1991.
- Webb and Summers, *Technique*, 2:173-188, 1990.
- Webb *et al.*, *Biotechniques*, 11:512, 1991.
- 5     Weinstein *et al.*, *J. Biol. Chem.*, 262:17735-17743, 1987.
- Weiss *et al.*, in: *Baculovirus Expression Protocols*, (C. D. Richardson ed.), Humana Press, Clifton, N.J.79, pp. 79-95, 1995a.
- Weiss *et al.*, In: *Baculovirus Expression Protocols*, (C. D. Richardson ed.), Humana Press, Clifton, N.J., pp. 65-78, 1995b.
- 10     Welply, *Bio/Technology*, 17:59, 1991.
- Westwood *et al.*, *Virology*, 195:90, 1993.
- Weyer and Possee, *J. Gen. Virol.*, 72:2967, 1991.
- Weyer and Possee, *J. Gen. Virol.*, 70:203, 1989.
- Weyer *et al.*, *J. Gen. Virol.*, 71:1525, 1990.
- 15     Whiteheart *et al.*, *Meth. Enzymol.*, 179:82-95, 1989.
- Whitford *et al.*, *J. Virology*, 63:1393-1399, 1989.
- Wickham *et al.*, *Biotechnology Progress* 8:391-396, 1992.
- Williams *et al.*, *Biochim. Biophys. Acta*, 1075:146-153, 1991.
- Wilson *et al.*, *J. Virol.* 61:661-666, 1987.
- 20     Wilson *et al.*, *J. Virol.*, 61:661, 1987.
- Winter *et al.*, *Ann. Rev. Immunol.*, 12:433, 1994.
- Wong *et al.*, *Cytotechnology*, 15:157, 1994.
- Xia *et al.*, *Virology*, 196:817, 1993.
- Xie *et al.*, *J. Biol. Chem.*, 267:4939, 1992.
- 25     Xu *et al.*, *J. Virol.*, 69, 2912-2917, 1995.
- Yamshchikov *et al.*, *Virology*, 214:50, 1995.
- Yanisch-Perron *et al.*, *Gene*, 33, 103-119, 1985.

- 168 -

Yeh *et al.*, *Biochemistry*, 32:11087-11099, 1993.

Yoshihisa and Anraku, *Biochem. Biophys. Res. Comm.*, 163, 908-915, 1989.

Zilberstein *et al.*, *Cell*, 21, 417-427, 1980.

Zuidema *et al.*, *J. Gen. Virology*, 71:2201-2209, 1990.

- 169 -

**SEQUENCE LISTING****(1) GENERAL INFORMATION:****(i) APPLICANT:**

- (A) NAME: The Texas A&M University System
- (B) STREET: 310 Wisenbaker
- (C) CITY: College Station
- (D) STATE: Texas
- (E) COUNTRY: USA
- (F) POSTAL CODE (ZIP): 77843-3369

**(ii) TITLE OF INVENTION: MODIFYING INSECT CELL GLYCOSYLATION PATHWAYS  
WITH BACULOVIRUS EXPRESSION VECTORS**

**(iii) NUMBER OF SEQUENCES: 30**

**(iv) COMPUTER READABLE FORM:**

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

**(v) CURRENT APPLICATION DATA:**

APPLICATION NUMBER: Unknown

**(vi) PRIOR APPLICATION DATA:**

- (A) APPLICATION NUMBER: US US 60/024,078
- (B) FILING DATE: 16-AUG-1996

**(2) INFORMATION FOR SEQ ID NO: 1:****(i) SEQUENCE CHARACTERISTICS:**

- (A) LENGTH: 2167 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

**(ix) FEATURE:**

- (A) NAME/KEY: CDS
- (B) LOCATION: 46..2010

**(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:**

CTATTTATTT AGATTTTAA GTGTAGGTTT TGTGTTTACG TAAAC ATG ACG GGG	54
Met Thr Gly	
1	
ATT TTA CCT ACC TAC CAG CGA TTT GTA AAT GGA GTT CCT GTA CCG TCC	102
Ile Leu Pro Thr Tyr Gln Arg Phe Val Asn Gly Val Pro Val Pro Ser	
5 10 15	
ATT TCT CGA CGT TCG TTC CGT CTA CGG GAG AAA TAT TTG ATT GTT TCT	150
Ile Ser Arg Arg Ser Phe Arg Leu Arg Glu Lys Tyr Leu Ile Val Ser	
20 25 30 35	

- 170 -

GTA CTT TTG ACA TTC GGG ATC GTG TGG TTA GGA GCA TTA TTC TAC TTG Val Leu Leu Thr Phe Gly Ile Val Trp Leu Gly Ala Leu Phe Tyr Leu 40 45 50	198
CCA GAG TTT AAA AGT TCA AAT AGT GTG AAC GAT AGT GTT TAC AAT GTA Pro Glu Phe Lys Ser Ser Asn Ser Val Asn Asp Ser Val Tyr Asn Val 55 60 65	246
TAC AAA AGA ATC CAG AAA GCT GGC CCA GAG CTG CTC ATG CCG CCT CCT Tyr Lys Arg Ile Gln Lys Ala Gly Pro Glu Leu Leu Met Pro Pro Pro 70 75 80	294
CTG GCA CAA AAC GAT GTC GGT GAC TTT CCT GTG ATT GGG ATC GCT CAC Leu Ala Gln Asn Asp Val Gly Asp Phe Pro Val Ile Gly Ile Ala His 85 90 95	342
CAT GGT GAA GGG GGT GAT GAT CCT CAC GTA ATT GAG GAC AGG AAC CGG His Gly Glu Gly Gly Asp Asp Pro His Val Ile Glu Asp Arg Asn Arg 100 105 110 115	390
CTA CGA GCT AAG ATA GAG GAG GAT ATG GGA ATG AAA GTG TTG GAG AGG Leu Arg Ala Lys Ile Glu Glu Asp Met Gly Met Lys Val Leu Glu Arg 120 125 130	438
CCT CAG TTT GAC GTA GCA CCT TCC GTG TCG TCT TCG CGA GGG CCC AGC Pro Gln Phe Asp Val Ala Pro Ser Val Ser Ser Ser Arg Gly Pro Ser 135 140 145	486
AAG CCG CCA GTC GAT GCG ATT GAG GAG CCC GCG GTA GGG AAC AAT GCA Lys Pro Pro Val Asp Ala Ile Glu Glu Pro Ala Val Gly Asn Asn Ala 150 155 160	534
GCT AAC AAA GAC GTG TCG CCG TCA GGC CCG AAG GCT GAG AGC TCG GAC Ala Asn Lys Asp Val Ser Pro Ser Gly Pro Lys Ala Glu Ser Ser Asp 165 170 175	582
AAG TTT GTG GCT GTG GCC CTG GCA CCA GGA GCT GAC CCT GAG ATC AAG Lys Phe Val Ala Val Ala Leu Ala Pro Gly Ala Asp Pro Glu Ile Lys 180 185 190 195	630
CAC AAG CTG GAG ACT GTC AAA AAG ATG ATG CTG CAC GCG TGG TAC AAC His Lys Leu Glu Thr Val Lys Lys Met Met Leu His Ala Trp Tyr Asn 200 205 210	678
TAC AAG CTG TAT GCT TGG GGC AAG AAT GAG CTG AAG CCG ATG TCG AAG Tyr Lys Leu Tyr Ala Trp Gly Lys Asn Glu Leu Lys Pro Met Ser Lys 215 220 225	726
CGA GCT CAC TTG TCC AGC GTG TTC GGC GCG GGC GAA CTT GGC GCC ACC Arg Ala His Leu Ser Ser Val Phe Gly Ala Gly Glu Leu Gly Ala Thr 230 235 240	774
ATC GTC GAT GGT CTC GAC ACC CTC TAC CTC ATG GGA CTC AAC GAC GAA Ile Val Asp Gly Leu Asp Thr Leu Tyr Leu Met Gly Leu Asn Asp Glu 245 250 255	822



- 171 -

TTC CGA GAG GGC CGC GAC TGG GTC GCT GAA CAT TTG CAT ATT AAT GAA	870
Phe Arg Glu Gly Arg Asp Trp Val Ala Glu His Leu His Ile Asn Glu	
260 265 270 275	
ATC GAT TCC GAC TTA TCT GTG TTC GAG ACG ACG ATC CGG TTT GTC GGA	918
Ile Asp Ser Asp Leu Ser Val Phe Glu Thr Thr Ile Arg Phe Val Gly	
280 285 290	
GGT CTC CTG TCA TGT TAC GCG CTG ACC GGC GAC ACG ATG TTC CGA GAC	966
Gly Leu Leu Ser Cys Tyr Ala Leu Thr Gly Asp Thr Met Phe Arg Asp	
295 300 305	
AAG GCG GCG GAA GTA GGC GAC GCT TTG CTG CCA GCA TTC GAC ACA CCC	1014
Lys Ala Ala Glu Val Gly Asp Ala Leu Leu Pro Ala Phe Asp Thr Pro	
310 315 320	
ACC GGG TTG CCA TAT GCT CTC ATC AAC CCG TCC ACC AAG GCA AGC CGT	1062
Thr Gly Leu Pro Tyr Ala Leu Ile Asn Pro Ser Thr Lys Ala Ser Arg	
325 330 335	
CAG TAC CAC TGG GCG GGT CCG AAC AGC ATC CTA TCG GAG CTG GGA ACG	1110
Gln Tyr His Trp Ala Gly Pro Asn Ser Ile Leu Ser Glu Leu Gly Thr	
340 345 350 355	
CTC CAC CTC GAG TTC ACG TAC CTC AGT GAC GTC ACG GGC CGT GAT ATT	1158
Leu His Leu Glu Phe Thr Tyr Leu Ser Asp Val Thr Gly Arg Asp Ile	
360 365 370	
TAC AGA CAA AAA GTG AGC CGC ATC CGT GAG GTT TTG GAT CAG ATC GAC	1206
Tyr Arg Gln Lys Val Ser Arg Ile Arg Glu Val Leu Asp Gln Ile Asp	
375 380 385	
AAA CCT GGC GAC TTG TAC CCC AAC TTC ATC AAC CCA CGC ACT GGA CAA	1254
Lys Pro Gly Asp Leu Tyr Pro Asn Phe Ile Asn Pro Arg Thr Gly Gln	
390 395 400	
TGG GGA CAA AGG CAC ATG TCT CTG GGC GCT CTC GGC GAC TCG TTC TAC	1302
Trp Gly Gln Arg His Met Ser Leu Gly Ala Leu Gly Asp Ser Phe Tyr	
405 410 415	
GAG TAC TTA CTG AAG GCG TGG CTG ATG TCT GGC GGC GCT GAC GAG CAG	1350
Glu Tyr Leu Leu Lys Ala Trp Leu Met Ser Gly Gly Ala Asp Glu Gln	
420 425 430 435	
GCT CGC ATC ATG TTC GAC ACG GCC ATG CAG GCG GCG CTC GAC AAA ATG	1398
Ala Arg Ile Met Phe Asp Thr Ala Met Gln Ala Ala Leu Asp Lys Met	
440 445 450	
CTG CGT GTC TCG CCC TCC GGC CTC GCT TAC CTC GCC GAG CTC AAG TAC	1446
Leu Arg Val Ser Pro Ser Gly Leu Ala Tyr Leu Ala Glu Leu Lys Tyr	
455 460 465	
GGA CGT ATC ATT GAA GAG AAG ATG GAC CAC CTT TCG TGC TTC GCT GGC	1494
Gly Arg Ile Ile Glu Glu Lys Met Asp His Leu Ser Cys Phe Ala Gly	
470 475 480	

- 172 -

GGT ATG TTC GCA CTG GCG TCG ACT ACC CTG GAC AAC TCG ATG TCG GAG Gly Met Phe Ala Leu Ala Ser Thr Thr Leu Asp Asn Ser Met Ser Glu 485 490 495	1542
CGC TAC ATG GAC GTG GCC AAG AAG CTG ACC AAT ACC TGC CAC GAG AGC Arg Tyr Met Asp Val Ala Lys Lys Leu Thr Asn Thr Cys His Glu Ser 500 505 510 515	1590
TAC GCG CGA TCC GAG ACC AAA CTC GGC CCT GAA GCA TTC CGA TTC TCC Tyr Ala Arg Ser Glu Thr Lys Leu Gly Pro Glu Ala Phe Arg Phe Ser 520 525 530	1638
AAC GCG GCC GAG GCG CGT GCA CAG AAG AGC AAT GAG AAG GTG TAC CTC Asn Ala Ala Glu Ala Arg Ala Gln Lys Ser Asn Glu Lys Val Tyr Leu 535 540 545	1686
CTG CGG CCG GAG ACG TTC GAG AGC TAC TTC ATC ATG TGG AGA CTC ACC Leu Arg Pro Glu Thr Phe Glu Ser Tyr Phe Ile Met Trp Arg Leu Thr 550 555 560	1734
AAG CAA CAG ATG TAC CGC GAC TGG GCC TGG GAG GCT GTG CAG GCT CTG Lys Gln Gln Met Tyr Arg Asp Trp Ala Trp Glu Ala Val Gln Ala Leu 565 570 575	1782
GAG AAA CAC TGC CGC GTG GAG GGC GGC TAC ACC GGT CTC GTG AAC GTC Glu Lys His Cys Arg Val Glu Gly Gly Tyr Thr Gly Leu Val Asn Val 580 585 590 595	1830
TAC CAC GCC AAC CCT CAG GGA GAC GAC GTG CAG CAG AGC TTC TTC CTC Tyr His Ala Asn Pro Gln Gly Asp Asp Val Gln Gln Ser Phe Phe Leu 600 605 610	1878
GCT GAG ACA CTC AAG TAC TTA TAC CTG ATA TTC GGT GAC GAT TCG TTC Ala Glu Thr Leu Lys Tyr Leu Tyr Leu Ile Phe Gly Asp Asp Ser Phe 615 620 625	1926
CTG CCG CTC GAC GAG TGG GTG TTC AAC ACG GAA GCC CAT CCA TTC CCG Leu Pro Leu Asp Glu Trp Val Phe Asn Thr Glu Ala His Pro Phe Pro 630 635 640	1974
ATC AGG GGC AAG AAC CCG CTG TAC CGC GCT GTC GAC AAACCGGTCC Ile Arg Gly Lys Asn Pro Leu Tyr Arg Ala Val Asp 645 650 655	2020
TGCCAGAACC TGCGCATGCG CAAAACAACA GGATATAAGA CCGTCACTCA AGTAATTGT	2080
TTTAAAAATG TTTCATTTTG TTAGAACTGA AGAAGCCAGA CTGTACCAAC AGTGTCTGGT	2140
TAGGTATTGA CGAGAGTAAA TAGCAAG	2167

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 655 amino acids

- 173 -

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```

Met Thr Gly Ile Leu Pro Thr Tyr Gln Arg Phe Val Asn Gly Val Pro
 1             5             10             15

Val Pro Ser Ile Ser Arg Arg Ser Phe Arg Leu Arg Glu Lys Tyr Leu
          20             25             30

Ile Val Ser Val Leu Leu Thr Phe Gly Ile Val Trp Leu Gly Ala Leu
          35             40             45

Phe Tyr Leu Pro Glu Phe Lys Ser Ser Asn Ser Val Asn Asp Ser Val
          50             55             60

Tyr Asn Val Tyr Lys Arg Ile Gln Lys Ala Gly Pro Glu Leu Leu Met
          65             70             75             80

Pro Pro Pro Leu Ala Gln Asn Asp Val Gly Asp Phe Pro Val Ile Gly
          85             90             95

Ile Ala His His Gly Glu Gly Gly Asp Asp Pro His Val Ile Glu Asp
          100             105             110

Arg Asn Arg Leu Arg Ala Lys Ile Glu Glu Asp Met Gly Met Lys Val
          115             120             125

Leu Glu Arg Pro Gln Phe Asp Val Ala Pro Ser Val Ser Ser Ser Arg
          130             135             140

Gly Pro Ser Lys Pro Pro Val Asp Ala Ile Glu Glu Pro Ala Val Gly
          145             150             155             160

Asn Asn Ala Ala Asn Lys Asp Val Ser Pro Ser Gly Pro Lys Ala Glu
          165             170             175

Ser Ser Asp Lys Phe Val Ala Val Ala Leu Ala Pro Gly Ala Asp Pro
          180             185             190

Glu Ile Lys His Lys Leu Glu Thr Val Lys Lys Met Met Leu His Ala
          195             200             205

Trp Tyr Asn Tyr Lys Leu Tyr Ala Trp Gly Lys Asn Glu Leu Lys Pro
          210             215             220

Met Ser Lys Arg Ala His Leu Ser Ser Val Phe Gly Ala Gly Glu Leu
          225             230             235             240

Gly Ala Thr Ile Val Asp Gly Leu Asp Thr Leu Tyr Leu Met Gly Leu
          245             250             255

Asn Asp Glu Phe Arg Glu Gly Arg Asp Trp Val Ala Glu His Leu His
          260             265             270

```

- 174 -

Ile Asn Glu Ile Asp Ser Asp Leu Ser Val Phe Glu Thr Thr Ile Arg  
 275 280 285  
 Phe Val Gly Gly Leu Leu Ser Cys Tyr Ala Leu Thr Gly Asp Thr Met  
 290 295 300  
 Phe Arg Asp Lys Ala Ala Glu Val Gly Asp Ala Leu Leu Pro Ala Phe  
 305 310 315 320  
 Asp Thr Pro Thr Gly Leu Pro Tyr Ala Leu Ile Asn Pro Ser Thr Lys  
 325 330 335  
 Ala Ser Arg Gln Tyr His Trp Ala Gly Pro Asn Ser Ile Leu Ser Glu  
 340 345 350  
 Leu Gly Thr Leu His Leu Glu Phe Thr Tyr Leu Ser Asp Val Thr Gly  
 355 360 365  
 Arg Asp Ile Tyr Arg Gln Lys Val Ser Arg Ile Arg Glu Val Leu Asp  
 370 375 380  
 Gln Ile Asp Lys Pro Gly Asp Leu Tyr Pro Asn Phe Ile Asn Pro Arg  
 385 390 395 400  
 Thr Gly Gln Trp Gly Gln Arg His Met Ser Leu Gly Ala Leu Gly Asp  
 405 410 415  
 Ser Phe Tyr Glu Tyr Leu Leu Lys Ala Trp Leu Met Ser Gly Gly Ala  
 420 425 430  
 Asp Glu Gln Ala Arg Ile Met Phe Asp Thr Ala Met Gln Ala Ala Leu  
 435 440 445  
 Asp Lys Met Leu Arg Val Ser Pro Ser Gly Leu Ala Tyr Leu Ala Glu  
 450 455 460  
 Leu Lys Tyr Gly Arg Ile Ile Glu Glu Lys Met Asp His Leu Ser Cys  
 465 470 475 480  
 Phe Ala Gly Gly Met Phe Ala Leu Ala Ser Thr Thr Leu Asp Asn Ser  
 485 490 495  
 Met Ser Glu Arg Tyr Met Asp Val Ala Lys Lys Leu Thr Asn Thr Cys  
 500 505 510  
 His Glu Ser Tyr Ala Arg Ser Glu Thr Lys Leu Gly Pro Glu Ala Phe  
 515 520 525  
 Arg Phe Ser Asn Ala Ala Glu Ala Arg Ala Gln Lys Ser Asn Glu Lys  
 530 535 540  
 Val Tyr Leu Leu Arg Pro Glu Thr Phe Glu Ser Tyr Phe Ile Met Trp  
 545 550 555 560

- 175 -

Arg	Leu	Thr	Lys	Gln	Gln	Met	Tyr	Arg	Asp	Trp	Ala	Trp	Glu	Ala	Val		
				565				570				575					
Gln	Ala	Leu	Glu	Lys	His	Cys	Arg	Val	Glu	Gly	Gly	Tyr	Thr	Gly	Leu		
				580				585				590					
Val	Asn	Val	Tyr	His	Ala	Asn	Pro	Gln	Gly	Asp	Asp	Val	Gln	Gln	Ser		
				595				600				605					
Phe	Phe	Leu	Ala	Glu	Thr	Leu	Lys	Tyr	Leu	Tyr	Leu	Ile	Phe	Gly	Asp		
				610				615				620					
Asp	Ser	Phe	Leu	Pro	Leu	Asp	Glu	Trp	Val	Phe	Asn	Thr	Glu	Ala	His		
				625				630				635				640	
Pro	Phe	Pro	Ile	Arg	Gly	Lys	Asn	Pro	Leu	Tyr	Arg	Ala	Val	Asp			
				645				650				655					

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 3748 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: CDS  
(B) LOCATION: 177..3566

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GGCTTATTAA CCCTCACTAA AGGGAGAGTC AGGAGCACGC TGTGGTGTTT GGCTGTCGCA	60
TGCAAGTGCG AGCCGATAAC TTACACTGCA GATAAATAAA TAATTGACTT TATCTGGAGT	120
AAAATAAAAT GTAAACATTG TTTTCAAAAA AATCGTGACA TAAAAAATAT TGCACA	176
ATG AGG ACT CGT GTC CTT CGT TGC CGG CCG TTC TCC ACC CGG ATC CTG	224
Met Arg Thr Arg Val Leu Arg Cys Arg Pro Phe Ser Thr Arg Ile Leu	
1 5 10 15	
CTG CTG CTG CTA TTT GTC CTT GCG TTT GGG GTC TAC TGC TAT TTC TAC	272
Leu Leu Leu Leu Phe Val Leu Ala Phe Gly Val Tyr Cys Tyr Phe Tyr	
20 25 30	
AAT GCA TCT CCT CAG AAC TAT AAC AAA CCA AGA ATC AGT TAC CCA GCC	320
Asn Ala Ser Pro Gln Asn Tyr Asn Lys Pro Arg Ile Ser Tyr Pro Ala	
35 40 45	
AGT ATG GAG CAC TTC AAA TCT TCC CTC ACT CAC ACC GTC AAG AGC CGA	368
Ser Met Glu His Phe Lys Ser Ser Leu Thr His Thr Val Lys Ser Arg	
50 55 60	

- 176 -

GAC GAG CCA ACT CCG GAT CAA TGC CCT GCA TTG AAG GAA AGC GAA GCG Asp Glu Pro Thr Pro Asp Gln Cys Pro Ala Leu Lys Glu Ser Glu Ala 65 70 75 80	416
GAC ATC GAC ACC GTG GCG ATA TAC CCA ACT TTT GAT TTT CAG CCG AGC Asp Ile Asp Thr Val Ala Ile Tyr Pro Thr Phe Asp Phe Gln Pro Ser 85 90 95	464
TGG TTG CGT ACA AAG GAA TTT TGG GAC AAG TCC TTC GAG GAT CGG TAT Trp Leu Arg Thr Lys Glu Phe Trp Asp Lys Ser Phe Glu Asp Arg Tyr 100 105 110	512
GAA AGA ATT CAT AAC GAC ACT ACA CGG CCT AGA CTG AAG GTA ATC GTG Glu Arg Ile His Asn Asp Thr Thr Arg Pro Arg Leu Lys Val Ile Val 115 120 125	560
GTT CCT CAC TCA CAC AAC GAC CCG GGA TGG CTG AAG ACG TTT GAA CAG Val Pro His Ser His Asn Asp Pro Gly Trp Leu Lys Thr Phe Glu Gln 130 135 140	608
TAC TTC GAG TGG AAG ACC AAG AAC ATT ATC AAC AAC ATA GTG AAC AAA Tyr Phe Glu Trp Lys Thr Lys Asn Ile Ile Asn Asn Ile Val Asn Lys 145 150 155 160	656
CTG CAC CAG TAC CCC AAC ATG ACC TTC ATT TGG ACC GAG ATA TCG TTT Leu His Gln Tyr Pro Asn Met Thr Phe Ile Trp Thr Glu Ile Ser Phe 165 170 175	704
CTG AAT GCC TGG TGG GAA AGG TCG CAC CCT GTC AAA CAA AAG GCA TTG Leu Asn Ala Trp Trp Glu Arg Ser His Pro Val Lys Gln Lys Ala Leu 180 185 190	752
AAA AAA CTT ATC AAA GAA GGT CGT CTC GAG ATC ACG ACG GGC GGC TGG Lys Lys Leu Ile Lys Glu Gly Arg Leu Glu Ile Thr Thr Gly Gly Trp 195 200 205	800
GTG ATG CCG GAC GAA GCC TGC ACG CAT ATC TAT GCG CTA ATT GAC CAG Val Met Pro Asp Glu Ala Cys Thr His Ile Tyr Ala Leu Ile Asp Gln 210 215 220	848
TTT ATT GAA GGA CAT CAC TGG GTG AAA ACT AAT CTC GGC GTC ATC CCG Phe Ile Glu Gly His His Trp Val Lys Thr Asn Leu Gly Val Ile Pro 225 230 235 240	896
AAG ACA GGA TGG TCT ATT GAC CCC TTC GGC CAC GGG GCC ACT GTG CCT Lys Thr Gly Trp Ser Ile Asp Pro Phe Gly His Gly Ala Thr Val Pro 245 250 255	944
TAC CTG CTA GAC CAG AGC GGC CTT GAG GGA ACC ATT ATA CAG AGA ATC Tyr Leu Leu Asp Gln Ser Gly Leu Glu Gly Thr Ile Ile Gln Arg Ile 260 265 270	992
CAT TAT GCG TGG AAA CAG TGG CTG GCG GAG CGA CAG ATT GAG GAG TTT His Tyr Ala Trp Lys Gln Trp Leu Ala Glu Arg Gln Ile Glu Glu Phe 275 280 285	1040

- 177 -

TAC TGG CTG GCG AGT TGG GCT ACT ACG AAG CCG TCC ATG ATA GTG CAC Tyr Trp Leu Ala Ser Trp Ala Thr Thr Lys Pro Ser Met Ile Val His 290 295 300	1088
AAT CAG CCG TTT GAT ATT TAT TCA ATA AAA AGC ACG TGT GGC CCG CAC Asn Gln Pro Phe Asp Ile Tyr Ser Ile Lys Ser Thr Cys Gly Pro His 305 310 315 320	1136
CCT TCA ATT TGT CTC AGT TTC GAC TTC AGG AAG ATT CCC GGC GAA TAT Pro Ser Ile Cys Leu Ser Phe Asp Phe Arg Lys Ile Pro Gly Glu Tyr 325 330 335	1184
TCT GAA TAC ACA GCT AAG CAC GAA GAC ATC ACG GAA CAC AAC TTG CAC Ser Glu Tyr Thr Ala Lys His Glu Asp Ile Thr Glu His Asn Leu His 340 345 350	1232
AGC AAG GCA AAG ACT TTG ATA GAG GAG TAC GAC CGT ATC GGG TCC CTG Ser Lys Ala Lys Thr Leu Ile Glu Glu Tyr Asp Arg Ile Gly Ser Leu 355 360 365	1280
ACT CCA CAC AAC GTG GTG CTG GTG CCG CTC GGA GAC GAC TTC AGA TAC Thr Pro His Asn Val Val Leu Val Pro Leu Gly Asp Asp Phe Arg Tyr 370 375 380	1328
GAG TAC AGC GTC GAG TTT GAT GCC CAA TAC GTC AAT TAT ATG AAA ATG Glu Tyr Ser Val Glu Phe Asp Ala Gln Tyr Val Asn Tyr Met Lys Met 385 390 395 400	1376
TTT AAC TAC ATC AAT GCT CAC AAG GAA ATC TTC AAC GCT GAC GTA CAG Phe Asn Tyr Ile Asn Ala His Lys Glu Ile Phe Asn Ala Asp Val Gln 405 410 415	1424
TTC GGA ACT CCT CTC GAT TAC TTT AAC GCC ATG AAA GAA AGA CAT CAA Phe Gly Thr Pro Leu Asp Tyr Phe Asn Ala Met Lys Glu Arg His Gln 420 425 430	1472
AAT ATA CCC AGC TTA AAG GGA GAT TTC TTC GTT TAC TCC GAT ATT TTC Asn Ile Pro Ser Leu Lys Gly Asp Phe Phe Val Tyr Ser Asp Ile Phe 435 440 445	1520
AGC GAA GGT AAA CCA GCG TAC TGG TCA GGT TAC TAC ACT ACT AGA CCC Ser Glu Gly Lys Pro Ala Tyr Trp Ser Gly Tyr Tyr Thr Thr Arg Pro 450 455 460	1568
TAC CAA AAA ATC CTC GCC CGT CAG TTC GAA CAC CAA CTG CGA TCG GCA Tyr Gln Lys Ile Leu Ala Arg Gln Phe Glu His Gln Leu Arg Ser Ala 465 470 475 480	1616
GAG ATT TTA TTC ACC CTT GTA TCG AAC TAC ATC AGA CAG ATG GGT CGC Glu Ile Leu Phe Thr Leu Val Ser Asn Tyr Ile Arg Gln Met Gly Arg 485 490 495	1664
CAA GGA GAG TTC GGA GCT TCT GAG AAA AAG TTA GAA AAA TCT TAC GAG Gln Gly Glu Phe Gly Ala Ser Glu Lys Lys Leu Glu Lys Ser Tyr Glu 500 505 510	1712

- 178 -

CAG CTT ATC TAT GCT CGA CGG AAC TTG GGT CTG TTT CAA CAT CAC GAT Gln Leu Ile Tyr Ala Arg Arg Asn Leu Gly Leu Phe Gln His His Asp 515 520 525	1760
GCG ATT ACT GGA ACA TCA AAG TCC AGT GTG ATG CAA GAT TAC GGA ACC Ala Ile Thr Gly Thr Ser Lys Ser Ser Val Met Gln Asp Tyr Gly Thr 530 535 540	1808
AAA CTG TTC ACA AGT CTG TAT CAC TGC ATC CGC CTG CAG GAG GCC GCG Lys Leu Phe Thr Ser Leu Tyr His Cys Ile Arg Leu Gln Glu Ala Ala 545 550 555 560	1856
CTC ACC ACC ATC ATG TTG CCT GAC CAG TCG TTG CAC TCG CAG AGC ATT Leu Thr Thr Ile Met Leu Pro Asp Gln Ser Leu His Ser Gln Ser Ile 565 570 575	1904
ATA CAA AGC GAG GTT GAG TGG GAA ACT TAC GGA AAA CCG CCC AAG AAG Ile Gln Ser Glu Val Glu Trp Glu Thr Tyr Gly Lys Pro Pro Lys Lys 580 585 590	1952
CTG CAA GTG TCC TTC ATT GAC AAG AAG AAA GTT ATA CTT TTT AAT CCG Leu Gln Val Ser Phe Ile Asp Lys Lys Lys Val Ile Leu Phe Asn Pro 595 600 605	2000
TTG GCT GAG ACT CGA ACT GAA GTG GTC ACG GTT AGA TCC AAC ACG TCC Leu Ala Glu Thr Arg Thr Glu Val Val Thr Val Arg Ser Asn Thr Ser 610 615 620	2048
AAC ATC CGG GTG TAC GAT ACA CAC AAG AGG AAG CAC GTC TTG TAT CAG Asn Ile Arg Val Tyr Asp Thr His Lys Arg Lys His Val Leu Tyr Gln 625 630 635 640	2096
ATA ATG CCC AGC ATC ACA ATC CAA GAC AAC GGC AAG AGT ATC GTA AGC Ile Met Pro Ser Ile Thr Ile Gln Asp Asn Gly Lys Ser Ile Val Ser 645 650 655	2144
GAC ACC ACG TTC GAC ATA ATG TTC GTG GCC ACC ATC CCG CCC CTC ACC Asp Thr Thr Phe Asp Ile Met Phe Val Ala Thr Ile Pro Pro Leu Thr 660 665 670	2192
TCC ATC TCG TAC AAG CTG CAG GAG CAC ACC AAC ACT TCC CAC CAC TGC Ser Ile Ser Tyr Lys Leu Gln Glu His Thr Asn Thr Ser His His Cys 675 680 685	2240
GTC ATT TTC TGC AAC AAC TGC GAA CAA TAC CAG AAA TCC AAT GTG TTC Val Ile Phe Cys Asn Asn Cys Glu Gln Tyr Gln Lys Ser Asn Val Phe 690 695 700	2288
CAA ATT AAG AAA ATG ATG CCT GGT GAC ATA CAA TTA GAA AAT GCA GTG Gln Ile Lys Lys Met Met Pro Gly Asp Ile Gln Leu Glu Asn Ala Val 705 710 715 720	2336
CTA AAA CTT CTC GTT AAT AGG AAC ACC GGC TTT CTG AGA CAA GTC TAT Leu Lys Leu Leu Val Asn Arg Asn Thr Gly Phe Leu Arg Gln Val Tyr 725 730 735	2384



- 179 -

AGA AAG GAC ATC CGG AAG AGA ACT GTC GTT GAC GTA CAA TTC GGC GCA	2432
Arg Lys Asp Ile Arg Lys Arg Thr Val Val Asp Val Gln Phe Gly Ala	
740 745 750	
TAT CAA AGT GCC CAA AGA CAT TCT GGT GCT TAC CTC TTC ATG CCT CAT	2480
Tyr Gln Ser Ala Gln Arg His Ser Gly Ala Tyr Leu Phe Met Pro His	
755 760 765	
TAC GAC TCA CCT GAG AAG AAT GTT CTG CAT CCC TAC ACT AAT CAG AAC	2528
Tyr Asp Ser Pro Glu Lys Asn Val Leu His Pro Tyr Thr Asn Gln Asn	
770 775 780	
AAC ATG CAA GAT GAT AAC ATA ATC ATA GTG TCC GGA CCT ATT TCT ACG	2576
Asn Met Gln Asp Asp Asn Ile Ile Ile Val Ser Gly Pro Ile Ser Thr	
785 790 795 800	
GAA ATC ACG ACC ATG TAC TTG CCC TTC TTG GTG CAC ACT ATT AGG ATA	2624
Glu Ile Thr Thr Met Tyr Leu Pro Phe Leu Val His Thr Ile Arg Ile	
805 810 815	
TAC AAC GTG CCG GAC CCG GTA CTG TCG CGT GCT ATT CTA TTA GAG ACC	2672
Tyr Asn Val Pro Asp Pro Val Leu Ser Arg Ala Ile Leu Leu Glu Thr	
820 825 830	
GAT GTA GAT TTC GAG GCG CCA CCT AAG AAC AGA GAG ACT GAG TTA TTT	2720
Asp Val Asp Phe Glu Ala Pro Pro Lys Asn Arg Glu Thr Glu Leu Phe	
835 840 845	
ATG AGA TTA CAG ACT GAT ATA CAA AAC GGT GAC ATT CCC GAA TTT TAC	2768
Met Arg Leu Gln Thr Asp Ile Gln Asn Gly Asp Ile Pro Glu Phe Tyr	
850 855 860	
ACC GAT CAG AAC GGA TTC CAG TAC CAA AAG AGG GTC AAA GTG AAT AAA	2816
Thr Asp Gln Asn Gly Phe Gln Tyr Gln Lys Arg Val Lys Val Asn Lys	
865 870 875 880	
CTA GGA ATA GAA GCT AAT TAC TAC CCG ATC ACT ACC ATG GCG TGC CTG	2864
Leu Gly Ile Glu Ala Asn Tyr Tyr Pro Ile Thr Thr Met Ala Cys Leu	
885 890 895	
CAA GAC GAG GAG ACC CGG CTC ACT CTG CTG ACG AAC CAC GCT CAA GGC	2912
Gln Asp Glu Glu Thr Arg Leu Thr Leu Leu Thr Asn His Ala Gln Gly	
900 905 910	
GCT GCT GCA TAC GAA CCA GGA CGC TTA GAA GTC ATG CTC GAT CGT CGA	2960
Ala Ala Ala Tyr Glu Pro Gly Arg Leu Glu Val Met Leu Asp Arg Arg	
915 920 925	
ACT CTT TAT GAT GAC TTC AGA GGA ATC GGT GAA GGA GTA GTC GAT AAC	3008
Thr Leu Tyr Asp Asp Phe Arg Gly Ile Gly Glu Gly Val Val Asp Asn	
930 935 940	
AAA CCG ACG ACT TTC CAG AAC TGG ATT TTA ATT GAA TCC ATG CCA GGC	3056
Lys Pro Thr Thr Phe Gln Asn Trp Ile Leu Ile Glu Ser Met Pro Gly	
945 950 955 960	

- 180 -

GTG ACG CGA GCC AAG AGA GAC ACT AGT GAA CCA GGT TTC AAA TTT GTT Val Thr Arg Ala Lys Arg Asp Thr Ser Glu Pro Gly Phe Lys Phe Val 965 970 975	3104
AAT GAA CGT CGT TTT GGC CCC GGC CAG AAG GAA AGC CCT TAC CAA GTA Asn Glu Arg Arg Phe Gly Pro Gly Gln Lys Glu Ser Pro Tyr Gln Val 980 985 990	3152
CCG TCG CAG ACT GCG GAC TAC CTG AGC AGG ATG TTC AAT TAC CCG GTG Pro Ser Gln Thr Ala Asp Tyr Leu Ser Arg Met Phe Asn Tyr Pro Val 995 1000 1005	3200
AAC GTG TAC CTG GTG GAC ACT AGC GAG GTT GGC GAG ATC GAG GTG AAG Asn Val Tyr Leu Val Asp Thr Ser Glu Val Gly Glu Ile Glu Val Lys 1010 1015 1020	3248
CCG TAC CAG TCG TTC CTG CAG AGC TTC CCG CCC GGC ATC CAC CTG GTC Pro Tyr Gln Ser Phe Leu Gln Ser Phe Pro Pro Gly Ile His Leu Val 1025 1030 1035 1040	3296
ACC CTG CGC ACC ATC ACC GAC GAC GTG CTC GAA CTC TTC CCC AGC AAC Thr Leu Arg Thr Ile Thr Asp Asp Val Leu Glu Leu Phe Pro Ser Asn 1045 1050 1055	3344
GAA AGC TAC ATG GTA CTG CAC CGA CCA GGA TAC AGC TGC GCT GTC GGA Glu Ser Tyr Met Val Leu His Arg Pro Gly Tyr Ser Cys Ala Val Gly 1060 1065 1070	3392
GAG AAG CCA GTC GCC AAG TCT CCC AAG TTT TCG TCC AAA ACC AGG TTC Glu Lys Pro Val Ala Lys Ser Pro Lys Phe Ser Ser Lys Thr Arg Phe 1075 1080 1085	3440
AAT GGT CTG AAC ATT CAG AAC ATC ACT GCA GTC AGC CTG ACC GGC CTG Asn Gly Leu Asn Ile Gln Asn Ile Thr Ala Val Ser Leu Thr Gly Leu 1090 1095 1100	3488
AAG TCA CTC CGA CCT CTC ACA GGT CTG AGT GAC ATC CAC CTG AAC GCT Lys Ser Leu Arg Pro Leu Thr Gly Leu Ser Asp Ile His Leu Asn Ala 1105 1110 1115 1120	3536
ATG GAG GTA AAA ACT TAC AAG ATC AGG TTT TAAAGACTGC TAGTAGTAAT Met Glu Val Lys Thr Tyr Lys Ile Arg Phe 1125 1130	3586
AGGTGTAACA CATTTGTAAT TTTATAATAT TTACAACTT TATCGTGAAC TTACAGCCTC	3646
ACACCTCGGC TATGTAAGTG GAATAAGTAG GAAGATACAA TTTTGATGGT ACTTTAGTAG	3706
AGCCTCGTAC TAACGGGCCG CGTAATAGTA TAATGGTATT AG	3748

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 1130 amino acids

- 181 -

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

```

Met Arg Thr Arg Val Leu Arg Cys Arg Pro Phe Ser Thr Arg Ile Leu
 1             5             10             15

Leu Leu Leu Leu Phe Val Leu Ala Phe Gly Val Tyr Cys Tyr Phe Tyr
      20             25             30

Asn Ala Ser Pro Gln Asn Tyr Asn Lys Pro Arg Ile Ser Tyr Pro Ala
      35             40             45

Ser Met Glu His Phe Lys Ser Ser Leu Thr His Thr Val Lys Ser Arg
      50             55             60

Asp Glu Pro Thr Pro Asp Gln Cys Pro Ala Leu Lys Glu Ser Glu Ala
      65             70             75             80

Asp Ile Asp Thr Val Ala Ile Tyr Pro Thr Phe Asp Phe Gln Pro Ser
      85             90             95

Trp Leu Arg Thr Lys Glu Phe Trp Asp Lys Ser Phe Glu Asp Arg Tyr
      100            105            110

Glu Arg Ile His Asn Asp Thr Thr Arg Pro Arg Leu Lys Val Ile Val
      115            120            125

Val Pro His Ser His Asn Asp Pro Gly Trp Leu Lys Thr Phe Glu Gln
      130            135            140

Tyr Phe Glu Trp Lys Thr Lys Asn Ile Ile Asn Asn Ile Val Asn Lys
      145            150            155            160

Leu His Gln Tyr Pro Asn Met Thr Phe Ile Trp Thr Glu Ile Ser Phe
      165            170            175

Leu Asn Ala Trp Trp Glu Arg Ser His Pro Val Lys Gln Lys Ala Leu
      180            185            190

Lys Lys Leu Ile Lys Glu Gly Arg Leu Glu Ile Thr Thr Gly Gly Trp
      195            200            205

Val Met Pro Asp Glu Ala Cys Thr His Ile Tyr Ala Leu Ile Asp Gln
      210            215            220

Phe Ile Glu Gly His His Trp Val Lys Thr Asn Leu Gly Val Ile Pro
      225            230            235            240

Lys Thr Gly Trp Ser Ile Asp Pro Phe Gly His Gly Ala Thr Val Pro
      245            250            255

Tyr Leu Leu Asp Gln Ser Gly Leu Glu Gly Thr Ile Ile Gln Arg Ile
      260            265            270

```

- 182 -

His Tyr Ala Trp Lys Gln Trp Leu Ala Glu Arg Gln Ile Glu Glu Phe  
 275 280 285

Tyr Trp Leu Ala Ser Trp Ala Thr Thr Lys Pro Ser Met Ile Val His  
 290 295 300

Asn Gln Pro Phe Asp Ile Tyr Ser Ile Lys Ser Thr Cys Gly Pro His  
 305 310 315 320

Pro Ser Ile Cys Leu Ser Phe Asp Phe Arg Lys Ile Pro Gly Glu Tyr  
 325 330 335

Ser Glu Tyr Thr Ala Lys His Glu Asp Ile Thr Glu His Asn Leu His  
 340 345 350

Ser Lys Ala Lys Thr Leu Ile Glu Glu Tyr Asp Arg Ile Gly Ser Leu  
 355 360 365

Thr Pro His Asn Val Val Leu Val Pro Leu Gly Asp Asp Phe Arg Tyr  
 370 375 380

Glu Tyr Ser Val Glu Phe Asp Ala Gln Tyr Val Asn Tyr Met Lys Met  
 385 390 395 400

Phe Asn Tyr Ile Asn Ala His Lys Glu Ile Phe Asn Ala Asp Val Gln  
 405 410 415

Phe Gly Thr Pro Leu Asp Tyr Phe Asn Ala Met Lys Glu Arg His Gln  
 420 425 430

Asn Ile Pro Ser Leu Lys Gly Asp Phe Phe Val Tyr Ser Asp Ile Phe  
 435 440 445

Ser Glu Gly Lys Pro Ala Tyr Trp Ser Gly Tyr Tyr Thr Thr Arg Pro  
 450 455 460

Tyr Gln Lys Ile Leu Ala Arg Gln Phe Glu His Gln Leu Arg Ser Ala  
 465 470 475 480

Glu Ile Leu Phe Thr Leu Val Ser Asn Tyr Ile Arg Gln Met Gly Arg  
 485 490 495

Gln Gly Glu Phe Gly Ala Ser Glu Lys Lys Leu Glu Lys Ser Tyr Glu  
 500 505 510

Gln Leu Ile Tyr Ala Arg Arg Asn Leu Gly Leu Phe Gln His His Asp  
 515 520 525

Ala Ile Thr Gly Thr Ser Lys Ser Ser Val Met Gln Asp Tyr Gly Thr  
 530 535 540

Lys Leu Phe Thr Ser Leu Tyr His Cys Ile Arg Leu Gln Glu Ala Ala  
 545 550 555 560

- 183 -

Leu Thr Thr Ile Met Leu Pro Asp Gln Ser Leu His Ser Gln Ser Ile  
 565 570 575  
 Ile Gln Ser Glu Val Glu Trp Glu Thr Tyr Gly Lys Pro Pro Lys Lys  
 580 585 590  
 Leu Gln Val Ser Phe Ile Asp Lys Lys Lys Val Ile Leu Phe Asn Pro  
 595 600 605  
 Leu Ala Glu Thr Arg Thr Glu Val Val Thr Val Arg Ser Asn Thr Ser  
 610 615 620  
 Asn Ile Arg Val Tyr Asp Thr His Lys Arg Lys His Val Leu Tyr Gln  
 625 630 635 640  
 Ile Met Pro Ser Ile Thr Ile Gln Asp Asn Gly Lys Ser Ile Val Ser  
 645 650 655  
 Asp Thr Thr Phe Asp Ile Met Phe Val Ala Thr Ile Pro Pro Leu Thr  
 660 665 670  
 Ser Ile Ser Tyr Lys Leu Gln Glu His Thr Asn Thr Ser His His Cys  
 675 680 685  
 Val Ile Phe Cys Asn Asn Cys Glu Gln Tyr Gln Lys Ser Asn Val Phe  
 690 695 700  
 Gln Ile Lys Lys Met Met Pro Gly Asp Ile Gln Leu Glu Asn Ala Val  
 705 710 715 720  
 Leu Lys Leu Leu Val Asn Arg Asn Thr Gly Phe Leu Arg Gln Val Tyr  
 725 730 735  
 Arg Lys Asp Ile Arg Lys Arg Thr Val Val Asp Val Gln Phe Gly Ala  
 740 745 750  
 Tyr Gln Ser Ala Gln Arg His Ser Gly Ala Tyr Leu Phe Met Pro His  
 755 760 765  
 Tyr Asp Ser Pro Glu Lys Asn Val Leu His Pro Tyr Thr Asn Gln Asn  
 770 775 780  
 Asn Met Gln Asp Asp Asn Ile Ile Ile Val Ser Gly Pro Ile Ser Thr  
 785 790 795 800  
 Glu Ile Thr Thr Met Tyr Leu Pro Phe Leu Val His Thr Ile Arg Ile  
 805 810 815  
 Tyr Asn Val Pro Asp Pro Val Leu Ser Arg Ala Ile Leu Leu Glu Thr  
 820 825 830  
 Asp Val Asp Phe Glu Ala Pro Pro Lys Asn Arg Glu Thr Glu Leu Phe  
 835 840 845  
 Met Arg Leu Gln Thr Asp Ile Gln Asn Gly Asp Ile Pro Glu Phe Tyr  
 850 855 860

- 184 -

Thr Asp Gln Asn Gly Phe Gln Tyr Gln Lys Arg Val Lys Val Asn Lys  
 865 870 875 880  
 Leu Gly Ile Glu Ala Asn Tyr Tyr Pro Ile Thr Thr Met Ala Cys Leu  
 885 890 895  
 Gln Asp Glu Glu Thr Arg Leu Thr Leu Leu Thr Asn His Ala Gln Gly  
 900 905 910  
 Ala Ala Ala Tyr Glu Pro Gly Arg Leu Glu Val Met Leu Asp Arg Arg  
 915 920 925  
 Thr Leu Tyr Asp Asp Phe Arg Gly Ile Gly Glu Gly Val Val Asp Asn  
 930 935 940  
 Lys Pro Thr Thr Phe Gln Asn Trp Ile Leu Ile Glu Ser Met Pro Gly  
 945 950 955 960  
 Val Thr Arg Ala Lys Arg Asp Thr Ser Glu Pro Gly Phe Lys Phe Val  
 965 970 975  
 Asn Glu Arg Arg Phe Gly Pro Gly Gln Lys Glu Ser Pro Tyr Gln Val  
 980 985 990  
 Pro Ser Gln Thr Ala Asp Tyr Leu Ser Arg Met Phe Asn Tyr Pro Val  
 995 1000 1005  
 Asn Val Tyr Leu Val Asp Thr Ser Glu Val Gly Glu Ile Glu Val Lys  
 1010 1015 1020  
 Pro Tyr Gln Ser Phe Leu Gln Ser Phe Pro Pro Gly Ile His Leu Val  
 1025 1030 1035 1040  
 Thr Leu Arg Thr Ile Thr Asp Asp Val Leu Glu Leu Phe Pro Ser Asn  
 1045 1050 1055  
 Glu Ser Tyr Met Val Leu His Arg Pro Gly Tyr Ser Cys Ala Val Gly  
 1060 1065 1070  
 Glu Lys Pro Val Ala Lys Ser Pro Lys Phe Ser Ser Lys Thr Arg Phe  
 1075 1080 1085  
 Asn Gly Leu Asn Ile Gln Asn Ile Thr Ala Val Ser Leu Thr Gly Leu  
 1090 1095 1100  
 Lys Ser Leu Arg Pro Leu Thr Gly Leu Ser Asp Ile His Leu Asn Ala  
 1105 1110 1115 1120  
 Met Glu Val Lys Thr Tyr Lys Ile Arg Phe  
 1125 1130

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:

- 185 -

- (A) LENGTH: 18 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

CAGTATAAAT TGACGTTC

18

(2) INFORMATION FOR SEQ ID NO: 6:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 27 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

TTTTGGATCC ATAGTCACTT GGTGTT

27

(2) INFORMATION FOR SEQ ID NO: 7:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 52 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GTGACTATGG ATCTAGATCT GCGGCCGCAG GCCTCGCGAC TAGTTTAAAC CC

52

(2) INFORMATION FOR SEQ ID NO: 8:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 53 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GTGACTATGG ATCCCCGGGT TTAACTAGT CGCGAGGCCT GCGGCCGCAG ATC

53

(2) INFORMATION FOR SEQ ID NO: 9:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 52 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- 186 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GTGACCGCGG ATCTAGATCT GCGGCCGCAG GCCTCGCGAC TAGTTTAAAC CC 52

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 53 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

GTGACCGCGG ATCCCCGGGT TTAACTAGT CGCGAGGCCT GCGGCCGCAG ATC 53

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GTGACTATGG ATCCCCGGTA CCTTCTAGAA TTCCGGAGCG GCCGCTGCAG ATCTGATCC 59

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 59 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

GTGACCGCGG ATCCCCGGTA CCTTCTAGAA TTCCGGAGCG GCCGCTGCAG ATCTGATCC 59

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:3..18



- 187 -

(D) OTHER INFORMATION:/mod\_base= i  
/note= "N = Inosine"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:24  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "N = A or C or G or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:12  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "H = A or C or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:15..21  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "Y = C or T/U"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

GGNTGGNNNA THGAYCCNTT YGGNCA

26

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 29 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:3  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "N = A or C or G or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:5  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "K = G or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:7  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "S = G or C"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:8

- 188 -

(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "W = A or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:12..27  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "R = A or G"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:23  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "D = G or A or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:6..21  
(D) OTHER INFORMATION:/mod\_base= i  
/note= "N = Inosine"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

GGNCKNSWNN NRAARTANCC NSDCCARTA

29

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 22 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: misc\_feature  
(B) LOCATION:1..22  
(D) OTHER INFORMATION:/note= "5'-phosphorylated, 3'-amino  
blocked"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

TCCCTTTAGT GAGGGTTAAT TT

22

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 12 amino acids  
(B) TYPE: amino acid  
(C) STRANDEDNESS:  
(D) TOPOLOGY: linear

- 189 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

Asp Pro Ser Arg Phe Ser Gly Ala Lys Glu Ala Lys  
1                      5                      10

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 14 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS:
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

Asp Leu Asp Pro Ser Arg Phe Ser Gly Ala Lys Glu Ala Lys  
1                      5                      10

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 26 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:3..22
- (D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "Y = C or T/U"

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:4
- (D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "W = A or T/U"

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:5
- (D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "S = G or C"

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:6..21
- (D) OTHER INFORMATION:/mod\_base= i  
/note= "I = Inosine"

(ix) FEATURE:

- (A) NAME/KEY: modified\_base
- (B) LOCATION:24

- 190 -

(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "N - A, C, G, or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:15  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "R = A or G"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GAYWSNTTYT AYGARTAYYT NYTNAA

26

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 18 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:1..16  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "R = A or G"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:4..10  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "N = A or C or G or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:7  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "Y = C or T/U"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

RTGNGCYTCN GTRTTRAA

18

(2) INFORMATION FOR SEQ ID NO: 20:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 26 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:1..15

- 191 -

(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "R = A or G"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:10..19  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "Y = C or T/U"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:4..22  
(D) OTHER INFORMATION:/mod\_base= i  
/note= "N = Inosine"

(ix) FEATURE:

(A) NAME/KEY: modified\_base  
(B) LOCATION:25  
(D) OTHER INFORMATION:/mod\_base= OTHER  
/note= "N = A or C or G or T/U"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20:

RTANARRTAY TTNARNGTYT CNGCNA

26

(2) INFORMATION FOR SEQ ID NO: 21:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 17 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21:

GCATCATGTT CGACACG

17

(2) INFORMATION FOR SEQ ID NO: 22:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 20 base pairs  
(B) TYPE: nucleic acid  
(C) STRANDEDNESS: single  
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22:

GTGGTAGACG TTCACGAGAC

20

(2) INFORMATION FOR SEQ ID NO: 23:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 35 base pairs

- 192 -

- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23:

TTGCGTCTAC TGCAGTCTAC GACTCACTAT AGGGC

35

(2) INFORMATION FOR SEQ ID NO: 24:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 17 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24:

TTGCGTCTAC TGCAGTC

17

(2) INFORMATION FOR SEQ ID NO: 25:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 20 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25:

CCTTGCTATT TACTCTCGTC

20

(2) INFORMATION FOR SEQ ID NO: 26:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 19 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26:

TGTGTTTCGAG ACGACGATC

19

(2) INFORMATION FOR SEQ ID NO: 27:

- (i) SEQUENCE CHARACTERISTICS:
  - (A) LENGTH: 18 base pairs
  - (B) TYPE: nucleic acid
  - (C) STRANDEDNESS: single
  - (D) TOPOLOGY: linear

- 193 -

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27:

GACATCGAGT TGTCCAGG

18

(2) INFORMATION FOR SEQ ID NO: 28:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28:

GTGTAGGTTC TGTGTTTACG

20

(2) INFORMATION FOR SEQ ID NO: 29:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 19 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29:

TTCACCATGG TGAGCGATC

19

(2) INFORMATION FOR SEQ ID NO: 30:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 20 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30:

AAGTGAGCTC GCTTCGACAT

20

**CLAIMS**

1. A baculovirus expression vector characterized as:
  - a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a first and second promoter; or
  - b) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.
2. The vector of claim 1, comprising at least a first a glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.
3. The vector of claim 1, comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding oligosaccharide processing enzymes, each gene operatively positioned under the control of a promoter.
4. The vector of claim 3, further comprising a second glycosylation enzyme transcriptional unit comprising a structural gene encoding a second oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
5. The vector of any preceding claim, further comprising a third glycosylation enzyme transcriptional unit comprising a structural gene for a third oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.



- 195 -

6. The vector of any preceding claim, further comprising a fourth glycosylation enzyme transcriptional unit comprising a structural gene for a fourth oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
- 5 7. The vector of any preceding claim, further comprising a fifth glycosylation enzyme transcriptional unit comprising a structural gene for a fifth oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
8. The vector of any preceding claim, further comprising a sixth glycosylation enzyme transcriptional unit comprising a structural gene for a sixth oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
- 10 9. The vector of any preceding claim, further comprising a seventh glycosylation enzyme transcriptional unit comprising a structural gene for a seventh oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
- 15 10. The vector of any preceding claim, further comprising an eighth glycosylation enzyme transcriptional unit comprising a structural gene for an eighth oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
- 20 11. The vector of any preceding claim, further comprising a ninth glycosylation enzyme transcriptional unit comprising a structural gene for a ninth oligosaccharide processing enzyme, said gene operatively positioned under the control of a promoter.
- 25 12. The vector of any preceding claim, wherein said oligosaccharide processing enzyme is an  $\alpha$ -glucosidase, an  $\alpha$ -mannosidase, an N-acetylglucosaminyltransferase, a fucosyltransferase, a galactosyltransferase or a sialyltransferase.
- 30 13. The vector of claim 12, wherein said oligosaccharide processing enzyme is a galactosyltransferase or a sialyltransferase.

- 196 -

14. The vector of any preceding claim, wherein said first or second promoter is an insect cell promoter.

5 15. The vector of any of claims 1-13, wherein said first or second promoter is a viral promoter.

16. The vector of claim 15, wherein said first or second promoter is a baculovirus promoter.

10 17. The vector of claim 16, wherein said first or second promoter is a baculovirus early promoter.

18. The vector of claim 16, wherein said first or second promoter is a baculovirus immediate early promoter.

15 19. The vector of claim 16, wherein said first or second promoter is a baculovirus delayed early promoter.

20 20. The vector of claim 16, wherein said first or second promoter is an IE1, IEN (IE2), IE0, 39K, gp64, DA26, ETL, 35K, capsid (p39), p6.9, p10 or polyhedrin promoter.

25 21. The vector of claim 16, wherein said first or second promoter is obtained from the viral DNA of *Autographa californica* NPV, *Trichoplusia ni* NPV, *Rachipulsia ou* NPV, *Orgyia pseudosugata* NPV, *Bombyx mori* NPV, *Heliothis zea* NPV, *Spodoptera exigua* NPV or *Galleria mellonella* NPV.

22. The vector of any preceding claim, further comprising an enhancer operatively positioned to enhance expression of said transcriptional unit or units.

30 23. The vector of claim 22, wherein said enhancer is a baculovirus hr1, hr2, hr3, hr4 or hr5 enhancer.

24. The vector of claim 22, wherein said enhancer is obtained from the viral DNA of *Autographa californica* NPV, *Trichoplusia ni* NPV, *Rachipulsia ou* NPV, *Orgyia pseudosugata* NPV, *Bombyx mori* NPV, *Heliothis zea* NPV, *Spodoptera exigua* NPV or  
5 *Galleria mellonella* NPV.
25. The vector of any preceding claim, further comprising a structural gene encoding a protein disulphide isomerase operatively positioned under the control of a promoter.
- 10 26. The vector of any preceding claim, further comprising a structural gene encoding a peptidyl prolyl *cis-trans* isomerase operatively positioned under the control of a promoter.
27. The vector of any preceding claim, further comprising a structural gene encoding  
15 a chaperone protein operatively positioned under the control of a promoter.
28. The vector of claim 27, wherein said structural gene is BiP/GRP78.
29. The vector of claim 28, wherein said BiP/GRP78 is an insect cell BiP/GRP78.  
20
30. The vector of any preceding claim, further comprising a structural gene encoding a selectable marker protein operatively positioned under the control of a promoter.
31. The vector of claim 30, wherein said structural gene is an antibiotic or toxin  
25 resistance gene.
32. The vector of any preceding claim, further comprising a structural gene encoding a protein kinase operatively positioned under the control of a promoter.
- 30 33. The vector of any preceding claim, further comprising a baculovirus structural gene.

34. The vector of claim 33, wherein said baculovirus structural gene is gp64, p10 or polyhedrin.
- 5 35. The vector of any preceding claim, further comprising a cloning restriction site.
36. The vector of claim 35, wherein said cloning restriction site comprises a DNA insert comprising a multiple cloning cassette.
- 10 37. The vector of any preceding claim, further comprising at least one heterologous structural gene encoding a selected protein, said gene operatively positioned under the control of a supplementary promoter.
- 15 38. The vector of claim 37, wherein said supplementary promoter is a baculoviral promoter.
39. The vector of claim 38, wherein said baculoviral promoter is a very late promoter.
- 20 40. The vector of claim 39, wherein said very late promoter is a polyhedrin or p10 promoter.
41. The vector of claim 38, wherein said baculoviral promoter is a late promoter.
42. The vector of claim 41, wherein said late promoter is a p6.9 or capsid promoter.
- 25 43. The vector of claim 37, wherein said supplementary promoter is a promoter naturally associated with said heterologous structural gene.
- 30 44. The vector of claim 37, wherein said vector comprises at least one structural gene encoding an insecticidal protein.

- 199 -

45. The vector of claim 44, wherein said vector comprises at least one structural gene encoding a *Bacillus thuringiensis* crystal toxin, a protease inhibitor, a lectin, a chitinase, a juvenile hormone esterase, a toxin or a trypsin inhibitor insecticidal protein.
- 5 46. The vector of claim 45, wherein said vector comprises at least one structural gene encoding a juvenile hormone esterase.
47. The vector of claim 45, wherein said toxin is AaIT or LqhIT2.
- 10 48. The vector of any preceding claim, further comprising a 5' end flanking baculovirus viral DNA and a 3' end flanking baculovirus viral DNA.
49. The vector of any preceding claim, wherein said transcriptional unit replaces a portion of the baculovirus genome.
- 15 50. The vector of claim 49, wherein said portion of the baculovirus genome is the gp64, p10 or polyhedrin locus.
- 20 51. The vector of any of claims 3 to 50, wherein the first oligosaccharide processing enzyme structural gene encodes galactosyltransferase and the second oligosaccharide processing enzyme structural gene encodes sialyltransferase.
- 25 52. The vector of claim 51, further comprising structural genes encoding N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II operatively positioned under the control of a promoter.
53. The vector of claim 51, further comprising a baculoviral enhancer.
- 30 54. The vector of any preceding claim, encapsulated within a baculovirus.

- 200 -

55. The vector of any of claims 1-53 for use in the preparation of a recombinant baculovirus.
56. Use of the vector of any of claims 1-53 in the preparation of a recombinant baculovirus.
57. A baculovirus expression vector comprising a gene encoding an oligosaccharide processing enzyme, a chaperone protein or a protein kinase operatively positioned under the control of a promoter, a baculoviral structural gene, a 5' end flanking baculovirus viral DNA and a 3' end flanking baculovirus viral DNA.
58. The vector of claim 57, wherein said gene is operatively positioned under the control of a promoter and a baculoviral enhancer.
59. The vector of claim 57, wherein said vector further comprises a structural gene encoding a selectable marker protein operatively positioned under the control of a promoter.
60. The vector of claim 59, wherein said gene encoding said selectable marker protein encodes an antibiotic or toxin resistance gene.
61. The vector of claim 57, further comprising a DNA insert comprising a multiple cloning site.
62. The vector of claim 61, further comprising a heterologous structural gene inserted into said multiple cloning site.
63. A baculovirus comprising a baculovirus expression vector characterized as:  
a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second

- 201 -

structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or

b) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

64. A baculovirus containing a baculovirus expression vector in accordance with any of claims 1-53.

65. A population of baculovirus particles containing a baculovirus expression vector in accordance with any of claims 1-53.

66. A baculovirus containing a baculovirus expression vector in accordance with any of claims 1-53 for use in the preparation of an insecticidal formulation.

67. Use of a baculovirus containing a baculovirus expression vector in accordance with any of claims 1-53 in the preparation of an insecticidal formulation.

68. An insecticidal composition comprising a population of baculovirus particles, said baculovirus particles comprising a baculovirus expression vector characterized as:

a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or

b) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

- 202 -

69. The composition of claim 68, wherein said baculovirus expression vector further comprises a structural gene encoding a chaperone protein operatively positioned under the control of a promoter.

5 70. The composition of claim 69, wherein said baculovirus expression vector further comprises a structural gene encoding an insecticidal protein operatively positioned under the control of a promoter.

71. An insect cell comprising a baculovirus expression vector characterized as:  
10 a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene operatively positioned under the control of a promoter; or  
b) comprising at least a first glycosylation enzyme transcriptional unit, said  
15 transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene operatively positioned under the control of a baculoviral immediate early, delayed early, early or late promoter.

72. The insect cell of claim 71, wherein said insect cell is a stably transformed insect  
20 cell clone.

73. The insect cell of claim 72, wherein said insect cell is a Lepidopteran insect cell.

74. The insect cell of claim 73, wherein said insect cell is a *Spodoptera frugiperda*,  
25 *Bombyx mori*, *Heliothis virescens*, *Heliothis zea*, *Mamestra brassicas*, *Estigmene acrea* or *Trichoplusia ni* insect cell.

75. An insect cell containing a baculovirus expression vector in accordance with any of claims 1-53.



76. A baculovirus containing a baculovirus expression vector in accordance with any of claims 1-53 for use in the preparation of an engineered insect cell.
77. Use of a baculovirus containing a baculovirus expression vector in accordance with any of claims 1-53 in the preparation of an engineered insect cell.
78. An engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme.
79. An engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme and at least a first heterologous gene that encodes a selected protein.
80. A method for metabolically engineering an insect cell, comprising providing to said cell at least a first baculovirus expression vector characterized as:
- a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned under the control of a promoter operative in said insect cell;
  - or
  - b) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in said insect cell.
81. The method of claim 80, wherein said insect cell is provided with said baculovirus expression vector by infection.
82. The method of claim 80, wherein said insect cell is provided with said baculovirus expression vector by transfection.

83. The method of claim 80, wherein said baculovirus expression vector is maintained extrachromosomally.

5 84. The method of claim 80, wherein said baculovirus expression vector stably integrates into the genome of said insect cell to provide a stably transformed insect cell.

85. The method of claim 80, wherein said baculovirus expression vector expresses a galactosyltransferase oligosaccharide processing enzyme.

10

86. The method of claim 85, wherein said first baculovirus expression vector further expresses sialyltransferase.

15

87. The method of claim 86, wherein said first baculovirus expression vector further expresses N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II oligosaccharide processing enzymes.

88. The method of claim 80, wherein said insect cell is a Lepidopteran insect cell.

20

89. The method of claim 80, wherein said insect cell is a cultured insect cell.

90. The method of claim 80, wherein said insect cell is comprised within a living insect.

25

91. The method of claim 80, wherein said insect cell is provided with a heterologous structural gene that expresses a selected protein in said insect cell.

92. The method of claim 91, wherein said heterologous structural gene is comprised within said baculovirus expression vector.

30

93. The method of claim 91, wherein said heterologous structural gene is comprised within a second baculovirus expression vector that is provided to said insect cell.

5 94. A method for metabolically engineering an insect cell, comprising providing to an insect cell a baculovirus expression vector in accordance with any of claims 1-53.

95. A baculovirus expression vector in accordance with any of claims 1-53 for use in metabolically engineering an insect cell.

10 96. Use of a baculovirus expression vector in accordance with any of claims 1-53 in the metabolic engineering an insect cell.

15 97. A method for producing a selected protein in an insect cell, comprising preparing an engineered insect cell that expresses at least a first heterologous oligosaccharide processing enzyme and expressing in said engineered insect cell a heterologous gene that encodes said selected protein.

20 98. The method of claim 97, further comprising collecting said selected protein from said cell.

99. A method for producing a selected protein in an insect cell, comprising providing to an insect a baculovirus expression vector in accordance with any of claims 1-53 and an expressible nucleic acid segment encoding said selected protein.

25 100. A baculovirus expression vector in accordance with any of claims 1-53 for use in producing an oligosaccharide-containing selected protein in an insect cell.

101. Use of a baculovirus expression vector in accordance with any of claims 1-53 in the production of an oligosaccharide-containing selected protein in an insect cell.

30

- 206 -

102. A baculovirus expression vector in accordance with any of claims 1-53 for use in preparing a formulation for use in producing an oligosaccharide-containing selected protein in an insect cell.

5 103. Use of a baculovirus expression vector in accordance with any of claims 1-53 in the preparation of a formulation for use in producing an oligosaccharide-containing selected protein in an insect cell.

10 104. A method for producing a selected protein in an insect cell, comprising providing to said insect cell at least a first baculovirus expression vector that expresses at least a first oligosaccharide processing enzyme in said insect cell, and further providing to said cell a heterologous structural gene that expresses said selected protein in said insect cell.

15 105. The method of claim 104, comprising the steps of:  
a) preparing a first baculovirus expression vector in which an oligosaccharide processing enzyme gene is positioned under the control of a promoter operative in said insect cell;  
b) introducing said baculovirus expression vector into an insect cell; and  
c) maintaining the insect cell under conditions effective to allow expression  
20 of said selected protein.

106. The method of claim 105, further comprising collecting the expressed selected protein and purifying said expressed protein away from total cell components.

25 107. The method of claim 104, wherein said heterologous structural gene is provided to said insect cell by means of said baculovirus expression vector.

108. The method of claim 104, wherein said heterologous structural gene is provided to said insect cell by means of a second baculovirus expression vector.

30

- 207 -

109. The method of claim 104, wherein said first baculovirus expression vector expresses galactosyltransferase and sialyltransferase oligosaccharide processing enzymes.

5 110. The method of claim 109, wherein said first baculovirus expression vector further expresses N-acetylglucosaminyltransferase I and N-acetylglucosaminyltransferase II oligosaccharide processing enzymes.

111. A selected protein produced by the method of claim 105.

10

112. A method for producing a selected protein in an insect cell, comprising the steps of:

a) creating an engineered insect cell by providing to an insect cell at least a first baculovirus expression vector characterized as:

15

i) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned under the control of a promoter operative in said insect cell; or

20

ii) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in said insect cell; and

25

b) expressing in said engineered insect cell a heterologous gene that expresses said selected protein.

30

113. A method for producing a selected protein in an insect cell, comprising preparing a stably transformed insect cell that expresses at least a first oligosaccharide processing enzyme and infecting said stably transformed cell with a baculovirus comprising an

- 208 -

expression vector that comprises a heterologous gene that expresses said selected protein in said insect cell.

5 114. A method for killing an insect cell, comprising contacting said insect cell with at least a first baculovirus expression vector that expresses at least a first oligosaccharide processing enzyme in said insect cell.

10 115. The method of claim 114, wherein said baculovirus expression vector is encapsulated within a baculovirus.

116. The method of claim 114, wherein said insect cell is housed within a living insect.

15 117. The method of claim 114, wherein said baculovirus expression vector is characterized as:

20 a) comprising at least a first and a second glycosylation enzyme transcriptional unit, said transcriptional units comprising a first and a second structural gene encoding a first and a second oligosaccharide processing enzyme, each gene positioned under the control of a promoter operative in said insect cell;  
or

25 b) comprising at least a first glycosylation enzyme transcriptional unit, said transcriptional unit comprising a structural gene encoding an oligosaccharide processing enzyme, said gene positioned under the control of a baculoviral immediate early, delayed early, early or late promoter operative in said insect cell.

118. The method of claim 114, wherein said baculovirus expression vector further expresses an insecticidal protein in said insect cell.

- 209 -

119. The method of claim 118, wherein said vector expresses *Bacillus thuringiensis* crystal toxin, a protease inhibitor, a lectin, a chitinase, a toxin, juvenile hormone esterase or a trypsin inhibitor insecticidal protein.

5 120. The method of claim 118, wherein said vector expresses a glycosylatable insecticidal protein and said oligosaccharide processing enzyme functions to modify the glycosylation pattern of said insecticidal protein.

10 121. The method of claim 120, wherein said vector expresses the glycosylatable insecticidal protein juvenile hormone esterase and the oligosaccharide processing enzyme galactosyltransferase.

122. The method of claim 121, wherein said vector further expresses the oligosaccharide processing enzyme sialyltransferase.

15

123. An insect containing a baculovirus expression vector in accordance with any of claims 1-53.

FIG. 1A




FIG. 1B

1/23





FIG. 1C





2/23




FIG. 2




FIG. 3

3/23




FIG. 4

4/23




FIG. 5A

5/23




FIG. 5B

6/23




FIG. 6

7/23




FIG. 7A




FIG. 7B

8/23




FIG. 8A




FIG. 8B




FIG. 9





10/23




FIG.11

11/23




FIG. 12

12/23


N-linked oligosaccharide processing

FIG. 13

13/23




FIG. 14




FIG. 15A




FIG. 15B

15/23




FIG.16A




FIG.16B

16/23




FIG.17A




FIG.17B

17/23




FIG.17C




FIG.17D



18/23




FIG.18A




FIG.18B

19/23




FIG.19

20/23




FIG. 20A




FIG. 20B

21/23




FIG. 20C




FIG. 20D

22/23




FIG. 21A




FIG. 21B

23/23




FIG. 21C





FIG. 21D

